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ABSTRACT
Large geographical variations in cancer survival are seen across Europe and the UK. Within 
Scotland there are also large differences between groups of society defined by material 
deprivation.
The main goal o f this thesis is to identify the most important determinants of social 
variation in cancer survival in Scotland and to assess how these might be addressed in order 
to reduce inequalities. The underlying purpose is to investigate the usefulness of routine 
data sources in examining prognosis and patterns of cancer care in the general population. 
Scodand is ideal for this because of the routine linkage of cancer registry data w ith all 
hospital inpatient discharge records.
Chapter 1 of the thesis introduces the statistical methodology, and the measures of 
deprivation and comorbidity that have been used. Chapter 2 covers the data, definitions 
and quality issues. Chapter 3 reviews cancer survival in Scodand, including trends over time, 
and age-, sex- and deprivation-related differences. Chapter 4 explores the concept of 
avoidable deaths, and compares the methods available for computing this statistic. Six 
cancers, each with strong evidence of a deprivation gradient in survival in Scodand, were 
investigated further (breast, colon, rectum, bladder and kidney, and melanoma of the skin), 
using data for patients diagnosed in 1997. The analyses focus on patient and tumour 
characteristics, and health care system and treatment factors.
The main findings are that deprived patients have higher comorbidity at diagnosis and 
appear to present with more advanced tumours. There are wide differences in the treatment 
offered to affluent and deprived patients, which will be to some extent appropriate because 
of differences in stage of disease and general health but appear too large to be equitable. 
Almost half of the excess cancer deaths occurring from these cancers each year, due to 
differences in survival between deprivation groups, would appear to be avoidable by changes 
in policy or practice.
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INTRODUCTION
There is extensive information in both the national and international literature describing 
large variations in cancer survival. Within Scotland, regional and social differences in 
survival have been reported1, and similar variations are observed in England and Wales2'4. 
Survival from many cancers in Scodand is not as high as in comparable European 
countries5'6. Many possible factors contributing to these inequalities have been individually 
studied for some cancers, but the relative importance of these factors and the public health 
implications need to be addressed.
It has long been recognised that the socially disadvantaged have a shorter life expectancy 
due to the combination of greater incidence of life threatening diseases (including cancer) 
and then poorer chances of surviving the disease, and these inequalities have widened in 
recent years7. The first reports of socio-economic status being linked to survival time 
following a diagnosis of cancer date back to the 1950s*. Subsequently, socio-economic 
differences in survival have been reported for many cancers4,917 and for most cancers it has 
been found that the more affluent live longer after a cancer diagnosis than the deprived. 
Socio-economic differences in cancer survival, i f  not artefactual, may be related to 
differences in the extent of disease at time of diagnosis1517, in the treatment provided1* “ , in 
access to a cancer specialist27 “ , or attendance at a  specialised cancer hospital31 (although 
evidence on this is conflicting32), in the biological characteristics o f the cancer or in host 
factors33. Measures to reduce socio-economic differences in survival depend on our 
comprehending the complex relations between social factors, individual behaviour, disease 
processes, and medical interventions, and their combined prognostic significance.
Socio-economic inequalities in cancer survival could in principle be accounted for by three 
types of explanation: artefactual, random variation in the data and true systematic variation34. 
Establishing the magnitude of any true systematic variation and the factors involved is, 
potentially, o f great public health importance as this represents the extent to which changes 
can be made which will reduce the inequalities.
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Artefactual explanations for observed differences in cancer survival include data quality, 
methodological limitations in the estimation of survival causing bias55, and the measurement 
of deprivation - ideally material deprivation would be measured on an individual basis using 
information on income, education or occupation. In practice, however, this information is 
not often available from cancer registries. Random variation is accounted for in statistical 
analyses. Some o f the factors that have been explored in the literature to explain systematic 
variation in survival between socio-economic groups are now introduced. Each of these 
has been explicitly considered in the analysis and discussion of cancer survival in Scotland in 
the subsequent chapters.
Tumour biology
The histological type of malignancy can be an important prognostic factor in cancer survival, 
because it is associated with aggressiveness of the tumour for many cancers. Differential 
distribution of histological types of a given cancer between deprivation groups has been 
seen and may be due to differences in exposure to known risk factors. However, studies 
adjusting for histological type in survival analyses have generally not found that it accounts 
for much of the variation in cancer survival between different races54 or deprivation 
groups57.
Delay in  diagnosis and tumour stage a t diagnosis
The literature suggests that stage of disease at diagnosis is the most important factor 
contributing to deprivation-specific differences in cancer patient survival. This has been 
observed for a number of cancers, and most of the studies suggest that cancer is diagnosed 
at an advanced stage more often in lower than in higher social classes. Despite these 
differences, the survival variations by social class have generally persisted even after 
adjustment for stage1517,5\
Differences in tumour stage at diagnosis are linked to the speed with which the patient seeks 
medical advice when experiencing symptoms, the quality of primary diagnosis, the speed of 
referral to a specialist, and the thoroughness of investigation and diagnosis. The survival 
advantage conferred by earlier diagnosis may be artificial (lead-time bias): the time of 
diagnosis is advanced but death is not delayed - that is, treatment does not alter the natural 
history of the disease59,40.
Q uality and timeliness o f  treatment
Differences in treatment by deprivation group have not been widely studied. Studies in the 
USA have found differences in treatment for breast cancer by race, as a surrogate for 
deprivation41, and lung cancer by whether or not patients had private medical insurance42. 
Differences in cancer survival based on the quality of treatment have been estimated by 
looking at survival in specialist hospitals31 and treated by cancer specialists27 M, but these 
differences have not been investigated in the context of deprivation. The choice of 
treatment will be influenced by clinical judgement based on stage at diagnosis and other 
tumour characteristics.
Comorbidity and host response
Host factors include both biological factors such as co-morbidity, and psychosocial factors 
such as health behaviour. Berg et a iA> propose a hypothesis that poor nutritional status, 
general health and immunological status (related to alcoholism) of deprived social groups 
leads to lower survival from cancer. Co-morbid conditions experienced by cancer patients 
may vary substantially between populations. They could in turn affect survival by presenting 
an additional source of risk of death, making it less likely that a patient will be offered 
curative treatment or, if it is offered, less likely that the patient will be able to withstand the 
effects of the treatment itself.
The government is committed to reducing mortality from cancer44 47 and has acknowledged 
that there are inequalities in cancer survival. Although many studies to investigate variations 
in cancer survival exist, there is no comprehensive investigation of the relative importance 
of all factors known to affect survival and their relationship w ith deprivation. Differences in 
tumour biology and host response between deprivation groups need to be identified and 
quantified but they are difficult to change. If delay in diagnosis and the quality and 
timeliness of treatment could be shown to be important influences on socio-economic 
differences in survival, however, that would be of great public health relevance. These 
factors can be influenced by improvements of health care systems and health information, 
which would in turn reduce the socio-economic gradient in survival.
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The aims o f this thesis
The main aim o f this PhD thesis was to identify the most important determinants of social 
variations in cancer survival in Scodand and to assess how these factors should be addressed 
in order to reduce inequalities in Scodand. The underlying purpose o f the thesis was to 
investigate the use of routine data sources to look at prognosis and the patterns of cancer 
care in population-based cohorts of cancer patients. Routine data sources, if suitably 
reliable, are very valuable. They allow “up-to-date” analyses, can by updated regularly with 
comparative ease, and they are not resource intensive. Results of retrospective audits are 
often published many years after the date o f collection, by which time case-mix and 
treatment practice may have substantially changed, and this reduces their usefulness. 
Scodand is the ideal place to investigate routine data sources, due to the central resource of 
data collected from all hospital computer systems and the linkage o f these data to form 
patient care histories.
Chapters 1 and 2 of the thesis discuss the methodology and materials used. Chapter 3 
presents a brief overview o f survival from cancer in Scodand including trends over time, and 
age-, sex-, and deprivation-related differences. Chapter 4 looks at the concept of avoidable 
deaths and compares the methodology available for computing this statistic. The research is 
then focused on six cancers (Chapters 5-8) to investigate differences in tumour biology, 
delay in diagnosis, tumour stage at diagnosis, the quality and timeliness o f treatment, and co­
morbidity. These in-depth analyses cover cancers of the breast, colon, rectum, kidney and 
bladder, and melanoma o f the skin. These are all common malignancies with substantial 
mortality, and for each o f them there is strong evidence of a significant deprivation gradient 
in survival in Scotland. Detailed discussion is included in each of these chapters. There is 
also a general discussion at the end of the thesis containing broad comments and an overall 
interpretation o f the results.
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C h a p t e r  1
METHODOLOGY
Cancer survival rates
The simplest estimate of survival is observed survival, which is the probability that a person 
with a given disease will be alive at a specified time-point after diagnosis. It does not take 
cause of death into account; however, survival of cancer patients depends both on the risk 
o f death due to the cancer, and on the background risk of death in the general population 
which the cancer patient is a member. The risk of death due to the cancer tends to decline 
with increasing time since diagnosis, while the background risk from other causes of death 
will increase as the surviving patients get older. It is therefore important to separate the 
background risk o f death and the risk o f death from the cancer. Observed survival is always 
likely to be lower in older patients, because they are at greater risk o f  dying from other 
causes. This makes it difficult to compare survival between age groups or between 
populations with different age distributions. Cause-specific and relative survival attempt to 
overcome this problem; they can be thought of as a measure of net survival expectation after 
contracting cancer, or the probability o f survival from cancer in the absence o f other causes o f 
death.
Observed (or crude) survival
Observed survival and its standard error are calculated by,
t
2
where
=j  th observed time of death
17
1----   — Conditional probability of surviving to t j , having survived to just before t j
d j = Number of deaths occurring at time-point t  ■
rij = Number of patients alive just before time t J (i.e. including deaths at t j but
excluding patients censored before t j )
Censored patients are those whose vital status is not known after a given time-point. For 
example, in  this thesis patients who are still alive on 31st December 1999 are censored on 
that date because, at the time the data extract was taken, the death data were not complete 
on the cancer registration file after that date. Similarly, patients who have emigrated during 
the period o f follow-up are censored on their date of emigration.
Crude survival is a useful measure: it gives the “real” survival of the patients diagnosed with 
cancer.
Cause-specific (or net or corrected) survival
Cause-specific survival is calculated using the same methodology as observed survival, with 
the cause o f  death from the death certificate used to attribute the death either to the cancer 
or to o ther causes. Deaths from causes other than cancer are censored in the survival 
analysis to give a cause-specific survival rate. This method is used as standard in the clinical 
trials setting. However, in the population-based setting, problems arise particularly for 
patients w ith long follow-up. Firstly, it is not always clear which deaths should be 
considered as attributable to the cancer o f interest (e.g. suicide, surgical complications, a 
second cancer). Secondly, the cause of death information is not always available, accurate 
and complete. Since the 1990s, the completeness of death certificate information in 
Scotland has been high (99% of deaths have at least one cause of death recorded). The 
most recent study of the accuracy o f death certificates in Scodand was for death certificates 
completed from 1975-197741; at that time, the death certificate information was found to be 
highly unreliable as a source of diagnostic data. This information is believed to be much 
more reliable now, but there is no recent evidence on this point.
For each cancer, Appendix 1.1 shows the causes o f death which were deemed to be cause- 
specific fo r the purposes of this thesis. The aggregation of the deaths defined as cause-
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specific for each cancer gives the cause-specific deaths for 'all malignant neoplasms'. The list 
is not necessarily exhaustive or definitive. If causes which should be attributed to the cancer 
of diagnosis are excluded, cause-specific survival will over-estimate ‘net’ survival; conversely, 
if too many causes of death are included, cause-specific survival will underestimate ‘net’ 
survival.
There may be differences between areas or countries in the conventions used for 
completing death certificates, so cause-specific survival is likely to be m ost useful for 
comparing sub-groups within a country, for example between areas or deprivation groups, 
as in this thesis. The use o f cause-specific methods to assess socio-economic differences in 
survival of cancer patients depends partly on the assumption that the accuracy of death 
information does not vary by social class49. Although one study in Scodand suggested that 
this assumption may not be valid, it was based on a relatively small and selected series of 
autopsy cases50.
Due to the uncertainty o f the accuracy o f the death certificates and the subjectivity of the 
definition of “cause-specific”, this method is used only in an exploratory manner in this 
thesis.
Relative aurvival
Relative survival is the usual method of estimating net survival in population-based studies. 
It is the ratio o f observed survival compared to the survival that would have been expected 
in the cohort of patients if they had been subject only to the mortality rates of the 
background population (expected survival). At time-point relative survival is calculated by
R, =
Sj_
e ,
S' is the observed survival as described earlier; E, is the expected survival, that is the average 
expected survival in a comparable group o f the general population with respect to the main 
factors affecting survival (e.g. age and sex). The expected probabilities are obtained from 
life tables for Scotland (described later) allowing the calculation of the expected probability 
o f survival at each single year of age at death.
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While relative survival is expected to give values that are more comparable between different 
populations, it should be borne in mind that it is unlikely to represent the true ‘net’ survival 
completely. For example, it is possible that patients diagnosed with cancer are more likely to 
die from other causes than the general population and hence relative survival may still be an 
overestimate o f ‘net’ survival.
Two early methods by Ederer et a l?' for calculating relative survival are documented. With 
the first method (Ederer I), the probability o f surviving t  years after diagnosis is obtained 
from relevant life tables for each individual in the study cohort; the expected number of 
survivors is obtained by dividing the sum o f these probabilities by the initial size o f the 
cohort. This method was then enhanced (Ederer II), with the probability of survival in each 
“actuarial” interval being estimated at the beginning o f the interval for each individual still at 
risk at that time. Again, the probabilities are summed to estimate the expected number o f 
survivors in the interval. The relative survival at t  years after diagnosis is the product o f the 
ratios of observed to expected actuarial survival within each interval up to t.
However, even with this enhanced method there is a problem with heterogeneity within the 
study cohort, of covariates (e.g. age) which affect survival, and to changes in their 
distribution as the study cohort is depleted by death and censoring52. For example, in the 
longterm, th e  net survival will be dominated by the net survival of the group with the 
longest life expectancy (usually the youngest), and for many cancers net survival is better for 
those diagnosed at a younger age. Hakulinen et a li l suggested changing the calculation so 
the expected survival is updated at each event (death) using the demographic information 
for the case at that point in time, hence correcting for heterogeneity in expected survival 
and patient withdrawal (i.e. young patients may be more likely to withstand treatment; young 
patients may be less likely to die from an unrelated condition; young patients may be more 
likely to emigrate from the cancer registry area).
Esteve et al?*  were still concerned that this method may over-estimate long term net survival 
in cohorts w ith heterogeneous life expectancies, because the expected survival relies only on 
the initial composition o f the cohort and on the potential follow-up times. They, therefore, 
proposed modelling the data using a lull likelihood approach based on individual-level data. 
With this method the death rate from cancer, in each of a series of (pre-defined) time 
intervals since diagnosis, is estimated from the survival times o f individual patients. The
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background mortality rate within the interval is assumed to be constant. The net mortality 
rate in each time interval is estimated using an iterative procedure to maximise the likelihood 
of the parameters and the net mortality rates, given the observed data. Simplistically, this 
method consists o f subtracting the number of expected deaths from the observed deaths in 
each interval and inferring the excess mortality rate from this adjusted number.
Detailed methodology for the two approaches are not repeated here, as they can be found 
in the references53'*4.
Computer packages fo r  calculating relative survival rates
Observed and cause-specific survival can easily be calculated using any statistical analysis 
package. However, the calculation of relative survival involves quite complicated 
programming. A stand-alone computer package, surv3, is available to compute the  Ederer 
and Hakulinen estimates55. Also available is a STATA algorithm, strel2, based on th e  relative 
survival approach outlined by Estéve e t aL
The surv3 programme analyses the data at every event, so there are no input decisions to be 
made by the user. With the strel2 algorithm however, the analysis is performed at time 
points (known as breaks) decided by the user. The choice of these time points is important 
because the excess hazard is assumed constant within each interval, however, when there are 
many deaths the excess hazard will in fact change rapidly. After testing a selection of 
options for these break points on different types of survival data, the following guidelines 
seem appropriate for users of the algorithm (see box).
The estimates produced by the surv3 package and the strel2 algorithm are quite similar for 
analyses containing at least 50 patients. For analyses including fewer than 50 cases, the 
estimates are often not comparable. The estimates produced by the strel2 algorithm are 
generally (85%) somewhat lower than those produced by the surv3 package.
In this thesis, both crude and relative survival methodologies have been used. In Chapter 3, 
the Estéve relative survival method has been used to allow comparison with published work. 
In Chapter 4, where the relative survival rates are modelled, the Hakulinen method has been 
used as it was not possible (at the time o f analysis) to model the estimates produced by the
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Esteve method. For Chapters 5-8, crude survival estimates are used as only short-term 
survival (2-years) is considered and complex modelling is performed.
Box 1.1: Comparison of the surv3 package and stn l2  survival estimates
Life tables
A life table is an age-speciftc mortality table constructed using numbers of deaths and 
population estimates. When the number of deaths is small it is appropriate to smooth the 
constructed table, which can be done using several methodologies including a relational life 
table approach“ . Background mortality varies by sex, time period, region and deprivation 
group, so comparisons o f survival between groups need to take account of this by using 
appropriate life tables. For example, when comparing survival between deprivation groups, 
the general life table will tend to over-adjust the background mortality in the affluent group 
and under-adjust the background mortality in the deprived group, so that the differences in 
excess cancer mortality between affluent and deprived look wider than they actually are.
Figure 1.1 illustrates this point with a published hypothetical example: when a single life 
table is used (i.e. the expected survival is constant at 90% across all deprivation groups) the
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difference in relative survival between the most affluent and deprived groups is 23% (i.e. 
60/90 - 40/90), and when deprivation-specific life tables are used (i.e. the expected survival 
ranges from 95% to 85%) the gap in relative survival between the most affluent and 
deprived groups drops to 16%\
Figure 1.1: Difference in relative survival estimates when using deprivation-specific
compared to general life tables
Source: Coleman et aL*
This effect can be demonstrated in Scottish data. The difference in survival between 
deprivation groups is over-emphasised for all cancers when a general life table is used, with a 
large variation in the differences for some cancers (Table 1.1). It is worth noting that when 
results for all deprivation groups are shown as a combined estimate, the results are similar 
whichever life table is used (data not shown).
Deprivation-specific life tables for Scodand had to be specially constructed for the analyses 
in this thesis. Numbers of deaths by deprivation category were calculated using the 
postcode information for each death (supplied by the Scottish General Registrars Office 
(GROS)). Population estimates by postcode sector were available from the 1991 census, 
and adjustments for known undercount57 were obtained from the Manchester University 
Census website (MIMAS) to attempt to account for deprivation-related bias in the census
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coverage. The resulting mortality rates were in five-year age bands up to age 85+. These 
were then smoothed and extrapolated to give single-year-of-age estimates for ages 0-99 using 
the relational life table approach, using excel macros kindly supplied by Mr A Sloggett, 
LSHTM (personal communication). Published life tables for Scotland were used as the 
standard against which to smooth the deprivation-specific mortality rates.
Table 1.1: Comparison of five-year relative survival rates by deprivation group when
using general and deprivation-specific life tables: patients aged 15-99 
diagnosed in Scotland during 1991-95
Cancer General life table Deprivation-specific life tables
Affluent Deprived D i f f e r e n c e Affluent Deprived D i f f e r e n c e
Oral cavity 56.8 43.0 13.9 55.4 44.4 11.0
Oesophagus 6.5 6.4 0.1 6.3 6.7 -0.4
Stomach 10.0 9.7 0.3 9.7 10.0 -0.3
Colon 40.9 35.1 5.9 40.0 36.2 3.8
Rectum 41.3 33.5 7.8 40.2 34.7 5.5
Pancreas 2.8 2.0 0.8 2.7 2.1 0.7
Larynx 70.9 56.8 14.1 68.7 58.9 9.8
Lung 6.3 4.9 1.4 6.1 5.1 1.0
Malignant melanoma 82.2 72.3 9.9 81.1 73.7 7.4
Breast 71.3 61.5 9.8 70.5 62.5 8.0
Cervix uteri 66.9 60.9 6.0 66.3 61.7 4.6
Body of the uterus 74.6 69.1 5.5 73.5 70.5 3.1
Ovary 30.8 27.6 3 2 30.4 28.1 2.3
Prostate 45.3 37.4 7.9 43.0 39.5 3.6
Testis 93.5 85.9 7.6 93.1 86.5 6.6
Bladder 67.7 56.4 11.3 65.5 58.7 6.8
Kidney 40.1 33.7 6.3 39.1 34.8 4.3
Brain and other CNS 14.7 12.5 2 2 14.5 12.7 1.9
Thyroid 78.1 70.0 8.1 77.0 71.5 5.5
Non-Hodgkin lymphoma 49.7 40.7 9.0 48.6 41.9 6.8
Hodgkin's disease 79.8 70.5 9.3 78.9 71.4 7.5
Multiple myeloma 19.9 18.1 1.8 19.3 18.7 0.6
Leukaemia 28.8 22.9 5.9 28.2 23.6 4.6
Age standardisation of age-apedfic survival rates
Both relative and cause-specific survival estimates account for age-specific differences in 
background mortality, but not for the fact that survival after a diagnosis of cancer also 
differs with age, and is in general likely to be worse in older patients. In order to compare 
survival in can cer patient populations with different age structures, survival estimates can be age- 
standardised by calculating the survival in a 'standard population' of fixed age/sex 
distribution. T he standardised survival rate is the sum o f the age- and sex-specific survival rates 
multiplied by the corresponding sex- and age-group weight for the standard population. The 
following steps are used to standardise for age and sex:
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1. Specify a standard age and sex distribution by calculating the proportion of the standard 
population falling within each age and sex group, P(J.
2. Calculate survival within each age and sex group in the population of interest, .
3. Calculate the standardised survival rate ( A) as a weighted sum of the age- and sex-specific 
survival estimates, Sÿ , with weights given by the standard population proportions, Pv ,
i.j
The weights used for age-standardisation can be based on the age-specific incidence pattern 
of each cancer site in the dataset being analysed (as in 1 above). A set of standard weights 
based on the pattern of cancer in the world (analogous to the World Standard Population 
used for age-standardised incidence) has also been published“ . The World Standard Cancer 
Patient Population has a greater proportion o f younger patients than in Scotland so  the 
standardised survival rate is weighted towards that of younger patients. For this reason, 
world-standardised results for Scotland will often be higher than unstandardised results.
Standardisation with Scottish cancer patient population weights and world standard cancer 
patient population weights produces very different standardised survival estimates (Figure 
1.2), highlighting the importance of using the set of same weights when comparing different 
survival estimates. Care must be taken when using the world standard cancer patient 
population weights if age-specific estimates with a substantial weight are based on a small 
number of cases (e.g. at young ages). This can result in misleading estimates, as observed for 
Hodgkin’s disease (world standardised rate is 14% lower), thyroid cancer (10% lower), 
multiple myeloma (10% higher) and ovarian cancer (7% higher) in the analyses shown.
The choice of age bands used to construct the standardised estimate can also have a subtle 
effect on the standardised estimates, particularly when small numbers of cases are involved 
in analyses. If possible, the age bands should be consistent across the analyses being 
compared. Age-standardisation requires a sufficient number of cases in each age group to 
compute a survival rate.
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Figure 1.2: Age-standardised five-year relative survival estimates, comparison of Scottish 
and World standard cancer population weights: patients aged 15-99 
diagnosed in Scotland during 1991-95
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The World Standard Cancer Patient Population (see Appendix 1.2) is used to estimate age- 
standardised survival rates in Chapter 3 of this thesis. It specifies a separate set of weights 
for each cancer. For cancers where no world standard weights were available (brain and 
other CNS, thyroid), the ‘all cancers’ weights were used. Using a different set of weights for 
each cancer means that age-standardised survival rates can be compared across areas (or 
between deprivation categories, over time, etc.) for a particular cancer, but cannot so readily 
be compared between cancers.
Multivariate analysis of survival data
An alternative approach to standardisation is to estimate adjusted survival rates. This 
approach is appropriate when a comparison is to be made between several populations for 
which data on individual patients are available. It involves fitting a regression model with 
‘adjustment’ factors (e.g. age and sex) included as independent variables. This produces 
estimates for each population that are ‘adjusted’ for the factors included. Adjusted estimates 
can be thought of as ‘averaged’ over the factors included in the model. For example, age-,
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sex- and deprivation-adjusted hazard ratios for each health board in Scotland correspond to 
estimates based on patients with the average distribution of age, sex and deprivation across 
Scotland. Two multivariate methods are considered in this thesis: Cox proportional hazards 
regression analyses and generalised linear modelling.
Cox proportional hazards regression
This method was first introduced by Cox59 and is the most commonly used regression 
model for survival data. It is used to study the relationship between time to an event and a 
set of independent variables, and depends only on the ranks of the survival times. The time 
until an event occurs can be censored, i.e. the event of interest need not occur for all cases. 
The dependent variable is the length of time a patient survives (for those who are still alive 
the dependent variable is the time until censoring). The independent variables can be the 
age of the patient, hospital of treatment, stage of disease at diagnosis, treatment given, etc. 
Different selection (e.g. forward or backward selection) methods can be used to identify the 
subset o f independent variables that are related to the dependent variable.
Cox proportional hazards regression is described in detail in most epidemiological text 
books. In brief, if Z^/) is the vector of covariates for the rth individual at time t, the model 
assumes that the hazard for a subject is of the form
X(hZJ = X»(t).r,(t),
where r, ( t)  = e bZlin is referred to as the risk score for the /th subject, P is a vector of 
regression parameters and X„(t) is an arbitrary and unspecified baseline hazard function. The 
exponential function guarantees that X is positive for any P-
Assuming that a death has occurred at time t*, then conditional on this death occurring, the 
likelihood that it would be subject / rather than some other subject is
L .(5 )=  -------= -------
/ y
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The partial likelihood is the product of the terms over all death times L(f3) = r i M / » .  
Maximisation of ¿^(L(P)) gives an estimate for P without the need to estimate the nuisance 
parameter X„(t). An estimator of the covariance matrix is given by the inverse of the second 
derivative matrix.
Cox proportional hazards regression modelling is available in most statistical computer 
packages. The STATA statistical package is used to model the data for Chapters 5-8 o f this 
thesis.
M odel checking and validation
The adequacy of the model can be investigated using Cox-Snell residuals which are obtained 
from the cumulative hazard (r) for each individual. These values are taken as the ‘survival 
times’ and analysed in a Kaplan-Meier analysis to obtain the values of S(/). A plot o f the 
log(-log S(/)) versus log(r) should give a straight line with slope 1 and intercept 0, which 
implies that the residuals can be assumed to come from a unit exponential distribution 
which, in turn, implies a good model fit.
The assumption of proportional hazards can be assessed initially by checking the survival 
curves for each of the factors in the analysis to check they do not cross or diverge 
considerably. Also, the log cumulative hazard can be plotted against time since diagnosis to 
look for departures from parallelism. However, the interpretation of these plots is 
subjective, and proportionality can be examined formally using time-dependent modelling. 
Each level of a factor with a tim e interaction can be compared to the baseline. The 
interaction term is added to the full model so that time-dependency can be checked after 
allowing for the effects of the other explanatory variables in the model. For each model, the 
other factors are assumed to be independent o f time. The p-value for the Wald statistic will 
be non-significant (i.e. no changing risk ratio o f death over time) if the proportionality 
assumption is met. In STATA proportionality can be examined using the scaled Schoenfeld 
residuals command.
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Generalised linear modelling
Hakulinen and Tenkanen60 outlined an approach to model relative survival using generalised 
linear models (GLMs). The survival data are grouped and the total mortality (p) in each 
interval is modelled using a binomial distribution. The model is based on the sum of the 
known baseline mortality (expected mortality), p*, and the excess mortality due to a 
diagnosis o f cancer, V. Such that,
U = U* + Vr n i |  r *  ns w nsj
where j  = follow-up interval and r,i,s are stratification variables such as age, sex and stage.
The baseline mortality in this approach is allowed to vary with each stratification variable, 
which can be categorical or continuous. Interaction terms can be added to obtain an 
acceptable fit to the data if non-proportional excess hazards are suspected.
The excess mortality is assumed to be a multiplicative function of the covariates, such that 
V * = exp(p, + P, + P. + Pj)
This method is based on aggregated data, so it is not as powerful as the Cox proportional 
hazards regression modelling, however, its advantage is that it takes underlying mortality into 
account. The problem o f heterogeneous withdrawal can be minimised by careful selection 
of stratification variables.
Generalised linear modelling of relative survival estimates can be programmed in SAS or 
STATA. Programs written in SAS have been used in Chapter 4 of this thesis.
M odel checking tend validation
One of the advantages of this method is that the theoretical basis o f generalised linear 
models can be utilised for regression diagnostics and assessment of goodness of fit.
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The deviance statistic is used to assess the goodness of fit, and a good fit is assumed if it 
follows a chi-square distribution with degrees of freedom equal to the number of residual 
degrees o f freedom of the model (number of observations minus number of estimated 
parameters). The residuals and influence statistics are studied for evidence of lack of fit.
Missing data
Three approaches have been used in this thesis to investigate problems of missing values for 
breast cancer. Firsdy, and most simply, cases with missing data are excluded from the 
analysis under the assumption that these patients are representative of the whole population 
and are not a biased group. Secondly, an additional category for “unknown” is included for 
each variable, although this has been shown to lead to biased estimates of odds ratios61. 
Thirdly, the missing values have been imputed. Imputation relies on the data being missing 
completely at random (MCAR) or missing at random (MAR; the probability that data are 
missing varies only with respect to specified categorical variables e.g. age group).
The missing data for stage (for example) can be imputed ad-hoc, based on knowledge o f the 
proportions of known stage within different sub-groups (e.g. age group and treatment 
group)61,42 or multiple imputation can be used, where the data are repeatedly modelled and 
all the values (both known and unknown) replaced based on the model parameter 
estimates63. The resulting n versions o f  the complete data are then analysed in the standard 
manner and the results combined to produce confidence intervals that incorporate missing- 
data uncertainty. An algorithm called hotdeck is available in STATA which uses the 
approximate Bayesian bootstrap multiple imputation method of Rubin and Schenker 
(1991)64. The missing values are imputed stochastically i.e. the missing values in each 
specified sub-group (e.g. age group) are sampled with replacement from the complete data 
in the same sub-group, and the missing values are sampled at random (again with 
replacement) from the bootstrap sample. This is the imputation approach taken in this 
thesis. The sub-groups for stratification have been selected using logistic regression where 
the outcome (for the variable of interest) was missing or non-missing.
Measures of deprivation
Deprivation is a concept that overlaps but is not identical to, that of poverty. Absolute 
poverty can be defined as the absence of the minimum resources for physical survival,
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whereas relative poverty relates to the standards of living in a particular society. Deprivation 
includes material and social deprivation and these are often discussed interchangeably in the 
literature. There is no generally agreed definition of deprivation. Ideally, socio-economic 
status (or material deprivation) would be measured on an individual basis using information 
on income, education or occupation. In practice, however, this information is rarely 
available from cancer registries. Instead, deprivation for individuals is estimated from 
aggregate data derived from the census.
Census area-based deprivation indices
These are used to estimate deprivation of individual cancer patients in small census areas e.g. 
census enumeration districts (approx. 400 households) for England and Wales, or postcode 
sectors (approx. 2 000 households) for Scotland. The smallest area base available should be 
used to minimise misclassification; however, the smaller the geographical area, the more it 
will be influenced by the arbitrariness of the boundaries (e.g. postcode sectors are allocated 
to ease postal deliveries, not because the residents have similar social features). In Scotland, 
postcode-sector is the smallest area base available, and the deprivation score for each patient 
is assigned on the basis of his or her postcode-sector of residence at the time of diagnosis.
The problems with using small-area deprivation indices are well documented65. The most 
important is that they rely on the census, so information is only available at 10-year intervals 
(e.g. 1971, 1981, 1991, 2001), during which time the level of deprivation within an area may 
change. This can be investigated with the Scottish data. There are 886 postcode-sectors in 
Scotland to which we can assign a Carstairs deprivation score (described later) based on 
either the 1981 or 1991 census. If we compare the seven-level deprivation categories that 
postcode-sectors are assigned to, based on the two scores, many remain in the same 
deprivation category (59%), a third shift up or down by one category (36%) and 43 (5%) of 
the postcode sectors shift by more than one category (Table 1.2).
A second concern is that the census variables chosen to represent material deprivation may 
not be realistic. For example, some indices use car ownership as an indicator of affluence, 
but the use of a car in rural areas may be essential, so rural poverty may not be properly 
measured by this component o f deprivation, and the resulting scores would be more likely 
to be ‘true’ indicators of deprivation in urban than rural areas.
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T a b le  1 .2 : Carstairs score (seven levels) for postcode-sectors in Scotland: a comparison 
of the agreement between the 1981 and 1991 scores1
Affluenti C2 C3 C4| C5 CóT Deprived
1 Shaded areas are number of postcode sectors that changed by more than two levels between 1981 and 1991
Another problem is that the defined areas may not contain homogenous populations 
(ecological fallacy: ‘poor’ areas contain som e affluent people, ‘rich’ areas contain some poor 
people). It has been estimated that 55% o f  the most deprived individuals in England and 
Wales live outside the 20% of areas that are most deprived“ , and areas containing a mixture 
of deprived and less deprived households will be likely to get middle-ranking deprivation 
scores. The ecological fallacy is a particular problem with the elderly, because although the 
level o f deprivation of a given area may change, old people tend to move less frequently 
than younger people, and may therefore be mis-classified more often (Table 1.3).
Table 1.3: Correlation of mortality w ith  deprivation, Scotland, 1979-83
Census variable Townsend 
ages 0-64
Carstairs 
ages 0-64
Carstairs 
ages 65+
Deprivation1 0.62 0.75 0.53
Unemployed 0.61 0.70 0.51
Overcrowded housing 0.55 0.64 0.49
Lacking car 0.61 0.74 0.50
Head of household in low social class 0.57 0.62 0.39
Not in owner-occupier housing 0.39 - -
Source: Hanai and Fujimoto67 
1 Definitions differ
The census does contain a social class variable, indicating the proportion of households of 
which the head of household is in social class IV and V, based on his or her occupation. 
This variable was assigned for only a 10% sample of the census, and may therefore be based 
on very few cases at the small-area level. This is less of a problem in Scotland, where the 
smallest area base is the postcode sector, which contains many more residents than the 
enumeration districts used in England and Wales.
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However, despite these potential problems, deprivation indices are often the “best” estimate 
of deprivation that can be gained without actually contacting individuals with a 
questionnaire. Although some work has been performed on deprivation using data from 
the 1971 census, most of the important work follows from the improved geographic base 
provided by the 1981 census68 and the more consistent use of postcodes as a basis for 
determining the area of residence in routine statistical records systems. The two most 
widely used health-related deprivation indices for cancer analyses are the Carstairs index69 
and the Townsend index70, both developed to represent material deprivation.
C ontain Index
This index is a combination of census information on household overcrowding, male 
unemployment, low social class and car ownership. Percentage values for each small area 
(e.g. census enumeration district or postcode sector) are standardised by subtraction of the 
mean value for all small areas in Great Britain and division of the result by the population 
standard deviation. The standardised scores for each o f the four census variables are then 
summed into a single score for each small area, and these deprivation scores are then 
divided into percentiles (e.g. quintiles), ranging from very high to very low deprivation.
Townsend Index
This index is calculated in the same way as the Carstairs index but using census information 
on household overcrowding, male unemployment, car ownership and housing tenure (i.e. 
percentage of households not in owner-occupied accommodation).
Analyses using the Carstairs and Townsend indices give very similar results71, and both 
correlate reasonably well with mortality in Scotland, particularly in the younger age groups 
(Table 1.3). The housing tenure variable does not correlate well for Scottish data because 
renting is (or was until recently) much more common in Scotland and was not related to 
wealth. The Carstairs index is used as the measure of deprivation in this thesis, because it 
was developed for Scottish data and is widely used in Scottish health statistics. It better 
represents material deprivation in Scotland because it does not include the housing tenure 
variable, and the problems with the social class variable are minimised by the larger size of 
the Scottish census areas compared to those in England and Wales. Problems of mis-
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classification will tend to dilute rather than enhance any deprivation gradient observed, so 
true differences are less likely to picked up but erroneous differences are unlikely to occur
Measuring comorbidity
Comorbidity is an important prognostic indicator for cancer patients, but it presents the 
analytic challenge of being multi-dimensional. Several scoring systems for prospective 
analyses have been proposed, with completion of a form or chart by the clinician. 
Measurements of co-morbidity from routine data sources have had mixed success.
The most widely used comorbidity measure in epidemiological research is the Charlson 
index % because the information for the index (originally designed for a chart setting) can be 
extracted from clinically coded (e.g. ICD-9) databases. However, the correlation between 
the data derived in the two different ways (chart versus database) has been shown to be 
quite low (0.36-0.47)75. The Charlson index comprises a list of 19 diseases (certain of them 
representing two degrees of severity of the same condition) with different weights attached 
(from 1, least severe, to 6, most severe) (see Appendix 1.3). Additional points can be added 
for increasing age. The sum of these points (weights) can then be collapsed in to four 
ordinal categories: 0, 1-2, 3-4, 5+. Four o f  the disease items relate to cancer and, for the 
study of cancer patients, these are generally excluded from the score, resulting in a shorter 
range of scores. A potential limitation in the cancer setting is that the index ignores several 
co-morbidities that may be relevant to treatment of cancer patients, such as haematopoietic 
disorders (other than malignancies), polyneuropathy or moderate renal dysfunction75. 
However, a review of the main comorbidity indices found the Charlson index to have the 
best predictive power for survival74. For the purposes of this thesis, the score was compiled 
based on presence of the non-cancer diseases in the 2 years before the diagnosis of the 
cancer o f interest, and the score defined as 0, 1-2, 3+ points.
In Scotland, another comorbidity score has been compiled75, based on the presence of 
seven conditions in the 2 years before to  1 month after the diagnosis of the cancer of 
interest. These include diabetes (ICD-9 code: 250), hypertension (401-405), ischaemic heart 
disease (410-414), other heart disease (390-400, 406-409, 415-429), cerebrovascular disease 
(430-438), respiratory disease (490-496) and arthritis (714, 715, 719). The co-morbidity score
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was then defined as: 0=no admissions, l=only admitted for one condition (no matter how 
often), and 2=admitted for more than one condition.
Other major comorbidity indexes include the ICED, CIRS, and Kaplan-Feinstein indices, 
which are all disease severity indices that cannot be implemented with routine data. The 
association o f these indices, and the Charlson index, with length of hospitalisation or rate of 
hospitalisation has been studied, with contrasting results74.
For this thesis the Charlton and Scottish indices along with a hospitalisation measure of 
comorbidity have been considered. The hospital measure was the cumulative time (bed- 
days) spent as a hospital inpatient in a defined time period prior to the cancer diagnosis; the 
bed-days for each set o f patients studied were split into ordinal categories based on 
percentiles. The bed-days method was tested on five different sets of patients: all the 
patients included in in-depth analyses in Chapters 5-8 combined, all colorectal cancer 
patients diagnosed 1986-96 within a restricted age range, colorectal cancer patients 
diagnosed in 1997 (to look at adjustment for tumour stage), all patients with a first inpatient 
diagnosis of diabetes 1986-96, and all patients with a first inpatient diagnosis of rheumatoid 
arthritis 1986-96. For each set of patients, increasing bed days was increasingly predictive of 
death within two years o f diagnosis, after adjustment for age and sex (Table 1.4). Restricting 
the analysis to exclude cancer-related bed-days, and applying a time limit (e.g. only inpatient 
stays in the two years preceding the cancer diagnosis) did not change the predictive power 
o f the score. The weaker effect of comorbidity in the cancer patient than in the diabetes and 
rheumatoid arthritis patient analyses may be because of the complex relationship between 
comorbidity and cancer mobidity. The number o f bed-days in each centile varied for each 
analysis.
For colorectal cancer patients diagnosed in 1997, the relationship between bed-days in the 
previous two years and mortality within two years of diagnosis o f the cancer, was still seen 
after adjusting for age, sex and stage. The adjusted survival curves are plotted in Figure 1.3, 
along with similar curves for the Charlton and Scottish comorbidity indexes. Additionally, 
all three measures were independently predictive of survival if included together in a 
multivariate model (data not shown).
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T a b le  1 .4 : Risk of death according to number of days spent in hospital preceding 
diagnosis of the condition o f  interest, adjusted for age and sex: patients 
diagnosed in Scotland, selected conditions and time periods
Bed-days
percentile
Patients diagnosed with breast, 
colorectal, bladder and kidney 
cancer and melanoma in 1997
Colorectal 
1986-96, 
ages 60-69
Colorectal,
19972
Diabetes
1986-96
Rheumatoid
arthritis
1986-96
All All Preceding Preceding Preceding Preceding Preceding
preceding preceding bed-days bed-days bed-days bed-days bed-days
bed-days non-cancer1 within 2 within 2 within 2 within 2 within 2
bed- days years years years years years
25* 1.00 1.00 1.00 1.00 1.00 1.00 1.00
50* 0.94 0.97 0.93 0.65 ~ 1.13 1.25 ™ 0.76
75* 1.03 0.97 1.10 * 0.82 ~ 1.06 2.66 ” 1.38 •"
90* 1.19 ” 1.21 1.21 ** 1.33 •“ 1.18 ' 4.13 *" 2.38
95* 1.71 1.65 1.77 *'• 2.05 1.61 “ 5.57 •" 3.52
Where p<0.05, p<0.01, p<0.001
1 Cancer-related bed-days were defined as inpatient stays with cancer mentioned in one of the diagnosis fields
2 Adjusted for tumour stage
It is difficult to decide whether it is only a  few specific diseases that are important as 
comorbid factors in cancer survival, or if it is the overall burden o f disease that matters. 
Certainly from these analyses, it would appear to be a combination. Some diseases, such as 
myocardial infarction or stroke, might be expected to have a strong impact on prognosis 
from cancer; however, older patients generally have more comorbid conditions which may 
be minor, but the accumulation of which m ay also have a strong impact on survival from 
cancer. Such minor illnesses might have a  simple additive effect on prognosis, or the 
additional effect might decrease as the number of comorbid conditions increases.
To attempt to overcome problems with uncertainty of how comorbidity affects the survival 
of cancer patients, I have used both the indices that are based on hospital admissions for 
specific diseases (Charlson and Scottish indices) and my own index o f the overall burden of 
recent morbidity (all bed-days in the previous two years). The three measures used here are 
all derived from routine data, and they only reflect co-morbidities resulting in a hospital 
inpatient admission. There may, of course, be variations in diagnostic criteria and admission 
threshold for different diseases. Equally, the diseases that require hospital admission and 
that predict mortality may not be the same as those that predict functional decline or 
tolerance of cancer treatment, but these issues cannot be addressed using routinely collected 
data.
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F ig ure  1 .3 : Patients diagnosed with colorectal cancer in Scotland in 1997: survival (%) by 
comorbidity score, adjusted for age, sex and tumour stage
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A p p e n d ix  1 . 1 :  C a u se s  o f  d e a th  d e e m e d  to  b e  “ c a n c e r  ca u se s 9*1
Cancer diagnosis (ICD-9 codes) Relevant causes of death (ICD-9 codes)
Oral cancer (141,143-145) 140-149, 195.0,196-199, 210.1-210.9, 235.0, 235.1, 238.9, 239.9
Head and neck (140-149, 160, 161) 140-149, 160, 161, 195.0, 196-199, 210, 212.0, 212.1, 235.0, 235.1, 
235.6, 238.9. 239.1, 239.9
Oesophagus (150) 150, 151, 159, 195.1, 196-199, 211.0, 211.1, 211.9, 235.2, 235.5, 
238.9, 239.0, 239.9
Stomach (151) 150, 151, 159, 195.2, 196-199, 211.0, 211.1, 211.9, 235.2, 235.5, 
238.9, 239.0, 239.9
Colon (153),
Rectum (154),
Large owel (153+154)
153, 154, 159, 195.2, 195.3, 196-199, 211.3, 211.4, 211.9, 235.2, 
235.5, 238.9, 239.0, 239.9
Pancreas (157) 157, 159, 195.2, 196-199, 211.6, 211.7, 211.9, 235.5, 238.9, 239.0, 
239.9
Larynx (161) 146, 149, 161, 165, 195.0, 196-199, 210.6, 210.8, 210.9, 212.1, 
212.9, 235.6, 235.9, 238.9, 239.1, 239.9
Trachea, bronchus and lung (162) 162, 165, 195.1, 196-199, 212.2, 212.3, 212.9, 235.7, 235.9, 238.9, 
239.1, 239.9
Malignant melanoma of the skin (172) 172, 173,195,196-199, 216, 238.2, 238.9, 239.2, 239.9
Female breast (174) 174,195.1,196-199, 217,238.3,238.9, 239.3, 239.9
Cervix uteri (180) 179, 180, 184.9, 195.3, 196-199, 219, 221.9, 236.0, 236.3, 238.9, 
239.5,239.9
Corpus uteri (182) 179, 182, 184.9, 195.2, 195.3, 196-199, 219, 221.9, 236.0, 236.3, 
238.9, 239.5, 239.9
Ovary (183) 183, 184.9, 195.2, 195.3, 196-199, 220, 221.9, 236.2, 236.3, 238.9, 
239.5,239.9
Prostate (185) 185, 187.9, 195.3, 196-199, 222.2, 222.9, 236.5, 236.6, 238.9, 
239.5,239.9
Testis (186) 186, 187.5, 187.9, 195.3, 196-199, 222.0, 222.3, 222.9, 236.4, 
236.6, 238.9,239.5,239.9
Bladder (188) 188, 195.2, 195.3, 196-199, 223.3, 233.9, 236.7, 236.9, 238.9, 
239.4, 239.9
Kidney (189) 189,195.2,196-199, 223.0,223.1, 223.9,236.9, 238.9,239.5,239.9
Brain and other CNS (191+192) 191, 192, 196-199, 225, 237.5, 237.6, 237.9, 238.9, 239.6, 239.7, 
239.9
Thyroid (193) 193,195.0,196-199, 226,237.4,238.9, 239.7,239.9
Non-Hodgkin's lymphoma (200+202), 
Hodgkin’s disease (201),
Multiple myeloma (203),
Leukaemia (204-208)
200-208,229.0,238.5, 238.6,238.7,238.9,239.9
Source: Scottish Cancer Intelligence Unit (2000)1
1 ICD-9 codes 196-198 are included although they are not intended to be used for coding the underiying 
cause of death
3 8
Appendix 1.2: World Standard Cancer Patient Population: percentage of patients in each 
age group
Cancer Group (ICD-9 code) Aite group
15-44 45-54 55-64 65-74 75-84 85-99 15-99
Head and Neck (140-149) 18.1 19.2 23.3 19.0 14.7 5.6 100.0
Oesophagus (150) 10.6 16.6 22.7 22.8 19.2 8.2 100.0
Stomach (151) 12.0 15.5 19.4 21.9 21.2 10.0 100.0
Large bowel (153-154) 8.6 10.8 17.0 22.3 26.6 14.6 100.0
Pancreas (157) 10.3 13.7 17.4 21.8 24.0 12.8 100.0
Larynx (161) 11.3 18.4 26.1 21.6 16.1 6.4 100.0
Trachea, bronchus and lung (162) 7.6 13.6 23.0 24.2 21.8 9.8 100.0
Malignant melanoma of the skin (172) 25.4 17.8 18.1 17.1 15.1 6.5 100.0
Breast (174) 22.2 20.5 19.9 17.2 14.2 5.9 100.0
Cervix uteri (180) 28.3 24.1 20.7 14.5 9.3 3.0 100.0
Corpus uteri (182) 11.1 18.9 27.2 21.6 15.2 5.9 100.0
Ovary (183) 23.7 19.5 21.6 17.4 13.0 4.9 100.0
Prostate (185) 0.6 2.4 9.5 20.8 38.2 28.5 100.0
Testis (186) 80.4 10.3 4.7 2.4 1.6 0.5 100.0
Bladder (188) 6.9 10.2 17.9 23.3 27.0 14.6 100.0
Kidney (189) 11.6 14.1 23.3 22.5 19.8 8.7 100.0
Lymphomas and multiple myeloma (200-203) 25.5 14.4 17.6 18.1 16.8 7.6 100.0
All malignant neoplasms (140-208)1 32.4 12.5 14.7 16.2 16.4 7.8 100.0
Source: Black and Bashir (1999)“
1 Excluding non-melanoma skin cancer (ICD-9 173)
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A p p e n d ix  1 .3 : C h a r ls o n  c o m o rb id ity  in d e x , w ith  o p tio n a l age a d d itio n
Cotnorbidity Points
Myocardial infarction 1
Congestive heart failure 1
Peripheral vascular disease 1
Cerebrovascular disease (except hemiplegia) 1
Dementia 1
Chronic pulmonary disease 1
Connective tissue disease 1
Ulcer disease 1
Mild liver disease 1
Diabetes (without complications) 1
Diabetes with end organ damage 2
Hemiplegia 2
Moderate or severe renal disease 2
2nd solid tumour (non-metastatic) 2
Leukaemia 2
Lymphoma, multiple myeloma 2
Moderate or severe liver disease 3
2nd metastatic tumour 6
AIDS 6
Total points:
OPTIONAL EXTENSION
Age Score
50-59 1
60-69 2
70-79 3
80-89 4
90-99 5
Total combined points (comorbidity+age):
Source: Charlson et al. (1987)72
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C h a p t e r  2
MATERIALS AND DEFINITIONS
Scottish cancer registry database (SOCRATES)
The Scottish cancer registry has been collecting population-based information on cancer 
since 1958. Details available for each case include personal, demographic and diagnosis 
information (site, histology*, behaviour, histological confirmation, date and hospital o f  
diagnosis). For patients diagnosed from 1997 onwards further information has been 
collected including tumour stage (for breast, cervical and colorectal cancer), tumour grade, 
more hospital details, and treatment information (dates and locations of surgery, 
chemotherapy, radiotherapy and hormone therapy). In 1997 the tumour-based database 
was converted into a patient-based database, and was named SOCRATES (Scottish Open 
Cancer Registration And Tumour Enumeration System).
Potentially new cases are identified from a number o f sources, including hospital inpatient 
discharge records (SMROls), pathology and oncology databases, and death records. The 
information is linked using probability matching (described later) and a provisional 
registration created. Cancer Registration Officers (CROs) visit the hospitals and pull the 
medical records for these provisional registrations and the registration is then either 
confirmed, in which case extra information is collected from the medical notes, or deleted if  
the patient did not in fact have cancer. The hospital visit does not occur until at least six 
months after the cancer diagnosis to allow treatment details to accumulate.
There are approximately 24 000 new diagnoses o f malignant disease entered onto 
SOCRATES each year. Studies of the data quality suggest that it is high, both in terms o f 
accuracy and completeness o f ascertainment74 7*.
• Hiitology it  not available* for the whole period from 1958.
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Timeliness of registrations
Timeliness is a measure of the time delay between the diagnosis and registration of cancers. 
Some delay is desirable in order to obtain complete information on initial treatment 
delivered, so registries are not expected to fully register a patient until at least 6 months after 
their diagnosis unless they have died within this time interval. The UK Association of 
Cancer Registries (UKACR) recommend that all cases diagnosed in a given year should be 
registered 18 months after that year end (for example, all cases diagnosed in 1997 should be 
registered by mid 1999)79. Prior to the introduction o f the new computer system 
(SOCRATES) the Scottish registry was very timely. However, with the change over and 
training for collection o f the extra variables a backlog of registrations has occurred and 
timeliness in Scodand currendy falls behind other registries in Great Britain (Table 2.1). For 
this reason, it was only possible to consider cases diagnosed up to the end of 1997 in this 
thesis.
Table 2.1: Timeliness1 of registering Scottish cancer data2 compared to Great Britain
Cancer Registry % 1996 % 1997 %  1998 % 1999
by mid 1998 by tnid 1999 by m id 2000 by mid 2001
Initial3 Full4 Initial3 Full4 In itia l1 Full4 Initial3 Full4
Scodand 0 103 44 74 35 44 95 30
Average for Great Britain 30 89 30 80 9 87 26 75
Source: UKACR QA Reports 1998,1999, 2000 and 2001™ “
1 90% of all cases diagnosed in a given calendar year should be completed and entered onto the registry 
computer system within 18 months of the end of the calendar year
2 All invasive cases excluding non-melanoma skin cancer
3 Initial covers cases where not all the basic information has been received o r validity has not been confirmed 
(in Scodand many of these will turn out to be false registrations)
4 Full is defined as ‘of a standard useable for analysis and in publications’
Quality and ascertainment
There is no absolute measure for assessing registry ascertainment and quality. The UKACR 
Quality Assurance group has drawn up a report recommending a number of methods to 
assess the quality of registry data. The methods proposed are widely accepted and used, but 
are also recognised as imperfect measures of quality. The quality and ascertainment o f the 
Scottish cancer registry data for 1997 is now investigated using these methods.
Death Certificate Only registrations
The cancer registry receives all death certificates that mention cancer from the Scottish 
General Registrars Office (GROS). If the patient is not registered already and there are no
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other source records on the registry database, then a death certificate initiated (DCI) 
registration is created. If no further information can be found about this patient, the only 
information about the cancer is from the death certificate and the registration will be 
classified as a death certificate only (DCO) registration for analytical purposes. These cases 
are often excluded from analyses as the cancer coded on the death certificates may be wrong 
and there is no information about the genuine time of diagnosis.
The percentage of DCO registrations gives an estimate of the quality of registry data and 
some indication of ascertainment. A more useful statistic to assess ascertainment would be 
the DCI rate (the proportion of cases escaping the registration process at diagnosis), which 
is informative because these are cases that would not have been registered unless a death 
certificate mentioning cancer had been received, i.e. they were not being picked up from 
hospital sources. A high proportion o f DCI registrations would suggest that non-fatal cases 
are being under-ascertained, as most DCI registrations are rapidly fatal cases’3. 
Unfortunately, it is not possible to calculate the DCI statistic from the Scottish data at 
present because death certificate information is entered on to the computer as soon as it 
arrives rather than after all the other routinely arriving source data has been processed.
The DCO rates for Scotland are amongst the lowest of the registries in Great Britain (Table 
2.2) indicating that the Scottish data for patients diagnosed during 1997 is of good quality. 
Knowledge of changing trends in the DCO rates is important in interpreting survival rates. 
If a high proportion o f DCO registrations are not included in the survival analysis this may 
lead to over-estimation of true survival, since the survival of these excluded patients has 
been shown to be poorer, on average, than that of all the other cases’4'*5. DCO percentages 
vary by cancer for a variety of reasons’6 with higher rates in cancers diagnosed in very elderly 
patients and in cancers with a poor prognosis in Scotland'.
In the early 1970s in Scotland, information was recorded only on patients who were 
admitted to hospital, and death certificates were not used as a source o f case ascertainment'7. 
The missed cases were thought to be patients with poor prognosis who were not considered 
amenable to treatment. More recently such patients would have been admitted to hospital 
for diagnosis and possibly therapy, and therefore would be included in the data analysed. 
More complete cancer registration data, particularly for elderly patients with poor prognosis 
cancers, would be expected to result in decreased survival rates over time. Additionally,
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DCO cases were less likely to be recorded as such in Scotland in 1970s, resulting in DCO 
cases being included as non-DCO zero-survival cases in analyses. This would lead to an 
increase in survival rates over time. True non-DCO zero-survival cases are those patients 
who have died on the date of diagnosis, for instance during an investigative operation. The 
proportion of DCOs in Scotland rises from 1.7% for patients diagnosed during 1971-75 to 
3.4% for patients diagnosed during 1991-951. The percentage o f  cases with non-DCO zero- 
survival have decreased1, possibly due to earlier presentation and improvements in 
diagnostic techniques, as well as the problem mentioned above. These changes may have 
some influence on the survival trends presented in Chapter 3.
Table 2.2: Quality and ascertainment of the Scottish data compared to Great Britain:
patients diagnosed in 19971
Cancer Registry % DCO2 %MV> M:I ratio4
Scotland 0.4 84.9 58.8
Average for Great Biitain 4.7 80.8 58.4
Source: UKACR QA Report 2000™
1 All invasive cases excluding non-melanoma skin cancer
2 DCO (death certi6cate only) registrations are those where the only source is the death certificate despite 
exhaustive searching for information.
3 The %MV (microscopically verified) includes cases with histology, cytology or peripheral blood reports.
4 The M:I (Mortality/Incidence) ratio is calculated using official mortality figures from ONS and GROS
Microscopic verification
The percentage of cases diagnosed microscopically (%MV) has been used by the 
International Agency for Research on Cancer" as an indicator of data quality: a very high 
%MV may indicate under-ascertainment due too great a reliance on pathology by the 
registry, whereas a very low %MV may indicate that registry information is of poor quality. 
The definition relates to the basis of the diagnosis made by the  treating clinician (which is 
outside the registry’s control) as well as the availability of the information to the registry, 
although the registry may not have seen the pathology report. For patients diagnosed 
during 1997, the Scottish cancer registry has microscopic verification rates which are higher 
than the average for Great Britain (Table 2.2) indicating good quality of diagnostic 
information, but not too high as to worry about over reliance on pathology reports for 
registration.
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Trends in proportion of microscopically verified cases in Scotland over time show that the 
accuracy of diagnoses of cancer reported has improved since the early 1970s1. Improved 
understanding of the symptoms of cancer and the increasing availability of biochemical and 
other diagnostic techniques (for which no information is currendy collected in the Scottish 
cancer registry) may have an important influence on survival rates for particular cancer sites. 
Modan et aLM argue that the apparent increases in brain tumour incidence reported for most 
Western countries can be attributed to the increasing availability of a non-invasive diagnostic 
technique (computed axial tomography) and changing attitudes towards the diagnosis of the 
elderly. Increasing precision o f this kind would be expected to decrease survival rates as 
poor prognosis patients would be correcdy classified and the numbers of cases not detected 
or coded to the 'unspecified primary site' category correspondingly reduced. Improved 
diagnostic precision is recognised with each change in the international classification of 
diseases (ICD8, ICD9, ICD10), with a larger variety of codes becoming available. These 
changes can also influence survival rates and are often not easy to measure.
Mortality to Incidence ratio
The mortality to incidence ratio gives an indication of under- or over-ascertainment. It is 
calculated as
M:I = Deaths certified in specified period, with diagnosis C as underlying 
Incident cases in same period with diagnosis C
This measure looks at diagnoses and deaths in a specific period, and does not apply to the 
same patients as the deaths can occur in patients diagnosed over a long period of time. 
However, when there have been no major changes in incidence or prognosis for a particular 
tumour site, the M:I ratio is equivalent to one minus the survival probability. The M:I ratio 
is difficult to interpret if there are significant trends in incidence (for example, due to 
screening) or survival (for example, new successful treatment), or if the cause of death 
information is thought to be poor.
If the M:I ratio is greater than 1.0, then under-registration is suspected. However a high 
ratio may be expected in the ill-defined sites (such as ICD-9 159, 179, 199) and metastatic 
sites such as liver. The M:I ratio by site should be relatively constant across somewhere like 
Great Britain where death registration, diagnostic practice, and prognosis are fairly uniform.
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The M:I ratio for Scotland is very similar to the average of G reat Britain, suggesting that 
there are no problems in case ascertainment (see Table 2.2).
Table 2.3: Completeness' of the Scottish data2 compared to  Great Britain: patients 
diagnosed during 1997
Database variable Scotland
Average for 
Great Britain
Patient's name 100.0 100.0
Patient's address 100.0 100.0
Post code 100.0 99.7
Sex 100.0 100.0
Date of birth 100.0 100.0
NHS number 21.4 56.0
Anniversary (diagnosis) date 100.0 99.4
Site of primary growth 94.9 94.4
Date of death (where dead) 100.0 99.9
Type of growth 86.9 82.1
Behaviour of growth 100.0 98.5
Basis of diagnosis 99.7 94.5
Treatment codes (% yes)
Surgery 51.0 48.3
Radiotherapy 27.9 22.7
Chemotherapy 19.5 15.5
Hormone 15.8 10.3
Tumour stage present3 and known
Breast cancer 62.6 51.4
Cervix invasive 87.6 65.8
Colorectal cancer 84.3 56.6
Melanoma cancer 0.0 70.5
Grade - Breast cancer only 62.6 65.5
Source: UKACR QA Report 2000™
1 Percentage of cases with a valid and informative code on the database
2 All invasive cases excluding non-melanoma skin cancer
5 Using any valid staging system; not all registries used the same methods
Completeness o f  data fields
The completeness of the variables collected by the cancer registry is evident, to a certain 
extent, from the proportion of DCO and MV registrations. However, poor recording in 
specific areas can be highlighted by comparing completeness o f the  variables between cancer 
registries. Completeness of most of the variables is very high for Scotland (Table 2.3). NHS 
number is not well recorded, but will improve with a mapping exercise to be undertaken in 
the registry. The information on stage and grade is higher than the average for Great Britain 
but is actually lower than the other registries which access the case-notes, indicating that 
further training of cancer registration officers may be necessary in  this area.
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Random sample review o f  1997 registrations
A review of a random sample of 3 175 registrations, for patients diagnosed in 1997, was 
conducted by the quality assurance and accreditation unit in ISD Scotland. We then 
compared the re-extracted data (from medical records) to the data on the registry database 
to assess the accuracy of the cancer registry data90 (Table 2.4). Although there was exact 
agreement on the allocation of incidence date in only 2 384 (75%) cases, the re-abstracted 
incidence date was within six weeks of the registered date in 3 013 (95%) cases. 
Discrepancies in grade of differentiation, staging variables and oestrogen receptor (ER) 
status were largely due to variables being recorded as ‘not known’ on one database but 
allocated to a specified category or value on the other. The implications o f the results of the 
QA exercise on the analyses in this thesis are reviewed in the general discussion.
Table 2.4: Review of random sample of patients diagnosed with cancer in Scodand in
1997
Registry database variable Number of 
caaea 
compared
Percentage of 
diaciepanciea
Incidence date 3,175 24.5
ICD10 (3 digit) 3,175 3.1
Histological verification 3,175 Z0
Morphology code 3,175 18.8
Method of detection 3,175 3.4
Date of birth 3,175 1.3
Sex 3,175 0.0
Postcode 3,175 5.8
Grade 3,175 9.3
Breast clinical size 461 18.2
Breast clinical nodal status 461 17.1
Breast clinical metastatic status 461 10.2
Breast tumour size 461 17.6
Breast nodes examined? 461 11.1
Number of nodes examined 461 3.5
Any positive nodes? 461 1.5
Number of positive nodes 461 Z4
Breast ER status 461 4.8
Colorectal stage 457 13.3
Surgery 3,175 4.0
Date of 1“ surgery 1,769 16.5
Hospital of 1“ surgery 1,769 7.9
Treated with RT 3,175 1.9
Date 1" RT 954 24.2
Hospital of !•< RT 954 6.4
Chemotherapy 3,175 1.7
Date 1“ chemotherapy 689 15.4
Hormone therapy 3,175 1.7
Date 1" hormone therapy 559 17.5
Source: Brewster tt alT0
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Definitions
Disease classification and diagnostic details from  SOCRATES
The anatomical location (topography) of the tumour, ideally the site o f  origin of the primary 
tumour, is recorded to the 10* revision of the International Classification of Disease (ICD- 
10)”  for cases diagnosed in 1997 (DCOs are recorded to ICD-9, necessarily, as GROS 
deaths are coded this way). The main primary site of the tumour is denoted by the first 
three digits of the ICD code, and a more precise indication of the origin of the tumour (sub­
site) is denoted by the fourth digit. The tumour type is the morphological type of the 
tumour as determined by a pathologist either on the basis of histology or cytology. It is 
based on the second revision of the International Classification of Diseases for oncology 
(ICD-02)92. When two (or more) notifications with different morphology codes are 
received for the same tumour, then the more specific ICD-02 morphology code is used.
Identification of the histology of the malignancy by microscopical verification of a specimen 
is generally accepted as the most accurate method of diagnosis. The method of diagnosis is 
recorded as clinical only, clinical investigation, exploratory surgery/endoscopy/autopsy, 
biochemical/immunological tests, cytology, histology of metastasis, histology of primary, or 
autopsy (with histology), in a hierarchical manner. Whether the tumour was microscopically 
verified is also recorded.
The method of first detection is recorded as screening examination (e.g. routine cervical 
smear or mammogram in the absence of symptoms), incidental findings during life (e.g. on 
examination/at surgery for an unrelated reason), clinical presentation with relevant 
symptoms or signs, or incidental findings at autopsy where cancer was previously 
unsuspected.
Tumour grade is an indication of how rapidly the tumour is extending, as determined from 
the pathology report. For most cancers the ICD-O/UICC (Union Internationale Contre le 
Cancer) system is used:
Grade I -  Well differentiated or low grade
Grade II -  Moderately (well) differentiated or intermediate grade or average 
Grade III -  Poorly differentiated or high grade 
Grade IV -  Undifferentiated or anaplastic
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If the description of the tumour overlaps categories then the worst mentioned grade is 
chosen. The exceptions to this coding system are breast cancer where the Nottingham 
grading system is used, prostate cancer where the Gleason score is used and for T-Cell and 
B-Cell lymphomas and leukaemias where the origin takes priority over grade.
Incidence date
The incidence date is defined as the date that the cancer in question becomes formally 
known to NHS Scodand as follows:
(a) For patients seen as outpatients and/or day cases and/or inpatients (other than long 
stay or residential) this is the earliest available date from the following:
Date of first consultation as an outpatient relating to the diagnosis 
Date of first pathology report confirming the diagnosis 
Date of first admission to hospital relating to the diagnosis 
Date of first hospital-initiated treatment for the condition
(b) For long stay or residential patients, or patients receiving care at home:
Date of diagnosis (or best estimate)
(c) For death certificate only cases, and for cases first diagnosed by autopsy:
Date of death
(d) For patients seen and diagnosed by their GP only:
Date if diagnosis (or best estimate)
Additionally, the date of first positive mammogram is used for patients detected through 
breast screening and the date patients commenced on Tamoxifen is used if it was prescribed 
by their GP before attending hospital.
Disease stage
Tumour stage is a measure of the extent to which the disease has spread at the time of 
diagnosis. Of the cancers covered in detail in this thesis, colorectal and breast have stage 
information available on SOCRATES.
Dukes’ staging classification. This is primarily based on histological findings and is gained 
from the pathology report plus a search of the medical notes for evidence of distant 
metastases. The options are:
A Tumour limited to muscularis propria, regional lymph nodes negative 
B Tumour invades through muscularis propria into serosa/subserosa or penetrates 
through the peritoneum but regional lymph nodes negative 
C l Regional lymph nodes positive but apical node negative
C2 Regional lymph nodes positive, apical node positive
C Regional lymph nodes positive (apical node status unknown or not stated)
D Distant metastases
Regional lymph nodes are the pericolic nodes and perirectal nodes and those located along 
the ileocolic, right colic, middle colic, left colic, inferior mesenteric and superior rectal 
(haemorrhoidal) arteries.
Breast cancer
Clinical TNM (Tumour/Node/Metastases) staging classification. If this is not specifically 
recorded in the medical notes then the CRO will attempt to derive it from the available 
information. The three measures are recorded as follows:
cTX Primary tumour cannot be assessed
cTl Tumour 2cm or less without direct extension to chest wall or skin 
cT2 Tumour 2cm-5cm without direct extension to chest wall or skin
cT3 Tumour more than 5cm without direct extension to chest wall or skin
cT4 Tumour of any size with direct extension to chest wall or skin
cNX Regional lymph nodes cannot be assessed
cNO No regional lymph node metastasis
cN 1 Metastasis to movable ipsilateral axillary node(s)
cN2 Metastasis to ipsilateral axillary node(s) fixed to one another or to other structures 
cN3 Metastasis to ipsilateral internal mammary lymph node(s)
cMX Presence o f distant metastisis cannot be assessed 
cMO No distant metastasis 
cM l Distant metastatis
The T, N and M can be analysed separately, or combined into an overall stage score where:
I T l, NO, MO
IIA T1,N1, MO or T2, NO, MO
IIB T2, N l, MO or T3, NO, MO
IIIA Tl-2, N2, MO or T3, N l-2, MO
IIIB T4, Any N, MO or Any T, N3, MO
IV Any T, Any N, M l
Pathological tumour size and information on nodes is also recorded by the CROs. The 
sizes have been grouped for this project using the same bands as cTl-cT3. Nodal status has 
been grouped into positive if  positive nodes were sampled, negative if >3 nodes were sampled 
and all found to be negative, and negative inadequate if < 3 nodes were sampled and all found 
to be negative.
Additionally, for breast cancer, oestrogen receptor (ER) status is recorded as positive or 
negative where positive is defined as > 20 finol m g1 cytosolic protein or > 10% staining.
Morphoiqgcal type
Grouping of morphologies has been performed for some cancers:
Bladder: Transitional cell (M81203), Papillary Transitional cell (M81303) and
other/unknown
Breast: Ductal (M85003), Lobular (M85203) and other/unknown
Colon: No grouping
Rectum: No grouping
Kidney: Renal cell (M83123), Clear cell (M83103) and other/unknown
Melanoma: Superficial (M87434), Lentigo maligna (M87423), Nodular (M87213), Acral
(M87443) and other/unknown
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Specific site o f  tumour
For melanoma of the skin, the specific site of the cancer (4* digit of the ICD10 code) was 
used in the analyses:
Face, head and neck: 
Trunk:
Upper limb:
Lower limb:
Other and unknown:
C43.0-C43.4
C43.8-C43.9
C43.6
C43.7
C43.5
Deaths data (GRO database)
Beginning in 1971 each case registered on SOCRATES was followed-up through the 
National Health Service Central Register (NHSCR), a population-based register of every 
person resident in Great Britain. The NHSCR records of individuals who were diagnosed 
with cancer were 'flagged' so that when an individual died the cancer registry could be 
notified o f the date of death. The registry was also notified about any other individuals 
dying with cancer mentioned on the death certificate.
In 1996, a computerised probability linkage was made between the Scottish general registrars 
office (GROS) death file for 1974-1994 and the cancer registration file, in order to add up to 
four causes of death on to all registrations that had a date of death and for which a link 
could be found. A further annual death link was made of 1995 deaths, and then the whole 
cancer registration file was internally linked to create a patient-based register, to which 1996 
deaths were added, again by an annual link. Thereafter, as part of the new cancer 
registration process, deaths and causes of death have been added within a few months o f  the 
death occurring, although there will also continue to be an annual link at the end of each 
year to pick up any missed deaths. Deaths are coded to ICD9”  from 1979 to 1999 and 
ICD10 from 2000 onwards.
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Hospital discharge data (SMR01 database)
The Scottish hospital discharge record (SMR01) is an episode-based record relating to all 
inpatients and day cases discharged from non-psychiatric, non-obstetric wards in Scottish 
hospitals, and these have been computerised since 1968. A record is formed when a patient 
is discharged from hospital, changes consultant or is transferred to another hospital or 
hospital department. Approximately 1 million records are created annually. The range of 
information collected was expanded and codes changed from April 1996 with the 
introduction of the core patient profile information system (COPPISH).
SMROls contain clinical and non-clinical data including information on locations and 
transfers, waiting times, referral types, diagnostic information and operation and procedure 
information. The database has not been widely utilised to assess public health issues relating 
to cancer.
Quality and ascertainment
There is no information on the ascertainment o f SMROls to my knowledge. However, since 
1989, information from the SMROls has been used to plan the financial management of 
hospitals so this should ensure that ascertainment is high.
Completion of the SMR01 is often delegated to clerical staff and unsupervised by clinicians, 
making quality assessment very important. Detailed quality assessments of the SMR01 data, 
using the full medical records, are carried out every few years by the quality assurance and 
accreditation unit in ISD Scotland. An assessment of discharges in 2000 is currently 
underway, but the most recent results currently available at a national level are from a 1% 
assessment of episodes from 1996/97’4. This study and a previous one conducted on 
episodes from 1994 both indicate that personal information is over 99% accurate (Table 
2.5). However, the postcode field has actually reduced in accuracy over time (from 96.6% in 
1994 to 92.3% in 1996/97) which is a concern when conducting linkage work.
The main diagnostic code was 89% accurate, a slight reduction on the 1994 figure that could 
be due to the change from ICD9 to ICD10 during 1996. The most frequently occurring 
errors concerned the wrong use of check cystoscopy and check endoscopy, errors relating 
to symptoms and signs and accuracy of recording angina and myocardial infarction. Cancer
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was not highlighted as a problem coding area. O f more concern is the variation in accuracy 
of main diagnosis between hospitals from 96.6% to 79.8% (data not shown).
Table 2.5: Accuracy of the SMR01 database for patient discharges during 1994 and
1996/7
Database variable Percental
1994
accuracy
1996/97
Hospital patient identifier 99.9 100
Surname 99.8 99.9
Date of birth 99.9 99.9
Postcode 96.6 92.3
Specialty 99.9 99.9
Date placed on waiting list 90.2 89.9
Waiting list type N/A 96.7
Type of admission N/A 97.7
Admission/Transfer from 98.6 97.3
Date of admission 99.8 99.7
Date of discharge 99.3 99.5
Main diagnosis (3 digit) 89.9 89.3
Other diagnoses (3 digit) 89.9 90.7
Main operation/procedure (3 digit) 93.9 94.7
Other operations/procedures (3 digit) 90.7 93.2
Source: Quality assessment and accreditation unit (1998)94
Another five diagnoses fields are available for recording other diagnoses that coexist or 
develop during an episode of care and affect the management of the patient. The variation 
in accuracy between hospitals ranged from 100% to 77.8%, and completeness of recording 
ranged from 95.9% to 60% (with an outlier of 38.7%).
The accuracy o f coding of main operation/procedure was 95% in 1996/7 and had been 
increasing since the OPCS4 classification came in to operation in 1989. The main errors 
were in the wrong use of diagnostic endoscopic examination codes. The QA group found 
some under-reporting of non-operations including radiotherapy and intravenous 
chemotherapy. Accuracy of the main operation/procedure ranged from 100% to 85.5% 
between hospitals, and the completeness ranged from 100% to 89.1%. The accuracy of the 
other operation/procedure codes had also increased, with accuracy and completeness similar 
to the main operation/procedure field.
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Probability matching
The potential for bringing records together on a patient basis was first outlined by Heasman 
in 1968. The basis of forming a linked data set is the comparison of two records, and the 
decision as to whether or not they relate to the same person. However, due to errors in 
recording, exact matching could miss many true links. To allow for imperfections in the 
data, the Scottish Record Linkage System uses methods of probability matching95 which has 
been developed over the past 35 years in Canada94, Oxford97 and in Scotland9*. A computer 
matching algorithm calculates a score for each pair of records; the “odds” that they belong 
to the same person. The overall score is the sum o f scores derived from the comparison of 
each item of identifying information, weighted according to the rarity of the information 
(e.g. the initial Z in a person’s name has a high weight). Similar negative weightings are 
applied to levels of disagreement between items. The identifying information used is:
Surname (and its phonetic code to overcome differences in spelling)
First initial (also full forename and second initial when available)
Sex
Year, month and day of birth 
Postcode
Date of death, if available
The phonetic code used is the Soundex coding system which reduces a name to a code 
consisting of the leading letter followed by 3 digits. All the vowels after the first letter are 
ignored, as are W and H . The remaining letters are coded as 1 (B,P,F,V), 3 (D,T), 4 (L), 5 
(M,N), 6 (R), and 2 (all other consonants). If the name has fewer than 3 coded letters, 
trailing zeros are added. A Soundex weight is assigned to each code, reflecting the rarity of 
the Soundex code throughout the Scottish population, with a maximum weighting of 15.00. 
The Soundex weight is used by the computer matching algorithm in the calculation of the 
comparison scores.
The records are blocked on (1) phonetic code of surname and first initial, and (2) date of 
birth. A full comparison is only carried out for records which agree on either o f the 
blocking criteria. A cross-comparison of first and second forename initials is carried out. 
The threshold (that is, the score at which the decision to link is made) is determined by 
clerical checking of a sample of records. Subjects with more than one death record, or with
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a hospitalisation occurring after a death record are also clerically checked. From an 
independent check o f the quality of linkages carried out by the Scottish record linkage (SRL) 
team there was a false positive (incorrect links) rate of 3.7% and a false negative (missed 
links) rate of 1.9% between two incidence databases (3 077 subjects). In that analysis, the 
rates were higher for non-postcoded data (4.2% false positive and 2.4% false negative). The 
independent analysis was based on ‘clinical’ events and would be lower if transfers and 
additional treatments were included” . Linkage with death information was found to be 99% 
accurate although the sample was small (166 deaths). A previous investigation found linkage 
with death information to be 98% accurate” .
The SRL team have created a linked database which contains (as at September 2000) 
information on all SMROls for patients discharged from hospital between January 1981 and 
September 1999, cancer registrations for patients diagnosed between January 1980 and 
December 1997 and deaths from January 1980 to September 1999. The records are stored 
together in a flat file, in chronological order, retaining their original unlinked format and 
preceded by the unique personal identifier for each patient group. The database is updated 
at quarter yearly intervals.
Setting up the working data file
As at September 2000 there were 38 206 cancers on the linked database and 38 337 cancers 
on the SOCRATES database with a 1997 diagnosis date (figures include non-melanoma skin 
cancers and non-malignant tumours). The extra 131 cancers on the SOCRATES system 
were registered after the linkage was performed. A selection of cancers are considered for 
analysis in the main part of this thesis (see chapter 4 for rationale) including bladder (ICD-9 
188, ICD-10 C67), breast (174, C50), colon (153, C18), rectum (154, C20) and kidney (189, 
C64) cancers and malignant melanoma of the skin (172, C43).
Exclusions
For DCO registrations the date of diagnosis is unknown so these cases are excluded from 
survival analyses. However, when analysing survival by deprivation group it may actually be 
appropriate to include DCO cases, because deprivation factors could have contributed to 
the cancer not being registered100. In this dataset there were very few DCO registrations 
and little variation in the number of DCOs by deprivation category (data not shown) so it
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was assumed reasonable to exclude the DCOs from the analysis. If time from diagnosis to 
death was zero days and the case was not a DCO then the date of diagnosis was re-coded to 
one day earlier to ensure the inclusion of the case in the analysis (the STATA statistical 
package used for the analyses does not allow cases with zero survival in survival analyses).
The small number of patients (n=30) diagnosed with cancer at young ages were excluded 
from the analysis, including bladder, kidney and rectal cancers in under 30s, colon and breast 
cancers in under 25s, and melanoma of the skin in the under 15s. Patients with two 
independent cancers diagnosed at the same cancer site on the same day are only included in 
the analysis for that cancer site once. Therefore, 54 breast, 38 colon, 2 kidney, and 7 rectal 
cancers, and 1 melanoma of the skin were excluded from the analyses.
A working file was set up , containing all the SOCRATES fields of interest, for the 8 739 
patients fitting the inclusion criteria who were diagnosed with one of the cancers of interest 
in 1997. For these patients the linkage number (from the linked database) was added where 
available (8 719 records; 99.8%). As a result o f adding the linkage number, 25 duplicate 
registrations were identified and the duplicate removed leaving 8 714 cases (Table 2.6). 
Patients without an SMR01 history (146 patients; 1.7%) were included in the working file 
with their SMR01 variables set to “unknown". All SMR01 and death records were included 
in the analyses.
Table 2.6: Cases available for analysis, Scotland, 1997
Cancer Number on 
SOCRATES
Number on the 
linked database
Number with an 
SMR01 hiatory
Bladder 1,209 1,203 1,195
Breast 3,309 3,307 3,259
Colon 2,148 2,141 2,121
Kidney 487 485 479
Melanoma 673 671 636
Rectum 888 887 878
Total1 8,714 8,694 8,568
1 52 individuals appear in more than one cancer group so are counted twice in the totals
Creating and defining the variables
The SOCRATES variables
Variables on patient demographics, diagnosis, hospitals and treatment were selected from 
the SOCRATES database. The patients’ sex (variable name in final dataset: x«x), date o f 
birth (in order to assign age), and postcode sector o f residence at diagnosis {posted) were 
included in the dataset.
Diagnostic information included the incidence date {diagdt), diagnosis {drag), morphology 
code {morph), histological verification {histver, coded as yes, no or unknown), method of first 
detection {methdet, recoded as screening or other), grade {grade), and for breast cancer, the 
oestrogen receptor status {erstatus). Information on stage of the tumour at diagnosis was 
available for colorectal cancers {erstage) and breast cancer (cT, cN, cM, p T  and pN  ). For 
breast cancer, for field cN of the cTNM, it was necessary to combine the cN=2 and cN=3 
categories due to the small number of cases (10) with cN =3.
The hospital of diagnosis (ibospdiag) was recorded, along with the hospitals where main 
surgery, radiotherapy, chemotherapy and hormonal therapy took place {hospsurg, hosprad, 
hospehemo and hosphomi). Treatment information included whether treatment was received 
{surgery, rt, chemo and horrrr, coded as yes, no, planned or unknown) and whether this was 
within 6 months of diagnosis, location of radiotherapy {rudprim, radmets, radoth), and date the 
treatment was first received {dtsurg, dtrad, dtchemo and dthom). A field was also available 
indicating whether the patient had been referred to a radiotherapy department {nfrud). For 
analysis of the treatment information, the category indicating that treatment was planned at 
a later date was included with the unknowns due to small numbers. Days between diagnosis 
and treatment {days_surg> daysjrad, days_chemo and days_honti) were calculated.
The date of death {dtdth) and causela, lb , lc  and 2 from the death certificate {causela, 
causelb, causelc and cause2) were also available. Vital status and days between diagnosis and 
death {status2yrs and days2yrs) were calculated and patients still alive were censored at two 
years after diagnosis as complete death data was only available up to the end of 1999.
58
Multiple primary cancers
Patients with previous or concurrent primaries were kept in the working file. A field 
multprim was created to identify them, with the following codes:
Y First primary
Y2 First primary with another independent primary diagnosed at same time 
N1 Not first primary - previous primary at a different site
N2 Not first primary - previous primary at the same site
Non-malignant cancers and non-melanoma skin cancers were not considered as previous 
cancers when allocating the flag. For patients with previous or concurrent primary tumours, 
the diagnosis and date of diagnosis fields o f the other tumours were added to the patient 
record (diag!, dtdiagl, diag2, dtdiag2, diag3, diagl and dtdiag34).
Table 2.7: Multiple primary information for selected cancers, Scotland, 1997
Cancer Y> Y22 N l3 N2«
Bladder 1,092 2 110 5
Breast 3,104 0 105 100
Colon 1,939 18 148 43
Kidney 445 4 36 2
Melanoma 626 2 44 1
Rectum 813 14 59 2
Total3 8,019 40 502 153
1 First primary malignancy
2 First primary with another primary diagnosed on the same day at another cancer site
3 Not first primary, previous primary at another cancer site
'• Not first primary, previous primary at the same cancer site
3 52 individuals appear in more than one cancer group so are counted twice in the totals
Overall, 40 patients had two primaries at different cancer sites diagnosed on the same day, 
502 had a previous primary a t a different cancer site and 153 had a previous primary at the 
same cancer site (Table 2.7). All patients with a previous primary or a simultaneous primary 
at another cancer site were included in the analyses, because this could be an important 
factor related to deprivation-specific differences in survival.
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Age groups
An age group (agegrp) variable was created specific to each cancer. The selection was made 
by visual inspection of Kaplan-Meier survival curves of each 5-year age band calculated as 
age at diagnosis. Concurrent age groups with similar survival curves in the first two years 
after diagnosis were then grouped together. A minimum of 50 cases per age group was 
allowed. The age groupings and proportion of cases within each age group were as follows:
Bladder
Breast:
Colon:
Rectum:
Kidney:
Melanoma:
30-49 (3%), 50-59 (12%), 60-69 (28%), 70-79 (35%) and 80+ (22%) 
25-34 (2%), 35-49 (19%), 50-59 (26%), 60-69 (21%), 70-74 (10%), 
75-79 (9%), 80-84 (6%) and 85+ (7%)
25-49 (5%), 50-59 (11%), 60-69 (24%), 70-74 (17%), 75-79 (19%), 
80-84 (15%) and 85+ (11%)
30-44 (3%), 45-49 (3%), 50-59 (14%), 60-69 (25%), 70-79 (33%), 
80-84 (13%) and 85+ (9%)
0-49 (10%), 50-64 (32%), 65-74 (38%), 75-79 (11%) and 80+ (10%) 
15-49 (40%), 50-59 (16%), 60-64 (8%), 65-69 (7%), 70-74 (8%), 
75-79 (10%) and 80+ (11%)
Postcode information
Standard look-up tables were applied to the postcode information to assign each patient to a 
health board of residence at diagnosis (hb), a Carstairs deprivation quintile (depcat) based on 
the 1991 census (see Chapter 1) and to identify the place o f residence as urban or rural 
(urb_ruf).
There are currently 15 Health Boards in Scotland, and for the purposes of analysis the 
smaller Health Boards were merged with neighbouring Health Boards to give 10 areas for 
analysis. Orkney, Shetland and the Western Isles were combined with the Highlands, 
Borders with Lothian, and Dumfries and Galloway with Ayrshire and Arran.
The basic urban or rural variable defined by the GROS was used. The total population for a 
given area is found by taking each town and adding each directly adjacent town i.e. those 
which make up one continuous area. All postcodes that lie within each continuous area are
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then assigned a category based on the population for the total continuous area. The 
categories are:
1 Over 1,000,000 people
2 100,000 - 999,999
3 10,000 - 99,999
4 1,000 - 9,999
5 500 - 999
6 Not in a locality
These were then grouped with categories 1-2 signifying urban areas and 3-6 signifying rural 
areas.
Hospitals
The Chief Medical Officers of England and Wales published the Calman-Hine report101 in 
1995, recommending that a number of cancers be managed by specialist cancer teams in 
locations with the necessary specialist resources. The Scottish Cancer Coordinating and 
Advisory Group (SCCAQ proposed a similar network for Scotland in 1996102, with the aim 
that all patients have access to high levels o f specialist cancer care to provide optimal 
treatment. Five regional centres with radiotherapy provision were identified: Raigmore 
Hospital (Inverness), Aberdeen Royal Infirmary, Ninewells Hospital (Dundee), Western 
General Hospital (Edinburgh) and the Western Infirmary/Beatson Oncology Centre 
(Glasgow).
A variable bospsurg based on the numbers of patients receiving their main treatment at each 
hospital was calculated. The regional centres were included as a separate category. If 
surgery was performed then the hospital of surgery was identified from SOCRATES or the 
SMR01, otherwise the main treatment hospital was assigned as the hospital where the first 
non-surgical treatment was performed (radiotherapy, chemotherapy or hormone therapy).
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The hospsurg variable was defined:
0 Regional centre with radiotherapy provision
1 Other hospitals treating large number of patients
2 Hospital treating medium to high number of patients
3 Hospital treating medium to low number of patients
4 Hospital treating low number of patients
7 Non-hospital (Hospice, GP, health centre, nursing home, breast screening centre, 
home only)
8 No treatment received
Also, a variable hospever, indicating whether the patient was seen at a high workload hospital 
at any time during their spell was calculated. The hospever variable was defined in the same 
way as the hospsurg variable but was assigned on a hierarchical basis (i.e. 1: if the patient had 
attended a regional centre with radiotherapy provision at any time during the cancer spell; if 
not then 2: if the patient has attended another high workload hospital during their cancer 
spell; if not then 3: etc)
The distribution of the numbers of cancer patients receiving treatment at each hospital 
during the period 1996-1998 were used to define the cut-points o f high, medium and low 
workload hospitals (using the 25*, 50* and 75* percentiles, after restricting this analysis to 
hospitals treating at least 5 patients per annum). The year-on-year numbers were scrutinised 
to ensure that hospitals with changing workloads for cancer treatment were not wrongly 
assigned for the year o f interest (1997). The cut points were as follows 4950
Bladder: High >
Breast: High >
Colon: High >
Kidney: High >
Melanoma: High >
Rectum: High >
49, Medium to High 34-48, Medium to Low 24-33, Low <24 
104, Medium to High 56-103, Medium to Low 15-55, Low <15 
80, Medium to High 63-80, Medium to Low 36-62, Low <36 
18, Medium to High 14-17, Medium to Low 12-13, Low <12 
23, Medium to High 15-22, Medium to Low 12-14, Low <12
50, Medium to High 36-49, Medium to Low 24-35, Low <24
6 2
Waiting times
The time from diagnosis to surgery was calculated and split into two categories: less than 
two weeks or more than two weeks. Information on other waiting times (e.g. between 
surgery and radiotherapy) were investigated but not used in the final analyses.
The SMR01 variables
Analysis o f  SMR01 data is complex because patients may have many SMR01 records and it 
is often not obvious which is the first visit relating to the cancer diagnosis. A number of 
variables were constructed to identify important SMROls. For this purpose, a file was 
constructed containing all the SMR01 information for the 8 568 cancer cases with an SMR01 
history. This file contained 85 530 SMROls for 8 516 patients, giving an average of 10 
SMROls per person. Overall, 9% of patients had more than 20 SMROls and 7 patients had 
over 100 SMROls.
Identifying records with cancer mentioned
A field was created called diagadmit to identify SMROls that encompassed the cancer 
diagnosis date and whether these mention the specific cancer (defined as having the same 
ICD-10 code at the three-digit level) or another cancer:
Y1 Within stay and specific cancer mentioned
Y2 Within stay and another cancer mentioned
Y3 Within stay and cancer not mentioned
N1 Outwith stay and specific cancer mentioned
N2 Outwith stay and another cancer mentioned
N3 Outwith stay and cancer not mentioned
Of the 8 568 patients with an SMR01 history, 8 044 (94%) had an SMR01 mentioning cancer 
at some point. Overall, 2 345 (27%) patients had their specific cancer mentioned on an 
SMR01 encompassing the cancer diagnosis and 3 429 (40%) patients had their specific 
cancer mentioned on an SMR01 with date o f admittance during the month after diagnosis. 
Of those not falling into one of these two categories, 294 (3%) had a different cancer 
mentioned on an SMR01 either encompassing or in the month after diagnosis; 74 (1%) had 
the specific cancer mentioned before diagnosis; 53 (1%) had a different cancer mentioned
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before diagnosis; 1 768 (21%) had the specific cancer more than one month after diagnosis; 
and 81 (1%) had a different cancer mentioned more than one month after diagnosis (Table 
2.8) .
Table 2.8: Number and percentage of patients with an SMR01 containing a cancer
diagnosis
Cancer A=Y1+Y2> B=N1+N22 
(excluding those in A)
C=Y3+N33
(excluding those in A or B)
Bladder 489 40.9 660 551 46 3.8
Breast 431 131 2,649 81.3 179 5.5
Colon 1,083 51.1 951 44.8 87 4.1
Kidney 195 40.7 255 531 29 6.1
Melanoma 72 11.3 415 64.3 149 23.4
Rectum 301 34.3 543 61.8 34 3.9
Total4 2,571 30.1 5,473 63.9 524 6.1
1 Cancer mentioned on SMR01 encompassing the cancer diagnosis date
2 Cancer mentioned on an SMR01 not encompassing die cancer diagnosis date
3 Cancer not mentioned on any SMROls
4 52 individuals appear in more than one cancer group so are counted twice in the totals
Identifying the fir s t and subsequent records relating to the cancer diagnosis
When SRL perform the linkage o f the dataset, they add in a variable that identifies all 
records relating to a ‘continuous inpatient stay’ (cis), linking transfers during a hospital visit 
which are all recorded as separate SMROls. Apart from using information on whether the 
type o f discharge o f the first record or the type of admission of the second record was a 
transfer, the decision on what constitutes a CIS also hinges on the length o f  the interval 
between the discharge of one record and the admittance of the next. The records are linked 
as a CIS if this interval is negative, or if  the interval is less than 2 days and type of discharge 
or admission recorded as transfer. The “type of admission” (tadm), “admission/transfer 
from” (adtf), “date o f admission” (dtadmit) and “date of discharge” (dtdis) fields are used. 
Incremental numbers are used in the CIS field to link the records.
For this thesis, further identification o f related records was needed so that the initial SMR01 
(i.e. the one representing the initial hospitalisation resulting in the diagnosis o f  the cancer) 
and all subsequent SMROls relating to the cancer could be identified. This group of records 
has been called the cancer spell, and spells are identified using the tadm, adtf, dtadmit, dtdis, 
CIS, specialty (sped) and diagnoses (diagl-S ) fields. The specialty field was used to identify 
return visits for radiotherapy and the diagnosis fields were used to identify admissions for
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common cancer symptoms. Once all records in a spell have been identified, incremental 
numbers are assigned (order) to link the records and the type o f record in the spell is 
recorded (spelt)-.
99 Record starts a new spell
88 Record starts a new spell but manual check needed
1 Continuous inpatient stay within a  spell
2 Subsequent related visit within a spell
It was important to correctly identify the SMR01 marking the start o f  the hospitalisation due 
to the cancer o f interest (the index SMR01) so that relevant information from this record 
onwards could be extracted for the working file. If the patient visited with symptoms prior 
to diagnosis then this record would be identified as the index SMR01, otherwise an 
algorithm was used to identify the index record and the rest o f the cancer spell (see 
Appendix 2.1). A visual check of the accuracy of the algorithm was performed using the 
kidney data (479 patients) by assigning the index SMR01 from visual inspection without 
knowing how the algorithm had assigned it. Overall, 26 (5%) records were incorrectly 
assigned by the algorithm. The decision rules for these cases were too diverse to be 
successfully programmed.
Symptom lists were created by examining all the diagnoses reported on the SMROls in the 
period 1 year prior to 3 months after the cancer diagnosis. Relevant diagnoses (symptoms) 
were selected with help from a medical expert and common symptoms requiring urgent 
referral, as recorded in published referral guidelines for suspected cancer9'  were also included 
(see Appendix 2.2).
The SMR01—related variables described below were computed in two ways:
(1) All SMR01 records from the index SMR01 to the end of the identified cancer spell were 
included. When it was not possible to identify an index SMR01 (i.e. if there were no 
relevant SMR01 records; affecting around 4% of patients) then the date o f diagnosis 
from SOCRATES was used as the index date.
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(2) All SMR01 records from a fixed time interval of 1 month prior to 6 months after 
diagnosis were included. The six-month time interval was selected to correspond with 
the time band for collecting treatment information defined by the cancer registry.
Only the variables computed by the second method were used in the final analyses due to 
difficulties in identifying the cancer spell.
Specialist department
Whether the patient was seen in a specialist department was calculated. The SMROls in the 
cancer spell were used to define the variable speedept using the specialty code on each SMR01 
in the spell. The variable was defined as follows:
0 Never seen in a specialist department
1 Transferred to a specialist department within 3 months of diagnosis
2 Transferred to a specialist department within 3-6 months of diagnosis
3 Transferred to a specialist department more than 6 months after diagnosis
The specialist departments were defined as follows:
Clinical oncology for all cancers 
Medical oncology for all cancers 
Urology for kidney and bladder cancers
General surgery for breast, colon, rectal and melanoma skin cancers 
Plastic surgery for breast and melanoma skin cancers
Consultant workload
Whether a high-workload consultant saw the patient at some point during their cancer spell 
(conswkld) and, for surgically treated patients, was managing the patient when they had 
surgery (surgwkld) was calculated. The number of patients seen by each consultant was 
extracted from the SMR01 data and the consultants were then banded into workload 
groups. The cut-offs for the groups were decided based both the distribution o f  workloads 
and bandings previously used in the literature:
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Breast:
Colorectal:
Kidney:
Bladder:
Melanoma:
1-9, 10-29, 30-99, 100+ cases per year 
1-9, 10-19, 20-29, 30+ cases per year 
1-4, 5-9, 10+ cases per year 
1-9, 10-19, 20-29, 30+ cases per year 
1-9, 10-19, 20-25, 26+ cases per year
Another important factor is whether the surgeon worked in a multidisciplinary team. This 
information is not collected routinely and so it was not possible to include in this thesis.
Emergency or planned admission
The variable em ergl was extracted from the type of admission o f the index SMR01 in the 
cancer spell and defined as follows:
0 Non-emergency
1 Emergency
Operations
Information on whether patients received key operations1 within the cancer spell was 
extracted from the SMR01 database for breast cancer, and was supplemented by the 
SOCRATES information on whether treatments were received. The variable ops was 
created and was assigned hierarchically in the order listed:
1 Mastectomy (OPCS4 B27)
2 Breast conservation surgery (OPCS4 B28, B33-B35)
3 Other (B37, L91, S06) and unspecified surgery (surgery=yes on SOCRATES 
database but SMR01 not coded as above)
0 No Surgery with curative intent performed
Type of operation was not was not taken into account for colon, rectal, kidney or bladder 
tumours, and was not relevant for melanoma of the skin.
b Operations included were defined using published information. The Edinburgh clinical coding office validated the 
codes.
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Transfer patterns
The number of transfers between (not within) hospitals during the cancer spell was 
calculated and a variable nhosps was computed:
1 No transfers — one hospital throughout
2 One — two transfers during spell
3 More than two transfers during spell
The number of hospital admissions from home during the period from the date of the 
index admission up to the date of surgery was also calculated to attempt to investigate 
differences in the path o f cancer care. This variable nvisits was defined:
1 One continuous inpatient stay
2 Two or three visits
3 More than three visits
Co-morbidity
Co-morbidity was assessed using three different measures — two based on the burden of 
specific diseases (Charlson and Scottish indices) and the other based on the time spent in 
hospital (bed-days index) to give an idea of overall burden of illness (see Chapter 1).
Charlson: 0 No comorbidity
1 Score o f 1-2
2 Score of 3+
Scottish: 0 No comorbidity
1 1 previous condition
2 2+ previous conditions
Bed-days: 0 No bed-days in previous 2 years
1 1-4 bed-days in previous 2 years
2 5-10 bed-days in previous 2 years
3 11+ bed-days in previous 2 years
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Identify as the beginning of a new spell (spell=99) if one of the diagnosis fields contains a symptom from the list, and the date of 
admittance is not more than six months prior to diagnosis.
Identify as the beginning of a new spell (spell=99) all SMROls with admittance/transfer from a private or institutional residence whose date 
of admittance is greater than 7 days since the previous date of discharge, except if they 
Have type of admission recorded as planned transfer
Have their specialty recorded as haematology, oncology or urology (as these are usually repeat visits relating to the spell) with 
admittance less than 6 months since last discharge
Have a waiting list type of planned repeat admission (as these are also usually repeat visits relating to the spell) with admittance less 
than 6 months since last discharge
Have die same diagnosis (diagl) as the previous record with admittance less than 2 months since the discharge of the previous record 
(probably related to the spell)
Allocate subsequent SMROls to the same spell if
The date of admittance is less than the date of discharge (plus 7 days) of any other records assigned to the spell (spell=1)
The specialty is haematology, oncology or urology and the previous discharge date was less than 6 months earlier (spell=2)
The diagnosis is the same as the previous record and the discharge date of previous record was less than 2 months previously 
(spell=2)
If the waiting list type is planned repeat admission and the previous discharge date was less than 6 months earlier (spell=2)
For those not allocated to a spell, identify the beginning of a new spell for those transferred from accident and emergency (spell=99). 
Repeat step (3).
For those still not allocated to a spell, identify the first SMR01 in each sequential run of unallocated SMROls as a new spell (spell=88). 
Repeat step (3).
A lg orithm  to  identify the index cancer S M R 01 and subsequent SM R O ls in a spell
6. Allocate sequential numbers in the order field, incrementing at each new spell to group together SMROls occurring within one spell.
A p p en d ix  2Jh R eferral guidelines fo r  suspected  cancer -  co m m o n  sym ptom s requiring urg en t re fe rra l
O ncer Symptom« ICD9 code ICD10 code
Colorectal Rectal bleeding without anal symptoms 5693 K625
Palpable right-sided abdominal or rectal (not pelvic) mass 789 R190
Change of bowel habit to looser or increased frequency of defecation, persistent for 6 weeks 558,5640 K52.K590
Iron deficiency anaemia without an obvious cause 280,2810 D50
Breast Lump 6117 N63X
Ulceration 6110 N61X
Skin nodule or distortion . .
Nipple eczema 6112 N640
Recent nipple retraction or distortion 6117 N645
Bladder Macroscopic or microscopic haematuria 5997 N02.R31
Kidney Macroscopic or microscopic haematuria 5997 N02.R31
Loin pain 7880 N23
Renal mass 5939 N28
Anaemia 280,2810 D50
Weight Loss 7832 R634
Pyrexia 7806
Melanoma Pigmented lesions with one or more of the following features 7090 R234, R238, R22
Growing in size Mixed or changing colour 
Changing shape Ulceration 
Irregular outline Inflammation
Source: Referral guidelines for suspected cancer103
C h a p t e r  3
CANCER SURVIVAL IN SCOTLAND 1971-1998
Background
One in three people develop cancer during their lifetime, and most people are therefore 
affected either directly or indirecdy with it. Around 25 000 new cancers are diagnosed every 
year in Scodand, o f which half are in people aged under 70 years. Cancer is responsible for 
a quarter of all deaths in Scodand, with survival among the worst in Europe5,6. Cancer 
mortality can be reduced both by primary prevention (fewer new cases diagnosed) and by earlier 
diagnosis leading to more effective and timely treatment (improved survival).
Cancer patient survival is a key indicator of the  efficacy and equity o f cancer patient 
management, a process including timely diagnosis, effective treatment, and appropriate care. 
This chapter provides general analyses of cancer survival in Scodand by period of diagnosis, 
age, sex and deprivation, giving a background to th e  more detailed investigation of survival 
from selected cancers presented in subsequent chapters.
Data and Methods 
Data
Trends in cancer survival are presented for patients diagnosed between 1971 and 1995 and 
followed up until the end of 1998. The start date o f  1971 was chosen because prior to that 
date follow-up o f cases was thought to be less complete. The end date was chosen because 
1998 was the latest year of complete follow-up at the time of analysis (autumn 1999), and so 
all patients diagnosed in the period 1991-95 were followed up for at least three years, and the 
majority for at least five years. The analyses were stratified by the five-year periods 1971-75, 
1976-80, 1981-85, 1986-90 and 1991-95. Results are presented for 25 major cancers, 
together with all malignancies combined (ICD-9 140-208, excluding non-melanoma skin 
cancer ICD-9 173). Non-melanoma skin cancers were excluded because registration is
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known to be incomplete, particularly in earlier years. They are common tumours, and are 
very rarely fatal. Only adults (aged 15+ years) were considered.
Registrations for patients who live outside Scodand, or have no recorded health board of 
residence, were excluded. A relatively high proportion (5%) o f registrations did not have a 
health board of residence assigned in the first five-year period analysed, due to the fact that 
the postcode system was not as commonly used in the early 1970s (only half the 
registrations had a postcode in this period; Table 3.1). An exploratory analysis of the data 
for the period 1971-75 was performed, both excluding and including the cases with no 
residence details. Excluding the patients with no health board of residence led to slightly 
higher estimates of survival for cancers of the bladder, cervix, ovary and prostate, because 
for these cancers survival was worse for patients with no health board of residence 
recorded. This leads to conservative estimates of the gradient of improvement over time. 
There was no difference in the survival for all other cancers (data not shown).
Only first malignant tumours were included, as patients with a previous malignant tumour 
are likely to have poorer than average survival. The numbers of second or subsequent 
malignant tumours increased over the time period due to improvements in registration 
practice and a longer calendar period over which to accumulate registrations. Diagnoses of 
non-melanoma skin cancer, which were excluded from the extracted data set, were ignored 
when identifying multiple malignant tumours. An exploratory analysis of the data for the 
period 1991-95 was performed, both excluding and including second and subsequent 
malignant tumours. The estimates were very similar for most cancers, but not for malignant 
melanoma o f the skin and corpus uteri cancers, where a significantly poorer survival was 
seen when patients who had a previous malignant tumour were included in the analyses 
(data not shown).
Cancers registered from a death certificate only (DCO) were also excluded, as the true date 
o f  diagnosis is unknown for these individuals. It has been shown that the true survival for 
these patients is lower than average*4,104. In Scotland, DCO registrations are more common 
in the elderly (with 1%, 26%, 31% and 42% of DCO registrations occurring in patients aged 
<50, 50-69, 70-79 and 80+ years, respectively). They comprise largely lung cancer (32% of 
DCO registrations; 6% of lung cancer registrations), ‘other malignancies' (19%; 6%), large 
bowel (10%; 3%) and breast cancer (9%; 2%)'.
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Table 3.1: Patients diagnosed with cancer in Scotland during 1971-95: registrations included and excluded from the survival analyses
Period of diagnosis
1971-75 1976-80 1981-85 1986-90 1991-95 Total
Total registrations1 82,132 100% 97,236 100% 106338 100% 113386 100% I23325 100% 522,421 100%
Age < 15 at diagnosis 653 1% 713 IV. 584 IV. 613 IV. 639 IV. 3302 IV.
Age > 99 at diagnosis 1 Of/. 10 Of/, 29 Of/. 24 Of/. 37 Of/. 101 Of/.
T otal elig ib le 81,478 99% 96,513 99% 106,025 99V. 112349 99% 122349 99% 519,118 99%
Excluded from survival analysis (% of eligible)
Unknown residence or outwith Scotland 4/111 4.9V. 41 0.0V. 9 0.0V. 4 0.0V. 7 0.0V. 4,072 0.8%
Age unknown 5 0.0V, 1 0.0V. 0 0.0V. 0 0.0V. 0 O.OV. 6 0.0%
Not first primary malignancy2 2,056 2JV, 3,761 3.9V. 5354 5.0V. 6,958 62V. 9331 7.6V. 27,460 5.3%
Vital status unknown / migrated 13 0.0V. 18 0.0V. 46 O.Of/. 321 0.3V. 285 02V. 683 0.1%
Invalid dates 13 0.0V. 1 0.0V. 6 O.OV. 7 0.0V. 29 O.OV. 56 0.0%
Death Certificate Only case1 1,266 1.6V. 4,731 4.9V. 4,078 3.8V. 3,739 3JV. 3345 3.1V. 17,659 3.4%
Total excluded from the survival analysis (% of eligible) 7364 9V. 8353 9V. 9,493 9V. 11,029 10V. 13,497 11V. 49,936 10V.
Total included in  survival analysis (*/• o f elig ib le) 74414 91% 87,960 91% 96332 91% IOI3 2 O 90% 109,052 89% 469382 90%
Of those included in survival analysis
Noo-DCO zero survival tune4 2349 4V. 2,727 3V. 2348 2V. 1,835 2V. 2381 2V. 12,040 3V.
Dead by 31/12/98 but no cause of death on cancer file 27,246 37V. 2,039 2V. 953 1V. 637 IV. 403 Of/. 31378 7%
Source: Scottish cancer intelligence unit'
1 All malignant neoplasms (I CD-9 140-208) f ir  hiding non-melanoma skin cancer (ICD-9 173).
2 Where a patient’s first malignancy was a non-melanoma skin cancer (ICD-9 173) or a non-malignant tumour (ICD-9 210-239) the second malignancy was included in the 
survival analysis.
1 Registered on the basis of a death certificate diagnosis only (DCO).
4 These are not DCO cases but have apparently zero survival.
In total for the whole period, just under half a million records were analysed, and the 
proportion of cases included in the analyses was fairly consistent over time (ranging from 
90.2% for cases diagnosed in 1971-75 to 88.5% for cases diagnosed in 1991-95). The main 
reasons for exclusion being not a first primary tumour (5.3%), death certificate only 
registrations (3.4%) and missing postcode (0.8%). Patients with zero survival times, but not 
DCO, were included in the analysis.
Methods
The methodology is described in detail in Chapter 1.
Observed, cause-specific and relative survival estimates, with 95% confidence intervals, are 
presented in this chapter. The estimates were computed using the STATA algorithm str cl?  
based on the relative survival approach outlined by Esteve et a l (1990)54.
Scottish life tables for single year of age at death from 0-99 years and six periods of death 
(1971-75, 1976-80, 1981-85, 1986-90, 1991-95, 1996-98) were used in the relative survival 
analyses. Scottish deprivation-specific life tables were used in the deprivation-specific 
relative survival analyses, based on deaths occurring around the 1991 census (1990-92) and 
using populations derived from the 1991 census with adjustment for the known census 
population undercount.
For each cancer, Appendix 1.1 shows the causes of death which were deemed to be cause- 
specific. Cause-specific analyses are presented for the period 1991-95, when causes of death 
on the cancer registration file were most complete (99.6%). For the small numbers of 
registrations for which the cause of death was not available, it was assumed to be the same 
as the cancer diagnosis.
The survival estimates were age-standardised, using the world standard cancer patient 
population“  (see Appendix 1.2), to allow valid comparisons between survival rates of a given 
cancer over time and between deprivation groups. For the time trend analyses, the age 
bands 15-44, 45-54, 55-64, 65-74, 75-84 and 85-99 years were used. For the deprivation 
analyses, the age bands 15-54, 55-74 and 75-99 years were used.
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If there are fewer than 9 cases in an analysis group, then a survival estimate was not be 
computed. The following approach was adopted for the calculation of age-standardised 
survival rates:
(1) If there were age-specific survival rates available in an earlier (first choice) or later 
time period then this value was used. The assumption being that differences in 
survival between time periods will generally be less than differences in survival 
between age groups and sexes.
(2) If there were no age-specific survival rates available for any of the time periods then, 
if possible, a truncated rate was calculated.
(3) Otherwise no standardised rate was calculated.
As the world standard cancer patient population generally gives a low weight to the younger 
age groups which have small numbers of cases in Scotland, using approach (1) above will 
generally only have a very small effect on the overall standardised survival estimate.
The STATA algorithm requires that all patients have greater than zero survival time, so to 
avoid the exclusion of non-DCO patients with zero survival times, the survival time for 
these patients was reset to 1 day. If there are no deaths in an analysis group, then the 
STATA algorithm does not run, and so the estimates were set at 99.99%.
The Carstairs deprivation index69 was used as the measure of material deprivation, derived 
from 1991 census data. Each patient diagnosed between 1991 and 1995 was assigned to a 
quintile of deprivation, ranging from affluent to deprived.
Results and commentary
The numbers of registrations of malignant neoplasms (excluding non-melanoma skin 
cancer) in Scotland increased from over 82 000 during 1971-75 to over 123 000 during 1991- 
95 (Table 3.1). This is due partly to ageing of the population (since cancer is primarily a 
disease of the elderly)' but mainly due to a genuine increase in risk of many cancers105. In 
addition, ascertainment has probably been more complete since the mid-1970s10*.
c When cancer-, age- and »ex-specific first primary incidence rates for the 1971-75 patients axe applied to the 1991-95 
population estimates, then we would expect 81 396 cases compared to 109 052 observed cases. Therefore, 20% o f the 
increase between 1971-75 and 1991-95 is a direct consequence population ageing.
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Cancers of the testis and cervix are the most common in young adulthood. In older age 
groups, lung cancer and large bowel cancer, together with prostate cancer and breast cancer 
are the most frequent forms of the disease, accounting for over 50% of cancers. Over the 
period studied there were substantial increases in incidence. In particular, oral, oesophageal, 
prostate and thyroid cancers and malignant melanoma of the skin all showed increases in the 
number of cases of over 40%. Large increases were also seen for laige bowel and breast 
cancers. Lung cancer increased significantly in females, but reduced in males, and stomach 
cancer was also declining (Table 3.2).
Table 3.2: Patients diagnosed with cancer in Scotland during 1971-95: number of
patients entered into the survival analyses by cancer and time period
Cancer (ICD-9 code) Period o f diagnosis
1971-75 1976-80 1981-85 1986-90 1991-95
Oral cancer (141,143-145) 586 726 917 1,075 1,261
Head and neck (140-149, 160,161) 2,630 2,985 3,322 3,482 3,874
Oesophagus (150) 1,851 2,269 2,541 2,694 3,293
Stomach (151) 5,845 5,678 5,837 5,328 4,722
Large bowel (153+154) 10,788 11,788 12,788 13,788 14,788
Colon (153) 7,073 7,788 8,275 8,926 9,615
Rectum (154) 3,715 4,171 4,242 4,407 4,806
Pancreas (157) 2,166 2,776 2,849 2,764 2441
Larynx (161) 775 837 1,091 1,131 1,308
Trachea, bronchus and lung (162) 17,047 19,376 21,083 20,426 20,851
Malignant melanoma (172) 762 1,167 1,580 2,187 2,546
Breast (174) 9,753 10,722 11,597 12,481 14,449
Cervix uteri (180) 1,515 1,936 2,058 2,128 1,859
Corpus uteri (182) 1,153 1,307 1,530 1,515 1,518
Ovary (183) 1,443 1,984 2,311 2,473 2,508
Prostate (185) 2,546 3,861 4,694 5,648 7,151
Testis (186) 409 514 608 727 844
Bladder (188) 3,027 4,608 5,235 5,706 6,063
Kidney (189) 1,418 1,516 1,860 1,989 2451
Brain and other CNS (191 + 192) 1,000 1,265 1,384 1410 1,515
Thyroid (193) 382 445 452 443 508
Non-Hodgkin lymphoma (200+202) 1,492 2,005 2,433 2,956 3,323
Hodgkin's disease (201) 696 665 691 602 631
Multiple myeloma (203) 785 1,029 1,116 1,228 1,338
Leukaemia (204-208) 1,459 1,726 2,043 2,072 2,138
All malignant neoplasms3 74414 87,960 96432 101420 109,052
1 ICD-9 140-208 excluding non-melanoma skin (ICD-9 173)
In the most recent time period, survival at five years after diagnosis varied from under 4% 
(for patients with pancreatic cancer) to over 90% (for patients with testicular cancer, Figure 
3.1). Survival was lowest in patients with cancers which often present at an advanced stage 
and are less amenable to treatment (examples being pancreatic, lung and oesophageal
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cancers). Survival tended to be better for cancers for which patients are more likely to 
present at an early stage (for example, cancers of the corpus uteri, bladder and thyroid, and 
malignant melanoma of the skin), for cancers which can be detected early by screening (for 
example, breast cancer), and cancers for which there have been major advances in treatment 
(for example, cancer of the testis and Hodgkin’s disease). For many cancers, the survival 
rate five years after diagnosis was over 50%. These include malignant melanoma of the skin, 
cancers of testis, corpus uteri, breast, bladder, thyroid, cervix uteri and larynx, and Hodgkin’s 
disease, which together account for 27% of malignancies.
Survival by age
A patient's prognosis after a diagnosis of cancer is highly dependent on age; an individual’s 
risk of dying from a particular cancer once diagnosed tends to increase with age, as does 
their risk of dying from another cause. Even after adjustment for age-specific competing 
risks of death, however, using relative survival, survival was generally better in younger 
patients (Table 3.3). This could be due to better general health, earlier diagnosis or better 
availability and effectiveness o f treatment.
Survival was rarely similar across the age groups, occurring only for patients aged under 85 
with large bowel cancer or malignant melanoma of the skin in males. Large variations in 
survival between age groups were seen for many cancers, in particular thyroid and brain 
cancers, non-Hodgkin lymphomas, Hodgkin’s disease, multiple myeloma, and genitourinary 
cancers in females. Some o f the estimates for the youngest age group were, however, based 
on very few cases, as indicated by their large confidence intervals.
Survival was low in the youngest patients with laryngeal, breast and prostate cancers, and 
bladder and multiple myeloma in females. The low rates for laryngeal cancer and multiple 
myeloma in the youngest age group are again based on very few cases. Young females with 
bladder cancer also comprise a small patient group, however survival from bladder cancer 
was lower in females than males in all age groups.
7 7
Figure 3.1: Patients diagnosed with cancer in Scotland during 1991-95: five-year relative 
survival* (with 95% confidence intervals), by cancer1 2 and sex
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1 These rates are directly standardised to the world standard cancer patient population.
2 For some cancers (testis, brain and other CNS, thyroid and Hodgkin's disease in males; larynx and Hodgkin's 
disease in females) there were less than 9 cases in the 85-99 age group in any time period. For these sites the 
standardised rate is based on the age group 15-74.
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The pattern for breast cancer is unusual with low survival in younger women, followed by a 
peak in menopausal women, and decreasing survival in older women. This has been 
reported elsewhere4, and may be related to differences in tumour biology in pre- and post­
menopausal women107. Higher survival seen around menopause could be because lower 
levels of circulating sex hormones may result in reduced stimulation of tumour cell growth.
Low survival for prostate cancer in men under 60 may also be due to differences in tumour 
biology10'. Prostate-specific antigen (PSA) testing became widely used in Scotland in 1991 
causing a steep increase in incidence between 1992 and 1993. The extent to which this 
increase represents the early diagnosis of tumours which would eventually cause symptoms 
or be life-threatening, or detection of latent disease which would never have become 
symptomatic, is not yet clear. Improvements in survival seen in older men in the 1990s are 
probably an artefact of the increase in PSA testing, and would not be as likely to be seen in 
the younger men100.
Survival by aex
For ‘all malignant neoplasms’, the survival at one year after diagnosis increased from 36% 
during 1971-75 to 52% during 1991-95 for males, and from 51% to 61% for females. 
Survival at five years after diagnosis improved by around 12% for both sexes. The smaller 
improvement at one year for females than males is a reflection o f the comparatively small 
improvement over the period for survival from breast and gynaecological cancers, rather 
than because cancer survival has improved more in males than females for specific cancers. 
These cancers contribute a large proportion (37%) of the cancers in females, for which 
survival is already relatively high.
The main reasons for the lower overall survival in males than females is the higher 
proportion of males with lung cancer (25% of male cancers compared to 13% of female) 
which has a very poor prognosis, and because women have a  higher proportion of the 
cancers which have a good prognosis. Two in 5 women have cancers with an average five- 
year relative survival rate of over 50%, compared to only 1 in 7 men (Figure 3.2).
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Table 3.3: Patients diagnosed with cancer in Scodand during 1991-95: five-year relative
survival (with 95% confidence intervals shown for youngest and oldest age 
group) by cancer, sex and age group1
Cancer Sex 15-44 45-54 55-64 65-74 7S-842 85-99*
Oral cavity M 53.5 (39.5, 65.7) 41.6 44.6 40.0 43.5 30.0 (4.6, 62.6)
F 70.9 (462, 85.8) 54.6 62.7 44.8 40.4 18.8 (6.3, 36.4)
Head and neck M 56.8 (48.3, 64.3) 49.8 51.1 47.5 44.9 44.5 (20.4, 662)
F 64.5 (49.4, 76.1) 58.7 56.0 47.4 45.9 27.0 (14.0, 41.9)
Oesophagus M 19.5 (9.6, 32.0) 11.0 9.8 7.0 Z2 0.2 (0.0, 2.5)
F 0.0 (0.0, 0.0) 14.1 11.2 9.0 7.1 0.8 <0.1, 42 )
Stomach M 19.4 (11.1,29.4) 17.4 12.9 10.9 6.9 1.5 (02, 6.5)
F 23.2 (11.7, 36.9) 18.9 13.8 15.1 9.7 Z1 (0.8, 4.6)
Large bowel M 46.6 (39.7, 532) 45.9 47.0 46.4 42.6 27.5 (19.7, 35.8)
F 50.8 (432, 57.9) 50.2 50.8 49.5 42.5 28.9 (24.0, 34.0)
Colon M 48.5 (39.9, 56.5) 45.4 48.7 46.9 44.0 31.9 (22.0, 422)
F 48.3 (38.6, 57.3) 49.0 48.8 50.6 44.3 30.3 (24.5, 36.3)
Rectum M 43.7 (322, 54.6) 46.6 44.6 45.7 39.8 15.6 (6.4, 28.5)
F 55.1 (42.6, 65.9) 52.9 55.2 46.7 37.7 23.8 (15.7, 32.8)
Pancreas M 9.7 (2.6, 22.7) 2.9 4.3 1.5 1.0 0.4 (0.0, 2.5)
F 5.4 (0.5, 20.1) 3.4 4.1 3.6 1.1 0.8 (0.1, 3.0)
Larynx M 67.5 (46.9, 81.5) 69.6 63.7 59.9 47.7 45.4 (7.8, 78.3)
F 56.8 (14.1, 85.0) 82.2 55.7 52.6 42.2 -
Trachea, M 17.4 (11.9,23.8) 11.1 8.5 5.5 2.8 2.3 (1.1, 4.3)
bronchus and lung F 17.7 (112 ,25 .4 ) 9.0 9.2 4.7 Z3 Z7 (12 ,5 .1 )
Malignant M 86.0 (80.8, 89.9) 75.9 80.9 77.3 83.4 56.1 (15.9, 83.4)
melanoma F 92.4 (89.5, 94.6) 92.1 93.7 87.9 76.5 6Z4 (33.3, 81.7)
Breast F 76.0 (73.8, 78.0) 79.8 80.4 71.0 60.7 45.8 (39.1, 522)
Cervix uteri F 80.3 (77.1, 83.0) 65.8 53.7 42.2 25.1 4.7 (0.5, 16.8)
Corpus uteri F 85.3 (73.3, 922) 87.7 80.0 70.3 6Z5 22.7 (8.7, 40.6)
Ovary F 66.6 (59.5, 72.8) 39.5 32.1 19.7 13.7 5.1 (1-1 1*3)
Prostate M - 45.1 65.8 58.3 51.0 36.4 (28.8,44.1)
Testis M 96.0 (942, 97.3) 88.5 82.8 52.2 - .
Bladder M 87.3 (79.3, 92.4) 81.5 75.2 70.7 60.9 42.9 (29.0, 56.1)
F 75.0 (58.4, 85.8) 80.1 72.4 65.3 46.5 26.9 (16.8, 38.0)
Kidney M 48.7 (36.4, 59.9) 48.0 44.4 38.2 25.9 15.4 (52, 30.5)
F 62.8 (48.0, 74.4) 55.0 38.0 35.8 27.0 8.1 (2.8, 172)
Brain M 42.5 (352, 49.6) 12.9 3.0 4.6 4.0 -
and other CNS F 59.0 (502, 66.8) 19.6 5.1 1.1 5.4 6.9 (0.5, 26.4)
Thyroid M 89.1 (72.1, 96.0) 79.1 74.7 39.7 31.2 -
F 97.8 (93.1, 99.3) 93.8 73.3 56.6 30.1 8.4 (0.6, 30.7)
Non-Hodgkin M 63.8 (57.4, 69.5) 56.7 47.6 3Z5 21.5 8.0 (12, 23.7)
lymphoma F 65.6 (56.7, 732) 66.6 54.3 40.8 28.1 15.1 (6.9, 262)
Hodgkin's disease M 88.4 (82.8, 922) 74.9 63.9 25.1 26.9 -
F 84.7 (77.1, 89.9) 56.2 45.0 39.7 36.2 -
Multiple myeloma M 76.1 (42.4, 91.7) 28.3 17.7 19.8 14.8 10.0 (0.9, 32.5)
F 0.0 (0.0, 0.0) 39.1 29.3 19.0 15.1 7.9 (1.6, 20 .7)
Leukaemia M 46.4 (37.6, 54.8) 32.0 37.4 27.5 20.8 11.5 (32, 25.7)
F 45.7 (35.9, 54.9) 41.4 44.4 29.8 21.7 14.6 (7.0, 24.8)
All malignant M 65.7 (63.9, 67.4) 36.8 32.2 28.6 23.0 18.0 (13.6, 20.6)
neoplasma2 F 7 2 J (71.1, 73.8) 61.9 5 1 J 34.8 26.7 18.1 (16.4,19.9)
1 It was not possible to calculate survival rates for some cancers because of small numbers of cases. 
1 ICD-9 140-208 excluding non-melanoma skin cancer (ICD-9 173)
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Figure 3.3: Patients diagnosed with cancer in Scodand during 1991-95: absolute
difference1 in five-year relative survival2 by cancer males compared to 
females
Oial cavity 
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Absolute difference in % survival
1 Absolute differences in survival between males and females have been shown, for example, the % survival for 
thyroid cancer was 77.6% in females and 68.2% in males, which by subtraction gives a difference of 9.4%.
2 These rates are direedy standardised to the world standard cancer patient population.
l  For these sites the comparison was made using standardised rates for the age group 15-74, because there were less 
than 9 cases in the 85-99 age group either for males or for females.
A multivariate Cox proportional hazards regression analysis59 was performed to investigate 
the apparent higher survival in males with bladder cancer. When sex alone was included in 
the model a decreased relative risk of death was observed for males compared to females 
(RR=0.87; p<0.001). However, when age (5-year bands) and morphological type (M8120, 
M8130, M8010, M8070 and other) were added to the model there was no longer a significant 
difference in the relative risk o f death between the sexes (RR=1.01; p=0.84).
Survival by calendar period
For the majority of cancers, survival at one year and five years after diagnosis improved over 
the period surveyed ^Tables 3.4 and 3.5). The largest improvements were seen for large 
bowel cancers, lympho-haematopoietic malignancies (probably due to the development and 
implementation o f increasingly effective therapies), malignant melanoma of the skin, kidney
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and thyroid cancers. Broadly similar findings are seen in cancer survival in England and 
Wales4.
Improvements in survival at five years after diagnosis were generally smaller than those seen 
at one year indicating that although survival is improving, because of earlier diagnosis and/or 
improved treatment, the majority of cancer patients are not being ‘cured’. Large sustained 
improvements in survival at five years after diagnosis were seen for malignant melanoma of 
the skin, large bowel cancers, Hodgkin’s disease, leukaemia, and breast, testicular and thyroid 
cancers. For some cancers the absolute improvement in survival was small, but it 
represented a large proportional gain. These included oesophageal cancer in males 
(proportionate improvement of 13%) and stomach cancer (8% in males and 10% in 
females). No real improvements in survival were seen for lung, pancreatic o r laryngeal 
cancer in males, or cervical cancers.
Survival declined over the period in cancers of the head and neck in males, due to a large 
decrease in the proportion of lip tumours (22% of all head and neck cancers during 1971-75 
to 8% during 1991-95). Lip tumours have a very favourable prognosis, with 91% patients 
still alive at five years after diagnosis, compared to other sites in the head and neck whose 
survival at five years after diagnosis ranges from 20% (hypopharynx) to around 60% (larynx 
and salivary glands). The proportion of lip tumours in females increased slightly over the 
same period (from 5% to 7%).
The cancers with the largest improvements in survival over time are now discussed.
Malignant melanoma o f the skin
The largest absolute improvements in survival at five years after diagnosis over the period 
1971 to 1995 were seen for malignant melanoma of the skin (31% in males and 20% in 
females). This improvement was sustained up to ten years after diagnosis, and so suggests 
that increasingly more patients are being cured of cancer. Incidence rates have increased 
dramatically for both sexes over recent years, which is thought to be due, at least in part, to 
a major public health education programme.
Tumour thickness of cases diagnosed in the West of Scotland was significantly reduced 
following a campaign to promote early reporting110. Prognosis is directly related to tumour
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thickness at diagnosis but the survival improvement seems to be only partly explained by an 
increasing proportion of thinner tumours'". The improvement in survival is seen in both 
sexes and in all age groups.
Hodgkin V disease
For Hodgkin’s disease (HD) there are also large sustained improvements in survival since 
the early 1970s (15%  in males and 16% in females). Incidence of HD is higher in men than 
women across all age groups. Survival decreases with increasing age but has increased over 
time within each age group. Due to improvements in diagnostic techniques and changes in 
the way lymphomas are classified, some cases that would have previously been recorded as 
HD are now recorded as non-Hodgkin’s lymphoma (NHL) which may have affected the 
survival estimates. However, there have been major improvements in treatment using 
combination chemotherapy and radiotherapy 1,2 over the period, and these appear more 
likely to be the reason for the improvement.
Breast cancer
The overall improvement in survival from breast cancer (16% at five years) has been 
occurring over the whole time period (1971-1995), but with a larger increase in the most 
recent time period. The incidence of breast cancer has also been increasing over the whole 
time period, with a very large increase following the introduction of the national breast 
screening programme in 1988, and it is now returning to levels similar to expected from the 
underlying incidence trends, but with improved prognostic characteristics"5. In any breast 
screening programme the survival benefits will be seen very soon after screening begins, but 
these are difficult to interpret until the prevalent round of screening is completed. This is 
because the initial screening round will pick up some very slow-growing tumours that may 
never have presented clinically during the patient’s lifetime (length bias).
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Table 3.4: R e la tiv e  s u rv iv a l1 (% ) a t  o n e  y e a r  a f te r  d iag n osis  (w ith  9 5 %  c o n f id e n c e
in te rv a ls )  b y  c a n c e r  a n d  se x , S c o t la n d , ages 1 5 -9 9 ,  p a tien ts d iag n osed  1 9 7 1 - 9 5
Cancer 1971-75 1981-85 1991-95
Males
Oral cancer 64.2 (482, 76.1) 71.8 (60.3, 80.4) 7X4 (62.5, 79.9)
Head and neck 77.2 (70.8, 821) 78.0 (72.6, 82.4) 76.5 (71.3, 80.7)
Oesophagus 14.5 (9.6, 20.9) 20.1 (15.0, 25.7) 29.0 (23.6, 34.5)
Stomach 15.2 (121, 18.5) 22.9 (19.0,27.0) 30.0 (25.3, 34.9)
Large bowel 43.7 (39.8, 47.5) 53.5 (49.8, 57.0) 64.7 (61.4, 67.7)
Colon 39.9 (35.0, 44.7) 51.3 (46.7, 55.7) 63.1 (58.9, 66.9)
Rectum 49.0 (42.6, 55.0) 57.2 (50.8, 62.9) 67.1 (61.7, 71.8)
Pancreas 7.1 (4.3, 11.1) 9.2 (5.7, 13.6) 10.1 (6.6, 14.8)
Larynx 76.0 (66.4, 81.7) 82.4 (73.1,88.9) 85.1 (76.1, 90.5)
Trachea, bronchus and lung 16.2 (14.6, 18.0) 18.3 (16.6, 20.1) 21.2 (192 ,232)
Malignant melanoma 75.5 (581, 86.6) 87.3 (72.1, 92.8) 93.7 (86.0, 97.1)
Prostate 63.3 (58.0, 68.0) 70.0 (66.0, 73.5) 75.2 (72.3, 77.7)
Testis2 81.1 (73.6, 86.3) 94.3 (89.1, 96.8) 96.3 (92.5, 98.1)
Bladder 69.6 (63.0, 75.1) 77.0 (72.3, 80.9) 8X4 (78.6, 85.4)
Kidney 41.6 (33.7, 49.5) 45.4 (36.8, 53.7) 56.7 (49.5, 63.3)
Brain and other CNS2 21.6 (15.9, 28.1) 23.1 (18.0, 28.8) 33.5 (27.7, 39.4)
Thyroid2 63.1 (37.5, 79.2) 46.9 (291, 591) 79.5 (582, 89.9)
Non-Hodgkin lymphoma 46.7 (37.8, 56.1) 52.1 (45.3, 58.9) 63.3 (57.1, 68.9)
Hodgkin's disease2 67.1 (56.0, 76.0) 73.3 (60.8, 82.6) 77.5 (65.8, 85.6)
Multiple myeloma 43.6 (29.6, 571) 60.6 (45.8, 69.7) 67.8 (50.5, 75.9)
Leukaemia 35.8 (27.6, 441) 50.9 (42.9, 58.4) 59.6 (51.8, 66.4)
All malignant neoplasms3 35.5 (34.1,36.9) 43.4 (42.2, 44.6) 52.2 (51.1, 53.4)
Females
Oral cancer 56.6 (431, 65.9) 77.3 (61.7,86.1) 7X7 (59.6, 81.8)
Head and neck 66.5 (571, 741) 74.6 (66.8, 80.5) 74.7 (67.0, 80.6)
Oesophagus 23.0 (15.3, 31.4) 25.2 (17.3, 33.3) 24.4 (19.6, 29.5)
Stomach 17.4 (13.3, 21.8) 24.7 (19.9, 29.7) 30.0 (23.7, 36.3)
Large bowel 44.8 (41.6, 48.0) 55.2 (52.0, 58.2) 65.4 (62.4, 682)
Colon 42.7 (38.9, 46.4) 53.5 (49.7,57.1) 64.2 (60.5, 67.6)
Rectum 50.2 (43.6, 56.3) 58.8 (53.0, 63.9) 68.1 (62.5, 72.9)
Pancreas 9.0 (5.1, 14.0) 10.2 (6.5, 14.9) 9.7 (5.8, 15.0)
Larynx2 76.4 (57.3, 871) 83.0 (64.1, 91.4) 88.3 (62.5, 78.6)
Trachea, bronchus and lung 14.5 (12.1, 17.4) 17.9 (15.5, 20.4) 21.7 (192, 242)
Malignant melanoma 89.0 (75.8, 94.3) 94.0 (87.6, 97.1) 97.0 (92.0, 98.8)
Breast 84.3 (821, 86.1) 87.5 (85.8, 88.9) 91.2 (89.9, 92.3)
Cervix uteri 75.3 (70.0,80.1) 75.2 (70.6, 79.3) 79.7 (74.7, 83.8)
Corpus uteri 81.9 (74.3, 87.5) 83.9 (78.3, 87.7) 87.0 (81.7, 90.6)
Ovary 49.3 (43.0, 55.3) 54.2 (49.6, 58.5) 6X1 (57.5, 66.2)
Bladder 57.4 (48.8, 64.8) 66.9 (60.5, 72.1) 72.4 (66.6, 77.0)
Kidney 38.2 (28.1,48.4) 44.5 (35.0, 53.3) 53.3 (44.9, 60.8)
Brain and other CNS 17.4 (12.3, 24.7) 20.7 (14.9, 28.4) 26.6 (20.4, 33.9)
Thyroid 53.9 (41.7, 63.7) 65.5 (52.6, 75.6) 7X3 (59.3, 81.8)
Non-Hodgkin lymphoma 53.0 (43.4, 61.7) 62.7 (55.9, 68.5) 66.7 (60.6, 71.9)
Hodgkin's disease2 67.2 (55.3, 76.7) 77.1 (64.0, 85.4) 79.9 (65.1,88.4)
Multiple myeloma 30.5 (221, 38.3) 42.7 (34.6, 49.6) 46.5 (39.3, 52.1)
Leukaemia 38.8 (29.5,48.1) 47.5 (38.7, 55.6) 57.1 (48.5, 64.5)
All malign ant neoplaama3 51.3 (50.0, 52.5) 55.4 (54.3, 564) 61.1 (60.2, 62.1)
1 These rates are directly standardised to the world standard cancer patient population.
2 These rates are standardised for the age group 15-74, rather than 15-99 because of small numbers in the 
older age groups.
1 ICD-9 140-208 excluding non-melanoma skin (ICD-9 173).
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T a b le  3 .5 : R e la t iv e  s u rv iv a l1 (% )  a t f iv e  ye a rs  a fte r  d ia g n o s is  (w ith  9 5 %  c o n f id e n c e
in te rv a ls )  b y  c a n c e r  a n d  sex , S c o d a n d , ages 1 5 - 9 9 ,  p a tie n ts  d ia g n o s e d  1 9 7 1 - 9 5
Cancer 1971-75 1981-85 1991-95
Males
Oral cancer 45.5 (28.8, 60.7) 44.5 (33.0, 56.1) 43.8 (32.6, 54.7)
Head and neck 59.9 (51.3, 67.3) 56.9 (49.6, 63.7) 49.9 (43.0, 56.3)
Oesophagus 3.2 (1.4. 7.5) 4.9 (2.5, 9.1) 8.1 (5.0, 12.4)
Stomach 5.8 (3.9, 8.3) 8.2 (5.7, 11.5) 11.5 (8.1, 15.8)
Large bowel 25.7 (21.9, 30.0) 33.3 (29.2, 37.7) 42.7 (38.5, 46.9)
Colon 26.1 (21.1,31.6) 33.7 (28.5, 39.0) 44.2 (38.9, 49.5)
Rectum 24.4 (18.9, 3122) 32.1 (25.5, 392) 39.5 (33.0, 46.3)
Pancreas 3.0 (11,6.3 ) 2.8 (1 .1 ,62 ) 2.8 (1.0, 6.2)
Larynx 58.4 (45.8, 682) 63.2 (51.9, 732) 60.6 (48.9, 70.5)
Trachea, bronchus and lung 6.2 (5.0, 7.7) 5.5 (4.5, 6.7) 6.9 (5.6, 8.5)
Malignant melanoma 48.0 (30.0, 652) 57.6 (45.0, 69.4) 79.4 (66.9, 87.4)
Prostate 36.4 (29.5, 43.8) 39.3 (33.8, 44.9) 49.3 (44.7, 53.9)
Testis2 67.5 (59.3, 742) 87.3 (81.1, 91.1) 93.5 (89.1, 962)
Bladder 54.0 (44.7, 62.3) 58.9 (52.0, 652 ) 67.0 (60.9, 72.5)
Kidney 26.7 (19.3, 35.3) 27.9 (20.9, 37.1) 37.8 (302, 45.8)
Brain and other CNS2 11.1 (7.0, 16.5) 10.4 (6.9, 15.0) 13.7 (9.9, 18.7)
Thyroid2 52.2 (28.5, 70.5) 37.1 (20.1, 51.8) 68.2 (46.0, 82.3)
Non-Hodgkin lymphoma 
Hodgkin's disease2
30.7 (22.5, 40.5) 33.7 (27.7, 40.7) 42.9 (36.6, 49.8)
49.6 (38.9, 60.0) 56.5 (43.5, 68.5) 64.9 (52.4, 75.3)
Multiple myeloma 18.3 (8.9,31.1) 22.1 (11.0, 34.7) 33.4 (18.6, 45.6)
Leukaemia 14.3 (8.9, 20.9) 23.3 (17.0, 30.7) 33.3 (25.6,41.5)
All malignant neoplasms3 21.6 (20.2,23.1) 26.4 (25 .2 ,27 .7) 34.4 (33.1,35.7)
Females
Oral cancer 37.4 (23.5, 50.3) 57.0 (40.5, 69.5) 53.5 (39.1,65.5)
Head and neck 48.9 (38.9, 58.3) 57.3 (48.0, 652) 53.3 (44.0, 61.7)
Oesophagus 8.5 (4.1, 15.4) 7.8 (3.7, 14.4) 8.3 (52, 12.5)
Stomach 6.7 (4.3, 10.0) 9.8 (6.5, 13.8) 14.0 (92, 19.6)
Large bowel 27.4 (24.1, 30.9) 34.1 (30.7, 37.5) 45.0 (412, 48.7)
Colon 27.5 (23.7, 31.5) 34.8 (30.8, 38.9) 45.3 (40.7, 49.7)
Rectum 26.8 (20.9, 33.5) 31.9 (262, 37.9) 43.8 (37.1, 50.3)
Pancreas 4.9 (2.1, 9.1) 3.1 (12, 6.6) 2.9 (1.1, 6.8)
Larynx2 50.8 (31.7, 662) 63.0 (43.1, 75.7) 61.3 (422, 74.9)
Trachea, bronchus and lung 5.7 (42. 7.5) 5.7 (4.3, 7.5) 6.6 (5.0, 8.5)
Malignant melanoma 67.6 (53.7, 78.7) 75.1 (66.5, 82.4) 87.5 (79.5, 92.6)
Breast 56.8 (53.7, 59.8) 62.8 (60.1, 65.3) 72.8 (70.4, 75.1)
Cervix uteri 57.5 (51.6, 63.5) 52.6 (47.6, 57.6) 58.3 (52.8, 63.8)
Corpus uteri 68.3 (59.0, 76.5) 69.4 (62.1, 75.6) 73.9 (66.5, 80.0)
Ovary 32.0 (26.3, 38.3) 32.7 (282, 37.4) 35.9 (31.1,40.7)
Bladder 46.1 (36.4, 55.6) 52.1 (44.7, 59.1) 58.1 (50.6, 64.6)
Kidney 24.3 (16.5, 33.6) 28.4 (20.0, 37.5) 38.0 (29.6, 46.3)
Brain and other CNS 8.9 (4.9, 15.6) 12.5 (7.8, 19.6) 14.6 (102, 21.4)
Thyroid 46.1 (34.3, 562) 55.5 (43.6, 66.3) 62.0 (48.5, 73.9)
Non-Hodglun lymphoma 37.8 (28.4, 47.8) 43.7 (36.4, 50.9) 49.1 (42.1, 55.8)
Hodgkin's disease2 43.2 (31.8, 54.6) 61.3 (47.6, 72.5) 59.2 (43.3, 72.8)
Multiple myeloma 11.9 (6.7, 192) 16.4 (10.6, 23.5) 17.4 (112 ,24.5)
Leukaemia 17.3 (10.7, 25.9) 24.8 (17.5, 32.9) 36.0 (27.4, 44.6)
All malignant neoplasms3 34.0 (32.6, 35.4) 37.3 (36.2, 3S.5) 44.6 (43.5, 45.8)
1 These rates are directly standardised to the world standard cancer patient population.
2 These rates are standardised for the age group 15-74, rather than 15-99 because of small numbers in the 
older age groups.
5 ICD-9 140-208 excluding non-melanoma skin (ICD-9 173).
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Another issue that complicates breast cancer survival estimates is ‘lead time’, where early 
diagnosis increases observed survival times without necessarily preventing or postponing 
death. The improvements in survival from breast cancer in Scotland are even larger at five 
years after diagnosis than at one year after diagnosis. The introduction and increasing use of 
adjuvant systemic therapy and improvements in the management of breast cancer patients 
are both likely to be playing an important role. That the improvements are seen across all 
age bands (with increases of 7% for the 15-44 year-olds, 18% at ages 45-54, 24% at ages 55- 
64, 14% at ages 65-74, 5% at ages 75-84, and 10% at ages 85-99 years), not just those in the 
screening age range, is evidence that at least some of the survival improvement is real. 
These issues are discussed in Chapter 5.
Testicular cancer
For testicular cancer, the large improvements in survival since the 1970s (26%) can be 
wholly attributed to the advent of effective chemotherapy4. In the youngest age group (15- 
44 years), where most (86%) testicular cancers occur, the 5-year relative survival rate is now 
96%.
Leukaemia
The improvements in survival since the 1970s for leukaemia (19% in both sexes) are also 
consistent with known advances in therapy. However, despite these improvements, the 
long-term survival prospects are still poor, and patients who have survived 5 years after 
diagnosis, still have only a 60% chance of surviving another 5 years (data not shown).
Large h ovel cancer
The improvements in survival since the 1970s for large bowel cancer (17% in males and 
18% in females) are seen across all age bands, and for colon cancer the largest improvement 
is seen for older patients. Improved treatment is the most likely cause of the increase.
Thyroid cancer
The improvements in survival since the 1970s for thyroid cancer (16% in both sexes) are 
based on an unstable trend due to small numbers. This is highlighted by the large
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confidence intervals surrounding the estimates. Some improvement is likely to be real due 
to a shift towards a less aggressive type o f thyroid cancer, papillary carcinomas4.
Prostate cancer
Small improvements in survival are observed between all the time periods of analysis; 
however, the large improvement observed in the most recent period is likely to be a length 
bias artefact, as a result of the introduction of prostate-specific antigen (PSA) testing. 
Prostate cancer incidence had been steadily increasing since the 1970’s, then a large increase 
in incidence occurred in the 1990s, largely attributed to the increased detection of small, 
non-lethal tumours through PSA testing.
C em cal cancer
The lack of improvement in survival over time for cervical cancers may reflect the activity of 
the cervical screening programme. Cervical screening aims to pick up tumours at a pre­
invasive stage, so those diagnosed when actually invasive may be more aggressive tumours, 
i.e. although the incidence of cervical cancer is declining, the proportion of incident invasive 
tumours with unfavourable prognosis may be increasing.
Whether gains in survival observed in the recent past are likely to continue in the future 
depends on why survival has improved. Better treatment is likely to account for all or most 
of the gains in survival from cancers o f the testis and bone, Hodgkin’s disease and non- 
Hodgkin lymphoma, and leukaemia; earlier diagnosis may account for higher survival from 
melanoma of the skin; while higher survival from breast cancer is probably the result of 
both earlier diagnosis and better treatment114, and gains for thyroid cancer are at least partly 
due to a shift in the type of disease.
Survival by deprivation group
Relative survival at five years after diagnosis among patients diagnosed in Scotland during 
1991-95 was 11% higher in females and 12% higher in males in the most affluent group than 
in the most deprived group (Table 3.6). The largest differences in survival were seen for
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leukaemia (17%) and malignant melanoma of the skin (16%) in males, and bladder cancer 
(19%), Hodgkin’s disease (18%), kidney (15%) and cervical (13%) cancers in females. 
Differences of over 5% were also seen for head and neck (11%), stomach (8%), colon (7%) 
and laryngeal (7%) cancers, non-Hodgkin lymphoma (8%) and multiple myeloma (7°/o) in 
males; and stomach (8%), colon (6%), breast (7%) and ovarian (8%) cancers in females. 
Caution must be used when interpreting these results, because some of the sex-age- 
deprivation combinations are based on small numbers of cases that may produce unreliable 
estimates.
The large difference in survival between affluent and deprived females with bladder cancer 
was restricted to patients aged over 55 years old. There was a strong survival gradient at 
five-years after diagnosis across the deprivation groups for the 55-74 year olds, ranging from 
82% in the most affluent group (139 patients) to 58% for the most deprived group (223 
patients). There was no evidence of a survival gradient in the oldest age group with survival 
of around 46% for patients in deprivation groups 1-4, but a large decrease in survival for 
patients in the most deprived group (25%; 161 patients).
The difference observed for Hodgkin’s disease in females (ages 15-74) was probably 
artefactual due to a large difference survival for patients aged 55-74 years, ranging from 70% 
for the most affluent to 42% for the most deprived group, based on only 12 and 13 cases, 
respectively.
Despite the large overall difference in survival between the most affluent and deprived 
women with kidney cancer, there was no clear gradient across the deprivation groups a t any 
age. For 55-74 and 75-99 year-olds, the most affluent women had higher survival than 
women in the other deprivation groups.
For cervical cancer, the deprivation gradient in five-year survival was clearly defined for 
women aged under 55 years: 82% for the most affluent (184 women) compared to 71% for 
the most deprived (277) women. For women aged 55-74 years, survival was higher for those 
in the most affluent group (63%) than in the other deprivation groups (around 47%). There 
was no trend across the deprivation groups for older women.
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Table 3.6: Difference in five-year relative survival estimates1,2 between affluent and 
deprived groups, Scodand, ages 15-99, patients diagnosed 1991-95
Cancer Males Females
Affluent Deprived D ill Affluent Deprived D itt
Oral cavity 43.6 (25 .0, 61.7) 36.7 (25.5, 51.5) 6.9 51.3 (26.1, 712) 37.8 (19.6, 57.8) 13.5
Head and neck 53.4 (41.7, 65.6) 42.5 (54.0, 50.6) 10.9 55.3 (39.0,68.6) 50.8 (382, 61.9) 4.6
Oesophagus 10.5 (5.5, 17.5) 5.9 (2.5, 11.8) 4.6 8.3 (2.3, 192) 8.4 (3.5, 16.1) 4.1
Stomach 18.2 (11.4,26.1) 10.6 (62, 16.4) 7.6 18.9 (9.7,29.9) 10.5 (5.5, 18.8) 8.4
Large bowel 46.7 (40.6, 52.7) 40.9 (54.6, 47 2 ) 5.8 48.8 (432, 542) 44.2 (38.0, 502) 4.6
Colon 46.6 (59.0, 55.9) 39.2 (51.1, 47 2 ) 7.4 49.5 (42.8, 55.8) 43.7 (36.5, 50.6) 5.8
Rectum 45.9 (55.6, 55.7) 44.9 (55.9, 55.3) 1.0 46.6 (36.5, 56.0) 44.8 (32.7, 55.8) 1.8
Pancreas3 2.3 (0.4, 8.0) 1.2 (0.2, 5 2 ) 1.1 2.0 (0.5, 5.4) 2.3 <0.7, 5.9) ■0.3
Larynx4
Trachea,
61.7 (58.5, 78.0) 55.2 (39.9, 67.5) 6.5 *
bronchus, lung 
Malignant
7.7 (5.5, 10.7) 6.2 (4.7, 8.1) 1.3 5.1 (3 .0 ,82) 5.7 (4.0, 7.8) ■0.6
melanoma 83.4 (65.0, 92.4) 68.0 (44.6, 83.6) 15.5 89.3 (76.4, 95.1) 84.7 (68.3, 92.9) 4.6
Breast - - 77.2 (73.6, 80.4) 70.3 (66.1, 742) 6.9
Cervix uteri - - 68.6 (57.9, 77.7) 56.1 (48.0, 64.4) 12.5
Corpus uteri - - 14.4 (62.3, 83.3) 71.3 (56.7, 81.4) 3 2
Ovary - - 33.3 (25.8,41.0) 25.0 (17.6, 33.1) 8.3
Prostate 54.6 (48.5, 60.5) 51.7 (43.7, 59.3) 2.9 • -
Testis5 95.5 (90.9, 97.8) 92.4 (85.7, 96.0) 3.1 - -
Bladder 70.2 (61.9, 76.8) 67.4 (57.4, 75.7) 2.8 66.6 (53.0, 76.6) 47.9 (372, 572) 18.7
Kidney 40.4 (292, 52.0) 35.5 (23.3, 48.5) 4.9 45.3 (30.1, 59.1) 30.2 (17.4, 44.1) 15.0
Brain
and other CNS 11.9 (7.8, 212) 14.4 (7.0, 27.7) ■2.4 20.0 (12.1, 30.6) 15.6 (9.0, 27.3) 4.4
Thyroid4 - - - -
Non-Hodgkin
lymphoma 46.7 (55.8, 57.0) 38.7 (28.7, 50.3) 8.0 50.5 (39.1,60.7) 48.4 (35.6, 59.7) 2.1
Hodgkin's disease6 64.3 (45.5, 79.7) 71.6 (50.0, 85.6) ■7.3 82.6 (55.0, 942) 64.3 (40.0, 81.4) 18.3
Multiple myeloma3 27.3 (9.1,48.4) 20.6 (6.2, 39.6) 6.7 21.7 (10.9, 34.8) 20.5 (10.3, 35.3) 12
Leukaemia 
All other
38.1 (25.4, 50.6) 21.4 (112, 34.6) 16.7 37.4 (24.7, 49.6) 33.7 (20.5, 47.4) 3.7
malignancies 
All malignant
16.9 (12.8, 21.5) 11.1 (7.9, 15.0) 5.8 19.6 (15.0,24.4) 14.8 (11.0, 19.1) 4.8
neoplaams 40.3 (38.1, 42.4) 27.9 (26.0, 29 .7) 12.4 49.5 (47.7, 51.3) 38.6 (36.9, 40.4) 10.9
1 Standardised (ages IS-54, 55-74,75-99) to the world standard cancer patient population
2 Using deprivation-specific life tables
3 Truncated standardised rate (ages 55-99) for the females
4 Too few cases to perform the analysis (larynx - females, thyroid - both sexes)
3 Age-specific rate for ages 15-54
6 Truncated standardised rate (ages 15-74)
Survival differences for males with leukaemia are difficult to interpret, because there was no 
evidence of a trend across the deprivation gradient for any of the age groups, but for each 
age group the most deprived group had much lower survival than the other deprivation 
groups. Survival for young men in deprivation groups 1-4 was around 42% compared to 
28% for the most deprived men. For the 55-74 year-old age group, survival was around 
35% for men in deprivation groups 1-4 and 24% in the most deprived men; and for the
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oldest age group, survival was around 20% for men in deprivation groups 1-4 compared to 
7% for the most deprived men.
For males with malignant melanoma of the skin, the magnitude of the difference between 
the deprivation groups was partly an artefact of the standardisation procedure, because the 
estimates in the oldest age group are based on a small number of cases. However, in the 
other age groups, there was clear evidence of a deprivation gradient; five-year survival for 
15-44 year-old men from affluent areas was 82% (129 men), compared to 74% for men in 
the most deprived areas (60 men), and for 45-74 year-old men from affluent areas survival 
was 89% (95 men) compared to 67% for men from the most deprived areas (60 men).
Deprivation-specific survival estimates vary depending on the type of survival analysis 
undertaken. Three methods were compared: (1) relative survival using deprivation-specific 
life tables, (2) relative survival using general life tables, and (3) cause-specific survival. For ‘all 
malignancies combined’ the difference in survival estimates between the most affluent and 
deprived females at five years after diagnosis was 12.3% using method 1, 14.4% using 
method 2 and 13.3% using method 3, and between affluent and deprived males was 14.4%, 
15.0% and 14.1%, respectively (Table 3.7).
Table 3.7: Comparison of five-year survival rates (with 95% confidence intervals) using
(1) relative survival with deprivation-specific life tables {dep), (2) relative 
survival with general life tables (gen), and (3) cause-specific survival, Scotland, 
ages 15-99, patients diagnosed 1991-95, all malignancies combined
Deprivation
category Relative (d ep )
1-year survival 
Relative O reli) Cause-specific Relative (d ep )
»-year survival 
Relative ( g en ) Cause-specific
Males
Affluent 58.3 (57-60) 58.5 (57-60) 64.0 (62-66) 39.6 (38-42) 40.3 (38*2) 51.0 (49-53)
2 54.4 (53-56) 54.4 (53-56) 59.5 (58-61) 36.4 (34-38) 36.3 (34-38) 46.8 (45*9)
3 51.9 (50-54) 51.8 (50-54) 57.2 (55-59) 34.6 (33-37) 34.2 (32-36) 44.9 (43*7)
4 49.7 (48-51) 49.4 (48-51) 55.3 (53-57) 31.7 (30-34) 30.8 (29-33) 43.0 (41*5)
Deprived 43.9 (42-46) 43.5 (42-45) 49.9 (48-52) 27.3 (26-29) 25.9 (24-28) 37.7 (36*0)
Overall S1.4 (51-52) 51.3 (51-52) 57.0 (56-56) 33.7 (33-35) 33.2 (32-34) 44.6 (44-46)
Females
Affluent 65.3 (64-67) 65.4 (64-67) 69.2 (68-71) 48.8 (47-51) 49.1 (47-51) 56.4 (54-58)
2 62.1 (61-64) 62.1 (61-64) 66.0 (64-67) 45.5 (44-47) 45.6 (44*7) 53.3 (52-55)
3 60.0 (59-62) 60.0 (59-62) 64.5 (63-66) 43.8 (42*6) 43.7 (42*5) 52.1 (50-54)
4 57.5 (56-59) 57.4 (56-59) 61.9 (60-63) 42.3 (41*4) 41.7 (40*3) 50.4 (49-52)
Deprived 54.8 (53-56) 54.6 (53-56) 59.3 (58-61) 37.9 (36*0) 37.0 (35-39) 47.0 (45*9)
Overall 59.9 (59-61) 39.8 (59-61) 64.1 ( “ 0 2 43.6 Æ Q 2 433 J4 3 * 4 l 31.8 (51-53)
The survival estimates produced by the three methods when specific cancers were analysed 
were very different for some cancers (data not shown). However, all three methods showed 
similar trends across the deprivation groups for all cancers. The two relative survival 
methods produced similar overall survival estimates, and where the estimates did differ 
(difference of more than 2%), this was because the survival estimates using deprivation- 
specific life table were higher for the more deprived groups (deprivation categories 4 and 5) 
than if general life tables were used. This most notably occurred for males in the oldest age 
group (75-99) for a number of cancers (data not shown).
The cause-specific estimates did not appear to be comparable to the relative survival 
estimates, with differences in survival of up to 25% for some cancers. Many of the large 
differences were in the lympho-haematoetic malignancies: for example, for men from 
deprivation group 3 aged 75-99 diagnosed with leukaemia (75 men) the relative survival 
estimate was 13% compared to a cause-specific survival estimate of 38%. The cause-specific 
survival estimates were generally higher than the relative survival estimates at both one and 
five years after diagnosis. This very probably indicates an under-assigning of deaths to 
cancer on death certificates, particularly in older patients. However, for patients with 
malignant melanoma of the skin and large bowel, bladder and prostate cancers, the cause- 
specific survival estimates were lower than the relative survival estimates. This is difficult to 
explain, as it seems unlikely that patients with cancer have a better underlying mortality than 
the general population. For prostate cancer, this may again be an artefact of PSA testing, 
resulting in over-reporting of prostate cancer as the primary cause of death on death 
certificates"5.
Despite the improvements in survival observed over time in Scotland, there are still large 
variations in survival between deprivation groups for patients diagnosed during 1991-95 for 
some cancers, in particular for colon, breast, cervix, ovary, bladder and kidney cancers, and 
malignant melanoma of the skin. These differences are quantified in Chapter 4.
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C h a p t e r  4
AVOIDED AND AVOIDABLE DEATHS
Background
There are a number of references to “avoidable mortality” in the literature. The concept 
was first proposed by Rutstein et a t16 and was defined as “mortality wholly or substantially 
avoidable by adequate medical care”. The authors presented lists of causes of death defined 
as “avoidable” or “partly avoidable”, either through prevention or treatment. The 
“avoidable mortality” list included a number of cancers (ICD-10 codes: C02, C04, C06, C32, 
C33, C34, C44, C67, C73 and C92). Subsequently, these lists have been used in other 
studies"7 m to investigate the risk o f death from avoidable causes in relation to socio­
economic status and area o f residence. This method relies on the adequacy of the lists, on 
the reliability of the information recorded on death certificates and the comparability of 
death certificates between different populations. The method can be used for calculation of 
avoidable mortality in the population as a whole but cannot be restricted to, for example, a 
cohort of cancer patients’ excess mortality. This has been achieved through retrospective 
follow-up studies where death is attributed to either the cancer, unrelated causes and 
avoidable (treatment or care related) causes through the examination of medical records120.
The idea of estimating “avoidable mortality” is being increasingly used in Public Health. The 
government health target o f July 1999 stated the aim “to reduce mortality from cancer in 
people aged under 75 in England by at least 20% by the year 2010 [compared to 1997] - 
saving up to 100,000 lives”47. The extent to which this target is likely to be met can be 
partly investigated by looking at avoidable mortality, or avoidable deaths.
Population-based methods of estimating “avoidable deaths” - without the problems of 
creating lists of avoidable illnesses and having to rely on death certificate information - have 
recently been published. 'Iliey can be used to look at excess mortality in specific 
populations of patients e.g. cancer patients. They are based on differences in cancer survival 
between groups of patients, and are defined as the number of deaths attributable to cancer
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that would be avoidable if patients in all groups were to have the same relative survival as 
that actually observed for patients in the “best” group. This approach can be applied to 
differences between socio-economic groups, geographic regions or countries. An equivalent 
question is to ask how many deaths have been avoided through improvements in survival 
between two time periods, and this can be termed the number of “avoided deaths”.
Two methods of calculating “avoidable deaths” have been identified in the literature: one 
based on a standardisation-type technique'' and the other based on a modelling approach35. 
These methods are presented in detail in the methods section, and the number of cancer 
deaths that would be avoidable if  all socio-economic groups in Scotland had the same 
survival as the most affluent socio-economic group and the average survival for Europe are 
presented in the results section. The numbers of cancer deaths that have been avoided due 
to improvements in survival over time in Scotland are also presented.
These are the only references found in the literature where avoidable deaths are calculated 
using survival analysis techniques. However, similar methodology has recently been used in 
a different context - to investigate the reduction in persons being admitted to hospital if
personal risk factors could be changed121. The authors use the term “ What i f . ........?”
scenarios and their approach is to manipulate regression coefficients calculated in a 
multivariate logistic regression model. For example, to calculate the predicted probability of 
hospital admission [what] if their entire cohort had never smoked, the regression coefficient 
of the ‘never smoked’ category was assigned to the other categories of the smoking variable 
(i.e. ‘ex-smoker*, ‘current smoker’), whilst the coefficients of the other predictor variables 
were unaltered. The resulting predicted probability was then summed to calculate the 
predicted number of persons admitted to hospital if none of the cohort had ever smoked 
and this was compared to the number of persons actually admitted to hospital in the cohort.
Data and Method«
Data
Survival variations in Scotland betw een deprivation groups and over time
Trends in survival for patients diagnosed with cancer in Scotland between 1971 and 1995 
and followed up to the end of 1998 have been reported in Chapter 3. For the analyses in this
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chapter, 5-year relative survival estimates for patients diagnosed during 1971-1995 were 
extracted by type of cancer, sex, period of diagnosis, age at diagnosis and deprivation 
category. Deprivation-specific life tables for Scodand were used in the calculation of relative 
survival. See Chapters 1, 2 and 3 for a detailed description of the analytic methods for the 
estimation o f the cancer survival trends, data collection and exclusion criteria. For the 
standardisation analysis, information on numbers of cases and the cumulative relative survival 
rates at five and ten years after diagnosis was extracted. For the modelling analysis, information 
on the numbers of cases, number of deaths, interval-specific expected survival rates and interval- 
specific relative survival rates was extracted for each 6-month follow-up interval up to five years 
after diagnosis.
Survival in Scotland compared to Europe
The number of avoidable deaths may be calculated as compared to, for example, the 
“average” survival between societies or to the society with the “best” survival. In this 
chapter, survival in Scotland has been compared to that in the other countries within 
Europe using data from the EUROCARE II study6. Numbers o f cases and five-year relative 
survival rates for patients diagnosed during 1985-1989 (the most recent period available) 
were extracted by type of cancer, country, sex and age at diagnosis (15-44, 45-54, 55-64, 65- 
74, 75-99 years).
The countries included in the EUROCARE II study are:
Austria Denmark England Estonia
Finland France Germany Iceland
Italy Netherlands Poland Scotland
Slovakia
Switzerland
Slovenia Spain Sweden
Methods
The two methods for calculating avoided and avoidable deaths, identified in the literature, 
are explained below:
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Methods
The two methods for calculating avoided and avoidable deaths, identified in the literature, are 
explained below:
Standardisation S let bod
The standardisation method4 calculates the number of avoided (or avoidable) deaths as the 
difference between the observed and expected excess cancer mortality, where the excess cancer 
mortality is defined as the number of deaths observed within (say) 5 years of diagnosis, over and 
above the number of deaths that would have occurred if the patients had only experienced the 
same mortality as that of the corresponding sex and age group of the general population during 
the same calendar period.
For example, the observed excess cancer mortality, for patients diagnosed 1991-95, is estimated 
by multiplying the complement of the relative survival rate for 1991-95 for each category of 
sex and age by the corresponding number o f  patients diagnosed during 1991-95. The excess 
mortality for each cancer is then the sum o f these estimates across all subgroups. The 
expected excess cancer mortality is estimated in a similar fashion, but using the complement of 
the relative survival rate for patients diagnosed during 1986-90, multiplied by the number of 
patients diagnosed during 1991-95. This represents the excess deaths that would have been 
expected among patients diagnosed during 1991-95 if there had been no improvement in 
relative survival over the previous five years.
The number of avoided deaths in patients diagnosed during 1991-1995 compared to those 
diagnosed during 1986-90 is, therefore, calculated for each cancer (by i=age, j=sex) as
Avoided = £  Nm l_„v (RSRtl99l-95(/
where.
^iw i-9 s = Number of patients diagnosed (and in the analysis) during 1991-95
/?5/?,w|_,j = Relative survival rate for patients diagnosed during 1991-95
f t ^ i 9**-9o = Relative survival rate for patients diagnosed during 1986-90
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The percentage of avoided deaths is calculated as the number o f avoided deaths divided by 
the expected excess cancer mortality.
The number of avoidable deaths if patients in all groups of society had the same prospects as 
those in the most affluent group is calculated for each cancer (by i=age, j=sex) as
The percentage of avoidable deaths is calculated as the number of avoidable deaths divided 
by the observed excess cancer mortality summed over the deprivation categories.
Mode /liny, M ethod
The modelling method35 uses the interval-specific numbers o f cases, deaths and expected 
mortality (calculated from life tables) in a multiple regression model. The total mortality rate 
(number of deaths divided by person-years at risk) for persons diagnosed with cancer is 
modelled as the sum of the known baseline mortality (the expected mortality) and the excess 
mortality due to a diagnosis o f cancer.
The excess mortality, v, is assumed to be a multiplicative function of the covariates (e.g. 
p=period, i=age, j=sex), such that
where,
k = Deprivation category (2 to 5)
= Number of patients in deprivation category k
= Relative survival rate for patients in deprivation category 1 (most affluent) 
= Relative survival rate for patients in deprivation category kRSRk
Pii ’
(.Pp+Pi+Pj)
and the annual interval-specific relative survival is
9 7
R R
P
The magnitude of the expected random variation (s2b) can be estimated based on the
number o f  cases and the survival rate. The variance of the true systematic effects ((T2p) can 
therefore be estimated (V) as
and n represents the number of time periods (J>). The mean of the Ps ( b )  is set to zero.
V will be zero or negative if no systematic variation in survival exists and will increase in 
magnitude as the level of systematic variation increases. Shrinkage estimates (i.e. estimates 
that are adjusted to remove the effect o f random variation) of the relative risk of excess 
mortality due to cancer for patients diagnosed in time period p, are calculated by shrinking 
the crude relative risks towards the mean (RR=1), such that
Finally, the number of cancer deaths in follow-up interval f ,  age i, and sex j  is defined as the
RR
P
ifV>0 , where
RR* -1 otherwise
P
number of deaths (calculated from the number of cases {t) and the model-based interval- 
specific relative survival (i)) minus the number of expected deaths {(p") calculated from life 
tables), such that
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The number of cancer deaths if there was no variation in survival over time period (or social 
groups etc.) is calculated as
s-iitv  . * .. new ,
c *  r V ° ' V  >
_ new -—-
Where r ™  = , #  and v ™  = , 196vM „
tv  tv  it
and vf  is based on the estimates from a model containing no time period term.
The calculation is based on the lower confidence interval of the shrinkage estimates in order 
to look at improvements that have been made (i.e. comparing higher estimates to lowest 
estimate). When looking at avoidable deaths between deprivation groups (i.e. comparing 
lower estimates to the highest estimate) then the calculation is based on the upper 
confidence interval which in practical terms means inserting a minus sign in front of the 1.96 
in the above equation.
The number of avoided (or avoidable) deaths is then calculated as
M=X c * - c r  i fv  > o
* iA = 0 J  otherwise.
The choice for the model used for each analysis is based on the change in deviance as extra 
terms are added to the model (compared to the chi-squared distribution). Generally, the 
smaller s2 (=deviance/d.f.) represents a better model fit. The significance of the period (or 
deprivation) term in the chosen model can be similarly investigated by looking at the 
significance of the difference in déviances between the chosen model and the same model 
with the period (or deprivation) term omitted. The model-based interval-specific relative 
survival estimates can be compared to the true relative survival estimates to visually assess 
model fit.
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Choosing the comparison group - “average" or “best”
When comparing survival in Scotland to that in Europe, different scenarios can be 
considered. We have estimated how many cancer deaths could be avoidable within five 
years of diagnosis among cancer patients diagnosed in Scodand (based on relative survival 
estimates for Scodand from Eurocare II) if survival rates for these patients was equivalent
to :
(a) The weighted average cancer survival in Europe
(b) The “best” cancer survival in Europe
The “weighted average” cancer survival in Europe was calculated by multiplying each 
countries cancer-, age- and sex-specific relative survival rates by a weight calculated as the 
totality of cases diagnosed in country k divided by the totality of cases diagnosed in all the 
countries considered (excluding Scodand). These weights were calculated and applied 
separately for each cancer, age and sex.
The “best" cancer survival in Europe was calculated as the analysis weighted average of the 
relative survival estimates of the three countries with highest cancer-specific age- 
standardised relative survival estimates (excluding England, Scodand and Switzerland*1). The 
cancer-specific (but not age- and sex-specific) weight was calculated as the number of cases 
analysed in country k divided by the number o f  cases analysed in the three “best” countries. 
The cases analysed weight rather than a totality o f  cases weight was chosen to avoid giving too 
much weight to estimates based on small numbers (because for some countries the survival 
estimates are based only on a small area of the country). The weights were applied to the 
age- and sex-specific relative survival estimates for the three countries.
The three countries with the highest age-standardised relative survival rates are included for 
each cancer. Austria and Sweden are the two countries which appeared amongst the “best” 
the most frequendy (Table 4.1). For example, Austria was one of the “best” three for 11 of 
the 22 cancers studied. The majority of countries appearing in the “best” three were only 
represented by a small proportion of the countries population and so may not be
d Switzerland (bated on the Geneva cancer registry data) is  excluded from the choice o f “best” because o f problems 
identifying dead patients due to a highly transient population
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representative o f the country. However, their survival estimates still indicate a level of 
survival that is achievable even if this may not have been achieved countrywide.
Table 4.1: The countries with the highest survival as identified by EUROCARE-11‘ , by
cancer
Country Number 
of cancers1
% Coverage of the 
national population2
Austria 11 7.8
Denmark 1 100
Estonia 1 100
Finland 5 100
France1 7 3.0-5.6
Germany 5 1.7
Iceland 7 100
Italy 2 9.7
Netherlands1 6 5.7-20.5
Slovakia 4 100
Slovenia 1 100
Spain1 5 9.6-12.9
Sweden 14 17.5
1 The number of cancer sites for which each country had first, second or third highest age-standardised 
survival
2 The proportion of the national population included in the EUROCARE-II data
5 These countries also have specialised cancer registers leading to increased coverage for some cancers
The number of avoidable deaths for the European analysis was calculated for each cancer 
(by i=age, j=sex) as
Avoidable = l N #(MR d -*S R ScotLmd )
y  9 y
where,
N = Totality of cases diagnosed in Scodand during 1985-89
RSRfmmd = Eurocare II relative survival rate for the European "weighted average” or "best”
Thefollow-up interval
The calculation o f avoided deaths covers a finite follow-up interval, say five years, and it 
does not represent the number of deaths avoided due to changes in the effective “cure” of 
patients over time. Where sustained improvements in survival are seen for cancers with 
long-term excess cancer mortality (e.g. breast cancer), the number of avoided deaths will
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continue to increase as time since diagnosis increases. By contrast, for cancers with very 
poor survival for which improvements in survival tend to extend life rather than increase the 
proportion of patients cured (e.g. lung cancer), the number of avoided deaths will decrease 
with time since diagnosis as the initial survival advantage is lost (see Table 4.2). Ideally, one 
would measure the number of avoided deaths from diagnosis to the time of cure, which will 
vary between cancers, and over time.
Table 4.2: The number of avoided deaths within a specific time interval: patients
diagnosed in Scotland during 1986-90 with breast and lung cancer
Time since 
diagnosis
Breast
cancer
Lung
cancer
1 year 276 176
3 years 701 91
5 years 1,025 83
10 years 1,141 61
The number o f  cases used in the calculations
It can be argued that the number o f cases included in the analysis should be used in the 
calculation of “avoidable deaths” instead of totality o f  cases diagnosed. This is because the 
main reasons for exclusion of cases from survival analyses are generally if the cancer was not 
a first primary or if the only information about the cancer was from the death certificate. 
These cancers are expected to have a poorer than average survival, and therefore it would 
seem inappropriate to include them in the calculation. Including only the number of cases 
analysed leads to conservative estimate o f  the number of avoidable deaths. However, the 
Eurocare II study population covered only 50% of England (100% of Scotland, 0% of 
Wales) and so in an analysis of avoidable deaths in England compared to Europe it would be 
inappropriate to base the number (N) in the avoidable deaths calculation on cases included in 
the anatysis. The choice of N can greatly effect the estimated number of “avoidable deaths” 
and so should be carefully considered and clearly stated when presenting results. It was felt 
to be appropriate to use number of cases included in the anatysis for this chapter, as a high 
proportion of Scottish cases were included in the Eurocare analyses, and the exclusions were 
for valid reasons as mentioned above.
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Variability in the data
When comparing many survival rates — e.g. by cancer, age, sex, period, country or 
deprivation category - there will be some estimates based on very small numbers which may 
not be stable. When there are very few cases, or few cases and no deaths, the survival 
estimates will not be computed. For the standardisation method, when making comparisons 
over time, the effect o f unstable or missing estimates on the final estimates of avoided 
deaths will be small, as the N  corresponding to the unstable or missing survival estimates 
will be, by definition, very small. However, when comparing countries with very different 
incidence of cancers, particularly over age, this can be more of a problem and should be 
borne in mind. The modelling technique includes a random variation component to 
account for these situations, although there are still problems if estimates are missing.
R esults an d  com m en tary  
Avoided deaths
Cancer survival in Scodand has been increasing over time (see Chapter 3). The numbers of 
deaths that have been avoided within 5 years of diagnosis, due to improvements in survival 
for cases diagnosed in 1991-95 compared to those diagnosed in 1986-90, was calculated 
using the both the standardisation and modelling method. The “all malignancies combined” 
estimate was calculated both from (1) the sum o f the individual cancers plus the “other 
malignancies” group and (2) from an analysis of the whole data set combined. The 
individual cancers included amounted to 90% o f all malignant neoplasms (excluding non­
melanoma skin cancer).
In the standardisation analyses the estimated number of avoided deaths was 3 316 (4.6% of 
cancer deaths that would of occurred) when the individual cancers were summed or 4 276 
(5.8%) if the whole data set combined was analysed fTable 4.3). Using the sum of individual 
cancers should be a more reliable estimate as it takes account of cancer case-mix (changes in 
the proportion of different cancers, with varying survival, diagnosed). The “other 
malignancies” group may be confounded by problems of case-mix, but the analysis of this 
group was not split down further due to the small numbers for individual cancers and 
because half o f this group comprise of cancers of ill-defined primary site, secondary 
malignancies and unspecified site (ICD9 195-199). The largest numbers o f avoided deaths
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were seen for cancers of the breast (1 026 deaths avoided), large bowel (824), prostate (466) 
and bladder (353). Results for England and Wales, based on an analysis of deaths avoided 
by improvements in survival between 1981-85 and 1986-90, showed the same cancers as 
having the largest numbers of avoided deaths122 with the exception of prostate cancer (but 
this may be explained by the different time periods studied - the increases in prostate cancer 
survival in Scotland in the 1990s are likely to be largely an artefact of PSA testing).
Table 4.3: Avoided deaths within five-years of diagnosis due to improvements in
survival over time using the standardisation method: patients aged 15-99 
diagnosed in Scotland during 1991-95 compared to 1986-90
Cancer Number
of
patienta
Number 
of deaths
Number o f excess 
cancer deaths'
Avoided
Observed Expected N %
Oral cavity 1,261 759 697 731 34 4.6
Oesophagus 3,285 3,055 3,044 3,086 42 1.4
Stomach 4,722 4,250 4,214 4,296 82 1.9
Large bowel 14,421 9,152 7,998 8,822 824 9.3
Colon 9,615 6,069 5,259 5,796 537 9.3
Rectum 4,806 3,083 2,747 3,030 284 9.4
Pancreas 2,541 2,474 2,481 2,481 0 0.0
Larynx 1,302 619 520 530 10 1.8
Lung 20,850 19,670 19,667 19,754 86 0.4
Melanoma 2,542 600 384 432 48 11J
Breast (females) 14,449 4,874 3,926 4,951 1,026 20.7
Cervix uteri 1,859 751 721 752 31 4.1
Body of the uterus 1,518 520 417 473 56 11.9
Ovary 2,507 1,827 1,813 1,841 28 1.3
Prostate 7,147 4,274 3,281 3,748 466 12.4
Testis 834 60 50 67 17 23.0
Bladder 6,062 2,908 2,117 2,470 353 14.3
Kidney 2,251 1,501 1,417 1,485 68 4.6
Brain and other CNS 1,505 1,260 1,267 1,315 49 3.7
Thyroid 504 135 126 139 13 9.3
Non-Hodgkin's lymphoma 3,319 2,027 1,916 1,965 49 2.3
Hodgkin's disease 618 189 183 223 40 17.8
Multiple myeloma 1,335 1,093 1,080 1,083 3 0.3
Leukaemia 2,129 1,554 1,495 1,538 43 2.8
Other malignancies2 12/118 10,262 10,249 10,200 -49 0.4
All malignancies3 108,979 73,814 69,746 74,022 4/76 5 .8
All malignancies4 108,979 73,814 69,070 72/86 3/16 4 .6
1 Excess deaths = number of cases x  (1- relative survival rate)
2 Including ICD9 140,142,146-149,152,155,156, 158,159,160,163,164,165,170,171,175, 179, 181,184, 
187,190 and 194-199
3 Calculated from an analysis of the whole dataset combined (excluding non-melanoma skin cancer)
4 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
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The number of avoided deaths is dependent both on the incidence of the cancer and on the 
survival gradient itself. It highlights those cancers for which the improvements in survival 
over time have had the largest impact on total cancer mortality. The percentage o f avoided 
deaths highlights those cancers for which there have been the largest improvements in 
survival, and is not dependent on incidence. The cancers with the largest percentages of 
avoided deaths are testis (25%), breast (21%), Hodgkin’s disease (18%), bladder (14%), 
prostate (12%), corpus uteri (12%) and malignant melanoma o f the skin (11%).
Looking at the numbers of avoided deaths within five years and ten years of diagnosis over 
the whole time period 1971-1995, the number of avoided deaths within 5 years of diagnosis 
for “all malignancies combined” increased by a similar amount over each time period (Table 
4.4), and the percentage of deaths avoided within 5 years increased from 1% to 5% over the 
whole period. For almost all cancers a gain was seen within each period compared to the 
previous period although the magnitude of the gain varied over time (data not shown). The 
gains 10 years after diagnosis were generally smaller than those seen after 5 years due to the 
prolonging of life but no cure for a proportion of the patients. The exceptions to this were 
testicular cancer, thyroid cancer and malignant melanoma o f the skin indicating that a 
sustained and increasing improvement in survival was occurring as time since diagnosis 
increased for these cancers. For lung cancer, bladder cancer and leukaemia, deaths had been 
avoided at 5 years after diagnosis but these had disappeared by 10 years after diagnosis. The 
proportion of deaths avoided within 10 years o f diagnosis was also increasing with time, with 
3% of deaths avoided within 10 years o f diagnosis in patients diagnosed 1986-90 compared 
to those diagnosed 1981-85, whereas only 1% of deaths were avoided in patients diagnosed 
1981-85 due to improvements in survival from 1976-80 (Table 4.4).
Two models were adopted for the regression analysis: model 1 (period, sex and age terms) 
and model 2 (period, sex, age and an age by follow-up interaction terms). For cancers where 
the model fit was poor for both models, examination of the relative risk estimates for period 
by age and sex, led to additional age terms being added in some instances. For some cancers 
where estimates were based on small numbers of cases, the model fit was improved by 
reducing the number of follow-up intervals in the analysis. When the estimated variance of 
the true systematic effects (V) was zero or negative then the number of deaths avoided were 
assumed to be zero.
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Table 4.4: Number and percentage of deaths avoided within 5 and 10 years of diagnosis
due to improvements in survival over time using the standardisation method: 
patients diagnosed in Scotland during 1971-95, each period compared to the 
previous period1
Time since 
diagnosis
Cancer 1976-80
N %
1981-85
N •/,
1986-90
N •/,
1991-95
N %
5 yean All malignancies2 1,147 1.8 2,120 3.0 3,510 4.9 4,276 3.8
All malignancies3 729 1.1 1,633 2.3 2,622 3.7 3,316 4.6
10 yean All malignancies2 924 1.3 1,736 2.3 2,853 3.7 -
All malignancies3 509 0.7 1,378 1.9 2,189 2.9 -
1 Estimates for 1976-80 are based on improvements since 1971-75, etc
2 Calculated from an analysis of the whole dataset combined (excluding non-melanoma skin cancer)
3 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
The total number o f cancer deaths was calculated from the model-based relative survival 
estimates and so varies from the numbers of cancer deaths shown in Table 4.3 for the 
standardisation method. The estimated number of avoided deaths for “all malignancies 
combined”, calculated as the sum of the individual cancers, was 2 411 (3.9% of cancer 
deaths that would o f occurred; Table 4.5). If the random variation component is not taken 
into account then the estimate is higher (3 260 deaths avoided; 5.2%). The largest numbers 
of avoided deaths were generally seen for the cancers where the period term was very 
significant in the chosen model. The cancers w ith the largest number of avoided deaths 
were the same as identified by the standardisation method, including cancers of the breast 
(738 deaths avoided), large bowel (712), prostate (214) and bladder (257).
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T a b le  4 .5 : Deaths avoided due to improvements in survival estimated with the 
modelling method: patients diagnosed in Scodand during 1991-95 compared 
to 1986-90
Cancer Sex Power 
of age 
term
Age by 
follow-up1 
interaction
Selected model P-value
for
period2
V2
Deviance D.F. Deviance
/D.F.
Oral cavity M 2 128.8 95 1.36 0.820 -0.0024
F 2 115.6 92 1.26 0.770 -0.0119
Oesophagus M 4 Yes 98.7 91 1.08 0.014 0.0002
F 3 98.3 94 1.05 0.608 -0.0023
Stomach M 3 Yes 94.7 92 1.03 0.000 0.0018
F 4 Yes 131.2 90 1.46 0.104 -0.0027
Colon M 3 Yes 145.5 89 1.63 0.000 0.0019
F 3 Yes 198.8 90 2.21 0.000 0.0028
Rectum M 2 Yes 148 92 1.61 0.002 0.0030
F 2 Yes 138.3 92 1.50 0.001 0.0036
Pancreas M 1 119.4 95 1.26 0.760 -0.0034
F 4 98.7 92 1.07 0.510 -0.0045
Larynx M 1 95.1 94 1.01 0.720 -0.0033
F 1 Yes 100.2 95 1.05 0.380 -0.0039
Lung M 3 Yes 223 92 2.42 0.045 -0.0001
F 2 Yes 184.7 93 1.99 0.420 -0.0004
Melanoma M 1 103.3 96 1.08 0.140 0.0044
F 2 88.1 95 0.93 0.970 -0.0126
Breast F 2 Yesl 400.9 88 4.56 0.000 0.0135
Cervix uteri F 3 Yes' 145 93 1.56 0.500 -0.0010
Body of the uterus F 2 Yes 115.7 94 1.23 0.050 0.0028
Ovary F 3 Yes 221.7 89 2.49 0.002 0.0018
Prostate M 3 Yes 195.1 68 2.87 0.000 0.0017
Testis M 2 91.2 93 0.98 0.270 -0.0275
Bladder M 3 Yes 92.8 91 1.02 0.001 0.0086
F 2 88.3 94 0.94 0.013 0.0019
Kidney M 2 118.2 91 1.30 0.220 -0.0038
F 2 111.1 94 1.18 0.109 -0.0017
Brain and other CNS M 2 Yes 115.1 92 1.25 0.022 -0.0019
F 3 Yes 91 92 0.99 0.009 -0.0006
Thyroid M 1 92.9 95 0.98 0.980 -0.0846
F 1 85.1 95 0.90 0.280 -0.0343
Non-Hodgkin's lymphoma M 2 145 93 1.56 0.190 -0.0014
F 2 Yes 134 92 1.46 0.080 -0.0008
Hodgkin's disease M 1 Yes 111.8 95 1.18 0.040 0.0097
F 2 120.4 93 1.29 0.190 -0.0088
Multiple myeloma M 1 Yes 92.6 91 1.02 0.029 0.0013
F 1 Yes 124.7 92 1.36 0.590 -0.0045
Leukaemia M 2 Yes 134 91 1.47 0.540 -0.0036
F 2 Yes 139.1 92 1.51 0.034 0.0000
All other malignancies4 M 1 119.2 95 1.25 0.410 -0.0004
F 1 113.1 95 1.19 0.230 -0.0039
All malignancies combined5 M - - - - - - •
F * “ * * -
1 Age by follow-up (i.e. time since diagnosis) interaction term
2 Significance of the pehod term in the selected model 
1 Variance of the true systematic effects
4 Including 1CD9 140,142,146-149,152,155,156,158.159,160,163, 164,165,170,171,175, 179, 181, 184, 
187,190 and 194-199
5 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
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T a b le  4 .5  c o n tin u e d .
Cancer Sex Relative Risk1 Expected 
excess cancer 
deaths2
Avoided
(crude)3
Avoided
(shrunken)4
Initial Shrunken N N %
Oral cavity M 0.98 1.00 429 0 0 0.0
F 0.97 1.00 224 0 0 0.0
Oesophagus M 0.91 0.97 1,587 111 45 2.8
F 0.98 1.00 1,302 0 0 0.0
Stomach M 0.90 0.92 2,349 194 193 82
F 0.94 1.00 1,578 0 0 0.0
Colon M 0.89 0.92 2,234 251 188 8.4
F 0.88 0.90 2,571 313 256 10.0
Rectum M 0.88 0.90 1,408 183 147 10.4
F 0.86 0.89 1,075 155 121 11.3
Pancreas M 0.99 1.00 1,135 0 0 0.0
F 0.97 1.00 1,233 0 0 0.0
Larynx M 0.97 1.00 374 0 0 0.0
F 1.15 1.00 101 0 0 0.0
Lung M 0.97 1.00 11,663 0 0 0.0
F 0.99 1.00 7,013 0 0 0.0
Melanoma M 0.83 0.88 177 35 22 12.4
F 1.01 1.00 162 0 0 0.0
Breast F 0.79 0.79 3,553 930 738 20.8
Cervix uteri F 0.96 1.00 680 0 0 0.0
Body of the uterus F 0.85 0.90 377 62 38 10.1
Ovary F 0.89 0.92 1,695 1691 136 8.0
Prostate M 0.89 0.92 2,720 337 214 7.9
Testis M 0.80 1.00 56 0 0 0.0
Bladder M 0.81 0.83 1,157 256 196 16.9
F 0.87 0.92 728 102 61 8.4
Kidney M 0.93 1.00 748 0 0 0.0
F 0.90 1.00 549 0 0 0.0
Brain and other CNS M 0.88 1.00 702 0 0 0.0
F 0.84 1.00 533 0 0 0.0
Thyroid M 0.99 1.00 35 0 0 0.0
F 0.83 1.00 73 0 0 0.0
Non-Hodgkin's lymphoma M 0.93 1.00 854 0 0 0.0
F 0.92 1.00 892 0 0 0.0
Hodgkin's disease M 0.74 0.82 91 30 16 17.9
F 0.81 1.00 84 0 0 0.0
Multiple myeloma M 0.86 0.93 453 64 31 6.8
F 1.04 1.00 499 0 0 0.0
Leukaemia M 0.97 1.00 742 0 0 0.0
F 0.88 0.99 610 67 8 1.3
M 1.01 1.00 4,397 0 0 0.0
F 0.96 1.00 3,748 0 0 0.0
All malignancies combined6 M - - 33,311 1,461 1,053 32
F - - 29,281 1,799 1,359 4.6
1 Relative risk of excess mortality due to cancer in 1991-95 compared to 1986-90
2 Estimated from the model-based relative survival estimates
3 Observed minus expected model-based excess mortality due to cancer (no adjustment for random variation)
4 Observed minus expected model-based excess mortality due to cancer (adjusting for random variation)
5 Including ICD9 140,142,146-149,152,155,156,158,159,160,163, 164,165,170, 171,175,179,181,184, 
187,190 and 194-199
6 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
The results for individual cancers were generally very different using the two methods of 
analysis (Table 4.6), however, the overall estimates for “all malignancies combined” were 
similar when the crude modelled estimates were compared to the standardisation estimates. 
When random variation in the data is not accounted for, the two techniques are actually 
computationally quite similar; the main difference being that the modelling analysis uses the 
modelled estimates of relative survival in its calculations rather than the observed estimates. 
This would imply that the model-based relative survival estimates are quite different than the 
observed estimates for some intervals or age groups. This may reflect instability in the 
original estimates, particularly at younger ages or in later follow-up intervals when there are 
fewer deaths.
Table 4.6: Comparison of the two methods of calculating avoided deaths due to
improvements in survival: patients diagnosed in Scotland during 1991-95 
compared to 1986-90
Caiscer Standardisation Modelling
(crude)
Modelling
(shrunken)
Difference1
Oral cavity 34 0 0 34
Oesophagus 42 111 45 -3
Stomach 82 194 193 -111
Colon 537 564 445 92
Rectum 284 338 268 16
Pancreas 0 0 0 0
Larynx 10 0 0 10
Lung 86 0 0 86
Melanoma 48 35 22 26
Breast (females) 1,026 930 738 288
Cervix uteri 31 0 0 31
Body of the uterus 56 62 38 18
Ovary 28 169 136 -108
Prostate 466 337 214 252
Testis 17 0 0 17
Bladder 353 359 257 96
Kidney 68 0 0 68
Brain and other CNS 49 0 0 49
Thyroid 13 0 0 13
Non-Hodglun's lymphoma 49 0 0 49
Hodgkin's disease 40 30 16 23
Multiple myeloma 3 64 31 -28
Leukaemia 43 67 8 35
Other malignancies2 -49 0 0 49
All malignancies combined3 3 316 3 260 2 411 904
1 Difference between standardisation analysis and model analysis with shrunken estimates
2 Including ICD9 140,142,146-149, 152, 155, 156,158,159, 160,163, 164, 165, 170,171,175,179,181. 184, 
187. 190 and 194-199
3 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
1 0 9
After accounting for random variation, the model estimates of avoided deaths were 
substantially reduced and the estimated number of avoided o f  deaths for “all malignancies 
combined” was 2 411 (compared to 3 316 with the standardisation method). The 
proportion of avoided deaths was similar (3.9% for shrunken model estimates compared to 
4.6% for standardisation estimates) because the expected number of excess cancer deaths 
varied between the two methods.
Avoidable deaths (comparing deprivation groups within Scotland)
A deprivation gradient in survival has been observed for m ost cancers in Scodand (see 
Chapter J), and estimates have been made using the standardisation method, of the number 
of deaths that could be avoidable if patients in lower deprivation groups had the same 
survival as those in the most affluent group.
The most affluent group had, by definition, zero avoidable deaths and the numbers of 
avoidable deaths in the other deprivation groups compared to the affluent group were 
calculated separately and then summed. When the data w as stratified by age, sex and 
deprivation category there were some strata with too few cases to perform an analysis (Table 
4.7) and so age-truncated analyses were performed. For patients with thyroid cancer and 
Hodgkin’s disease there were a number of strata with too few  cases and so these cancers 
were excluded from the analysis altogether.
Overall, 2 490 (2.6%) excess cancer deaths could have been avoidable within five years of 
diagnosis for patients diagnosed in Scotland in 1991-95 if a ll deprivation groups had the 
same survival as the most affluent group. The largest numbers of avoidable deaths were 
seen for patients with cancers of the breast (589 deaths avoidable), large bowel (492) and 
bladder (248). The cancers for which there were the largest deprivation-specific variations in 
survival were malignant melanoma of the skin (20% of deaths would be avoidable), testicular 
(19%), cervix uteri (18%), breast (15%), bladder (12%) and kidney (10%).
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T a b le  4 .7 : Avoidable deaths within five years of diagnosis if all deprivation groups had 
the same survival as the most affluent group using the standardisation 
method: patients diagnosed in Scotland during 1991-95
Cancer Number 
of cases
Age range 
included by sex
Cases
included
•/,
Number o f excess 
cancer deaths'
Avoidable
Observed Expected N •/.
Oral cavity 1,261 F 45-74, M 15-74 92.1 681 665 -19 ■2.8
Head and neck 3,874 F 45-99, M 15-99 98.6 2,195 2,001 43 22
Oesophagus 3,293 45-99 98.3 3,017 3,023 16 0.5
Stomach 4,722 F 45-99, M 15-99 99.1 4,219 4,195 190 4.5
Large bowel 14,420 15-99 100.0 9,152 8,087 492 6.1
Colon 9,614 15-99 100.0 6,068 5347 280 52
Rectum 4,806 15-99 100.0 3,084 2,779 203 7.3
Pancreas 2,541 F 55-99, M 45-99 95.4 2,365 2373 6 02
Larynx 1,308 F -, M 45-84 842 528 457 2 0.5
Lung 20,850 15-99 100.0 19,670 19,687 98 0.5
Melanoma 2,545 F 15-99, M 15-84 98.7 575 435 85 19.5
Breast (females) 14,448 15-99 100.0 4,875 4,026 589 14.6
Cervix uteri 1,859 15-84 97.5 707 693 121 17.5
Body of the uterus 1,518 15-84 94.3 445 372 21 5.6
Ovary 2,507 15-99 100.0 1,826 1,830 0 0.0
Prostate 7,151 45-99 99.9 4,276 3320 120 3.6
Testis 843 15-54 932 45 43 8 18.8
Bladder 6,063 F 45-99, M 15-99 99.3 2,898 2,148 248 11.5
Kidney 2350 15-99 100.0 1,500 1,437 138 9.6
Brain and other CNS 1,515 15-84 98.8 1,248 1356 18 1.4
Thyroid 508 F 15-54, M 85-99 44.1
Non-Hodgkin's lymphoma 3,323 15-99 100.0 2,028 1,952 97 5.0
Hodgkin's disease 631 15-54 56.6
Multiple myeloma 1,338 F 55-99, M 55-84 88.9 995 985 11 1.1
Leukaemia 2,136 15-99 100.0 1,556 1,525 15 1.0
Other malignancies2 10,707 15-99 100.0 9,428 9,522 149 1.6
All malignancies3 109,042 98.8 73,074 68,966 2,490 J .6
1 Excess deaths = number of cases x  (1- relative survival rate)
2 Including ICD9 152,155-156,158-159,163-165,170-171,175,179,181,184,187,190 and 194-199
3 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
Avoidable deaths (comparing Scotland to Europe)
The number o f cancer deaths that could be avoidable within five years of diagnosis among 
cancer patients diagnosed in Scodand during 1985-89 if survival rates for these padents was 
(i) equivalent to the weighted European average, and (ii) equivalent to the European best, 
have next been considered (Table 4.8). The “best” survival was calculated as the analysis 
weighted average of the cancer-, sex- and age-specific relative survival estimates of the three 
countries with highest age-standardised relative survival. The standardisation method was 
used because there was not enough information available on the Eurocare CD Rom to 
implement the modelling method.
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Table 4.8: Avoidable deaths within five years of diagnosis if survival in Scodand was the
same as (i) the European weighted average and (ii) the European best, using 
the standardisation method: patients diagnosed 1985-89
Cancer Cancer cases Expected 
excess cancer 
deaths'
Avoidable
(European
average)
Avoidable
(European
Best)
N '/• in c lu d ed N N •/, N
Oral cavity 707 932 376 -17 -4.6 118 31.3
Head and neck2 3,201 93.0 1,431 -55 -3.8 338 23.6
Oesophagus 2,872 92.3 2,677 52 2.0 85 3 2
Stomach 6,165 90.8 5,524 704 12.7 935 16.9
Large bowel 14,418 92.0 8,701 909 10.4 1,975 22.7
Colon 9,678 91.5 5,723 642 112 1316 23.0
Rectum 4,740 92.9 2,979 267 9.0 658 22.1
Pancreas 3,081 90.1 2,979 19 0.7 75 2.5
Larynx 1,215 932 456 -7 -1.5 148 32.5
Lung 23,326 89.9 21,976 888 4.0 1,899 8.6
Melanoma 2,280 94.4 404 -147 -36.5 35 8.7
Breast (females) 13,400 91.9 4,758 1,176 24.7 1,956 41.1
Cervix uteri 2,189 95.6 885 58 6.5 238 26.9
Body of the uterus 1,663 93.1 503 56 11.1 206 41.0
Ovary 2,698 91.5 1,944 108 5.6 364 18.7
Prostate 5,986 91.5 3,189 675 212 1,134 35.6
Testis 708 97.7 58 -15 -26.0 4 7.6
Bladder 6,097 93.7 2,423 197 82 636 262
Kidney 2,209 90.6 1,443 307 21.3 415 28.7
Brain and other CNS 1,333 95.3 1,184 80 6.8 109 9.2
Thyroid 509 92.9 161 25 15.6 90 55.7
Non-Hodgkin's lymphoma 635 98.4 228 38 16.6 60 26.4
Hodgkin's disease 3,099 93.6 1,842 167 9.1 390 212
Multiple myeloma 1302 91.6 1,060 127 12.0 217 20.4
Leukaemia 2366 87.7 1,757 217 12.4 447 25.5
Other malignancies3 3,439 882 2,589 41 1.6 163 6.3
All malignancies4 102,976 9 1 J 67,717 5,630 A 3 11,771 17.4
1 Excess deaths = number of cases x (1- relative survival rate)
2 Calculated as the sum of estimates for ICD9 140,141,142,143-5, 146, 147,148,160 and 161
3 Calculated as the sum of estimates for ICD9 152,155,156,163,170, 171,187 and 190
4 Calculated as the sum of the estimates from die individual cancers (excluding non-melanoma skin cancer)
European average: for most cancers the European average survival was higher than that in 
Scodand, the exceptions being oral cavity, head and neck, laryngeal and testicular cancers, 
and malignant melanoma of the skin. The largest numbers of avoidable deaths, over the 
period 1985-89, arose for breast (1 176, 25% of excess deaths from this cancer), prostate 
(675, 21%) and kidney (307, 21%) cancer. Over 10% o f  deaths were also potentially 
avoidable for cancers o f the stomach, colon, corpus uteri and thyroid, and for multiple 
myeloma, non-Hodgkin’s lymphoma and leukaemia. Overall, 5 630 deaths were avoidable 
for patients diagnosed during 1985-89, equating to over 1 000 (8%) cancer deaths per 
annum.
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European best; for all cancers the European best was higher than that in Scotland. The 
largest number o f avoidable deaths, over the period 1985-89, arose for breast (1 956, 41%), 
lung (1 899, 9%), colon (1 316, 23%) and prostate (1 134, 36%). More than 20% of deaths 
were also potentially avoidable for cancers of the oral cavity, head and neck, rectum, larynx, 
cervix and corpus uteri, bladder, kidney and thyroid, and all the haematological malignancies. 
Overall, 11 771 deaths were avoidable for patients diagnosed during 1985-89, equating to 
over 2 300 (17%) cancer deaths per annum. Some of these differences may be partly due to 
differences in the definition of the disease and the approaches commonly used for 
diagnosis104.
Table 4.9: Avoidable deaths within five years of diagnosis if survival in Scotland was the
same as (i) the European weighted average and (ii) the European best; 
patients diagnosed 1985-89, all malignancies combined1, by age group
Analysis 15-44 45-54 55-64 65-74 75-99
N % N N N % N •ai
European average 123 5 419 8 1,195 8 1,767 8 2,127 9
European best 608 24 1,019 20 2,190 15 3,312 15 4,705 20
1 Calculated as the sum of the estimates from the individual cancers (excluding non-melanoma skin cancer)
The largest numbers of avoidable deaths were seen in the oldest age group (Table 4.9). In 
the European average analysis, the oldest age group also had the highest percentage of 
avoidable deaths (9%), whereas in the European “best” analysis it was the youngest age 
group with the largest percentage (24%) of avoidable deaths. The youngest age group was 
based on the smallest numbers of cases within age and sex groups and so there may be 
instability in some of the estimates. The difference between the European average and 
“best” estimates illustrate the range o f improvement that could be achievable in Scotland, 
with between 9-20% of cancer deaths avoidable in the oldest age group if survival in 
Scodand improved in line with other European countries.
Discussion
There are three ways of reducing cancer mortality, namely, primary prevention (changing 
risk factors to reduce incidence and therefore mortality), secondary prevention (screening 
and earlier detection), and advancements in therapy. In Scodand, mortality from lung
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cancer is decreasing in men due to a reduction in smoking prevalence, and mortality from 
gastric cancer is decreasing, probably due to changing diet and eradication of the helicobactor 
pylori virus. The breast screening programme which aims to  detect cancer at an earlier stage 
has been running for 13 years and the cervical screening programme which aims to detect 
cancers before they becomes malignant has also been running for 13 years on an organised, 
national basis. All o f these factors should lead to a reduction in mortality without advances 
in therapy.
As well as the national screening programmes in Scotland, earlier detection may also be 
beneficial for colorectal and prostate cancers, and malignant melanoma o f the skin. A pilot 
of colorectal screening is currently underway in Scodand (but will not influence the data 
analysed here), and PSA testing has become common on an adhoc basis since the early 
1990s to detect prostate cancers early. There was a major public health education 
programme for malignant melanoma of the skin in the 1980s, which may be responsible for 
earlier diagnosis of these cancers.
Some of the factors mentioned above are taken into account in the analyses in this chapter 
which relate specifically to changes in survival from cancer (i.e. reductions in mortality due 
to earlier diagnosis and improvements in treatment), but not those influencing mortality 
through incidence (primary prevention and cervical screening).
Overall, the avoided deaths analysis showed the reduction in the number of deaths achieved 
due to improvements in survival over time, with between 2 411 (3.9%) and 3 316 (4.6%) 
excess cancer deaths avoided for patients diagnosed during 1991-95 compared to 1986-90. 
Overall, 80% of the avoided deaths (using either analytic method) were due to 
improvements in survival for patients with cancers of the breast, large bowel, prostate and 
bladder.
Breast, large bowel and prostate cancers are among those for which earlier detection is 
beneficial, as mentioned above. Breast screening and PSA testing for prostate cancer were 
both introduced during the time period examined (1986-95), and this leads to potential 
problems in interpretation of survival data due to lead-time and length bias. These issues are 
discussed in detail in Chapter 5. There have been substantial advances in the treatment of 
breast cancer over the time period, so at least some of the improvement observed is likely to
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be real. There is also a possible problem of bias in the survival estimates for bladder cancer, 
due to a change in the definition for coding. A large proportion of bladder tumours are 
papillomas, which have very good prognosis and can be difficult to diagnose unequivocally 
as invasive, and over time there may have been an increasing tendency for such papillomas 
to be registered with the malignant code (see Chapter 7).
Putting these potential data problems to one side, the proportion of deaths avoided 
increased for patients diagnosed over the whole 25 year time period studied (1971-95). For 
patients diagnosed during 1986-90, 3.7% of deaths were avoided within 5 years of diagnosis 
and 2.9% of deaths within 10 years of diagnosis (Table 4.4). This provides evidence that an 
increasing number of patients are being cured of cancer, particularly as noted previously, for 
patients with testicular and thyroid cancer, and leukaemia. This is most likely a reflection of 
major advancements in therapy for these cancers.
The second analyses investigated the additional numbers of deaths that could be avoidable 
in Scotland if survival variations between deprivation groups were removed. It is important 
to also consider that the prevalence of many risk factors that have been linked to cancer 
(e.g. smoking, high fat diet, alcohol consumption) also vary between deprivation groups; 
often to the detriment of the more deprived groups. Therefore, if deprivation-specific 
survival variations were removed, there may still be differences in mortality from cancer by 
deprivation group, because of a higher incidence of cancer in these patients.
Overall, 2 490 (3.6%) cancer deaths could be avoidable within 5 years of diagnosis, if 
patients in all deprivation groups achieved the survival of those in the most affluent group. 
The largest numbers of avoidable deaths were for patients with breast, large bowel, bladder 
and lung cancer, jointly accounting for around two-thirds of the avoidable deaths. 
Important differences in survival were also identified for patients with melanoma of the 
skin, and cancers of the testis, cervix and kidney. Chapters 5 - 8 of this thesis look in detail 
at why there are variations in cancer survival between deprivation groups in Scotland. The 
cancers investigated in-depth are those with the largest number of avoidable deaths of 
patients diagnosed during 1991-95, namely, breast, large bowel and bladder cancers, and 
those with the largest proportions of avoidable deaths, namely, malignant melanoma of the 
skin and kidney cancer. Other cancers with a large number or percentage of avoidable 
deaths were prostate cancer, which was not considered due to the potential confounding of
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PSA testing; cervical and testicular cancers, which were not considered due to the small 
number of cases involved; and lung cancer, which was not considered because the difference 
in survival between deprivation groups was actually small, but is significant because of the 
large number of patients involved.
The third analyses investigated the numbers of deaths that could be avoidable in Scotland if 
survival was the same as in other European countries. It is argued that European countries 
that are only represented by a small proportion of the countries population in EUROCARE 
should not be included in such comparisons, as the selected area m ay not be representative 
of the country (e.g. for Austria and Sweden). However, even the survival estimates for the 
most affluent patients in Scodand do not achieve the survival observed for these “non­
representative” countries for many cancers (data not shown).
We could restrict the analysis to only those countries with complete coverage (Denmark, 
Estonia, Finland, Iceland, Slovakia and Slovenia) but this would equally not be representative 
of Europe as a whole. It has been suggested that survival in Great Britain should be 
compared to that in the Nordic countries (included Denmark, Finland, Sweden and 
Iceland), as these countries are known to have very good cancer registration data123 and have 
similar life styles to the UK. If we had used the average survival o f  only these countries in 
the analyses shown in Table 4.9, then 4 039 (6%) cancer deaths could have been avoidable 
per annum (data not shown) compared to the estimate of 5 630 (8%) when all the European 
data was used for the analyses. Although the number of avoidable is reduced somewhat, it 
still represents a substantial number of avoidable deaths.
The relative survival estimates for 1985-89, available on the EUROCARE II CDROM, are 
not recorded with decimal places. This may have introduced bias in the computation o f 
avoided deaths, although the direction of the bias will vary between cancers. It is possible 
that some of the differences in survival between countries in Europe may be due to 
variations in disease definitions and in the approaches commonly used for diagnosis104'124. 
For breast cancer, which had the largest number of avoidable deaths, the survival estimates 
are complicated by screening, which was introduced across Europe over a large time 
window and was not introduced in Scotland until near the end o f  the period of analysis. 
However, the proportion o f avoidable deaths was not higher for women in the screening 
age groups; the biggest proportion of avoidable deaths was for women aged 75 and over, for
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whom 35% of deaths were estimated to be avoidable compared to the European average. 
For all cancers combined, the number of avoidable deaths increased with increasing age and 
so did the percentage o f  avoidable deaths. This poses questions about the treatment of 
older patients in Scotland.
The results of the European “best” analyses were highly dependent on the weightings used. 
If the three countries with the highest age-standardised relative survival rates were used to 
define “best”, the resulting estimates are much lower than if the countries with the highest 
age- and sex-specific relative survival rates were used (data not shown). The “best” 
countries were defined as those with the highest age-standardised relative survival estimates 
in this Chapter, because they are more stable. The age- and sex-specific relative survival 
estimates for the three “best” countries could be combined giving them equal weight or by 
weighting them according to the proportion o f cases they contribute to the analysis. Choice 
of analysis weights or equal weights did not gready affect the estimates of avoidable deaths 
(data not shown).
There are limitations that effect both of the analytical methods used in this chapter. Firsdy, 
the calculation of avoided deaths covers a finite follow-up interval, five years, and so does 
not represent the number of deaths avoided due to changes in the effective “cure” of 
patients over time. Secondly, there are problems because some estimates are based on few 
cases. The model-based estimates, which are essentially smoothed, will tend to give more 
conservative estimates o f  avoided deaths when the analyses are based on small numbers of 
cases or deaths.
The comparison of the two analytic methods is complicated because the survival estimates 
being used for the analyses may vary because o f the different methods of calculating relative 
survival used. Additionally, the results from the STATA algorithm are sensitive to the 
number of break options selected, particularly for rare or very fatal cancers (see Chapter 1). 
Partly because of these two factors, the proportion of avoided deaths estimated by the two 
methods is more similar than the absolute number of avoided deaths. Additionally, the 
contribution of the cancers with the largest proportions of avoided deaths are very similar, 
when again, the absolute numbers differ. When the analyses are not based on very large 
samples of patients, as in this chapter, it may be more appropriate to present avoided deaths 
in terms of proportion o f excess cancer deaths avoided rather than in absolute numbers.
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In conclusion, calculation of avoided and avoidable deaths is a novel and interesting 
approach to looking at improvements in cancer survival. Two methods to compute these 
statistics were introduced. Overall, between around 500 and 650 deaths have been avoided 
per year in Scodand for patients diagnosed during 1991-95 due to improvements in survival 
from 1986-90. Additionally, if differences in survival between deprivation groups in 
Scodand could be removed, up to 500 deaths a year could be avoidable.
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C h a p t e r  5
BREAST CANCER
Background
Breast cancer is the most common cancer among women in Scotland, accounting for 25% 
of all cancers, with a total o f 3 374 new cases o f invasive disease diagnosed in 1997. 
Incidence has been increasing over time since the 1970s, and has increased at an even 
greater rate in the 1990s, partly due to the introduction of the Scottish National Breast 
Screening Programme (SNBSP). Mortality from breast cancer had also been increasing until 
the late 1980s, since when there has been a 28% reduction (Figure 5.1). A similar reduction 
has also been observed in England125,126 and the United States127. In 1999, 1 129 women died 
of breast cancer in Scotland.
Figure 5.1: Breast cancer in Scodand: trends in incidence (1979-1997) and mortality
(1979-1999), all ages (European age-standardised rates)
As for many cancers, age is the most important known influence on incidence (Figure 5.2), 
with the highest risk in the elderly. Risk in women of screening age (50-64 years) has 
increased faster than expected from the underlying trend, whereas incidence in women aged
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65-69 years appears to have levelled off in the 1990s. Risk varies markedly between 
countries (Figure 5.3) with slighdy higher rates in Scotland than in England and Wales.
Figure 5.2: Breast cancer in Scotland: trends in incidence (1975-1997), by age band
1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997
Year of diagnosis
The SNBSP was introduced in 1988 for women aged 50-64 and the first (prevalent) round 
completed in 1994. The first time that women are screened (prevalent round), breast 
screening picks up many small and slow-growing tumours, some of which might not have 
presented clinically until later, if at all. The detection at screening o f  a large number of 
cancers with relatively good prognosis, which might never present symptomatically in a 
woman’s life-time, is known as length bias12*. It may explain why incidence is still higher 
than would be expected from a projection of the underlying historical trends. Length bias 
would affect both incidence and survival.
In the trial setting a reduction in mortality due to screening was seen seven years after the 
introduction of screening129, however, compliance to attend screening is lower in the routine 
setting so a longer interval may be expected before a reduction in mortality is seen. 
Therefore, screening has probably played a relatively small part in the large (16%) mortality 
reduction observed since 1990 in Scodand. Around 30% of the corresponding reduction in 
England has been attributed to the direct effects of screening, with the remainder due to 
improved adjuvant treatments and earlier presentation outside the screening programme114. 
Other researchers believe the screening effect may be lower130.
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Figure 5.3: International comparison o f breast cancer incidence, around 1988-1992
(world age-standardised rates per 100,000)
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A by-product o f the screening programme has been raised diagnostic standards and 
improved organisation of services across all age groups, which would also be expected to 
have had an impact on mortality rates.
Even before the introduction of screening, breast cancer survival in Scodand was improving 
steadily over time, due to improvements in stage at diagnosis, and to the increasing use of 
radiotherapy and chemotherapy22,151. For women diagnosed in 1971, the five-year relative 
survival rate was 53%, and for women diagnosed in 1993 this had increased to 73%. 
However, survival has been increasing more quickly in the age group which encompasses 
those invited for screening (ages 50-69; Figure 5.4).
The introduction of the screening programme complicates interpretation of the survival 
trends in the age range 50-69 because of length bias (very slow growing tumours) and lead- 
time bias (where the time of diagnosis is advanced but death is not delayed). The prevalent 
round of screening was completed in Scotland by the end of 1994, and survival might be 
expected to improve for women diagnosed during this round. However, it is sustained for 
women diagnosed after 1994, when most women had incident (second and subsequent) 
screens and is more pronounced at five years after diagnosis than at one year after diagnosis.
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Figure 5.4: Women diagnosed with breast cancer in Scodand during 1971-1995: trends 
in relative survival by age band
This is not typical of lead-time bias. The sustained improvement in survival could be due to 
the enhanced effectiveness of treatment being given at an earlier stage, in other words, the 
desired effect of screening, or it could be caused by length bias.
Length bias could play a role because incidence of breast cancer is higher in more affluent 
women, and compliance with screening was initially higher in these women, who also have 
better than average underlying mortality rates. If a large number o f affluent women were 
diagnosed with tumours that would not have presented clinically for a long time, then we 
would see survival increasing with time since diagnosis. The data analysed in detail in this 
chapter relate to 1997, 10 years after the introduction of screening, so the effects of lead 
time and length bias should be small.
Survival from breast cancer in Scotland is lower than in other countries in Europe6 and the 
USA (Figure 5.5). Several factors have been linked to poor breast cancer survival. These 
include co-morbidity132; tumour type, with invasive lobular carcinoma conferring better 
prognosis than invasive ductal carcinoma133; patient delay but not GP delay134; long-term oral 
contraceptive use135; treatment by a non-specialist surgeon27; low clinician workload26, and 
differences in the use of systemic adjuvant therapy136. One study found survival was poorer 
during the holiday months of the year when medical teams may be under-represented137. A 
study in Yorkshire found that hospitals with a special interest in breast cancer used more up-
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to-date methods and made more treatment options available1“ . In East Anglia, being treated 
at a specialist hospital was significantly beneficial in women aged under 75 years at 
diagnosis51, even after accounting for tumour stage. There is strong evidence that women 
managed by a multidisciplinary team do better22,26,27.
Figure 5.5: Breast cancer international comparison of five-year relative survival (with
95% confidence intervals), selected countries, women diagnosed around 
1985-1989, all ages
1 Women diagnosed 1986-90, aged 15-99
2 Women aged 15-99
Sources: Bemno i t  al.*, Gatta u  a/.'*9, Coleman i t  aL*
Breast cancer is more common among affluent women, but survival is also better in these 
women4,15,16140. Geographic and socio-economic differences in investigation and treatment 
have been reported in the UK and Europe1,,1,,U1,142. There is conflicting evidence on 
whether these differences remain after adjustment for stage at diagnosis, with differences 
remaining for studies in south-east England15,16, Finland54 and Glasgow15 and conflicting 
evidence from a different Glasgow study145, and studies from The Netherlands144 and 
Australia145. Tumour stage is a very significant prognostic indicator for breast cancer 
survival15,16,144,146 and is linked to delay at diagnosis147, however, within each category of 
tumour stage, delay was not found to be an important prognostic factor in an Argentinean 
study14*. In south-east England it was found that the low social classes were more likely to 
present as an emergency admission and less likely to have surgical interventions149. Tumour 
morphology does not appear to account for social class differences in Scotland15. Oestrogen 
receptor negative tumours have been linked both to poor survival and to social class150, but
in an audit of Scottish women diagnosed in 1987, only a third of the effect of deprivation on 
survival could be accounted for by differences in oestrogen receptor status22-151.
Projections of recent trends in incidence and mortality in Scotland152 suggest a further large 
increase in breast cancer incidence in the decade up to 2010, and a continuing decline in 
mortality rates (Figure 5.6). There could be as many as 4 775 cases diagnosed per year in 
2010. These trends underline the public health importance of breast cancer and the 
continuing need to understand and further improve survival from breast cancer.
Figure 5.6: Projections of breast cancer incidence and mortality in Scotland (numbers of 
cases and deaths, and European age-standardised rates)
1980-84  1 9 85-89  1 9 9 0 -9 4  1 9 9 5 -9 9  2 0 0 0 -0 4  2 0 0 5 -0 9  2 0 1 0 -1 4
In this chapter, the survival of 3 309 women diagnosed with breast cancer in Scotland in 
1997 is investigated to identify reasons for differences in survival by deprivation category. 
For definitions of the variables included in the analyses, please refer to Chapter 2.
Results and commentary
For women diagnosed in Scotland in 1997, incidence was 25% higher in women from the 
most affluent areas (37.8 per 100 000; herein referred to as the affluent group or affluent 
women) compared to women from the most deprived areas (30.3; the deprived group or 
deprived women). The mortality rates (for women dying in 1999) show very little variation 
across deprivation groups. The deprivation-specific trend in incidence is not matched by a
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similar trend in mortality because of differentials in survival, with two-year survival 8% 
higher in the affluent (85.3%) than the deprived (77.5%) group (Figure 5.7).
Figure 5.7: Women diagnosed with breast cancer in Scotland in 1997: incidence1 and
two-year relative survival2, and mortality1 in 1999, by deprivation category
1 2 3 4 5
Affluent Carstairs deprivation quintile Deprived
1 Age-standardised rates per 100 000 person-years at risk (European standard population)
2 Using deprivation-specific life tables; age-standardised using the world standard cancer patient population
Of the 3 309 women diagnosed with breast cancer in 1997, 1 418 (43%) were from 
deprivation groups 1 and 2 and 1 240 (37%) from deprivation groups 4 and 5 (Table 5.1). 
The median age of diagnosis was 61 years with inter-quartile range from 51 to 74 years, with 
no significant difference in age at presentation between the deprivation groups. Breast 
cancer was the first primary malignancy for 3 104 (94%) women, with 3% having had a 
previous breast cancer and a further 3%, a previous primary at another site. These 
proportions were similar between the deprivation groups, so the fact of a previous primary 
was not included in the multivariate analyses.
Deprived women mainly came from urban areas (81% compared to 41% for affluent 
women). Almost 80% of the most deprived women were resident in only three of the 
fifteen health boards: Greater Glasgow Health Board (GGHB; 50%), Lanarkshire (17%) and
1 2 5
Argyll and Clyde (12%). Within health board the mix of deprivation categories amongst 
women with breast cancer varied very widely (for example, GGHB: 50% deprived and 19% 
affluent; Lothian and Borders: 7% deprived and 28% affluent; Grampian: 3% deprived and 
54% affluent).
Table 5.1: Women diagnosed with breast cancer in Scotland in 1997: demographic data
by deprivation category (number and percentage of cases)
Deprivation
category
Number (%) 
of casca
Median age 
(inter­
quartile 
range)
Cases for which: Urban
resident1First
primary
Previous
breast
primary
Previous
primary
elsewhere
Affluent 734 (22%) 61 (51-73) 697 (95%) 20 (3%) 17 (2%) 302 (41%)
2 684 (21%) 60 (51-73) 642 (94%) 19 (3%) 23 (3%) 153 (.22%)
3 651 (20%) 61 (51-73) 615 (94%) 20 (3%) 16 (2%) 161 (25%)
4 644 (19%) 62 (51-74) 593 (92%) 22 (3%) 29 (5%) 291 (45%)
Deprived 5% (18%) 63 (53-75) 557 (93%) 19 (3%) 20 (3%) 485 (81%)
Total 3,309 (100%) 61 J5U 74L 3404 100 _J3%L 10S 1,392 (42% )
1 Chi-square test for association between urban residence and deprivation: p<0.001
Organisation of services
The Calman-Hine report101, published in 1995, recommended that specialist cancer teams in 
locations with the necessary specialist resources should manage women with breast cancer in 
England and Wales. The Scottish Cancer Coordinating and Advisory Committee (SCCAQ 
proposed a similar network for Scotland in 1996102, with the aim that all women should have 
access to high levels of specialist cancer care to provide optimal treatment. Audit data for 
women diagnosed in 1987 and 1993 showed that older women and those living in more 
deprived areas were less likely to travel to a cancer centre151. These disparities, whether 
appropriate or not, are still present. Among women diagnosed in 1997, 81% of those aged 
under 75 attended one of the regional centres with radiotherapy provision (regional RT 
centre) within their cancer spell, but only 50% of those aged over 75. Of the affluent 
women, 81% attended a regional RT centre compared to 64% of deprived women (Table 
5.2). It is, therefore, evident that inequalities in access to treatment by age and deprivation 
were still prevalent in 1997.
Overall, 74% of women attended a regional RT centre at some point during their cancer 
spell (Table 5.2), a further 10% attended other high-workload hospitals, 9% medium-
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workload hospitals and 6% low-workload hospitals (data not shown). The main hospital of 
treatment was a regional RT centre for 58% of affluent women and 35% of deprived 
women. A correspondingly higher proportion of deprived women were treated at other 
high-workload hospitals (9% affluent and 34% deprived). These gradients were seen for 
women living in both urban and rural areas; however, deprived urban residents were less 
likely to attend a regional RT centre or other high-workload hospital (74% compared to 
85% of affluent urban women).
There were also differences in the proportion o f women seen by a high-workload consultant 
(seeing at least 30 breast cancer cases per year), with those from the affluent areas more 
likely to see a high-workload consultant (66% compared to 56% in the deprived group). 
Those from the deprived areas were seen by more medium-workload consultants (10-29 
cases; 19% compared to 12% for affluent women), with similar proportions being seen by 
only a low-workload consultant (12% compared to 10% for affluent women). The 
proportion o f women for whom no details of contact with a consultant physician were 
recorded (around 11%), was similar between the deprivation groups.
The majority (87%) of women were seen in a specialist department (85% within 3 months 
of diagnosis), but with less likelihood for deprived women (81%). Women from the 
deprived group were more likely to have been initially admitted as an emergency (13% 
compared to 9% of affluent women; p=0.016).
Delay
For over half (51%) o f the 3 233 women with a known treatment date, at least two weeks 
elapsed between diagnosis and definitive treatment (Table 5.2). Women from deprived areas 
were less likely to have a wait (45% waited at least 2 weeks compared to 50% of affluent 
patients; p<0.001). Over half (58%) of women were seen throughout their cancer spell at 
one hospital, with 38% of women were seen at two hospitals. Deprived women were more 
likely to stay in hospital between diagnosis and treatment (86% compared to 69% of affluent 
women). These factors could reflect poorer health of these women at admission, or varying 
hospital policy, or lack o f support to return home.
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Table 5.2 : W o m en  diagnosed w ith  breast cancer in Scotland  in 19 97 : access to  health care by deprivation  category (num ber and percentage o f
patients)
Deprivation
category
No. of Attended a 
regional RT
centre1
Attended a 
specialist 
department2
Main 
treatment at 
a regional RT 
centre
Treated in a 
high-workload 
hospital3
Seen by a 
higb- 
woridoad 
consultant4
Emergency
admission
Treated at 
first 
admission
More than 
two weeks’ 
delay between 
diagnosis and 
treatment5
All of care in 
one hospital
Affluent 734 592 (81%) 623 <**•) 424 (581.) 491 (671.) 484 (66%) 63 (91.) 506 (691.) 358 (501.) 445 (61%)
2 684 526 (77%) 604 (881.) 312 (46%) 418 (61%) 451 (66%) 51 (71.) 529 (77%) 386 (571.) 391 (571.)
3 651 475 (731.) 558 (86%) 257 (391.) 408 (631.) 395 (61%) 60 (91.) 493 (76%) 346 (54%) 359 (55%)
4 644 463 (72%) 553 (86%) 238 (371.) 417 (631.) 386 (601.) 69 (11%) 494 (771.) 308 (491.) 345 (54%)
Deprived 596 379 (W%) 481 181%) 206 (331.) 413 (691.) 332 (561.) 77 (131.) 512 (86%) 262 (451.) 378 (631.)
Total 3J09 2,435 (74%) 2J19 (85%) 1,437 (43%) 2J47 (65%) 2,048 (62%) 320 (10%) 2,534 (77%) f I 1,918 (58%)
p<0.001 p=0.038 p<0.001 p=0.012 p<0.001 p-0.016 p<0.001 p<0.001 p-0.002
1 At some point in the cancer spell
2 Within 3 months of diagnosis
3 Hospital seeing at least 104 breast cancer patients per year (see Chapter 2 for details of the workload groupings)
4 Consultant who saw at least 30 breast cancer patients in 1997 (see Chapter 2 for details of the workload groupings) 
3 Days between diagnosis and definitive treatment; percentage of 3 233 patients with a definitive treatment date
6 Chi-square test for association
Mode of presentation
When a women presents with a suspected breast tumour, a clinical assessment is usually 
performed, followed by a fine needle aspiration, biopsy and possibly a mammogram, to 
confirm diagnosis. Once malignancy is confirmed, a pathological (surgical) examination is 
then performed to establish the size and nodal status of the disease. Métastasés are usually 
assessed by clinical examination or imaging. Large tumour size, nodal involvement and 
métastasés are all important prognostic indicators associated with poor survival37,154,155.
Pathological tumour size (pT) and nodal status (pN) are the most reliable prognostic 
indicators156, and these, along with clinical stage (cTNM) have been collected on the 
SOCRATES database for breast tumours for patients diagnosed from 1997 onwards. 
Among women diagnosed in Scodand in 1997, 27% of women had no pT recorded, 23% 
had no pN, 15% had no cT, 19% had no cN, and 34% had no metastatic status recorded. 
This could be because the CRO missed the information when extracting from the medical 
notes, but is more often because the information is not explicidy stated in the notes. 
Informadon was more often missing in deprived women for each of these factors (p<0.05). 
Of women with known details, there were no differences in tumour size or nodal status 
between the deprivation groups; however, deprived women did appear to be more likely to 
present with metastatic tumours (p<0.01; Table 5.3).
Based on previous, more complete stage information from Scottish audits153, 8.3% of 
women diagnosed in 1987 and 7.0% of women diagnosed in 1993 had metastatic disease, so 
it is likely that the unknowns in the 1997 data analysed here largely comprise non-metastatic 
cases. This is further supported by examination of the 1-year survival estimates (96% for 
women with non-metastatic disease, 58% for women with métastasés and 86% for women 
whose metastatic status was unknown).
Other important prognostic indicators include tumour grade37,154,157 with survival decreasing 
as grade increases; oestrogen receptor (ER) status, with ER-negative tumours having the 
poorer prognosis155,15* and comorbidity141,159 Among all women diagnosed in Scotland in 
1997, 22% had ER-negative tumours, 59% ER-positive tumours and 20% had unknown ER 
status (Table 5.4; different percentages shown, see table footnote 1).
1 2 9
Table 5.3: Women diagnosed with breast cancer in Scotland in 1997: tumour stage by deprivation category (number and percentage of cases)
Deprivation No. of Pathological size1 Pathological nodal statua1
category n T2 T3 Unknown NO N1 N0-
inadeq
Unknown
Affluent 734 349 (637.) 181 03%) 24 0%) 180 05%) 319 06%) 230 00%) 21 0%) 164 02%)
2 684 281 04%) 214 (41%) 30 (67, 159 05%) 307 06%) 220 00%) 19 0%) 138 00%)
3 651 289 00%) 173 06%) 18 (% ) 171 06%) 267 05%) 215 02%) 25 0%) 144 02%)
4 644 265 07%) 184 09%) 18 4%) 177 07%) 297 09%) 186 07%) 21 0%) 140 02%)
Deprived 5% 218 07%) 153 00%) 14 0%) 211 05%) 234 04%) 190 04%) 10 0%) 162 07%)
Total 3,309 1,402 (58%) 905 (58%) 104 (4%) 898 (27%) 1,424 (56%) 1,041 (41%) 96 (4%) 748 (23%)
p= 0.07t K O M I' fi=0271! P=0.047)
Deprivation fUniffl SÍSC1 Clinical nodal statua1 Metas tases1
caaegoty T l T2 T3 T4 Unknown NO N1 N2/N3 Unknown MO Ml Unknown
Affluent 273 04%) 239 (38%) 43 0%) 69 07%) 110 05%) 438 05%) 149 05%) 17 (37.) 130 (187.) 477 03%) 37 0%) 220 00%)
2 243 02%) 234 00%) 48 (8%) 58 004.) 101 05%) 431 04%) 127 02%) 25 0%) 101 05%) 483 (917.) 47 (97.) 154 05%)
3 239 02%) 231 (41%) 37 0%) 56 00%) 88 04%) 397 04%) 123 05%) 16 (3%) 115 (187.) 433 05%) 31 (77.) 187 09%)
4 216 09%) 218 00%) 50 (97.) 66 02%) 94 05%) 390 04%) 107 00%) 29 (6%) 118 (187.) 374 00%) 43 00%) 227 05%)
Deprived 192 00%) 202 02%) 32 0%) 51 (117.) 119 00%) 307 05%) 99 03%) 16 0%) 174 09%) 234 (867.) 37 04%) 325 05%)
Total U 63 (42%) 1,124 (40%) 210 (8%) 300 07%) 512 (15%) L963 ¿7.3%) 605 ¿23%) 103 (4%) 638 (19%) 2,001 (91%) 195 ¿9%) 1413 ¿34%)
Stpmñúma p=0226! p^OO l? P=0292p P<0.001‘ PKOOIO? pO.001’
1 Percentage of women with a known category. For 'unknown' category, percentage of all women
2 Significance of association between depnvanon category and percentage of women in each category, excluding those in the unknown category
3 Significance of proportion unknown across the deprivation categories
Table 5.4: W o m en  diagnosed w ith  breast cancer in Scotland  in 19 97 : oestrogen  recep to r (ER) status, grade and histological type by depnvation
category (num ber and percentage o f  cases)
Deprivation No. of ER status1 Micro- Histological type Grade1
category c a w Negative Positive Unknown acoptcaUy
verified
Ductal Lobular O ther 1 2 3/4 U nknow n
A ffluent 734 145 (25V,) 435 (75V.) 154 (21V.) 711 (97V.) 485 (65V.) 59 (8V.) 190 (25V.) 93 (18*/.) 231 (44V.) 204 (39V.) 206 (28V.)
2 684 157 (27V,) 414 (73V.) 113 (17V.) 661 (97V.) 451 (64V.) 67 (10V.) 166 (24V.) 93 (19V.) 196 (40%) 202 (41V.) 193 (28V.)
3 651 141 (27V.) 385 (73V.) 125 (19V.) 626 (96V.) 492 (74V.) 66 (10V.) 156 (24V.) 70 (15V.) 191 (42V.) 197 (43V.) 193 (30V.)
4 644 120 (23V,) 404 (77V.) 120 (19V.) 614 (95V.) 407 (62V.) 72 (11V.) 165 (25V.) 78 (17V.) 186 (41V.) 185 (41V.) 195 (30V.)
D eprived 596 151 (33V,) 310 (67V.) 135 (23V.) 562 (94V.) 385 (63V.) 30 (5V.) 181 (30V.) 51 (15%) 137 (40V.) 154 (45V.) 254 (43V.)
Total 3,309 714 (27%) 1,948 (73%) 647 (20%) 3474 (96%) 2220 (66%) 294 (9%) 858 (26%) 385 (17%) 941 (41%) 942 (42%) 1,041 (31%)
r po .o o? $=0,085’ $=0.0612 $=0,004* $=0,605* $<0.001‘
1 Percentage of women with a known category. For 'unknown' category, percentage of all women
2 Significance of association between depnvation category and percentage of women in each category, excluding those in the unknown category (where applicable) 
1 Significance of proportion unknown across the deprivation categories
Among those with known ER status, deprived women were more likely to have ER-negative 
tumours (33% compared to around 25% in the other deprivation groups).
Diagnosis was microscopically verified for most (96%) women, with no significant 
difference between the deprivation groups. Overall, 99% of sutgical and 77% of non- 
surgical patients had microscopically verified tumours. Ductal tumours were the most 
common histological type (66%) followed by lobular carcinomas (9%). There was evidence 
that the most deprived women were less likely to have lobular carcinomas.
Information on grade was missing for a high proportion (31%) of women, particularly in the 
deprived group. When only women with known grade were considered, then the deprived 
women were somewhat more likely to have poorly differentiated tumours (45% compared 
to 39% of affluent women; p=0.605).
Due to the large number of women with missing information on metastatic status, grade 
and treatment intent, two approaches were adopted in the multivariate analyses: (1) Missing 
information was treated as an extra category and (2) missing values were imputed (see 
Chapter 1). Before performing multiple imputation, women whose metastatic status was 
unknown were re-assigned to the non-metastatic group if their therapy objective was 
curative (21%) or they were screen-detected (1%). For the remaining 386 (12%) women 
with unknown metastatic status, multiple imputation was performed using information on 
age, clinical tumour size and nodal status. The multiple imputation of grade was performed 
using information on type of surgery, tumour morphology, ER status and imputed 
metastatic status. The multiple imputation o f treatment intent was performed using 
information on age, surgery, metastatic status and grade.
Screening
The proportion of all women diagnosed as a result of mammographie screening was similar 
between the deprivation groups (about 18%; Table 5.5). Among women aged 50-64, the 
proportion was 40%; around 88% of these women attended a specialist cancer centre. This 
proportion was also similar between the deprivation groups.
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Comorbidity
For all three comorbidity measures (see Chapter 1), deprived women had slightly greater 
comorbidity at the time of cancer diagnosis. The largest difference was seen when 
comorbidity was measured by the bed-days scale, where 17% of deprived women had spend 
more than 10 days in hospital in the preceding two years compared to only 12% of women 
in the other deprivation groups (Table 5.5). There was a gradient across the deprivation 
groups when comorbidity was measured by the Charlson and Scotland scales, but no clear 
gradient when measured by the bed-days scale.
Table 5.5: Women diagnosed with breast cancer in Scotland in 1997: screen-detected
cancers and comorbidity (number and percentage of cases)
Deprivation No. o f Screen-detected Comorbidity
category cases All ages Ages 50-64 Bed-days' Scotland2 Charlson3
Affluent 734 129 (18%) 102 (390/.) 85 (120/.) 68 (90/.) 35 (5o/.)
2 684 139 (20%) 115 (420/.) 85 (12V.) 62 (9o/.) 36 (5V.)
3 651 113 (IT-/.) 100 (39%) 74 (11%) 71 (11%) 41 (ó»/.)
4 644 108 (17V.) 86 (37V.) 80 (120/.) 77 (12V.) 46 (TV.)
Deprived 596 105 (18%) 95 (41V.) 102 (17V.) 76 (12o/.) 57 (10V.)
Total 3,309 594 (t**> 498 426 (13%) 354 ( I f/ .) 215 (6Vi)
Sixmficma p —0.486 p=0.785 p<0.001 ____ t =0.173 _____L=0.005
1 Greater than 10 inpatient bed-days in the two years prior to the cancer diagnosis
2 Any one of certain comorbid conditions recorded in the two years prior to one month after diagnosis (see 
Chapter 1)
3 Any one of certain comorbid condition recorded in the five years prior to diagnosis (see Chapter 1)
4 Chi-square test for association
Treatment
Curative treatment for breast cancer should be available for all women who do not have 
metastatic disease. This will involve surgery to remove the tumour (from the breast alone or 
also the lymph nodes) followed by adjuvant systemic therapy and/or radiotherapy“3. 
Increasingly, breast conservation (only the lump is excised) as opposed to mastectomy 
(whole breast is removed) is the preferred option. Breast-conserving surgery has been 
shown to be as effective as mastectomy when the lymph nodes can be shown not to be 
involved, whether by axillary clearance, node sampling or, more recently, sentinel node 
biopsy164. Breast conservation surgery is usually followed by radiotherapy to the breast or 
axilla. For women with ER-positive tumours, hormonal treatment (usually tamoxifen) is 
frequently given. For women with métastasés, palliative treatments are given, usually 
tamoxifen followed by chemotherapy.
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The Scottish Intercollegiate Guidelines Network (SIGN) published clinical guidelines for the 
management o f breast cancer in 1998165, with treatment increasingly being tailored to the 
tumour characteristics (stage, morphology, grade) and the oestrogen receptor status. 
Therefore, when investigating the differences in survival between deprivation groups, 
treatment variations need to be adjusted for differences in tumour characteristics so that 
causes and relationships can be correctly determined.
Prior to the publication of the SIGN recommendations, and probably as an indirect result 
of better organisation due to the SNBSP, the 1987 and 1993 breast cancer audits showed 
increases in the use of radiotherapy (42% to 57%), chemotherapy (8% to 19%) and adjuvant 
endocrine therapy (66% to 92%) as primary therapy in surgically treated women166. The 
proportions of women referred to an oncologist increased from 53% to 64% between 1987 
and 1993, but the number of consultant oncologists in Scotland only increased from 32 to 
37 over the same period22,131. The number of consultant oncologists rose to 40 in 1997 and 
46 in 2000167.
For women diagnosed in Scotland in 1997, 2 816 (85%) of women received surgery, in 
whom 1 361 mastectomy and 1 175 breast conservation (BCS) operations were performed 
within 6 months of diagnosis. Radiotherapy was received by 1 691 (51%) women, 
chemotherapy by 1 073 (32%) women, and hormone therapy by 2 636 (80%) women (Table
5.6). Among surgically treated women, 1 532 (57%) received radiotherapy, 979 (37%) 
received chemotherapy and 2 153 (80%) received hormone therapy.
Deprived women were more likely to have a mastectomy (45%) than affluent women (36%) 
within 6 months of diagnosis, and less likely to have BCS (30% compared to 37%) or 
radiotherapy (42% compared to 56%). Radiotherapy is the preferred ancillary treatment for 
BCS, and overall, 82% of women who had BCS received radiotherapy compared to only 
35% of women who had a mastectomy. However, deprived women who underwent BCS 
were still less likely to receive radiotherapy than women from the other deprivation groups 
who underwent BCS (73% compared to average o f 81%; p=0.039).
134
Table 5.6: Women diagnosed with breast cancer in Scotland in 1997: treatment received by deprivation category (number and percentage of
cases)
Deprivation
category
No. of Surgery Radiotherapy Chemotherapy Hormone Therapy
Mastectomy1 Breast
conservation1
Other/
unspecified2
Overall Within 6 
months
Overall Within 6 
months
Overall Within 6 
months
Overall
Affluent 734 263 (36%) 273 (77%) 104 (14%) 640 (87%) 280 (38%) 408 (56%) 232 (32%) 239 (33%) 506 (69%) 594 (81%)
2 684 276 w 256 (37%) 70 (107.) 602 (887.) 262 (38%) 358 (52%) 210 (31%) 221 (32%) 493 (72%) 548 (80%)
3 651 271 (**•) 250 (387.) 39 (6%) 560 (86%) 237 (36%) 339 (52%) 209 P * .) 221 (34%) 469 (72%) 528 (81%)
4 644 281 (44V.) 215 (33%) 49 545 (857.) 246 (38%) 334 (52%) 189 (29%) 198 (31%) 474 (74%) 522 (81%)
Deprived 5% 270 (45V.) 181 (301.) 31 (3%) 482 (81%) 153 (26%) 252 (42%) 184 (31%) 194 (33%) 399 (677.) 444 (74%)
Total 3r309 U61 (41%) 1,175 (36%) 293 (9%) 2JS29 (85%) 1478 (36%) 1491 (51%) 1,024 (31%) 1,073 (32%) 2441 (71%) 2,636 (80%)
f t * — 1 0=0.003 0=0.003 p<0.001 0<0.001 0=0.839 0=0.816 0=0.082 0=0.015
1 If received within 6 months of diagnosis (Mastectomy: 95% within 6 months; BCS: 90% within 6 months)
2 Other surgery includes breast conservation and mastectomy performed more than 6 months after diagnosis (77 and 64 women respectively), and cases where the woman had 
surgery but the type of surgery is not known (152 women)
3 Qh-square test for association
For those women who did receive radiotherapy, women who had a mastectomy received 
radiotherapy at a longer time since diagnosis than women who had BCS. Overall, 81% of 
women who had BCS received their radiotherapy within 6 months of diagnosis compared to 
55% of women who had a mastectomy. Of women who were irradiated, deprived women 
were less likely to receive radiotherapy within 6 months of diagnosis, whether they 
underwent BCS (71% compared to 79% in affluent women) or mastectomy (43% compared 
to 47% in affluent women).
The decision to treat a woman with BCS instead of a mastectomy was correlated with 
tumour size, nodal status and grade. Women were more likely to receive BCS if they had 
node negative tumours (54% of women with pNO tumours, 30% with pN l, and 47%  with 
small tumours (57% with pT l, 31% with pT2, and 13% with pT3), and low 
grade tumours (58% with grade 1, 43% with grade 2, and 39% with grade 3+). The T  and N 
proportions were similar when assessed using clinical stage information.
Half (50%) of the women with tumours directly extending to the chest wall or skin (stage 
cT4) did not have surgery. Women receiving surgery at a regional RT centre w ere more 
likely to receive BCS than those treated elsewhere (51% compared to 42% of those treated 
at other high-workload hospitals and fewer at medium- and low-workload hospitals; Table
5.7). This effect was seen both for women diagnosed by screening and those presenting 
with clinical disease, and was seen in subsets of women with the same pathological tumour 
size (pTl, pT2 or pT3) at presentation (data not shown).
Of women without metastases at diagnosis, 9% did not have surgery. Of these women, 64% 
were elderly (aged over 75) or had comorbidity (21%, compared to only 13% o f  whole 
group). Some women may have refused surgery.
Chemotherapy was given before surgery for 201 (6%) women, most probably to reduce 
tumour size. Adjuvant endocrine therapy (tamoxifen or ovarian ablation) was given to 80% 
of all women, but deprived women were less likely to receive this treatment (74% compared 
to 81% of women in the affluent group; Table 5.6). Women with ER-positive tumours were 
significantly more likely to receive adjuvant endocrine therapy than those with ER-negative 
tumours (90% compared to 55%; p<0.001). However, this did not explain the deprivation- 
specific differences: deprived women were less likely to receive adjuvant endocrine therapy
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with both ER-negative (49% compared to 57% of affluent women; p =0.440) and ER- 
positive (90% compared to 94%; p=0.157) tumours.
Table 5.7: Women diagnosed with breast cancer in Scotland in 1997: hospital of surgery
and type of surgery (number and percentage of cases)
Hospital o f surgery Mastectomy BCS Other,
unspecified1
None
Regional RT centre 544 (44%) 632 (51%) 53 (4%) 211 (15%)
High-workload hospital 358 (56%) 269 (42%) 11 (2%) 73 (10%)
Medium-high workload hospital 352 (57%) 248 (40%) 20 (5%) 101 (14%)
Medium-low workload hospital 126 (51%) 81 (33%) 39 (16%) 41 (14%)
Low-workload hospital 45 (49%) 22 (24%) 25 (27%) 34 (27>/<,)
Did not attend a hospital 0 <o%) 0 (0%) 0 <o%) 24 (100°/o)
Total 1,425 1,252 (38% ) 148 (¡% L 484 (15%)
Chi-square test for association between hospital and surgery type: p<0.001
1 Other surgery includes cases where the woman had surgery but the type of surgery is not known.
Women seen by high-workload clinicians were more likely to receive chemotherapy (40% of 
women compared to 31% for those seen by medium-workload and 7% by low-workload 
clinicians), and less likely to receive hormone therapy (78% compared to 82% for both 
medium- and low-workload clinicians). Previous research in Scotland had shown an increase 
of both chemotherapy and hormone therapy for women treated by high-workload 
clinicians“ .
Women who were treated with curative intent were more likely to receive surgery (98% 
compared to 44% o f women whose treatment intent was palliative), and radiotherapy (56% 
compared to 39%), and had a similar likelihood of receiving chemotherapy (33% compared 
to 29%) or hormone therapy (81% compared to 79%). Younger patients were also more 
likely to receive surgery (97% of women aged <50 compared to 35% of women aged 80+). 
Of the non-surgical patients, 82% received hormone therapy (89% of women with ER- 
negative tumours and 77% with ER-positive tumours), 11% received chemotherapy and 
18% received radiotherapy. The use o f hormone therapy was lower than observed in an 
audit of Yorkshire women diagnosed 1988-92, where 95% of women not treated surgically 
received hormone therapy, 7% received chemotherapy and 20% received radiotherapy1*1.
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T w o - y e a r  su rv iv a l
Univariate analyses
Factors which had an influence on differences in 2-year survival between deprivation 
categories were investigated in a Cox proportional hazards regression model. With the 
initial model (deprivation only) the relative risk o f death within two years of diagnosis was 
substantially raised (RR = 1.65 (95% Cl: 1.27-2.14); p<0.001) among deprived compared 
with affluent women. None of the factors reflecting access to health care, patient or tumour 
characteristics, and treatment, reduced the relative risk of death between deprived and 
affluent women below 1.3 or rendered this risk non-significant (see columns 1 to 4 of Table
5.8). The exception to this was when the women with unknown metastatic status were 
excluded from the analysis; however, the excluded women have a biased distribution with 
respect to deprivation (see Table 5.3). All of the factors, with the exception of urban 
indicator, health board of residence and radiotherapy provision, were important in 
predicting survival and improved the fit of the model compared to the null model including 
deprivation group and age (see column 5 of Table 5.8).
Patient characteristics
Survival was strongly related to age, with significantly poorer survival at two years after 
diagnosis for women aged 75 and over (61% compared to 89% for those aged under 75). 
The poorest survival was in those aged over 85 years. Including age in the model 
significantly improved the model fit but did not explain the difference in survival between 
affluent and deprived, only reducing the relative risk o f death from 1.65 to 1.60. Survival 
was similar for urban and rural residents, and this did not vary within deprivation groups. 
Including the urban indicator in the model, therefore, did not improve the model fit. 
Survival varied across the health boards, being highest in Fife and lowest in Forth Valley. 
The differences in survival between health boards were not significant after adjusting for 
age. This has been noted previously for women diagnosed with breast cancer in Scotland 
during 1991-95'.
Comorbidity was strongly related to survival even after adjustment for age. Women who 
spent more than 10 days in hospital in the two years prior to diagnosis had poorer survival 
than those who spent with fewer than 5 or no days in hospital (53% compared to 87%; 
p<0.001).
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Table 5.8: Women diagnosed with breast cancer in Scodand in 1997: univariate
influence o f  individual factors on the relative risk of death within two years 
of diagnosis among deprived compared to affluent women (Cox 
proportional hazards regression analysis)
Variable included in the m odel1 Relative
riak2
95% Cl 
Low High
P-value3 P -va lu e o l 
a d d ed  term 4
Initial model: Deprivation category 1.65 1.27 2.14 <0.001 -
Patient characteristics:
Age (null model? 1.60 1.23 2.07 <0.001 <0.001
Health board of residence 1.73 1.30 2.31 <0.001 0.458
Urban indicator 1.54 1.18 2.02 <0.01 0248
Bed-days comorbidity score 1.60 1.23 2.08 <0.001 <0.001
Charlson comorbidity score 1.61 1.24 2.09 <0.001 <0.001
Scodand comorbidity score 1.63 1.26 2.11 <0.001 <0.001
Health care system factors:
Attended a high workload hospital? 1.57 1.21 2.04 <0.01 <0.001
Treated at a high workload hospital? 1.56 1.20 2.02 <0.01 <0.001
Attended a specialist department 1.51 1.16 1.96 <0.01 <0.001
Emergency admission 1.57 1.21 2.04 <0.01 <0.001
Time from diagnosis to definitive treatment 1.58 1.20 2.08 <0.01 <0.001
Number of hospitals attended 1.65 1.27 2.14 <0.001 <0.001
Number of hospital from home visits 1.58 1.22 206 <0.01 <0.001
Consultant workload 1.58 1.22 205 <0.01 <0.001
Screen detected (yes/no) 1.61 1.24 208 <0.001 <0.001
Tumour characteristics:
Microscopic verification 1.58 1.22 204 <0.01 <0.001
Ductal, lobular or other 1.53 1.18 1.98 <0.01 <0.001
Pathological T size 1.36 1.05 1.76 0.021 <0.001
Pathological N status 1.48 1.15 1.93 <0.01 <0.001
Clinical T stage 1.63 1.26 212 <0.001 <0.001
Clinical N stage 1.51 1.16 1.96 <0.01 <0.001
Metastatic status6 1.33 1.02 1.73 0.033 <0.001
Metastatic status7 1.39 0.95 202 0.087 <0.001
Metastatic status* 1.34 1.03 1.73 0.029 <0.001
Grade6 1.36 1.05 1.76 0.021 <0.001
Grade7 1.95 1.27 299 <0.01 <0.001
Grade* 1.56 1.21 203 <0.01 <0.001
ER status 1.50 1.16 1.95 <0.01 <0.001
Treatment factors:
Therapy objective (curative o r palliative)6 1.58 1.22 2.05 <0.01 <0.001
Therapy objective* 1.34 1.03 1.74 0.027 <0.001
Surgery (yes/no; no time restriction) 1.36 1.05 1.77 0.021 <0.001
Surgery (yes/no; within 6 months) 1.63 1.26 2.12 <0.001 <0.001
Radiotherapy (yes/no) 1.59 1.22 206 <0.01 0.123
Chemotherapy (yes/no) 1.61 1.24 208 <0.001 <0.001
Hormone therapy (yes/no) 1.58 1.22 204 <0.01 <0.001
1 Each categorical variable it added separately to the null model containing deprivation category and age
2 Relative risk of death in the deprived compared to affluent group
3 Significance of the difference in die relative risk
4 Improvement in model fit when each categorical variable is added to the null model
’ The significance of the age term it tested against the initial model containing only deprivation category
6 Unknowns included as a separate category
7 Women with unknown values excluded from the analysis 
'  Unknowns imputed (see Chapter 1)
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Increasing comorbidity on the Charlson scale was associated with decreasing survival (85% 
for no comorbidity, 60% if 1-2 comorbid conditions, and 36% if 3+ comorbid conditions; 
p<0.001). Any comorbidity compared to no comorbidity was also associated with reduced 
survival using the Scottish scale (64% compared to 85%; p<0.001). Survival for women with 
comorbidity as measured by the Charlson index was significantly poorer for deprived 
women than those in the other deprivation groups (37% compared to an average of 61%;
p < 0 . 0 1 ) .
Health care system factors
Women who attended a regional RT centre or other high-workload hospital at some point 
during their cancer spell had the best two-year survival (86% compared to 70% for those 
attending medium-high and medium-low workload hospitals, and 65% for those attending 
low-workload hospitals). Survival was very poor for women who did not attend a hospital 
(5%; p<0.001).
Women whose main treatment was received in a regional RT centre or other high-workload 
hospital had better survival (92%) than those treated in medium-high workload (88%), 
medium-low workload (85%) or low-workload (87%) hospitals. Women who attended a 
specialist department within three months o f diagnosis had significantly better survival than 
women who attended a specialist department later or who did not attend one at all (88% 
compared to 56%; p=0.002). The three factors relating to hospital workload and specialty 
all improved the model fit when added to the null model, but did not explain the 
deprivation-specific gradient in survival (Table 5.8).
Women who presented as an emergency admission had poorer survival than women who 
were admitted routinely (45% compared to 87%; p<0.001), and deprived women were more 
likely to present as an emergency. However, inclusion of type of admission only reduced 
the relative risk o f death among deprived compared to affluent women from 1.65 to 1.57.
Women who waited less than two weeks between diagnosis and surgery (or other treatment 
for non-surgical patients) had poorer survival than women who had a longer wait (76% 
compared to 87%; p<0.001). Women who presented as an emergency were more likely to 
have a short wait (45% compared to 21% of non-emergency admissions); however, the 
difference in survival was seen for both women admitted as an emergency and those
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admitted routinely. The difference in survival is accounted for by the distribution of tumour 
characteristics (size, nodal status, metastatic status and grade) at diagnosis. Among women 
who attended hospital during their cancer spell, survival was better for women who attended 
more hospitals, and those who had the most visits to hospital between diagnosis and 
definitive treatment. Again, this appeared to be due to women with better prognosis 
attending more hospitals and being less likely to be retained in hospital on first admission. 
Survival was significantly worse for deprived patients who attended only one hospital (75% 
compared to 84% for affluent patients; p<0.05). These three health care system factors may 
be related to comorbidity.
Women who were seen by a consultant with a medium- or high-workload had similar two- 
year survival (88%), but women seen by a low-workload consultant had poorer survival 
(59%), as did those women who did not see a consultant or for whom the consultant details 
were not recorded (64%). Seeing a high-workload consultant was more important for 
women treated with palliative intent (survival at two years of 57%, compared to 41% for 
medium-workload and 35% for low-workload consultants; and 45% if consultant workload 
was not recorded) than those treated with curative intent (95% for high-workload, 94% for 
medium-workload, 90% for low-workload consultants; and 92% if the consultant workload 
was not recorded).
As would be expected, women aged 50-69 with screen-detected cancers had significantly 
better survival at two years after diagnosis than those who were not screen-detected (98% 
compared to 87%; p<0.001). Whether the woman’s tumour was microscopically verified 
was also very strongly related to survival (86% compared to 17% at two years) and this was 
not accounted for by age. Survival was similar for women with ductal and lobular tumours 
despite previous research indicating that lobular carcinomas confer a better prognosis111. 
Survival was worse for women with other or unknown histological type, and this was 
because a higher proportion o f women with other or unknown type were being treated with 
palliative intent (45% compared to 17% of women with ductal or lobular tumours).
Tumour characteristics
Two-year survival was significantly better for women with small tumours (for clinical size: 
94% for women with cTl tumours, 86% for cT2, 71% for cT3 and 56% for cT4; and for 
pathological size: 96% for p T l, 87% for pT2 and 68% for pT3), tumours with no nodal
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involvement (for clinical nodal status, 91% for cNO, 76% for cN l and 45% for cN2/3; and 
for pathological nodal status, 96% for pNO, 86% for pNl and 95% for pNmtdr<Iu. J ,  and non- 
metastatic tumours (91% for MO, 42% for M l). The relative risk of death between affluent 
and deprived women was non-significant when women with unknown metastases were 
included as a separate category in the analyses, but significant when metastatic status was 
imputed (Table 5.8). When only women with metastatic disease were considered, survival 
was significandy better for affluent compared to deprived women; when only women with 
non-metastatic disease were considered, the difference in survival between the deprivation 
groups was no longer significant if  women with imputed non-metastatic disease were 
included.
Within each tumour grade, survival was similar across the deprivation groups, except for 
Grade III tumours, where there was a clear gradient o f poorer survival with increasing 
deprivation. Women with grade I tumours had the most favourable prognosis (92%, 
compared to 87% for grade 2, and 75% for grade 3-4 tumours). Women with unknown 
grade had significantly poorer survival than those with known grade, because they were 
more likely to be treated with palliative intent. The deprivation-specific differences in 
survival remained whichever way the unknown grade information was dealt with (separate 
category, excluded or imputed).
Survival was poorer for ER-negative than ER-positive tumours (80% compared to 92%). 
Women with unknown ER status had significantly poorer survival than those with known 
ER status (60%), which was accounted for by these women being more likely to have 
treatment with palliative or unknown intent.
Treatment factors
None of the treatment variables independendy accounted for differences in two-year 
survival between the deprivation categories. Overall, survival was better for women who 
had BCS compared to mastectomy (93% compared to 89%; p<0.01) and significandy 
poorer for women who received other/unknown or no surgery (48%). The difference in 
survival by mastectomy or BCS was reduced and non-significant when an adjustment was 
made to account for differences in the distribution of age and pathological tumour stage. 
Survival from BCS was similar across the deprivation groups, but for women receiving a 
mastectomy, survival significantly decreased with increasing deprivation.
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Women receiving radiotherapy had a significantly more favourable outlook than those who 
did not (87% compared to 78%; p<0.001), although this was largely accounted for by 
differences in the distribution of age. Time to radiotherapy (<6 months compared to >6 
months) did not appear to influence survival. Women who received chemotherapy within 6 
months of diagnosis had higher survival at two years after diagnosis than those who did not 
receive chemotherapy (87% compared to 81%; p<0.001). This effect was enhanced when 
differences in the age distribution were taken into account. Women who received 
chemotherapy more than 6 months after diagnosis had significantly poorer survival (55%; 
p<0.001), and this difference was evident for women treated with curative and palliative 
intent. The benefit of chemotherapy varied significantly between deprivation groups.
Women who received hormone therapy more than 6 months after diagnosis, conversely, 
had significantly higher survival than those receiving hormone therapy within 6 months of 
diagnosis (92% compared to 83%; p<0.001), however this was again due to differences in 
the age distribution. Clinical trials predict a 3.5% survival advantage at five years for 
adjuvant systemic treatment14*, and in the data presented here there was a significant survival 
advantage at two years after diagnosis for women who received hormone therapy (84% 
compared to 76% for women who did not receive hormone therapy; p<0.001) which was 
not accounted for by age. Survival varied by deprivation group for women receiving 
hormone therapy, with 81% o f deprived compared to 86% of affluent women still alive two 
years after diagnosis. For women not receiving hormone therapy the gradient was larger 
(68% compared to 79%), resulting in a significant interaction between deprivation group and 
hormone therapy. However, differences in the provision of and survival from hormone 
therapy did not account for the difference in survival by deprivation group (RR reduced 
from 1.65 to 1.58; Table 5.8).
Multivariate analyses
The multivariate analysis was performed in two stages. Firstly the factors were modelled in 
groups to identify the most important factors relating to patient characteristics, service and 
presentation characteristics, and treatment. Deprivation category and age group were 
included in each model. Secondly, the significant variables in each group model were 
combined in a further model to identify the most important prognostic indicators overall,
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and their effect on the deprivation-specific differences (Table 5.9). Backward selection 
procedures were used.
If only deprivation is included in the model (model 0) then the relative risk (RR) of death at 
two years after diagnosis for deprived compared to affluent women was 1.65 (p<0.001). In 
model 1, when factors relating to the patient were added to the model, age and the bed-days 
comorbidity score were significant prognostic indicators. Addition of age and bed-days 
score to the model only reduced the RR from 1.65 to 1.60, thus not explaining the 
differences in survival between deprivation groups. Health board of residence, urban 
indicator, Charlson comorbidity score and Scotland comorbidity score were not important 
factors in the model when age and bed-days comorbidity score were present.
Model 2 looked at the health care system factors, and identified the hospital of treatment, 
consultant workload, type of admission (emergency or routine), number of visits to hospital 
between diagnosis and treatment, and whether the woman was screen-detected as important 
explanatory variables. Addition of these variables to the model increased the RR from 1.65 
to 1.71. Conditional on these variables being in the model, information on time from 
diagnosis to treatment, number of hospitals attended overall, whether attended a high- 
workload hospital at some point during the cancer spell, and whether they were seen in a 
specialist department did not improve the fit of the model in explaining survival differences.
The time from diagnosis to treatment variable was a significant explanatory variable, but was 
not included in the model because it was the group of women whose time interval was 
categorised as unknown, who had significantly different survival to those with a time 
recorded; these comprise largely o f patients who did not receive treatment and so is, in 
effect, a measure of treatment provision.
Model 3 looked at the presentation factors, with unknown grade and metastatic status either 
included as a separate category (columns 2-5) or imputed (columns 6-9). All the 
presentation factors with the exception of age were important prognostic indicators, and the 
same pattern of effect was seen for all factors whichever method of dealing with the 
unknowns was used.
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Table 5.9: Women diagnosed with breast cancer in Scodand in 1997: multivariate
influence o f  variables on the relative risk of death within two years of 
diagnosis among deprived compared to affluent women (Cox proportional 
hazards regression analysis)
Model
Variables included in the model
Unknowns' as separate group Unknowns' imputed
Relative
risk
95% Cl 
Low High
P -va lu e Relative
risk
95% C l P -va lu e 
Low High
Model 0: Null model
Depl: Affluent 1.00
Dep2 1.06 0.81 1.40 0.675
Dep3 1.28 0.98 1.67 0.075
Dep4 1.40 1.08 1.82 0.012
Dep5: Deprived 1.65 1.27 214 <0.001 _
Model 1: Patient characteristics
Depl: Affluent 1.00
Dep2 1.08 0.82 1.42 0.589
Dep3 1.33 1.01 1.73 0.040
Dep4 1.50 1.15 1.95 <0.01 _
Dep5: Deprived 1.60 1.23 2.08 <0.001 _
Ages 20-34 1.00
Ages 35-49 0.64 0.31 1.29 0J10 _
Ages 50-59 0.58 0.29 1.17 0.129 _
Ages 60-69 0.87 0.44 1.73 0.691 _
Ages 70-74 1.44 0.72 2.88 0.306
Ages 75-79 1.82 0.91 3.63 0.089
Ages 80-84 2.55 1.27 5.11 <0.01 .
Ages 85+ 3.75 1.89 7.46 <0.001 _
No bed-days comorbidity 1.00 .
1-4 bed-days comorbidity 0.93 0.73 1.20 0.594 -
5-10 bed-days comorbidity 1.23 0.94 1.63 0.135
11+ bed-days comorbidity 2.89 2.35 3.56 <0.001
Model 2: Health care system factors2
Depl: Affluent 1.00 -
Dep2 1.10 0.83 1.47 0.496 -
Dep3 1.27 0.96 1.69 0.095 -
Dep4 1.46 1.11 1.91 <0.01 -
Dep5: Deprived 1.71 1.31 225 <0.001 -
Treated at third visit 1.00 -
Treated at second visit 0.44 0.26 0.73 <0.01 -
Treated at flrst visit 0.70 0.44 1.11 0.130
Treated at a regional RT centre 1.00
Treated in a high workload hospital 0.55 0.42 0.72 <0.001
Treated in a med-high workload hosp 0.80 0.64 1.01 0.064
Treated in a med-low workload hosp 0.84 0.63 1.13 0257
Treated in a low workload hospital 1.00 0.68 1.48 0.989
Did not attend a hospital 3.56 2.08 6.10 <0.001
Low-workload consultant 1.00
Medium-low workload consultant 0.66 0.48 0.91 0.012
Medium-high workload consultant 0.59 0.45 0.78 <0.001
High-workload consultant 0.61 0.43 0.85 <0.01
Unknown consultant workload 0.79 0.61 1.03 0.079
Routine admission 1.00
Emergency admission 2.61 209 3.26 <0.001
Unknown admission type 1.02 0.51 2.04 0.965
Screen-detected 1.00 -
Not screen-detected 4.26 257 7.05 <0.001 -
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T a b le  5 .9  c o n t in u e d
Model
Variables included in the model
Unknowns' as separate group Unknowns' imputed
Relative
risk
95% C l 
Low High
P -va lu c Relative
risk
95% C l 
Low High
P -va lu e
Model 3: Presentation factors
Depl: Affluent 1.00 1.00
Dep2 1.00 0.76 1.33 0.977 0.98 0.74 1.30 0.899
Dep3 1.25 0.95 1.63 0.109 1.28 0.98 1.67 0.073
Dep4 1.14 0.87 1.49 0.352 1.13 0.86 1.48 0.379
Dep5: Deprived 1.29 0.99 1.68 0.058 1.33 1.02 1.73 0.034
Histologically verified 1.00 1.00
Not histologically verified 2.57 1.99 3.32 <0.001 2.42 1.87 3.13 <0.001
Ductal 1.00 1.00
Lobular 0.96 0.66 1.40 0.826 0.94 0.64 1.36 0.730
Other/unknown 1.27 1.02 1.57 0.033 1.29 1.04 1.59 0.018
Stage pTl 1.00 1.00
Stage pT2 1.89 1.33 2.68 <0.001 1.93 1.36 275 <0.001
Stage pT3 2.28 1.40 3.73 <0.01 232 1.42 3.81 <0.01
Pathological T stage unknown 1.92 1.35 2.72 <0.001 1.82 1.27 2.60 <0.01
Stage pNO 1.00 1.00
Stage pNl 2.34 1.67 3.29 <0.001 218 1.54 3.07 <0.001
Stage pNO inadequate sample 1.37 0.54 3.43 0.507 1.36 0.54 3.40 0.516
Pathological N stage unknown 6.95 4.85 9.95 <0.001 5.98 4.14 8.62 <0.001
Stage cTl 1.00 1.00
Stage cT2 1.20 0.88 1.63 0248 1.23 0.90 1.67 0.194
Stage cT3 1.30 0.88 1.92 0.185 1.40 0.95 2.06 0.093
Stage cT4 1.64 1.17 2.31 <0.01 1.70 1.21 240 <0.01
Clinical T stage unknown 1.51 1.09 209 0.013 1.59 1.15 221 <0.01
Stage cNO 1.00 1.00
Stage cN 1 1.43 1.12 1.84 <0.01 1.47 1.15 1.89 <0.01
Stage cN2/3 1.93 1.35 276 <0.001 217 1.54 3.05 <0.001
Clinical N stage unknown 1.02 0.78 1.33 0.869 0.90 0.70 1.16 0.407
No métastasés 1.00 1.00
Métastasés 2.74 2.09 3.59 <0.001 261 211 3.22 <0.001
Metastatic status unknown 1.46 1.16 1.85 <0.01
Grade 1 1.00
Grade 2 1.86 1.00 3.44 0.050
Grade 3-4 2.60 1.42 4.75 <0.01
Grade unknown 2.49 1.37 4.54 <0.01
ER —ve 1.00 1.00
ER +ve 0.43 0.34 0.55 <0.001 0.41 0.32 0.51 <0.001
ER status unknown 0.61 0.47 0.80 <0.001 0.55 0.42 0.71 <0.001
Model 4: Treatment factors
Depl: Affluent 1.00 1.00
Dep2 1.08 0.82 1.43 0.577 1.07 0.81 1.40 0.655
Dep3 1.22 0.93 1.60 0.151 1.14 0.87 1.49 0.339
Dep4 1.35 1.04 1.76 0.026 1.24 0.96 1.62 0.105
Dep5: Deprived 1.37 1.05 1.78 0.020 1.24 0.95 1.61 0.109
Curative treatment intent 1.00 1.00
Palliative treatment intent 6.97 5.39 9.01 <0.001 6.94 5.46 8.81 <0.001
Unknown treatment intent 4.17 3.13 5.55 <0.001 -
Mastectomy 1.00 1.00
BCS 0.65 0.50 0.84 <0.01 0.66 0.51 0.86 <0.01
Other or unknown surgery 3.25 2.56 4.13 <0.001 1.31 0.79 218 0.295
No surgery performed 1.31 0.80 2.15 0.286 2.63 2.06 3.36 <0.001
No chemotherapy 1.00 1.00
Chemo within 6 months 0.82 0.65 1.03 0.089 0.86 0.68 1.08 0.200
Chemo > 6 months 2.24 1.44 3.47 <0.001 2.21 1.42 3.43 <0.001
Unknown chemotherapy details 0.78 0.26 2.31 0.649 1.10 0.37 3.26 0.859
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Model
Variables included in the model
Unknowns' as separate group Unknowns' imputed
Relative
risk
95% Cl 
Low High
P-nU ue Relative
risk
95% Cl 
Low High
P -ra Ju e
Model 4 continued..
No hormone therapy 1.00 1.00
Hormone therapy within 6 months 0.44 0.35 0.54 <0.001 0.45 0.37 0.56 <0.001
Hormone therapy > 6 months 0.37 0.24 0.58 <0.001 0.41 0.27 0.63 <0.001
Unknown Hotmone therapy details 0.67 0.28 1.59 0.367 0.66 0.29 1.54 0.338
Model 5: Final model
Depl: Affluent 1.00 1.00
Dep2 0.93 0.70 1.23 0.594 0.97 0.73 1.29 0.820
Dep3 1.26 0.96 1.66 0.095 1.27 0.96 1.67 0.091
Dep4 1.20 0.91 1.59 0.191 1.17 0.89 1.55 0256
Dep5: Deprived 1.36 1.04 1.79 0.026 1.35 1.03 1.77 0.030
No bed-days comorbidity 1.00 1.00
1-4 bed-days comorbidity 1.14 0.88 1.47 0.311 1.11 0.86 1.43 0.438
5-10 bed-days comorbidity 1.26 0.95 1.67 0.110 1.30 0.98 1.72 0.069
11+ bed-days comotbiditv 1.74 1.40 2.15 <0.001 1.76 1.42 2.18 <0.001
Screen-detected 1.00 1.00
Not screen-detected 2.04 1.23 3.39 <0.01 2.14 1.29 3.55 <0.01
Treated in a regional RT centre 1.00 1.00
Treated in a high-workload hospital 0.72 0.54 0.95 0.019 0.71 0.54 0.93 0.012
Treated in a med-high workload hosp 1.10 0.87 1.39 0.427 1.07 0.85 1.34 0.556
Treated in a med-low workload hosp 1.17 0.87 1.57 0287 1.21 0.90 1.61 0203
Treated in a low-workload hospital 1.14 0.78 1.68 0.501 1.09 0.74 1.60 0.665
Did not attend a hospital 3.59 2.18 5.91 <0.001 2.96 1.82 4.81 <0.001
Histologically verified 1.00 1.00
Not histologicallv verified 1.77 1.33 2.35 <0.001 1.84 1.39 2.44 <0.001
Stage pTl 1.00 1.00
Stage pT2 1.62 1.13 2.33 <0.01 1.72 1.20 2.46 <0.01
Stage pT3 1.87 1.13 3.11 0.016 1.96 1.18 3.25 <0.01
radiological T stage unknown 1.12 0.75 1.67 0.573 1.13 0.76 1.69 0.555
Stage pNO 1.00 1
Stage pNl 1.95 1.37 2.78 <0.001 1.92 1.34 2.74 <0.001
Stage pNO inadequate sample 1.33 0.53 3.35 0.540 1.28 0.51 3.22 0.597
Pathological N stage unknown 3.05 2.01 4.62 <0.001 3.07 2.02 4.65 <0.001
Stage cTl 1.00 1.00
Stage cT2 1.05 0.77 1.44 0.743 1.08 0.79 1.48 0.624
Stage cT3 1.22 0.82 1.81 0.320 1.35 0.91 1.99 0.138
Stage cT4 1.45 1.03 2.06 0.034 1.55 1.10 2.19 0.012
Clinical T stage unknown 1.55 1.11 2.17 0.010 1.65 1.18 2.30 <0.01
Stage cNO 1.00 1.00
Stage cNl 1.27 0.99 1.64 0.060 1.39 1.08 1.78 0.010
Stage cN2/3 1.63 1.14 2.35 <0.01 1.98 1.40 2.79 <0.001
Clinical N stage unknown 0.96 0.73 1.26 0.762 0.94 0.73 1.23 0.673
No mctastases 1.00 1.00
Metastases 2.50 1.89 3.30 <0.001 1.66 1.32 2.09 <0.001
Unknown metastatic status 1.55 1.21 1.99 <0.01 -
Grade 1 1.00
Grade 2 2.00 1.07 3.73 0.029 •
Grade 3-4 2.79 1.52 5.12 <0.01 •
Unknown Grade 2.38 1.30 4.35 <0.01 »
ER —ve 1.00 1.00
ER +ve 0.49 0.38 0.63 <0.001 0.47 0.37 0.61 <0.001
ER status unknown 0.56 0.43 0.74 <0.001 0.57 0.43 0.74 <0.001
Curative treatment intent 1.00 1.00
Palliative treatment intent 3.55 2.69 4.67 <0.001 3.18 2.42 4.20 <0.001
Unknown treatment intent 2.80 2.07 3.79 <0.001 -
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Model
Variables included in the model
Unknowns' as separate group Unknowns' imputed
Relative
risk
95% C l 
Low High
P -va tu e Relative
risk
95% C l 
Low High
P -va lu e
Model S continued..
Mastectomy 1.00 1.00
BCS 0.98 0.75 1.30 0.907 1.02 0.77 1.35 0.902
Other or unknown surgery details 1.63 1.15 2.32 <0.01 1.47 1.03 2.10 0.033
No surgery performed 0.92 0.55 1.55 0.765 1.03 0.60 1.76 0.927
No chemotherapy 1.00 1.00
Chemo within 6 months 0.63 0.48 0.82 <0.01 0.75 0.58 0.97 0.029
Chemo > 6 months 1.97 1.24 3.11 <0.01 2.27 1.44 3.59 <0.001
Unknown chemotherapy details 0.70 0.22 2.22 0.546 0.86 0.25 2.99 0.811
No hormone therapy 1.00 1.00
Hormone therapy within 6 months 0.51 0.41 0.64 <0.001 0.55 0.44 0.68 <0.001
Hormone therapy > 6 months 0.42 0.27 0.64 <0.001 0.46 0.30 0.71 <0.001
Unknown Hormone therapy details 0.72 0.29 1.79 0.481 0.85 0.32 2.24 0.743
1 Includes unknown metastatic status, grade and treatment intent
2 Age was also significant in this model but the estimates are not presented on the table.
Grade was no longer significant when values were imputed, which may be because the 
imputation was based on four factors, three of which were in this model. These models 
explained around half the difference in survival between affluent and deprived women. 
When the unknowns were included as a separate category the RR was reduced from 1.65 to 
1.29 and was not significant. However, the distribution of missing data is biased which 
makes interpretation complicated. When the unknowns were imputed, the RR was reduced 
to 1.33, and the difference was marginally significant. The trend across the deprivation 
groups was less clear with model 3.
In model 4, treatment factors relating to treatment intent (palliative or curative), surgery 
provision and type, chemotherapy provision and timing and hormone therapy provision and 
timing, were all important in determining survival outcome. Age and radiotherapy were not 
significantly related to survival in a model containing the other factors. In the model where 
women with unknown treatment intent were included as a separate category, around half the 
difference in survival between affluent and deprived was explained (RR=1.37; p=0.020). 
When unknown treatment intent was imputed, the treatment model explained around two- 
thirds of the difference in risk of death between affluent and deprived women (RR reduced 
from 1.65 to 1.24) and the difference was non-significant.
Finally, model 5 was fitted including all the factors found to be important prognostic 
indicators in the sub-group models (1-4). The model with the unknowns included as a 
separate category was very similar to the model with values imputed, the exception being
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grade which was no longer significant when imputed. Overall, these models explained 
around half the difference in survival between affluent and deprived women (RR= 1.35-1.36), 
but the difference was significant despite the larger variation that had been explained by 
some of the sub-groups models. The important prognostic factors in the final model were 
bed-days comorbidity, whether screen-detected, hospital of treatment, whether the tumour 
was histologically verified, pathological T and N stage, clinical T and N stage, metastatic 
status, grade, oestrogen receptor status, treatment intent, type and timing of surgery, and 
provision and timing of chemotherapy and hormone therapy.
Discussion
These analyses show that deprived women compared with affluent women had more 
comorbidity at diagnosis, were more likely to present with metastatic disease and have ER 
negative tumours, and less likely to have lobular carcinomas. Deprived women were also 
more likely to present as an emergency and to stay in hospital after first admission; they 
were less likely to attend a regional RT centre or specialist department, less likely to see a 
high-workload clinician, and more likely to receive a mastectomy, and less likely to receive 
adjuvant radiotherapy, regardless o f  the surgical intervention. Deprived women were also 
less likely to receive hormone therapy, whether their tumour was ER negative or ER 
positive. Indeed, deprived women with breast cancer appear to be consistently worse off 
than affluent women throughout their cancer journey.
Differences in tumour characteristics at diagnosis, particularly metastatic status, appear to be 
the most influential in explaining the differences in survival between deprivation groups 
when looked at in isolation, although the picture is less clear when these factors are 
considered together with the hospital and treatment factors. The widely varying treatment 
offered to women with breast cancer across Scotland also appears to be to explain some of 
the differences in survival, and relates to the hospital they attend and the consultant who 
sees them.
An audit of Scottish women diagnosed with breast cancer in 1987“  found that a survival 
advantage for affluent women disappeared in their multivariate analyses, and around a third 
of the survival difference was accounted for by the higher proportion of ER-negative 
tumours in the deprived women who underwent surgery. The authors also found an
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influence of health board of first treatment for the surgically treated women, particularly 
those aged under 75 at diagnosis, which appeared to be due to differences in the use of 
adjuvant systemic therapy. The analyses for women diagnosed in Scotland in 1997 also 
identified deprived women as having a higher proportion ER-negative tumours, and this 
appeared to account for up to a quarter of the deprivation-specific survival differences. 
Differences in the use of adjuvant systemic therapy were also still clearly evident, despite a 
10-year period having elapsed, during which time breast cancer services were re-organised as 
a result of the introduction of the national breast screening programme.
It is encouraging that the 1987 audit, 1993 audit and these routine data for 1997 show 
progressively increasing use o f radiotherapy, chemotherapy and hormonal treatments. The 
proportion of women receiving breast conserving therapy rather than a mastectomy is also 
increasing, with 47% of surgically-treated women diagnosed in 1997 receiving breast- 
conserving surgery22 compared to 40% of women diagnosed in 1987. From trial data, 
treatment with breast-conserving surgery should not confer a survival benefit compared to 
mastectomy, so the differences in surgical interventions between the deprivation groups 
should not translate into a survival benefit; however, it may have a large impact on quality of 
life and speed of recovery164. In 1997, 44% of surgically-treated women underwent surgery 
at a regional RT centre, 23% at other high-workload hospitals (treating more than 104 
patients per annum; highest workload quartile), 22% at medium-workload hospitals (56-104 
patients) and 12% at low-workload hospitals (<56 patients). The regional RT centres were 
more likely to perform breast-conserving surgery (51% of patients) than the other high- 
workload (42%), the medium-high workload (40%) or the medium-low and low-workload 
(30%) hospitals. This difference was seen for screen-detected and non screen-detected 
women, and for women with the same pathological tumour size and nodal status at 
diagnosis. So, because deprived women were less likely to be treated at a regional RT centre 
they appear to be offered fewer treatment options.
Surgical treatment provides a good example. For women diagnosed in 1998, the prevalence 
of mastectomy (48%) and breast-conserving surgery (36%) was similar to that seen in 1997, 
and the treatment differences between the deprivation groups remained (45% of affluent 
compared to 54% of deprived women had a mastectomy; 40% compared to 28% had 
breast-conserving surgery). So, inequalities in treatment practice evident in 1997 were still 
prevalent in 1998. Even if these do not impact on survival, they should not exist. Around
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90% of breast cancer registrations for 1998 were matched on to the linked database at the 
time of this analysis (May 2001). The national clinical guidelines on breast cancer (October 
1998)165 produced by the Scottish intercollegiate guidelines network (SIGN) set out the 
clinical setting for mastectomy and breast-conserving surgery, and we will be able to assess 
their impact when the 1999 data are available.
Most o f the hospitals treating breast cancer patients in Scotland see women from all 
deprivation groups, but two of the largest hospitals do not. Thus, 17% of affluent women 
were treated in hospitals that did not treat any of the deprived women, the majority (16% of 
affluent women) in Aberdeen Royal Infirmary alone. Similarly, 7% of deprived women were 
treated at hospitals that did not treat any affluent women, and no less than 1 in 5 (21%) of 
all deprived women were treated in Glasgow Western Infirmary. Differences in treatment 
practice between hospitals can thus have a marked effect on the type(s) o f treatment 
received by women in different deprivation groups. Possible recording error in reporting 
the type of treatment on the hospital discharge records (SMROls) needs to be considered. 
Quality assurance exercises have been performed (see Chapter 2) by the ISD Quality 
Assurance Team on a sample of SMR01 data from 1997 for all hospitals in Scotland. The 
main operation code was found to be 96% accurate at the three-digit level and the ‘other’ 
operation codes were found to be 94% accurate. There were 62 mastectomy or breast- 
conserving operations in the QA exercise o f  which the majority (94%) were recorded in the 
main operation. No differences in recording these specific operations were observed 
between hospitals, so the differences in treatment options observed are real field (Fiona 
MacKenzie, ISD Quality Assurance Team, personal communication).
These data support previous findings: differences in ER status and treatment options varied 
between affluent and deprived women, but these differences were not strong enough to 
completely account for survival differences in these data; a Scottish audit of patients 
diagnosed in 1993 gave similar results15. Deprived women were also more likely to present 
with metastatic disease, as previously noted in a study of 417 women diagnosed with breast 
cancer in Glasgow during 1992-93141. An earlier study151 had noted that older women and 
those living in more deprived areas were less likely to be treated in a regional RT centre. 
The analysis presented here show this was still the case for women diagnosed in 1997, and 
there has been a recent demand for managed clinical networks and teleconferencing, as 
opposed to a small number of cancer centres treating all the cases152.
151
It has previously been noted that tumour stage, ER status and grade are not independent 
prognostic factors. Grade 3 tumours are more likely to be ER negative154 and large tumours 
are more likely to be node positive156. The data presented here support these findings; 48% 
of women with grade 3 tumours were ER-negative, compared to 8% with grade 1, 15% with 
grade 2 and 26% with unknown grade. The tumour was node negative for 68% o f women 
with small (pTl) tumours, 42% of women with pT2 tumours and 26% of women with pT3 
tumours.
There was evidence of a lower than expected proportion o f lobular carcinomas for deprived 
women, although survival did not vary by histological type. As this has not been noted 
before, to my knowledge, I investigated it further with datasets of women diagnosed with 
breast cancer in Scotland during 1986-90 and 1991-95, and England and Wales during 1986- 
90. Two of the English registries had a very higjt proportion of unspecified (80003 or 
80103) morphology codes and were excluded, however, for all the other datasets the 
proportion of lobular carcinomas was lower in the deprived group than expected, although 
not always significantly so. In Scotland, the proportion of deprived women with lobular 
carcinomas was 5.7% compared to 6.5% in affluent women in 1986-90 (p=0.192), and 6.5% 
compared to 7.8% in 1991-95 (p=0.014). For England and Wales as a whole the 
proportions were 5.6% in deprived compared to 7.3% in affluent women (p<0.001). If we 
consider one large Scottish hospital, Glasgow Western Infirmary, for patients diagnosed 
during 1997, the same results are evident. This does suggest that, in addition to ER status, 
the distribution o f tumour type may also vary by deprivation group.
A further point to note is that both clinical and pathological tumour size and nodal status 
were retained in the final survival model, indicating that both measures were independently 
predictive of survival. Within each pathological tumour stage, survival varied significantly by 
the clinical tumour stages grouped therein. Overall, 43% of women were assigned to a 
different clinical and pathological size group and 38% to different clinical and pathological 
nodal status groups (including unknown vs. known). These findings strongly support the 
view that the two types of measure should not be combined into a single variable.
The validity of the imputed data hinges on whether the missing data were missing at 
random, which is particularly uncertain given the bias of missing values towards the deprived 
groups. Tumours for which size, nodal status and ER status were unknown were treated as
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separate categories in the analyses. Imputation was only carried out for grade, metastatic 
status and treatment intent. It should be safe to assume that all women receiving treatment 
with curative intent or who were screen-detected did not have metastatic disease; applying 
this assumption meant that the final imputation was required for only 12% of the women. 
Grade, however, was based on imputation of almost a third of the dataset. Checks of 
survival differences between categories when using imputed data produced estimates similar 
to those expected from the literature. The main findings of the analysis are not influenced 
by the method of analysing the unknowns.
Significant deprivation-specific differences in survival obtained from a model including 
treatment intent (palliative, curative or unknown; Table 5.9, model 4a) became smaller (and 
non-significant) when the treatment intent was imputed (Table 5.9, model 4b). Treatment 
intent is difficult to interpret as it is a very “soft” variable; it is not often stated explicitly in 
the medical notes and the cancer registration officers may use their own judgement in 
recording it. The information used for the imputation of treatment intent was type of 
surgery, metastatic status, grade and age. If women were incorrectly assigned by the 
imputation process (based on metastatic status, grade, type of surgery and age), then the 
difference in estimates for model 4a and 4b would have been influenced by metastatic status 
and grade, because type of surgery and age were included in models 4a and 4b in their own 
right. Interestingly, a model containing type o f  surgery, chemotherapy, hormone therapy, 
imputed metastatic status and imputed grade appears to account for most differences in 
survival between affluent and deprived women (RR=1.11; p=0.421).
Overall, differences in tumour characteristics appear to be the most important at explaining 
the differences in survival between affluent and deprived women, and the results of this 
chapter confirm that deprived women are still more likely to present with ER-negative 
tumours and with metastatic disease. These are women diagnosed at a time when everyone 
should be well aware of breast cancer due to huge publicity it has had over recent years. 
However, some women are still not presenting with early breast symptoms. Survival will 
never be truly equitable across Scotland until w e succeed in encouraging these women to 
come forward before their disease is advanced.
The widely varying treatment offered to women with breast cancer across Scotland also 
appears to be important. The treatment options available to women with breast cancer
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seem to relate to the hospital they attend and the consultant who sees them. To a certain 
extent, treatment differences will be ‘appropriate’ when they are due to the different stage of 
disease and general health o f the patients, but within groups of women with similar tumour 
characteristics (e.g. tumour pathological size) substantial differences still remain, and this 
seems unacceptable.
It would be interesting to prolong the follow-up of the patients studied here; 2 years is a 
very short follow-up interval for breast cancer, where survival is relatively good. From 
previous work, however, it is not likely that deprivation-specific differences in survival 
observed at 2 years will reduce with time since diagnosis166. Similar data for women 
diagnosed during 1998 will be available shortly, and it would be worthwhile to repeat the 
analyses for these patients. We will be able to use routine data to assess whether hospitals 
are complying with the SIGN guidelines introduced in 1998, and whether changes in 
treatment practice have been made. In particular, the type of operation and workload of 
hospitals performing the operations can be monitored. A prospective breast cancer audit, 
which has recently been set up in Scodand, should answer these questions in the future.
In conclusion, the results of this chapter indicate that differences in tumour characteristics 
and treatment options are responsible for between half and two-thirds of the survival 
variations observed between affluent and deprived women diagnosed with breast cancer in 
Scodand during 1997. The data on treatment are crude, and data on tumour characteristics 
were missing for a substantial minority of patients, so the effects seen are likely to be even 
larger in reality. These differences in survival are largely avoidable. They could be reduced 
by carefully targeted awareness campaigns aimed at deprived women and more rigorous 
adherence by clinicians to SIGN guidelines on how to treat breast cancer. Even if they had 
no impact on survival, differences in treatment of the kind seen here should not exist in an 
equitable health service.
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C h a p t e r  6
COLORECTAL CANCER
Background
Colorectal cancer encompasses all tumours of the colon, recto-sigmoid junction, rectum and 
anus (ICD10 C18-C21). With the exception o f the international comparisons in the 
background section, the analyses in this chapter are restricted to colon (C l8) and rectal 
(C20) cancers, joindy referred to as colorectal cancer where applicable. Recto-sigmoid 
junction (C l9; 8% of large bowel cancers) and anal (C21; 2%) cancers are excluded due to 
small numbers, because oncologists treat anal cancers differendy, and because there is some 
argument about the classification of recto-sigmoid cancers.
Colorectal cancer is the third most common cancer in males (14.5% of all cancers) and 
females (13.1%) in Scodand. Cancer of the colon constitutes about two thirds of cases of 
colorectal malignancy, with 2 139 patients diagnosed with colon and 884 with rectal cancer 
in Scodand in 1997. For both colon and rectal cancers incidence is higher in males, and 
male incidence has been increasing, particularly for rectal cancer, widening the gap in 
incidence between males and females. Incidence in females remained stable over the 18-year 
period examined (Figure 6.1).
Incidence of both colon and rectal cancer increases with increasing age, and although 
incidence is higher in men overall, it is actually higher in women at older ages (Figure 6.2), 
particularly for colon cancer patients. This is not reflected in the overall (age-standardised) 
rates, which give more weight to the younger age groups. Mortality from colon cancer is 
decreasing slightly for both males and females, but there is no similar trend for rectal cancer, 
for which mortality rates have been stable over the 20-year period shown (Figure 6.1). In 
1999, 1 456 patients died of colorectal cancer in Scotland, making it the second most 
common cause of cancer-related death in Scotland after lung cancer.
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F ig ure  6 .1 : Colorectal cancer in Scotland: trends in incidence (1979-97) and mortality 
(1979-99), all ages (European age-standardised rates)
Year of diagnosis or death
Figure 6.2: Age-specific incidence of colorectal cancer in Scotland for patients diagnosed
in 1997, by sex
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Incidence of colon cancer is higher in Scotland than in most other European countries but 
lower than in the USA, Australia and New Zealand. Incidence of rectal cancer is similar to 
the average for Europe and the USA (Figure 6.3). Substantial differences in incidence 
between health boards within Scodand also exist, with comparatively low incidence in 
Lanarkshire and Forth Valley and high incidence in Grampian and Greater Glasgow169. It is 
estimated that around two thirds of colorectal cancers can be accounted for solely by the 
environment and the remaining third by genetic susceptibility170. Known inherited 
predisposition genes include hereditary bowel cancer which accounts for around 5% of cases 
(comprising the very rare familial adenomatous polyposis (FAP) and the more common 
hereditary non-polyposis colorectal cancer (HNPCQ)171.
Figure 6.3: International comparison of colorectal1 cancer incidence, around 1988-92*
(world age-standardised rates)
A) Colon cancer B) Rectal cancer
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Source: Cancer Incidence in Five Continents, Volume VI1“
1 Defined here as 1CD10 C18-C21
2 The Netherlands data includes the period 1989-92, England and Wales includes 1988-90, Spain includes 
1986-90 and Finland includes 1987-92
Over the next decade the incidence rate of colorectal cancer in Scotland is not expected to 
change, but since 45% of patients are aged over 75 at diagnosis and the population in 
Scotland is ageing, the annual number of new cases is expected to increase by around 
16%152, and substantially more if screening is introduced. These cancers will, therefore, be 
of continuing public health importance.
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Due to the somewhat vague symptoms of colorectal cancer, and because some patients may 
not appreciate the significance of more definite symptoms, such as rectal bleeding172, the 
majority of cases are not diagnosed until the disease has spread beyond the bowel. 
Consequently, around three in five patients die as a direct result of the disease within five 
years of diagnosis. Survival has, however, improved significandy for patients diagnosed over 
the 27-year period from 1971-97. For colon cancer patients, one-year survival increased 
from 44% to 66% and five year survival increased from 28% to 45%, and for rectal cancer 
patients, one-year survival increased from 54% to 71% and five-year survival from 28% to 
44% (Figure 6.4).
Figure 6.4: Patients diagnosed with colorectal cancer in Scotland during 1971-97: trends
in relative survival by sex
Period of diagnosis
Survival is most favourable in young females, and decreases with increasing age in both 
sexes. Most of the higher mortality in elderly patients is seen in the first year following 
diagnosis, so may be related to mode of presentation and stage of disease at diagnosis'. By 
around six years after diagnosis, patients with colon cancer have a similar survival to the 
general population. Rectal cancer patients continue to die from the cancer even 10 years 
after diagnosis.
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Despite recent improvements over time, survival is still significantly worse in Scotland than 
in other European countries and particularly the USA (Figure 6.5). Some studies173 indicate 
that international differences in survival are related mainly to stage at diagnosis, which is 
generally more advanced in countries with poor survival. However, not all of the 
international variability can be accounted for by stage at diagnosis, and it has been 
hypothesised that some of the remaining variation may be explained by differences in 
management of the disease174. The validity of these international comparisons are 
questioned elsewhere175.
Figure 6.5: Colorectal1 cancer: international comparison of five-year relative survival
(with 95% confidence intervals), selected countries , diagnosed around 
1985-89, all ages
Scotland I  
England & W ales 1 
Denmark I  
Italy J 
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Finland J 
France I  
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The Netherlands I  
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0
Sources: Berrino t l a£6, Gitta it  a t139, Coleman it at*
1 Defined here as ICD10 C18-C21
2 Patients aged 15-99 for Scodand; patients diagnosed 1986-90 and aged 15-99 for England & Wales
In this chapter, the survival of 3 009 patients (3 023 cancers; 14 patients had a cancer at both 
sub-sites during 1997) diagnosed with colorectal cancer in Scotland in 1997 is investigated to 
identify reasons for differences in survival by deprivation category. For definitions of the 
variables included in the analyses, please refer to Chapter 2.
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R esults and com m entary
The incidence rate of colon cancer was 8% higher in people from the most affluent areas 
(herein referred to as affluent patients or the affluent group) compared to people from the 
most deprived areas (deprived patients or the deprived group) in Scotland in 1997 (Figure 
6.6). There was little variation in mortality across the deprivation groups. Survival two years 
after diagnosis was slightly higher in the affluent than the deprived group (51% compared to 
48%) although there was no trend across the deprivation groups, indicating that differences 
in survival between deprivation groups seen in the earlier periods (see Chapter 3) have 
diminished.
The incidence rate of rectal cancer was also higher for people living in affluent compared to 
deprived areas, although there was no clear trend across the deprivation groups. There was 
also little variation in mortality across the deprivation groups, however, survival two years 
after diagnosis was significantly higher in the affluent than the deprived group (61% 
compared to 49%; Figure 6.6).
Overall, 2 139 patients aged 25 and over were diagnosed with colon cancer in Scotland in 
1997, o f whom 919 (43%) were from deprivation groups 1 and 2 and 763 (36%) from 
deprivation groups 4 and 5. There were 884 patients aged 30 and over diagnosed with rectal 
cancer, 375 (43%) from deprivation groups 1 and 2 and 316 (36%) from deprivation groups 
4 and 5 (Table 6.1).
Colon cancer was equally common in males and females (50%); however, rectal cancers were 
more common in men (60%). These proportions were similar between the deprivation 
groups. The distribution of age at diagnosis was similar for colon and rectal patients, and 
across the deprivation groups, with median age o f 73 years and inter-quartile range from 64 
to 80 years. Colon or rectal cancer was the first primary malignancy for 2 740 (91%) of 
patients; 20 patients had two cancers diagnosed simultaneously, and these were both within 
the large bowel for 12 patients; 45 patients had a previous primary at the same site; 204 
patients had a previous primary at another site, and these were both within the large bowel 
and diagnosed in 1997 for 2 patients. For the 14 (12+2) patients who had a diagnosis of 
both colon and rectal cancer within 1997, only the earliest is considered whenever data for 
colorectal cancers combined is analysed.
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F ig ure  6 .6 : Patients diagnosed with colorectal cancer in Scotland in 1997: incidence' and 
two-year relative survival1 2, and mortality1 in 1999, by deprivation category
A) Colon
Affluent . . . .  DeprivedCarstairs depnvation category
1 Age-standardised rate* per 100 000 penon-year* at risk (European standard population)
2 Using deprivation-specific life tables
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Table 6 .1 : Patients diagnosed with colorectal cancer in Scotland during 1997: demographic data by deprivation category (number and percentage 
o f  cases)
Deprivation No. of patienta No. of females Median age Caaea for which: No. of urban
category (inter-quartile
range)
First
primary
Simultaneous
primary2
Previous 
primary at 
same site
Previous
primary
elsewhere3
residents4
r j iM
Affluent 455 (21%) 222 (*97.) 74 (6532) 402 (887.) 3 (17.) 9 (27.) 41 (97.) 187 (417.)
2 464 (227.) 237 (517.) 74 (6530) 422 (917.) 4 (17.) 11 (27.) 27 (67.) 85 (107.)
3 457 (217.) 234 (517.) 73 (65-79) 409 (897.) 6 (17.) 8 (27.) 34 (77.) 132 (297.)
4 400 (197.) 1% (497.) 73 (6)30) 369 (927.) 2 (17.) 7 (27.) 22 (67.) 181 (457.)
Depnved 363 (177.) 181 (507.) 73 (6630) 328 (907.) 3 (17.) 8 (27.) 24 (77.) 298 (827.)
Total 2J39 (100%) 1,070 (50%) 74 (6531) 1,930 (90%) 18 (1%) 43 (27.) 148 (77.) 883 (41%)
Rectum
Affluent 176 (207.) 75 (4)7.) 71 (6)-79) 163 (9)7.) 2 (17.) 0 (07c) 11 (67.) 79 (457.)
2 199 (2)7.) 71 ()67.) 71 (60-79) 184 (927.) 4 (27.) 0 (07.) 11 (67.) 46 (257.)
3 193 (227.) 78 (407.) 72 (6)-79) 176 (917.) 5 ()•/.) 0 (O'/.) 12 (67.) 53 (277.)
4 164 (197.) 66 (407.) 72 (6430) 147 (907.) 2 (17.) 1 (17.) 14 (97.) 79 (487.)
Depnved 152 (177.) 60 (597.) 72 (64-75) 140 (927.) 1 (17.) 1 (17.) 10 (77.) 121 (807.)
Total 884 (100%) 350 (00%) 72 (63-79) 810 (92%) 14 (27 .) 2 (07 .) 58 (77.) 378 (43%)
Colorectal total' 3,009 (100%) M U J47%Á 73 (6430) 2,740 m 20 J1 % 1 45 J M 204 J7 % ¿ 1,257 J42% 1
1 14 patients aie in both analysis groups and ate only included once (earliest diagnosis) in these totals
2 For 12 of these 20 patients, the simultaneous primary vas also in the colon or rectum (20 patients, 32 colorectal primaries in 1997)
3 2 of these patients had a previous primary in die other sub-group (colon or rectum) in 1997 (204 patients, 206 colorectal primaries in 1997)
4 Où-square test for association between deprivation and urban dwelling p<0.001 for colon and rectal cancer patients
The patients with a previous primary at the same site are included in the analyses, as this fact 
could help explain the differences in survival being investigated.
The breakdown of deprivation group by health board and rurality was similar to that seen 
for breast cancer (see Chapter 5). Overall, 42% of patients came from urban areas, but due 
to variations in the affluent and deprived population mix in urban and rural areas, this varied 
considerably between deprivation groups, with 81% of deprived patients being urban 
residents compared to 42% of affluent patients (Table 6.1).
Organisation of services
The Calman-Hine report101, published in 1995, recommended increased specialisation 
amongst those treating patients with colorectal cancer in England and Wales, and the 
adoption of a truly multi-disciplinary approach to its management as being central to 
improved standards of care. Centralisation of the surgical management of colorectal cancer 
and the formation of a sufficient critical mass of specialist surgeons in such centres to allow 
24-hour emergency cover for colorectal emergencies was also the aim of the former Scottish 
Cancer Coordinating and Advisory Committee (SCCAQ102. The increasing use of pre­
operative radiotherapy will necessarily lead to centralisation o f care, as only large cancer 
centres can offer the necessary facilities.
Of the patients diagnosed with colorectal cancer in 1997, 50% of those aged under 75 
attended one of the regional radiotherapy (RT) centres; for those aged 75 and over this 
figure was 34%. The likelihood of attending a regional RT centre varied significantly by 
deprivation category. For colon cancer, 52% of affluent compared to 36% of deprived 
patients attended a regional RT centre; for rectal cancer, 64% o f affluent compared to 49% 
of deprived patients attended a regional RT centre (Table 6.2). Affluent patients were also 
significantly more likely than patients from other deprivation groups to receive their main 
treatment at a regional RT centre.
Around 33% of patients (31% colon and 37% rectal) were diagnosed in a low-workload 
hospital. For colon cancer there was no clear gradient across the deprivation groups. For 
rectal cancer, however, affluent patients were actually more likely to be diagnosed in a low- 
workload hospital (34% compared to 18% of deprived patients). In contrast, a study in
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south-east England found that colorectal cancer patients from the lower social classes were 
more likely to be admitted to hospitals with a small workload149.
For patients diagnosed with colorectal cancer in Scotland in 1997, 42% of patients had their 
main treatment (defined as the hospital of surgery, or for non-surgical patients the hospital 
of first ‘other’ treatment) in a high-workload hospital, 27% in a medium-high workload 
hospital, 20% in a medium-low workload hospital, and 10% in a low-workload hospital. For 
colon cancer there was no clear gradient across the deprivation groups. For rectal cancer, 
affluent patients were more likely to be treated in a high-workload hospital (53% compared 
to 39% of patients in the other deprivation groups; p<0.001). There is some evidence 
linking workload and outcome for colorectal cancer31, in particular for the surgery of rectal 
cancer176. However, workload was not found to be related to outcome in a study of patients 
in the north-west England177 or in an audit of Yorkshire patients17', once case-mix and 
treatment factors were taken into account. The authors o f the Yorkshire audit concluded 
that the importance of workload is difficult to measure, as it is not independent of treatment 
decisions or specialisation. In a study from Northern Ireland of patients diagnosed in the 
early 1990s, no surgeon effect was demonstrated and outcome was actually worse for 
patients treated at higher workload compared to low workload hospitals179.
The specialty of the surgeon has been shown to be an important prognostic indicator in 
studies in Glasgow2'  and south-east Scotland1*0. For patients diagnosed in Scotland in 1997, 
it was not possible to identify the operating surgeon from the routine data; however, the 
clinician responsible for the patient at the time of surgery could be identified. Of the 1 787 
colon cancer patients receiving surgery, 24% were managed by a high-workload clinician (at 
least 30 cases per year), 39% by a medium-workload clinician (20-29 cases) and 30% by a 
low-workload clinician (<20 cases). For the 711 rectal cancer patients receiving surgery, 
21% were managed by a high-workload clinician, 32% by a medium-workload clinician, and 
39% by a low-workload clinician. For those not treated surgically, 49% of colon and 45% 
of rectal cancer patients were seen only by a low-workload clinician in the three-month 
period after diagnosis. Affluent patients with rectal cancer were more likely to be seen by a 
high-workload clinician than rectal cancer patients in the other deprivation groups (36% 
compared to 23%; p=0.023). Most patients (83% of colon and 88% of rectal) were seen in 
a specialist department within 3 months o f their cancer diagnosis, and this proportion did 
not vary by deprivation group (Table 6.2).
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Table 6 . 2 Patients diagnosed with colorectal cancer in Scotland during 1997: access to health care by deprivation category (number and 
percentage of cases)
Deprivation
categoty
No. of 
patients
Attended a 
regional RT 
centre1
Attended a 
specialist 
department2 3
Main treatment 
at a régional 
RT centre1
Treated in a 
high-workload 
hospital4
Seen by a high- 
workload
clinician5 67
Emergency
admission
More than two 
weeks’ delay 
between 
diagnosis and 
treatment4
All of care in 
one hospital
Coton
Affluent 455 238 (52%) 373 (82V.) 191 (42V.) 236 (52V.) 126 (31%) 172 (38V.) 208 (54%) 66 (15V.)
2 464 190 (41%) 384 (83V.) 113 (24V.) 159 (34%) 114 (27V.) 171 (37V.) 217 (53%) 50 (11V.)
3 457 189 (41%) 381 (83V.) 133 (29V.) 199 (44%) 124 (29V.) 184 (40V.) 216 (54%) 52 (11%)
4 400 110 (28V.) 336 (84%) 57 (14%) 142 (36%) 102 (27V.) 153 (38V.) 166 (50V.) 60 (15V.)
Deprived 363 132 (36V.) 297 (82V.) 97 (27V.) 166 (46%) 97 (28%) 153 (42V.) 159 (53%) 52 (14%)
Total 2JS9 859 (40%) 1,771 (83% ) 591 (28%) 902 (42%) 563 (28%) 833 (39%) 966 (53%) 280 (13%)
SigaJÙJHa p<0.001 p=0.843 frc0.001 p<0.001 p=0.339 p=0.415 p=0258 p=0216
Rectum
Affluent 176 112 (64%) 155 (88V.) 79 (45V.) 93 (53V.) 57 (36%) 27 (15V.) 123 (77V.) 22 (13%)
2 199 90 (45V.) 168 (84%) 56 (28V.) 72 (36%) 46 (25%) 29 (15V.) 134 (75V.) 23 (12V.)
3 193 98 (51%) 176 (91%) 57 (30V.) 82 (42V.) 35 (20V.) 29 05V.) 129 (75V.) 20 (10°/.)
4 164 76 (46%) 139 (85V.) 28 (17V.) 59 (36%) 38 (26%) 29 (18V.) I l l  (80V.) 25 (15V.)
Deprived 152 74 (49V.) 138 (91%) 41 (27V.) 60 (39V.) 33 (23%) 24 (16%) 93 (75V.) 26 (IT/.)
Total 884 450 (51%) 776 (88%) 261 (30%) 366 (41%) 209 (26%) 138 (16%) 590 (76%) 116 (13%)
S in tficn a p=0.009 t>=0.399 ¡><0.001 ¡>=0.007 p=0.023 p=0250 p=0.195 p=0.518
1 At some point during the cancer spell
2 Within 3 months of diagnosis
3 Number of patients where m«in treatment was performed at a regional RT centre (hospital of surgery, or hospital where the first non-surgical treatment was received for non- 
surgical patients)
4 Hospital seeing at least 30 colon or 20 rectal cancer patients (see Chapter 2 for details of the workload groupings)
* Clinician seeing at least 20 colon or 20 rectal cancer patients (see Chapter 2 for details of the workload groupings); percentage of those with clinician details
6 Days between diagnosis and definitive treatment; percentage of those with a definitive treatment date
7 Chi-square lest for association
Delay
Most patients developing colorectal cancer will eventually present with symptoms. Primary 
symptoms include abdominal pain, persistent rectal bleeding without anal symptoms, and 
change in bowel habit. Secondary effects include severe iron deficiency anaemia, intestinal 
obstruction including abdominal mass or rectal mass, weight loss and nausea. A large 
proportion of colorectal cancer patients have previously been diagnosed with irritable bowel 
disease.
Among patients diagnosed in Scotland in 1997, 32% of patients presented initially as an 
emergency (39% of colon and 16% of rectal cancer patients). This is similar to England, 
where one in three colon and one in ten rectal cancer patients are reported to present as an 
emergency1*1. For colorectal cancer patients diagnosed in Glasgow in the 1980s, 36% 
presented as an emergency and had a poorer outcome than patients with an elective 
admission, even after accounting for tumour stage1*2.
For patients diagnosed in 1997, those from all deprivation groups were equally likely to 
present as an emergency (Table 6.2). This contrasts with a study of patients diagnosed in 
south-east England during 1992-95 where deprived patients were more likely to present as 
an emergency149. For patients diagnosed in Scodand in 1997, emergency admission was 
strongly related to age and tumour stage. Of patients aged 80 and over, 39% presented 
initially as an emergency compared to 29% of younger patients. O f patients with Dukes’ D 
tumours, 39% presented initially as an emergency compared to only 12% of patients with 
Dukes’ A, and 32% with Dukes’ B and C tumours.
Most patients presenting as emergencies are likely to benefit from resuscitation and 
stabilisation, with subsequent appraisal and operation by an appropriately trained surgeon 
and team. Few require early surgery. There is no definitive evidence that earlier referral in 
itself will change the stage of colorectal cancer at diagnosis, as it is probable that colorectal 
cancers are slow growing and may be present in the bowel for several years before 
diagnosed. The main probable benefit of earlier diagnosis is that it may allow disease 
management to be planned, thus avoiding emergency surgery which has a high post­
operative mortality1*2-1*5.
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For over half (53%) of colon and three-quarters (76%) of rectal cancer patients diagnosed in 
Scotland in 1997, at least two weeks elapsed between diagnosis and the definitive treatment. 
This is unlikely to greatly affect survival but may increase the patient’s anxiety. There was 
no clear gradient across the deprivation groups. There are three other main sources of delay 
in a cancer patient’s journey: patient delay, GP delay in referral, and delays in diagnosis. 
Together they can amount to a substantial length of time. It has been estimated that almost 
half of patients delay many weeks before consulting their G P1*4. There are guidelines for 
GPs on identifying patients with suspected colorectal cancer for urgent referral105 but each 
GP in the UK will on average only see one new case of colorectal cancer each year1“ , so 
delays will occur. Once the patient has been referred to hospital for investigation, it is 
estimated a third of patients wait more than one month from first hospital consultation to 
diagnosis1“ . This is estimated from a small (N=59) sample o f  colorectal cancer patients in 
an audit conducted at an Edinburgh teaching hospital. These sources of delay cannot be 
examined with the routine data available for this thesis.
Most patients (87%) attended more than one hospital during their cancer spell, which could 
be indicative of the patient having access to multidisciplinary teams. Deprived patients with 
rectal cancer were slightly less likely to transfer between hospitals (83% compared to 87% of 
affluent patients; not significant; Table 6.2).
Mode of presentation
When a patient presents with a suspected colorectal cancer they will usually receive a flexible 
colonoscopy followed by endoscopic removal of benign adenomatous polyps, or barium 
enema followed by other imaging procedure (ultrasound, conventional CT or MRI). 
Patients investigated by sigmoidoscopy (usually flexible), or patients whose colon was not 
visualised adequately at colonoscopy are generally investigated by double contrast barium 
enema (DCBE). Computerised tomographic (CT) colonography, which uses 3D imaging, 
was not used for patients diagnosed during 1997.
Survival is primarily determined by pathological tumour stage at presentation, and Dukes’ 
stage is recorded on SOCRATES (see Chapter 2). This measures the extent of bowel wall 
invasion, nodal status and the presence of metastases. For patients diagnosed in Scotland in 
1997, the proportion of staged tumours within each stage for colon cancer patients was 9% 
with Dukes’ A, 40% with Dukes’ B, 33% with Dukes’ C and 18% with Dukes’ D tumours.
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The corresponding proportions for rectal cancer patients were 23%, 32%, 29% and 16%, 
respectively (Table 6.3). These distributions are more favourable than that seen in Scodand 
in 1993, where 10% of colorectal cancers were Dukes’ A, 39% were Dukes’ B, 27% were 
Dukes’ C and 25% were Dukes’ D tumours1*7, and is also more favourable than reported in 
published data from other audits in the UK from the early 1990s1,0•1' ’ '1’, , indicating that 
patients are now being diagnosed earlier. Even given this improvement over time, however, 
almost half the tumours have still metastasised to the lymph nodes or beyond when 
diagnosed.
For patients diagnosed with colorectal cancer in Scodand in 1997, 15% did not have stage 
recorded. These were more likely to be older patients (28% of patients aged 80+ had stage 
missing compared to 11% of younger patients; p<0.001), affluent patients (19% compared 
to 12% of deprived patients), those not receiving surgery (61% compared to 7% of patients 
who did receive surgery), those treated with palliative intent (24% compared to 4% treated 
with curative intent, and 28% of those whose treatment intent was unknown), patients with 
serious comorbidity and patients seen by a low-workload clinician. Patients admitted as an 
emergency and patients not seen in a specialist department were also more likely to have 
missing stage information; however, this seemed to be a result of these patients being more 
likely to be seen by a low-workload clinician.
Of those patients with known stage, the distribution was similar across deprivation groups 
for colon cancer patients. However for rectal cancer, deprived patients were more likely to 
present with Dukes’ D disease (21% compared to 10% of affluent patients) although there 
was no clear trend in the stage distribution across the deprivation groups. The proportion 
of patients with no stage recorded (15%) was similar to that seen in an audit of colorectal 
cancer patients diagnosed in Scotland in 1993 (13%)117. In that audit the proportion with 
missing stage did not vary between deprivation groups and the investigators found that the 
stage distribution was similar between affluent and deprived patients; however they 
presented data for colon and rectal cancer patients combined, which may mask differences 
in stage at presentation at the two sites.
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Table 6.3 : Patients diagnosed with colorectal cancer in Scotland during 1997: clinical stage and grade by deprivation category (number and 
percentage of cases)
Deprivation
categtwy
No. of Dukes stage' Grade1
A B C D Unknown 1 2 3/4 Unknown
Colon
Affluent 455 31 m 154 (41%) 119 (329.) 70 (199.) 81 (19%) 20 (69.) 240 (719.) 78 (239.) 117 (269.)
2 464 35 m 147 (379.) 146 (379.) 66 (179.) 70 (159.) 17 (59.) 231 (709.) 83 (259.) 133 (299.)
3 457 32 w 175 (439.) 132 (329.) 69 (179.) 49 (119.) 26 (79.) 249 (7W.) 82 (239.) 100 (229.)
4 400 33 m 136 (399.) 103 (309.) 77 (229.) 51 (139.) 11 (49.) 226 (75%) 65 (22e/.) 98 (259.)
Deprived 363 30 (10V.) 117 (379.) 109 (359.) 58 (1S9.) 49 (139.) 13 (49.) 215 (749.) 62 (219.) 73 (209/.)
Total 2J39 161 (9% ) 729 (40%) 609 (33%) 340 (18%) 300 (14%) 87 (5%) 1,161 (72%) 370 (23%) 521 (24%)
S igufium t p=0.420? p=0.032* p-0.5351 r -0.0371
Rectum
Affluent 176 38 (279.) 39 (209.) 50 (359.) 14 (109.) 35 (209.) 8 (69.) 102 (739.) 30 (219.) 36 (209.)
2 199 39 (249.) 50 (31%) 42 (269.) 31 (199.) 37 (199.) 7 (59.) 121 (799.) 25 (169.) 46 (239.)
3 193 41 (26%) 51 (329.) 47 (3W.) 20 (139.) 34 (189.) 5 (39.) 125 (789.) 30 (199.) 33 (179.)
4 164 23 (179.) 55 (419.) 35 (269.) 22 (169.) 29 (189.) 7 (59.) 107 (79-/.) 21 (169.) 29 (189.)
Deprived 152 28 (21%) 39 (299.) 40 (299.) 29 (219.) 16 (119.) 5 (49.) 90 (769.) 24 (209.) 33 (229.)
T otal 884 169 (23%) 234 (32%) 214 (29%) 116 (16%) 151 (17%) 32 (5%) 545 (77%) 130 (18%) 177 (20>/.)
S çm ptm a p=0J74> p-02001 p=0.884p ____E■0.546‘
1 Percentage of patients with a known category, except 'unknown', presented as a percentage of the total
2 Significance of association (Chi-square test) between deprivation category and percentage of patients in each category excluding those in the unknown category 
1 Significance of proportion unknown across the deprivation categories (Chi-^ure test for association)
Grade is another important prognostic indicator for colorectal cancer. Of patients 
diagnosed in Scodand in 1997 with known grade, the proportion of patients presenting with 
well-differentiated (grade 1) tumours was very low (5%), compared to 74% presenting with 
moderately-differentiated and 21% with poorly-differentiated or undifferentiated tumours. 
These proportions were similar for colon and rectal cancer patients, and across the 
deprivation groups (Table 6.3). Grade was unknown for 23% of patients, and for colon 
cancer, affluent patients were more likely to have unknown grade (p=0.037). O f patients 
with missing stage, 69% also had missing grade.
For patients with known stage and grade there was also a relationship, with well- 
differentiated tumours being predominantly early stage (Dukes’ A or B). For colon cancer, 
81% of patients with well-differentiated tumours were early stage, compared to 54% of 
patients with moderately-differentiated and 31% with poorly-differentiated or 
undifferentiated tumours. For rectal cancer, around half of patients with well- and 
moderately-differentiated tumours were early stage compared to 28% of patients with 
poorly-differentiated or undifferentiated tumours.
Diagnosis was microscopically verified for most (92%) patients, with no significant 
difference between the deprivation groups (Table 6.4). The majority of tumours were 
adenocarcinomas (79% of colon and 90% of rectal cancers), with some mucinous tumours 
(8% of colon and 4% of rectal) and the rest being other or unspecific cell types. The 
proportion of each tumour type was similar across the deprivation groups. The specific 
cancer location (4* digit of the ICD code) was recorded for colon cancer patients (data not 
shown), with the most common locations being the sigmoid colon (29%) and caecum 
(22%). The location was significantly more likely to be unspecified for deprived patients 
(31% versus 13% of affluent patients; 18% overall), however for patients with known site 
there were no differences between the deprivation groups.
Screening
Screening is potentially important for colorectal cancer because symptoms do not usually 
become evident until the tumour is advanced, whereas most cancers result from malignant 
change in benign adenomatous polyps or villous adenomas that have developed in the lining 
of the bowel190. Larger polyps have a greater risk of becoming malignant than smaller ones, 
and the vast majority (90%) can be removed at colonoscopy191.
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Three randomised controlled trials of faecal occult blood test (FOBT) have shown a 
reduced risk of death for people offered FOBT screening. An overview of these192 predicts 
a reduction in mortality of up to 23% in those screened (16°/o for the whole population 
invited for screening). A pilot o f  FOBT colorectal cancer screening is currently underway in 
part o f Scodand for patients aged 50-69 years, and will be completed in 2002. If the pilot is 
successful and screening is started on a national scale, then it has been estimated that the 
maximum reduction in mortality for all ages combined will be 8% 152. This is due to lower 
compliance in the population setting, the accuracy of the FOB test and the restricted age 
range o f those who would be invited.
The sensitivity of FOBT is relatively low -  a third to half of cancers will be missed on each 
round of screening. Flexible sigmoidoscopy can detect 80% o f  colorectal cancers, and a 
multi-centre trial investigating this as a strategy for population screening is currendy in 
progress.
There were no screening trials underway in Scodand in 1997, so population screening is not 
considered in the interpretation o f  the analyses in this chapter.
Comorbidity
For patients diagnosed in Scodand in 1997, 54% of colon and 29% of rectal cancer patients 
had comorbidity at diagnosis, as measured by the bed-days score. These percentages were 
lower when comorbidity was measured by the Scodand or Charlson indices.
Patients from the most deprived areas had greater comorbidity at diagnosis than affluent 
patients, as measured by the bed-days comorbidity score (Table 6.4). For colon cancer, 60% 
of deprived compared to 51% o f affluent patients had spent more than 10 days in hospital 
in the two years prior to their cancer diagnosis. For rectal cancer, 39% of deprived 
compared to 24% o f affluent patients had spent more than 10 days in hospital (p=0.033). 
The gradient between affluent and deprived patients was smaller when measured by the 
Scotland index, and was reversed for rectal cancer patients when measured by the Charlson 
index.
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T a b le  6 .4 : Patients diagnosed with colorectal cancer in Scodand during 1997: 
microscopie verification, comorbidity and post-operative mortality by 
deprivation category (number and percentage of cases)
Deprivation
category
No. of 
patients
Microscopically
verified
Comorbidity 30-day post- 
operative 
mortality4
Bed-days1 Scotland2 Chari son'
Colon
Affluent 455 400 (88%) 231 (M o) 107 (24%) 58 ( 130/.) 16 (4%)
2 464 425 (92°/o) 243 (520/.) 98 (21%) 64 (14%) 26 (6‘/.)
3 457 419 (92%) 246 (54%) 121 (260/.) 72 (16%) 26 (7%)
4 400 361 (90%) 217 (54%) 107 (27%) 63 (16%) 18 (5%)
Deprived 363 324 (89%) 217 (60%) 100 (28*/.) 66 (18°/.) 26 (90/.)
Total 2439 1,929 (90% ) 1454 (U*/.) 333 (250/.) 323 (ISO/.) 112 (6% )
StfntficuMci p= 0.177 p=0.121 p= 0.152 P
2II p —0.176
Rectum
Affluent 176 172 (98%) 43 (240/.) 29 (16%) 29 (16%) 4 (3%)
2 199 191 (96%) 50 (25%) 32 (16%) 23 (120/.) 9 (5%)
3 193 183 (95%) 59 (31-/.) 41 (210/.) 26 (13%) 5 (3o/.)
4 164 154 (94%) 48 (290/.) 45 (27%) 25 (15%) 9 (70/.)
Deprived 152 147 (97«/.) 59 (390/.) 32 (21%) 19 (13%) 8 (7%)
Total 884 847 (96% ) 259 (29% ) 179 (20%) 122 (140/.) 35 (5% )
Sijtmficaiici1 p=0.420 p=0.053 p-0.058 ___ £ -0.659 p=0292
1 More than 10 inpatient bed-days in the two years prior to cancer diagnosis
2 Any one o f certain comorbid conditions recorded in the two years prior to one month after diagnosis (see 
Chapter 1)
3 Any one o f certain comorbid conditions recorded in the five years prior to diagnosis (see Chapter 1)
4 Percentage o f patients receiving surgery
5 Chi-square test for association
Treatment
Stage is an important guide to the clinical management of colorectal cancer. Colorectal 
guidelines published in 1997 by the Scottish Intercollegiate Guidelines Network (SIGN)195 
suggest that padents with early disease (Dukes’ A or B) should receive curadve surgery and 
may not require any further treatment. Padents with metastases (Dukes’ D) may undergo 
technically similar operations but with palliative rather than curative intent. For those with 
locally advanced disease, or when there is nodal spread (Dukes’ Q , adjuvant chemotherapy 
should be considered. Pre-operative radiotherapy may be considered for fixed or tethered 
rectal tumours where the objective is to down-stage the disease prior to surgery. Post­
operative radiotherapy is recommended for rectal tumours with a high risk of recurrence. 
Chemotherapy or radiotherapy may also be given as palliation for advanced colon or rectal 
disease.
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Surgical resection is the primary curative modality for colorectal cancer patients, with 
endoscopic resection representing another approach for the small minority of early 
malignant polyp-cancers. The proportion of curative operations performed, on average, in a 
recent audit of west of Scotland hospitals was 68% and palliative resection for 25% of 
patients1*4. In combination with curative surgery, pre-operative adjuvant radiotherapy for 
early stage rectal cancer can impart around 30% reduction in both local recurrence rate and 
in mortality1” . Although some centres use radiotherapy for all rectal cancers, most specialist 
centres only use pre-operative radiotherapy for fixed tumours, tethered tumours or very low 
lesions just above the anal sphincters. Use of peri-operative radiotherapy has been sporadic 
until recently.
For patients diagnosed in Scotland in 1997, 84% of colon and 80% o f rectal cancer patients 
received surgery (Table 6.5). The surgery was recorded as curative for 62% of patients, 
palliative for 32% and unknown for 6°/o of patients. Radiotherapy was rare for colon cancer 
patients (5%), where it is only recommended for palliative use. In comparison, over a 
quarter of rectal cancer patients received radiotherapy (30%) and 100 (11%) received 
radiotherapy before surgery. Radiotherapy prior to surgery was very rare for emergency 
admission patients. Chemotherapy was slightly more common for colon (19%) than rectal 
(17%) cancer patients, and comprised largely of patients with late stage (Dukes’ C and D) 
tumours. Overall, 39% of patients with Dukes’ C tumours received chemotherapy, which is 
lower than might be expected; however, around 25% of patients aged less than 80 years 
have significant cardiac co-morbidity that precludes chemotherapy152. Most primary 
treatment was received within 6 months of diagnosis. Deprived patients were slightly less 
likely than affluent patients to receive surgery, radiotherapy or chemotherapy.
Treatment rates declined with increasing age. Surgery was undertaken for only 71% of 
patients over age 80 compared to 88% aged 60-79 and 95% aged under 60. The 
corresponding rates for radiotherapy were 5%, 13% and 19%, and for chemotherapy were 
1%, 19% and 44%, respectively. No treatment at all was recorded for 27% of patients aged 
over 80, compared to only 9% of those aged 60-79 and only 3% of those aged under 60. A 
similar age-related treatment effect was also seen in an audit of Yorkshire patients17*.
Most early stage (Dukes' A and B) colon cancer patients received surgery (95%), either alone 
(86%) or in combination with chemotherapy and/or radiotherapy (9%). Surgery was also
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performed for most early stage rectal cancer patients (93%), and 19% received surgery in 
combination with chemotherapy and/or radiotherapy. Patients with late stage (Dukes’ C 
and D) tumours were less likely than those with early stage tumours to receive surgery alone 
as treatment for colon (85% received surgery; 34% in combination) or rectal cancer (81% 
received surgery; 49% in combination; Table 6.6).
Table 6.5: Patients diagnosed with colorectal cancer in Scotland during 1997: treatment
received by deprivation category (number and percentage o f cases)
Deprivation
category
No. of 
patients
Surg-cry Radiotherapy Chemotherapy
Within 6 
months
Overall Within 6 
months
Overall Within 6 
months
Overall
Colon
Affluent 455 363 (80%) 372 (82%) 17 (4%) 23 (5%) 83 (18%) 93 (20%)
2 464 392 (84%) 403 (87%) 15 (3%) 27 (6%) 86 (19°/.) 93 (20%)
3 457 385 (84%) 390 (85%) 19 (4%) 25 (5%) 73 (16V.) 81 (18%)
4 400 323 (81%) 329 (82%) 10 (3%) 17 (4%) 56 (14%) 66 (17%)
Deprived 363 288 (79%) 293 (81%) 9 (2%; 12 (3%) 64 (18%) 69 (19%)
Total 2,139 1,751 (82% ) 1,787 (84%) 70 (3% ) 104 (5% ) 362 (17%) 402 (19%)
Stgm ficana p=0.130 P-=0.077 />=0.572 P=0.471 / =0.370 P=0.555
Rectum
Affluent 176 136 (77%) 142 (81%) 59 (34%) 63 (36V.) 33 (19°/.) 38 (22%)
2 199 166 (83%) 170 (85%) 40 (20%) 50 (25%) 25 (13%) 33 (17V.)
3 193 157 (81%) 160 (83%) 52 (27%) 58 (30V.) 24 (12%) 29 (15%)
4 164 123 (75%) 126 (77V.) 45 (27V.) 50 (30V.) 23 (14%) 25 (15%)
Deprived 152 108 (71%) 113 (74%) 42 (28V.) 42 (28V.) 23 (15V.) 24 (16%)
Total 884 690 (78% ) 711 (80%) 238 (27% ) 263 (30% ) 128 (14%) 149 (17%)
Sixtuficana p=0.043 f>=0.065 ___ t =0.070 __ 0240 p=0.418 p=0.446
1 Chi-square test for association
For rectal cancer patients there is evidence that combining adjuvant therapy with curative 
surgery can provide worthwhile improvements in both local control and overall survival. 
The evidence for benefit of adjuvant chemotherapy is restricted to patients with Dukes’ C 
cancers who undergo curative resectionI,‘ ',,7. For rectal cancer patients with Dukes’ C 
cancer diagnosed in Scotland in 1997, almost all (96%) received surgery (curative* for 63%), 
and 41% received adjuvant chemotherapy. However, chemotherapy for patients with 
Dukes’ C tumours was not equally available to all the deprivation groups (52% of affluent
* Treatment intent is difficult to interpret as it ia a very "soft'’ variable; it it not often Hated explicitly in the medical notes 
and the CROt may u te their own judgement in recording it.
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patients compared to 32% of deprived patients received chemotherapy). There was not a 
clear trend in chemotherapy across the deprivation groups.
Table 6.6: Patients diagnosed with colorectal cancer in Scodand during 1997: treatment
received by Dukes’ stage at diagnosis (number and percentage o f cases)
Treatment combination Dukes stage 
A and B
Dukes stage 
C and D
Unstaged
Colon
Surgery alone
Chemotherapy alone
Radiotherapy alone
Surgery and chemotherapy
Surgery and radiotherapy
Sutgery, chemotherapy and radiotherapy
Chemotherapy and radiotherapy
No treatment or unknown combination
Rectum
Surgery alone
Chemotherapy alone
Radiotherapy alone
Surgery and chemotherapy
Surgery and radiotherapy
Surgery, chemotherapy and radiotherapy
Chemotherapy and radiotherapy
No treatment or unknown combination
767 (86%) 485 (51%) 83 (28%)
t (0%) 27 (3%) 5 (2-/-)
0 <o*J 3 (0%) 4 (1%)
43 (S%) 272 (29-/.) 11 (4%)
28 (3%) 23 (2-/.) 3 (1%)
9 (1%) 30 (3%) 2 (1%)
0 (0%) 1 (0%) 0 <0-/-)
42 (5%) 108 (11%) 192 (64%)
300 (74%) 106 (32-/.) 36 (24%)
0 (o %) 4 (1%) 1 (1%)
3 (1%) 12 (4%) 30 (20-/.)
6 (1%) 44 (13%) 4 (3%)
60 (15%) 57 (17-/.) 12 (8-/-)
12 (3%) 62 (19-/.) 4 (3%)
0 (0%) 8 (2-/.) 2 (1%)
22 37 J im 62
Of patients receiving surgery, the intent was recorded as curative for 88°/o of early stage 
colon cancer patients, 38% of late stage colon cancer patients, 90% of early stage rectal 
cancer patients, and 47% of late stage rectal cancer patients. For patients w ith treatment of 
known (recorded) intent, there were no differences in the intent (curative or palliative) 
between the deprivation groups, although treatment intent was less likely to be recorded for 
affluent patients (8% compared to 3% of deprived patients).
Colon cancer patients were less likely than rectal cancer patients to have surgery at a low- 
workload hospital, although the definitions o f hospital workload differ (see Chapter 2); 28% 
of colon and 26% of rectal cancer patients had surgery at a regional RT centre, 14% colon 
and 13% rectal at other high-workload hospitals, 30% colon and 25% rectal at medium- 
workload hospitals, and 28% colon and 36% rectal at low-workload hospitals.
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The national guidelines195 recommend that surgery for rectal cancer should be restricted to 
surgeons with a specialist interest in the procedure, due to the difficulty in achieving 
complete excision of the tumour (clear histological margins), and because wide variations in 
the rate of “curative” resection, colostomy formation, local recurrence rate, peri-operative 
mortality and cancer survival between surgeons have been reported in the UK"0'1*9'194. It is 
stressed that this may be an effect of workload and/or specialisation, but could also be due 
to case-mix rather than any intrinsic ability of the surgeon or the hospital in which they 
work. In one large Canadian study, the effect of surgeon-related variables could only 
account for 10-30% of observed mortality differences19*. This is supported by studies on 
the effect of specialisation in Germany and the north west of England177. For patients 
diagnosed in Scotland in 1997, affluent patients were more likely than deprived patients to 
be managed by a high-workload consultant at the time of surgery.
For patients diagnosed in Scotland in 1997, those attending a regional RT centre at some 
point during their cancer spell were the most likely to have their tumour histologically 
verified (95%), compared to patients attending high-workload (93%), medium-workload 
(92%) or low-workload (86%) hospitals. They were also more likely to receive 
chemotherapy (35% compared to 5% of patients seen elsewhere). This may be because 
patients most suited to adjuvant therapy were being referred to the regional RT centres.
Poat-operative mortality
Risk o f  peri-operative death has been shown to be higher after emergency admission than 
routine/elective admission, both in England1' 1 and in Scotland194. For patients diagnosed in 
Scotland in 1997, the 30-day post-operative mortality rate was 6% for colon and 5% for 
rectal cancer patients. Patients who first presented as an emergency had a higher post­
operative mortality rate than those presenting electively (10% compared to 4%; 11% for 
those with unknown type of admission). This is lower than that reported in a study 
conducted at a Glasgow hospital, where the post-operative mortality rate was 9% for 
elective and 19% for emergency operations194. In Trent and Wales audits conducted in the 
early 1990s, the 30-day post-operative mortality rate was 7.6% (22% for emergency and 6% 
for elective operations)1*9. However, in routine Scottish data it is only possible to identify 
emergency admissions, not emergency operations.
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For the Scottish patients diagnosed in 1997, those from deprived areas had the highest post­
operative mortality rate (8% compared to  4% in affluent patients; p=0.080), and they had 
higher post-operative mortality whether they were admitted routinely or as an emergency, 
although the difference was most marked for emergency admissions (5% post-operative 
mortality for affluent compared to 14% for deprived patients; p=0.084).
The 30-day post-operative mortality rate varied by type of hospital. For patients treated at a 
regional RT centre it was 4%, compared to 8% for those treated at other high-workload 
hospitals, 6% at medium-workload hospitals and 6% at low-workload hospitals (not 
significant). Patients seen by a high-workload clinician within 3 months o f diagnosis had the 
lowest post-operative mortality rates (2%) compared to those seen by a medium-workload 
clinician (5%) or low-workload clinician (8%; p=0.016). Patients who were managed by a 
medium- or high-workload clinician at the time of their operation also had a slightly lower 
post-operative mortality rate (5%) than those with a low-workload clinician (7%; not 
significant).
A small review o f in-hospital deaths for colorectal cancer patients in south-east Scotland in 
the 1990s found that 78 of the 187 deaths were avoidable. In particular, 26 occurred 
following an anastomotic leak, 17 because surgery was delayed, 12 because there was undue 
delay in making the initial diagnosis and 14 because developing complications were not 
recognised1” .
Two-year survival
Univariate analyses
Factors that had an influence on the differences in 2-year survival between deprivation 
groups were investigated in Cox proportional hazards regression models. In the initial 
model containing deprivation only, the relative risk of death within two years of diagnosis 
was substantially raised for deprived compared to affluent patients with rectal cancer (RR 
1.75 (95% Cl 1.25-2.46); p<0.01) but not colon cancer (1.13 (0.93-1.37); p=0.211) (Table 
6.7).
For colon cancer, adjusting for factors relating to the patient, the tumour, the health care 
system and treatment increased the relative risk of death between affluent and deprived
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patients, and after adjusting for differences in tumour characteristics or treatment factors the 
deprivation-specific differences were often significant, suggesting that differences in survival 
for colon cancer patients were being masked in the initial analysis including only deprivation.
For rectal cancer patients, adjustment for factors relating to the patient, the tumour, health 
care system and treatment did not reduce the relative risk of death between affluent and 
deprived patients with the exception of the workload of the clinician managing the patient at 
the time of surgery, which appeared to explain around a third of the difference in risk of 
death between affluent and deprived patients and rendered the difference non-significant 
(RR reduced from 1.75 to 1.57 (95% Cl 0.98-2.51)).
Patient characteristics
Survival was strongly related to age for colon and rectal cancer patients. Survival at two 
years was significantly higher (p<0.001) for younger compared to older patients (68% for 
patients aged <50 compared to 36% for patients aged 80+ with colon cancer, 72% 
compared to 36% for rectal cancer patients). However, because age did not vary across the 
deprivation groups, including age in the model significantly improved the model fit but did 
not account for differences in survival between affluent and deprived patients. Lower 
survival for older patients is generally attributed to greater comorbidity and more advanced 
tumour stage, with the proportion of surgically treated patients declining with increasing age. 
This is true for the patients diagnosed in Scotland in 1997 and has been observed across 
Europe for patients diagnosed in 1987“°. However, survival does not vary appreciably with 
age for patients diagnosed with colorectal cancer in the USA, and patterns of surgery do not 
vary for these patients20'. The models including deprivation and age are used as the null 
model for the analyses shown in Table 6.7.
Survival was higher for females than males, particularly at younger ages (aged <50; 2-year 
survival was 74% for females compared to 66% for males). Females tended to be diagnosed 
at a later age and had a higher proportion of the elderly (25% of females compared to 19% 
o f males were aged 80+), therefore, the overall survival estimates appeared similar for males 
and females. Inclusion of sex in the null model improved the model fit (see columns 5 and 
10 of Table 6.7) for colon and rectal cancer patients, but did not explain differences in the 
risk of death between the deprivation groups (the RR increased from 1.13 to 1.21 for colon 
cancer patients and stayed constant at 1.75 for rectal cancer patients).
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A northern Scotland study202 of patients diagnosed during 1995-96 found rural colorectal 
cancer patients to have a poorer survival because of more advanced disease at diagnosis. 
They measured rurality as distance from a cancer centre. For patients diagnosed in Scotland 
in 1997, rurality was measured using the GRO population density scale, because it was not 
appropriate to measure distance without taking into account accessibility1. Acessibility is 
complicated to measure with routine data because road size and directness needs to be taken 
into account, along with availability o f  public transport. For patients diagnosed in Scotland 
in 1997, there were no differences in stage at diagnosis for urban and rural residents 
measured with the GRO rurality scale, and no differences in survival. There were also no 
differences in survival by health board of residence or for patients who had a history of 
cancer. None of these factors improved the fit of the null models (Table 6.7).
Comorbidity was strongly related to survival. For colon cancer, two-year survival for 
patients who had spent more than 10 days in hospital in the preceding two years was 44%, 
compared to 70% for patients who had spent no time in hospital. For rectal cancer
patients, the corresponding survival estimates were 40% compared to 68%. Similar 
differences were observed for comorbidity measured with the Charlson and Scottish indices. 
Comorbidity did not explain the deprivation-specific gradient in risk o f  death, however, as 
inclusion o f comorbidity improved the model fit but did not reduce the relative risk of death 
between affluent and deprived patients.
Health care system factors
Differences in survival between patients treated at specialist and non-specialist hospitals 
have been reported previously but were accounted for by age and stage at diagnosis51,205. 
For colon cancer patients diagnosed in Scotland in 1997, two-year survival for patients 
receiving surgery at regional RT centres was similar to those treated at other hospitals. For 
surgically treated rectal cancer patients, survival was slightly higher for those treated at 
regional RT centres (72% compared to an average of 68% at other hospitals).
'  In the north o f Scotland study, accessibility was not as much o f an issue because access w ou ld  have been poor for most 
o f the long-distance travellers.
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Table 6.7: Patients diagnosed with colorectal cancer in Scotland in 1997: univariate influence of individual factors on the relative nsk of death
within two-years of diagnosis among deprived compared to affluent patients (Cox proportional hazards regression analyses)
Variables included in the model1 COLON RECTUM
Relative 95*/. a P-value3 P -va h teo i Relative 95% Cl P-value3 P -value o t
risk2 Low High a d d ed  tenu* risk2 Low High a d d ed  tem p
In itial model: Deprivation category 
Patient characteristics:
1.13 0.93 1.37 0.211 - 1.75 1.25 2.46 <0.01 -
Age 1.20 0.99 1.46 0.064 <0.001 1.80 1.28 2.52 <0.01 <0.001
Sex 121 0.99 1.47 0.058 0.020 1.75 1.25 2.46 <0.01 <0.01
Health board of residence 123 0.99 1.52 0.058 0.805 1.93 1.33 282 <0.01 0230
Urban indicator 1.21 0.99 1.49 0.063 0.770 1.79 1.26 254 <0.01 0.936
Previous history of primary cancer 1.20 0.99 1.46 0.065 0.623 1.78 1.26 249 <0.01 0J15
Bed-davs comorbidity score 1.15 0.95 1.41 0.150 <0.001 1.69 1.20 237 <0.01 <0.001
Charbon cotnorbidity score 1.15 0.95 1.40 0.155 <0.001 1.85 1.32 260 <0.001 <0.001
Scotland comorbidity score 1.18 0.97 1.43 0.104 <0.001 1.79 1.28 251 <0.01 <0.001
H eilth  c m  tyn c iti fsdorai
Attended a high-workload hospital? 1.18 0.96 1.44 0.108 0.019 1.91 1.35 270 <0.001 0.038
Workload of hospital of main treatment 1.17 0.96 1.43 0.121 0.008 1.84 1.30 261 <0.01 0.196
Attended a specialist department? 1.19 0.98 1.45 0.078 <0.001 1.89 1.35 266 <0.001 <0.001
Emergency admissioo 1.19 0.98 1.45 0.082 <0.001 1.79 1.28 252 <0.01 <0.001
Tune to diagnosis to surgery4 1.14 0.90 1.45 0.271 <0.001 1.65 1.05 260 0.030 <0.001
Workload of clinician overseeing surgery6 1.14 0.90 1.47 0.270 <0.001 1.57 0.99 248 0.051 <0.001
Workload of clinician seen within 3 months 
Tumour characteristics:
1.21 1.00 1.48 0.052 <0.001 1.80 1.28 253 <0.01 0.141
Histological verification 1.25 1.03 1.51 0.027 <0.001 1.82 1.30 256 <0.01 <0.001
Dukes stage 1.41 1.16 1.72 0.001 <0.001 1.88 1.33 266 <0.001 <0.001
Grade 1.28 1.05 1.56 0.013 <0.001 1.77 1.26 249 <0.01 <0.001
Tumour histological type 
Treatment faeton:
1.28 1.05 1.55 0.014 <0.001 1.79 1.27 251 <0.01 <0.001
Treatment intent (curative or palliative) 1.30 1.07 1.88 <0.01 <0.001 1.68 1.19 208 <0.01 <0.001
Surgery (yes or no) 1.19 0.98 1.45 0.075 <0.001 1.74 1.23 246 <0.01 <0.001
Radiotherapy (yes or no) 1.21 1.00 1.47 0.056 0.024 1.89 1.34 267 <0.001 0.095
Chemotherapy (yes or no) 121 0.99 1.47 0.060 0.797 1.82 1.30 257 <0.01 0.194
Treatment combination (see Table 6.6) 1.24 1.02 1.51 0.029 <0.001 1.74 1.24 246 <0.01 <0.001
1 Pjfti categorical variable is added separately to the null model, 1 Relative risk of death in the deprived compared to affluent group
1 Significance of the difference in the relative risk between affluent and deprived, 4 Improvement in model fit when each variable is added to the null model
s Significance of the age term is tested against a model containing deprivation category, 6 These analyses only include surgically treated patients
After adjusting for age and stage at diagnosis, rectal cancer patients treated at regional RT 
centres had significantly higher survival than patients treated at other hospitals (data not 
shown). When surgical and non-surgical cases are considered together, the deprivation- 
specific differences in risk of death for patients with rectal cancer was unaffected by hospital 
workload (RR 1.84; Table 6.7).
Colorectal cancer patients who didn’t attend a specialist department had significantly poorer 
survival than those who did (21% compared to 58%). This may be because older (aged 80+) 
patients and those with very early (Dukes’ A) or very late (Dukes’ D) stage tumours were 
less likely to attend a specialist department.
Survival from colorectal cancer is substantially influenced by the presence of complications, 
such as obstruction and perforation, which are more commonly associated with advanced 
tumours, and are especially pertinent for emergency admissions204. For patients diagnosed in 
Scotland during 1997, those who presented as an emergency did have a  significantly poorer 
outlook, with survival for colon cancer patients of 42% for those admitted as an emergency 
compared to 60% for those admitted routinely, and survival for rectal cancer patients of 
33% compared to 63%. Patients admitted as an emergency were more likely to be elderly 
(65% were aged 70+, compared to 56% o f elective admission patients), more likely to have 
Dukes’ B-D tumours (95% compared to 84%) and less likely to receive surgery (21% 
compared to 14%).
For colon cancer patients, those seen within 3 months of diagnosis by a medium-high 
workload (>=20 cases) clinician had significantly higher survival at 2 years after diagnosis 
(61%) than those seen by a medium-workload clinician (10-19 cases; 53%) or low-workload 
clinician (<10 cases; 45%; p<0.001). For rectal cancer, survival o f  patients seen by a 
medium-high workload clinician was 62% compared to 63% for those seen by medium- 
workload clinician and 54% for those seen by a low-workload clinician (p=0.030). This was 
true for elective and emergency admission patients, and was particularly evident for patients 
with higher stage (Dukes’ C and D) tumours. If a high-workload clinician was managing the 
patient at the time o f surgery survival was higher (68% compared to 56% for low-workload 
clinicians for colon cancer patients; 94% compared to 68% for medium- and low-workload 
clinicians for rectal cancer patients; p=0.036).
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Hospital and clinician workload appeared to be independently important. Patients treated in 
high-worldoad hospitals did better if seen by a high-workload clinician (2-year survival of 
78% compared to 58% for patients seen by a low-workload clinician in a high-workload 
hospital; p<0.01). A similar pattern was seen for patients treated in medium-workload 
hospitals, but was not repeated in low-workload hospitals.
For colon cancer patients, all of the health care system factors improved the model fit, but 
did not affect the relative risk of death between affluent and deprived patients (Table 6.7). 
For rectal cancer patients, all the health care factors with the exception of the hospital of 
treatment and clinician workload improved the model fit, but again, none of the factors 
explained the deprivation-specific differences in the relative risk of death. Adjusting for the 
workload of the clinician managing the patient at the time of surgery appeared to explain 
some o f the differences in deprivation-specific survival for rectal cancer patients (RR for 
surgical patients reduced from 1.66 to 1.57).
Tumour characteristics
Survival within two-years was 88% for patients with Duke A tumours, 76% with Dukes’ B, 
58% with Dukes’ C, 11% with Dukes’ D, and 20% for patients with unknown stage. These 
survival estimates are more favourable than those reported in the UK in the early 1990s1“ '1" , 
suggesting that general improvements seen in survival over time are due to improvements in 
treatment within each stage as well as to earlier diagnosis, as previously noted1“ ’1*9. 
Differences in survival between deprivation groups have been identified in previous 
studies13’17’“ ’147, and were not accounted for by stage at diagnosis17 or delay“ '147. Similarly in 
the Scottish data, adjusting for differences in stage at diagnosis did not explain the increased 
risk o f  death in deprived compared to affluent patients (for colon cancer patients the RR 
increased from 1.20 to 1.41; for rectal cancer patients the RR increased from 1.75 to 1.88).
Tumour grade is another important prognostic indicator, and differences in survival by 
grade were particularly marked for colon cancer patients (78% for patients with well- 
differentiated tumours, 64% for patients with moderately-differentiated, and 37% for 
patients with poorly-differentiated or undifferentiated tumours). In contrast for rectal 
cancer, patients with well-differentiated or moderately-differentiated tumours had similar 
survival (68%) compared to 50% for those with poorly-differentiated or undifferentiated 
tumours. For both cancer sites, only a third of patients with unknown grade survived for
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two years, and almost half of these patients did not receive surgery. Survival varied between 
deprivation groups for colon cancer patients with unknown grade (28% for affluent 
compared to 16% for deprived) but there was no clear pattern across the deprivation 
groups.
Patients with histologically verified tumours had significantly better survival than patients 
whose tumours were not histologically verified (p<0.001). Colon cancer patients with 
adenocarcinomas had slightly better survival than patients with mucinous tumours (59% 
compared to 54%), and patients with other or unspecified tumour types had significantly 
worse survival (12%). For rectal cancer patients the difference in survival between 
histological types was more marked (63% for patients with adenocarcinomas, 45% for 
patients with mucinous tumours, and 5% for patients with other and unspecified types).
Inclusion o f tumour characteristics including histological verification, stage, grade and 
histological type, improved the model fit for both colon and rectal cancer patients (Table 
6.7). For colon cancer patients, taking into account differences in tumour characteristics 
actually increased the deprivation-specific differences in risk of death and rendered the 
difference significant. For rectal cancer patients, the differences in risk of death were also 
enhanced by inclusion of information on tumour characteristics in the model. Missing stage 
and grade makes interpretation of these models more difficult; however, the results were 
similar if only patients with known stage and grade were included in the analysis (data not 
shown).
Treatment factors
Patients who were treated with curative intent had significantly better two-year survival 
(83%) than those treated with palliative intent (19%) or for whom the treatment intent was 
unknown (55%). Survival was also related to the type of treatment received, with better 
survival for patients receiving surgery compared to no surgery, chemotherapy compared to 
no chemotherapy, and conversely, no radiotherapy compared to radiotherapy. However, 
treatment options are not independent o f patient and tumour characteristics, o r hospital and 
consultant. Patients receiving radiotherapy followed by surgery and chemotherapy had the 
best survival (81%), then patients receiving radiotherapy followed by surgery (73%), surgery 
alone or with chemotherapy (63%), surgery followed by radiotherapy and chemotherapy 
(56%), surgery followed by radiotherapy (46%), chemotherapy alone (24%), radiotherapy
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alone (19%), or chemotherapy and radiotherapy in combination (9%). Inclusion of surgery, 
radiotherapy, treatment combinations and treatment intent information all improved the 
model fit, but did not explain differences in survival between affluent and deprived patients 
(Table 6.7). Inclusion of information on treatment for colon cancer patients accentuated 
the differences in the risk of death between affluent and deprived patients. For rectal cancer 
patients, the deprivation-specific risk o f death was largely unchanged when adjustment was 
made for differences in treatment.
Multivariate analyses
In the main multivariate analyses the factors were grouped into patient characteristics, health 
care system factors, tumour characteristics and treatment factors (Table 6.8; only factors that 
improved the model fit are displayed) and each factor examined allowing for all related 
factors (models 1-4). Deprivation group and age were included in each model. The 
significant factors in each of these group models were then included in the final model 
(model 5; Table 6.9).
In model 1, age and the bed-days comorbidity score were important patient-related factors 
improving the model fit. For colon cancer patients, Charlson comorbidity score and the 
Scottish comorbidity score were also important prognostic indicators independendy of each 
other. For rectal cancer patients, sex was an important prognostic indicator. Information 
on health board o f residence, rurality o f residence and history of cancer did not improve the 
fit of the model once age, comorbidity and sex had been included. For colon cancer 
patients, differences in age and comorbidity did not explain the deprivation-specific 
differences in the risk of death (RR remained 1.13). For rectal cancer patients, differences in 
age, sex and comorbidity explained around 10% of the deprivation-specific differences in 
risk of death (RR reduced from 1.75 to 1.66; Table 6.8).
Model 2 included the health care system factors, and type of admission (emergency or 
elective), whether seen in a specialist department, whether seen (for rectal) or treated (for 
colon) in a high-workload hospital or regional RT centre, whether a high-workload clinician 
was managing the patient at the time o f surgery, and the length of time between diagnosis 
and treatment all improved the model fit, so were important in explaining survival variations.
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Table 6.8: Patients diagnosed with colorectal cancer in Scodand in 1997: multivariate
influence of all the factors grouped on the relative risk of death within two 
years o f diagnosis among deprived compared to affluent patients (Cox 
proportional hazards regression analyses)
Model COLON RECTUM
Relative
risk
95% C l 
Low H igh
P -va lu e Relative
risk
95% Cl 
Low High
P -v a lu e
Model 0: Deprivation only
Dept: Affluent 1.00 1.00
Dep2 0.95 0.79 1.15 0.619 1.23 0.88 1.73 0223
Dep3 0.86 0.71 1.04 0.118 1.28 0.91 1.79 0.155
Dep4 1.05 0.86 1.27 0.648 1.46 1.04 2.06 0.029
Dep5: Deprived 1.13 0.93 1.37 0211 1.75 1.25 2.46 <0.01
Model 1: Demographic factors
Depl: Affluent 1.00 1.00
Dep2 1.00 0.83 1.20 0.978 1.18 0.84 1.66 0.328
Dep3 0.85 0.70 1.04 0.110 1.17 0.84 1.64 0.360
Dep4 1.04 0.86 1.26 0.683 1.26 0.89 1.78 0.187
Dep5: Deprived 1.13 0.92 1.37 0239 1.66 1.18 2.33 <0.01
Ages 20-49 (colon) / 30-44 (rectum) 1.00 1.00
Ages 50-59 / 45-49 1.10 0.74 1.63 0.643 1.66 0.57 4.87 0.356
Ages 60-69 / 50-59 1.17 0.82 1.68 0.390 1.01 0.39 2.62 0.989
Ages 70-74 / 60-69 1.47 1.02 2.12 0.037 1.65 0.66 4.09 0282
Ages 75-79 / 70-79 1.78 1.24 2.54 <0.01 241 0.98 5.92 0.054
Ages 80-84 (colon and rectum) 2.05 1.43 2.95 <0.001 289 1.15 7.25 0.024
Ages 85+ (colon and rectum) 3.17 2.20 4.56 <0.001 6.80 2.72 16.99 <0.001
Males . 1.00
Females - 0.72 0.58 0.89 <0.01
No bed-days 1.00 1.00
1-4 bed-days 1.42 1.10 1.84 <0.01 1.02 0.74 1.39 0.916
5-10 bed-days 1.75 1.36 2.25 <0.001 1.58 1.12 224 <0.01
11+ bed-davs 1.89 1.53 2.33 <0.001 2.02 1.55 2.64 <0.001
No comorbidity (Charlson index) 1.00 -
Comorbiditv (Charlson index) 1.39 1.16 1.68 <0.001 -
No comorbidity (Scottish index) 1.00 -
Comorbidity (Scottish index) 1.23 1.04 1.45 0.013 -
Model 2: Health care system factors1'2
Depl: Affluent 1.00 1.00
Dep2 1.07 0.89 1.30 0.469 1.18 0.83 1.68 0.352
Dep3 0.93 0.77 1.13 0.470 1.26 0.89 1.79 0.184
Dep4 1.03 0.85 1.26 0.738 1.32 0.93 1.89 0.124
Dep5: Deprived 1.14 0.93 1.39 0202 1.75 1.23 2.48 <0.01
Routine admission 1.00 1.00
Emergency admission 1.53 1.34 1.74 <0.001 210 1.65 268 <0.001
Admission type unknown 0.71 0.39 1.29 0256 0.44 0.15 1.32 0.142
Not seen in a specialist department 1.00 1.00
Seen in a specialist department 0.71 0.58 0.87 0.001 0.51 0.35 0.75 <0.01
Treated in a regional RT centre5 1.00 1.00
Treated at a high-workload hospital5 1.13 0.92 1.39 0237 1.11 0.77 1.61 0.577
Treated at a med-high workload hosp5 0.99 0.83 1.17 0.871 0.77 0.57 1.04 0.094
Treated at a med-low workload hosp5 1.04 0.86 1.25 0.678 0.81 0.58 1.13 0208
Treated at a low-workload hospital5 0.71 0.55 0.92 <0.01 0.54 0.35 0.82 <0.01
Not treated in a hospital5 1.26 0.63 2.54 0.513 2.75 0.98 7.68 0.054
Low-workload clinician at surgery4 1.00 1.00
Med-low workload clinician at surgery4 0.87 0.72 1.04 0.119 1.00 0.73 1.36 0.985
Med-higft workload clinician at surgery4 0.68 0.55 0.85 <0.01 0.89 0.62 1.30 0.560
High-workload clinician for surgery4 0.66 0.40 1.08 0.098 0.10 0.01 0.75 0.025
Patient didn't have surgery 1.23 0.94 1.60 0.137 1.70 1.22 2.36 <0.01
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T ab le  6 .8  c o n tin u ed .
Model COLON RECTUM
Relative
risk
95% C l 
Low High
P -vaJu c Relative
risk
95% Cl 
Low High
P -va lu e
Model 2 continued..
<2 weeks wait for treatment 1.00 1.00
>2 weeks wait for treatment 0.81 0.69 0.94 <0.01 0.74 0.57 0.97 0.029
No treatment received 3.12 2.33 4.19 <0.001 1.73 1.15 2.59 <0.01
Model 3: Presentation factors2.3
Depl: Affluent 1.00 1.00
Dep2 1.01 0.84 1.22 0.908 1.17 0.83 1.64 0.362
Dep3 1.03 0.85 1.25 0.740 1.33 0.95 1.87 0.099
Dep4 1.25 1.03 1.52 0.023 1.47 1.04 2.08 0.028
Dep5: Deprived 1.42 1.17 1.73 <0.001 1.88 1.33 2.66 <0.001
Dukes A 1.00 1.00
Dukes B 2.16 1.32 3.51 <0.01 1.87 1.15 3.04 0.011
Dukes C 4.43 2.74 7.16 <0.001 3.13 1.96 4.99 <0.001
Dukes D 16.22 10.04 26.20 <0.001 13.88 8.77 21.97 <0.001
Unknown staue 12.52 7.70 20.37 <0.001 8.22 5.18 13.04 <0.001
Grade 1 1.00 -
Grade 2 1.32 0.83 2.11 0235 -
Grade 3/4 2.48 1.55 3.98 <0.001 -
Unknown grade 2.28 1.43 3.64 <0.01 -
Model 4: Treatment factors2
Depl: Affluent 1.00 1.00
Dep2 1.09 0.91 1.32 0.352 1.21 0.86 1.70 0278
Dep3 1.00 0.82 1.21 0.965 1.24 0.88 1.75 0216
Dep4 1.13 0.93 1.37 0211 1.39 0.98 1.97 0.064
Dep5: Deprived 1.32 1.09 1.61 <0.01 1.58 1.11 Z23 0.010
Curative treatment intent 1.00 1.00
Palliative treatment intent 7.83 6.58 9.33 <0.001 8.07 6.00 10.85 <0.001
Unknown treatment intent 3.48 2.57 4.71 <0.001 3.70 2.11 6.50 <0.001
Surgery alone 1.00 1.00
Radiotherapy alone 4.40 2.06 9.36 <0.001 1.01 0.67 1.51 0.962
Pre-treatment RT, surgery & chemo 0.22 0.03 1.54 0.126 0.43 0.17 1.08 0.073
Surgery and radiotherapy 1.07 0.73 1.56 0.745 1.35 0.89 Z04 0.160
Surgery and chemotherapy 0.70 0.56 0.87 <0.01 0.86 0.52 1.43 0.561
Other treatment combinations 1.09 0.83 1.42 0.542 0.85 0.61 1.19 0.348
No treatment Z59 2.20 3.06 <0.001 1.55 1.14 Z13 <0.01
1 The workload of clinician seen within three months of diagnosis variable was also significant for colon 
cancer patients but is excluded because it was those with unknown clinician workload who had differing
survival
2 Age is also included in these models but results not presented on the table
3 For rectal cancer patients it  was the workload of die hospital the patient attended within three months of 
diagnosis that was important rather than the workload of the hospital of treatment
4 This is die workload of the clinician overseeing the patient at the time they had surgery — they may not have
been present at or performed die surgery.
3 Tumour type was also significant in these models but is excluded because it was those with unknown tumour 
type who had the different survival
After accounting for these factors, additional information on whether the patient saw a 
high-workload clinician within 3 months of diagnosis did not improve the model fit. 
Remarkably, after adjusting for differences in all these health care system factors between 
affluent and deprived patients, there was still no change in the deprivation-specific 
differences in the risk o f  death for either colon or rectal cancer patients.
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In model 3, stage and grade were important prognostic indicators for colon cancer patients. 
For rectal cancer patients, stage was a very important prognostic indicator, and grade was no 
longer an important prognostic indicator in a model that included stage. Whether the 
tumour was microscopically verified and the histological type of the tumour did not 
influence survival after adjusting for stage and grade (Table 6.8). After adjusting for 
differences in stage and grade, the deprivation-specific survival gradient became bigger, 
particularly for colon cancer patients (RR increased from 1.13 to 1.42), indicating that the 
null model was masking inequalities. If patients with unknown grade and stage were 
excluded from the analysis the deprived patients with colon cancer still had a higher risk of 
death than affluent patients (RR=1.24; p=0.10) but the difference was not significant. For 
rectal cancer patients, it is perhaps surprising that differences in the distribution of stage at 
presentation, an extremely important prognostic indicator, do not explain the deprivation- 
specific differences in survival (RR increases from 1.75 to 1.88). However, stage-by-stage, 
survival was higher for affluent than deprived patients with rectal cancer.
Final model: colon cancer
Colon cancer patients from deprived areas did not appear to have a survival disadvantage 
compared to affluent patients when the data were initially examined, however, after adjusting 
for the factors that had the strongest influence on survival, including age, comorbidity, type 
of admission (elective or emergency), tumour stage and grade, treatment received and 
whether surgery was overseen by a high-workload clinician, there was a significant difference 
in the risk of death for deprived compared to affluent patients (RR=1.33; p<0.01; Table 
6.9). This difference was reduced (from 1.33 to 1.19) and non-significant if patients with 
information on missing stage were excluded, an important consideration because stage and 
grade were more likely to be missing for affluent patients. Stage-by-stage survival was similar 
for affluent and deprived patients with colon cancer, however, deprived patients with 
missing stage had significantly lower survival than patients from the other deprivation 
groups with missing stage (p<0.01). If the “real” stage distribution differed across the 
deprivation groups for patients with stage missing then the risk estimate of 1.33 would be 
biased. This is explored further in the discussion.
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Table 6.9: Patients diagnosed with colorectal cancer in Scotland in 1997: multivariate
influence of all the significant factors combined on the relative risk of death 
within two years of diagnosis among deprived compared to affluent patients 
(Cox proportional hazards regression analyses)
Model COIjON RECTUM
Relative
riak
95% Cl 
Low High
P -va lu e Relative
riak
95% Cl 
Low High
P -va lu e
Model 5: Final model1
Dept: Affluent 1.00 1.00
Dep2 1.06 0.88 1.29 0.526 1.04 0.73 1.49 0.810
Dep3 0.96 0.79 1.17 0.679 1.18 0.83 1.67 0.350
Dep4 1.10 0.90 1.33 0.365 1.27 0.88 1.83 0201
Dep5: Deprived 1.33 1.09 1.62 <0.01 1.41 0.98 2.04 0.066
No bed-days - 1.00
1-4 bed-days - 1.14 0.82 1.57 0.439
5-10 bed-days - 1.47 1.02 2.11 0.040
11+ bed-days - 1.45 1.09 1.93 0.011
No comorbidity (Charlson index) 1.00 -
Comorbiditv (Charlson index) 1.25 1.02 1.52 0.032 -
No comorbiditv (Scottish index) 1.00 -
Comorbiditv (Scottish index) 1.26 1.06 1.50 <0.01 -
Routine admission 1.00 1.00
Emergency admission 1.34 1.18 1.53 <0.001 1.62 1.26 2.09 <0.001
Admission type unknown 1.30 0.76 2.25 0.341 0.65 0.21 2.05 0.463
Seen in a regional RT centre - 1.00
Seen at a high-workload hospital - 1.74 1.17 2.58 <0.01
Seen at a med-high workload hosp - 1.16 0.85 1.59 0.358
Seen at a med-low workload hosp - 1.15 0.82 1.62 0.428
Seen at a low-workload hospital - 0.87 0.56 1.35 0.525
Not seen in a hospital - 2.50 0.87 7.21 0.090
Not seen in a specialist department - 1.00
Seen in a specialist department - 0.41 0.28 0.60 <0.001
Low-workload clinician at surgery2 1.00 -
Med-low workload clinician at surgery2 0.91 0.76 1.09 0.317 -
Med-high workload clinician at surgery2 0.75 0.60 0.94 0.012 -
High-workload clinician at surgery2 0.87 0.53 1.42 0.574 -
Patient didn't have surgery 0.95 0.70 1.28 0.723 -
<2 weeks wait for treatment 1.00 1.00
>2 weeks wait for treatment 0.81 0.70 0.95 <0.01 0.70 0.53 0.93 0.014
No treatment received 0.97 0.46 2.06 0.942 0.87 0.59 1.27 0.467
Dukes A 1.00 1.00
Dukes B 2.11 1.29 3.46 <0.01 1.41 0.86 2.33 0.172
Dukes C 3.14 1.92 5.16 <0.001 1.78 1.07 2.95 0.026
Dukes D 5.39 3.27 8.86 <0.001 3.56 2.08 6.09 <0.001
Unknown stage 3.96 2.39 6.56 <0.001 2.27 1.33 3.88 <0.01
Grade 1 1.00 -
Grade 2 1.02 0.64 1.63 0.922 -
Grade 3 1.78 1.10 2.87 0.018 -
Unknown grade 1.48 0.91 2.39 0.110 -
Curative treatment intent 1.00 1.00
Palliative treatment intent 4.63 3.76 5.69 <0.001 5.14 3.67 7.19 <0.001
Unknown treatment intent 2.23 1.60 3.09 <0.001 1.90 1.04 3.47 0.037
Surgery alone 1.00 -
Radiotherapy alone 3.14 1.40 7.07 <0.01 -
Pie-treatment RT, surgery Sc chemo 0.21 0.03 1.50 0.120 -
Surgery and radiotherapy 1.12 0.77 1.64 0.557 -
Surgery and chemotherapy 0.58 0.46 0.73 <0.001 *
Other treatment combinations 0.93 0.68 1.27 0.653 -
No treatment received 1.88 0.88 4.00 0.102 -
1 Age ii also included in this model but the results not presented on the table
2 This is the workload o f the clinician overseeing the patient at the time they had surgery — they may not have
been present at or performed the surgery.
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Final model: rectal cancer
Rectal cancer patients from deprived areas had a significantly lower survival than affluent 
patients in the null model, and after adjusting for the factors that had the strongest influence 
on survival from rectal cancer, including age, comorbidity, type of admission (emergency or 
elective), specialty and workload of the hospital attended, whether seen in a specialist 
department, tumour stage and treatment intent, almost a half of the difference in risk of 
death between affluent and deprived patients was explained (RR reduced from 1.75 to 1.41), 
and the difference was rendered marginally non-significant (Table 6.9). There was still a 
clear trend across the deprivation groups, and although the difference in the risk was non­
significant a 40% increased risk of death is clearly important, and with a larger sample of 
patients, to give more power to detect differences, may well have remained significant.
Discussion
Differences in survival between socio-economic groups for both colon and rectal cancer 
have been reported elsewhere13’17’3*'147. For the patients diagnosed in Scotland in 1997, 
survival prospects also differed by deprivation group. On the surface, the differences appear 
small for colon cancer patients but large (12% at two years) for rectal cancer patients. There 
were no major differences between the deprivation groups in age at diagnosis, sex, tumour 
stage or tumour grade at diagnosis. However, deprived patients had a higher proportion of 
metastatic tumours, worse comorbidity at diagnosis, and were also less likely to attend a 
regional RT centre, be treated in a high-workload hospital or see a high-workload clinician 
within 3 months of diagnosis. They were also less likely to receive any form of treatment. 
These differences were all more pronounced for rectal cancer patients.
Colon cancer
The interpretation of the colon cancer results hinges on the validity of stage, particularly 
because of the large difference in survival between deprived and affluent patients for whom 
stage was not recorded. Affluent patients were more likely than deprived patients to have 
no stage recorded, which is surprising, and for these patients, survival was significantly better 
for affluent than deprived patients. This was not explained by a better stage-specific survival 
for affluent patients, because survival was similar for all the deprivation groups within each 
>t«ge.
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Our results provide some evidence for the interpretation that the increased risk of death for 
deprived patients (RR 1.33) is not simply an artefact. Firsdy, around 60% of patients with 
no stage recorded received no treatment, and this did not vary by deprivation group. 
Secondly, if we consider model 4 (Table 6.8) which does not include grade or stage, a 
significantly increased risk of death o f a similar magnitude to the final model was observed 
(RR 1.32 compared to 1.33), after adjustment for treatment intent and the combination of 
treatment(s) received. Since treatment choice is strongly related to stage, this lends support 
to the validity of the 33% excess risk o f death in deprived patients.
Given the large effect of stage on deprivation-specific differences in survival, stage migration 
should be mentioned. For example, if  radiological equipment is not available at one hospital 
or histology is poorly reported, then less rigorous investigations may lead to a patient being 
erroneously classified with an earlier stage tumour. In this situation, survival becomes 
apparently worse in the earlier stage to which these tumours are allocated, and (possibly) 
also in the group o f  patients with more advanced stage, from which they have been 
withdrawn, since the remaining patients, on average, have more advanced disease. 
Incomplete staging would lead to some patients being given inappropriate treatment; even 
stage-adjusted survival results would be biased as a result of this and stage migration. Stage 
migration is unlikely to be responsible for the enhanced difference in the risk o f death 
between affluent and deprived patients here, because survival did not vary by deprivation 
group within each stage.
Stage was collected by the cancer registry for the first time for patients diagnosed in 1997, 
and a subsequent exercise to assess the quality of these new data highlighted problems in 
recording (see Chapter 2). For 5% o f colorectal cancer patients, stage was not recorded on 
SOCRATES but it was found in the medical records on re-abstraction by the quality 
assurance team. Discrepancies in the recording of stage were identified for a further 6% of 
patients. If some cancer registration officers abstracting data in hospitals seeing mainly 
affluent patients were inefficient at extracting the stage information, this could explain why 
this information was more often missing for affluent patients. For patients diagnosed in 
1998, stage recorded is more often, and in contrast to 1997, is more often not recorded for 
deprived patients (17% compared to 13% of affluent patients). Before conclusions can be 
drawn regarding the observed deprivation-specific differences in survival for colon cancer 
patients, the analyses in this chapter should be repeated for patients diagnosed in 1998.
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Some other important results should also be highlighted. Firstly, after adjusting for case-mix 
factors, patients receiving surgery and chemotherapy had a significantly better oudook than 
patients receiving other combinations of treatment (Table 6.9). Adjuvant chemotherapy in 
the management o f colorectal cancer has been clearly linked to outcome, and the national 
guidelines recommending the use of chemotherapy were published in June 1997; however, 
only 38% of patients with Dukes’ C tumours received chemotherapy in 1997. The provision 
of chemotherapy was related to whether the patient was seen by a high-workload clinician. 
Secondly, the workload of the clinician responsible for the patient at the time they had 
surgery was clearly linked to outcome, even after adjusting for case-mix and treatment. This 
provides some empirical support to the national initiative to centralise colorectal cancer 
services.
Evidence of the effect of hospital and clinician workload and specialisation is conflicting, 
and usually relates to colorectal cancer combined. A Scottish study2* found a significant 
difference for patients treated by specialist and non-specialist surgeons. Improved survival 
was observed in Finland for colon cancer patients treated in teaching and non-teaching 
hospitals, but this was largely explained by differences in age and stage205. In East Anglia, 
higher survival for patients treated at cancer centres than those treated at all other hospitals 
was explained by differences in age, sex and stage for colon cancer, but not for rectal cancer. 
The remaining difference for rectal cancer patients was restricted to patients aged under 
75JI. A Northern Ireland study'79 found that the workload of the treating hospital but not 
of the surgeon had a significant impact on survival at two years, after adjusting for other 
significant factors (age, sex, stage, grade, type of admission and treatment intent). Patients 
treated in Northern Ireland hospitals with workloads above 33 cases per year had worse 
survival than those treated in hospitals with smaller workloads. I will refer back to this when 
discussing the rectal cancer analyses. A similar study conducted on patients diagnosed in the 
north-west of England177 found no influence of hospital or clinician workload after adjusting 
for other significant factors (age, stage, grade and type of admission). This study also found 
no effect of operator grade (consultant versus junior).
A small Edinburgh study investigated outcomes for 306 consecutive patients referred to one 
general surgeon. There were no differences in 30-day mortality or survival for patients 
whose operations were performed by the consultant compared to those who were operated
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on by supervised or independent trainees205. In a similar study in East Anglia200, outcomes 
for patients treated by a  general surgeon were compared with those treated by a colorectal 
specialist in one hospital were audited. There was no difference in overall survival, but the 
specialist had a lower clinical leak rate and lower rate of palliative diversional surgery.
In the Northern Ireland study, surgeons dealing with 15 or more cases per year managed 
only 44% of patients. In comparison, for patients diagnosed in Scotland in 1997, only 28% 
of patients were seen by high-workload clinicians (here defined as dealing with 20 or more 
cases per year). The workload of the clinician managing the patient at the time of surgery 
was shown to be an important prognostic factor, with a better outcome for high-workload 
than low-workload clinicians. Although patients treated at low-workload hospitals appeared 
to have a survival advantage when factors relating to hospital services were considered alone 
(Model 2), this advantage was reduced, and no longer statistically significant, after accounting 
for comorbidity, stage, grade and treatment received.
Rectal cancer
Rectal cancer patients who were seen in a regional RT centre, seen by a high-workload 
clinician within 3 months of diagnosis, and whose surgery was overseen by a high-workload 
clinician, all had a survival advantage when these factors were looked at individually (i.e. no 
adjustment for other factors). Deprived patients were less likely than affluent patients to fall 
in these groups, and differences in survival between affluent and deprived patients appeared 
to be partly explained by the workload of the clinician managing the patient at the time of 
surgery when considered alone (Table 6.7). This not only resulted in a higher post-operative 
mortality for deprived patients, but was also evident if  only patients who had already 
survived at least 1 month were considered (data not shown).
When all the factors relating to the health care system were considered alone (Model 2), 
whether the patient attended a high-workload hospital or regional RT centre was an 
important factor, but it was in the low-workload hospitals that patients appeared to fare the 
best. This was probably an artefact of case-mix, because in the final model containing all 
significant factors, the difference was smaller, and non-significant. Why patients seen at 
high-workload hospitals other than regional RT centres had significantly poorer survival is 
not clear, although it may be because those patients deemed well enough for adjuvant 
therapy were sent to a  regional RT centre rather than to other high-workload hospitals.
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This would also explain why treatment does not appear to be an important prognostic 
indicator in the final model, which would otherwise be surprising, given the importance o f 
chemotherapy for rectal cancer patients. Treatment decisions are not independent o f 
specialisation/workload, clinical and other case-mix factors. Despite the move to centralise 
surgery for rectal cancer patients since 1996, only 39% of rectal cancer patients diagnosed in 
1997 received their surgery in a high-workload hospital. After adjusting for hospital 
workload, clinician workload was no longer a significant prognostic indicator, even though 
surgery for rectal cancer patients is a highly specialised intervention. In the model including 
only hospital factors, patients managed by high-workload clinicians had a very large survival 
advantage compared to those managed by low-workload clinicians (RR 0.10; Model 2). The 
magnitude o f the difference was similar if this factor was included in the final model, but it 
was no longer significant. This may be due to the relatively small sample size for the rectal 
cancer analysis (844 patients). After adjusting for age and stage at diagnosis, rectal cancer 
patients treated at regional RT centres had significantly higher survival than patients treated 
at other hospitals.
Deprived patients with rectal cancer were less likely to receive any treatment (18% received 
no treatment compared to 11% of affluent patients). The proportion of rectal cancer 
patients with Dukes’ C tumours receiving chemotherapy (41%) was lower than might be 
expected, with very large variation between deprivation groups (52% of affluent and 30% o f 
deprived patients). For patients with Dukes’ C tumours, where a clear link between 
chemotherapy and outcome has been made, inequalities in treatment of this magnitude 
should not exist.
It is interesting to note that of the 17% of patients who did not receive any treatment, half 
of them only saw a low-workload clinician. This may reflect their physical state or might 
indicate that low-workload consultants are not providing appropriate treatments). 
Deprived patients treated with curative intent had significantly lower survival than affluent 
patients (two-year survival: 77% compared to 91%), as did those treated with palliative intent 
(21% compared to 29%). Affluent patients were significantly more likely to have unknown 
treatment intent, but even if we assume all the patients with unknown treatment intent were 
treated with curative intent, the deprived patients still have worse survival (77% compared to 
88%). So, deprived patients do worse whether they are treated with palliative or curative 
intent, and they are less likely to receive treatment.
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Deprived rectal cancer patients were also more likely to have metastatic tumours at diagnosis 
(21% compared to 15% of patients in all the other deprivation groups combined) which 
may explain why they were less likely to receive any treatment. This was also true for 
patients diagnosed in 1998 (26% of deprived compared to 21% of affluent patients had 
metastatic disease at presentation). Tumour stage is clearly an important prognostic factor 
in the final model (Table 6.9), and it is interesting that grade is no longer an important 
prognostic indicator after adjusting for stage. Insofar as deprivation-specific differences in 
survival are stage-dependent, then mass screening might help reduce inequalities in survival, 
although deprivation-specific differences in compliance and the poor reliability of the FOB 
test make this by no means a certainty207.
General
Overall, the distribution of stage at diagnosis appears to have improved over time. The 
Scottish cancer registry did not collect information on tumour stage prior to 1997; however, 
comparing the stage distribution with that observed in Scottish audits conducted in the early 
1990s, patients diagnosed in 1997 were less likely to present with metastatic disease, even 
though similar proportions w ere still presenting as an emergency. Also, within each tumour 
stage, survival for patients diagnosed in 1997 appears higher than that reported in previous 
audits. Given the fact that fewer patients are presenting with metastatic disease and stage- 
specific survival is improving, the trend for improved survival from colorectal cancer (see 
Figure 6.4) is likely to be due both to earlier diagnosis and to improvements in treatment, 
including peri-operative care.
A minor point that may be worth noting is that two-year survival for colorectal cancer was 
significantly worse (p=0.04) for patients diagnosed in December than in other months of 
the year (48.2% compared to 54.8%). This appears to echo a study in Finland in which 
patients treated during holiday periods had worse survival than those treated at other 
times157.
In conclusion, for colon cancer, deprived patients had a small (13%) and non-significant 
excess mortality compared to affluent patients, which increased to 33% after adjustment for 
differences in the main prognostic factors: age, comorbidity, clinician workload, stage, grade 
and treatment. However, it is hard to rule out the possibility of artefact in the recording of
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stage by deprivation group, and this relatively small excess cannot confidentially be ascribed 
to differences in clinician workload, tumour characteristics and treatment in these data.
For rectal cancer, there was a 75% excess risk of death in deprived compared to affluent 
patients, and a clear gradient across the deprivation groups. This excess was reduced to 40% 
by adjusting for differences in comorbidity, type of admission (emergency or elective), 
hospital specialty and workload, stage and treatment intent. This difference was statistically 
non-significant but it is clearly important. Repeating the analyses on a larger sample of 
patients, with more complete data on prognostic variables, would help elucidate these 
remaining differences, and determine if deprivation-related differences in survival can be 
explained by differences in access to care and treatment.
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C h a p t e r  7
BLADDER AND KIDNEY CANCERS
Background
Bladder and kidney cancers are examined together in this chapter as they comprise most 
(94%) of the urinary tract, have similar aetiology, are both managed by urologists, and have 
similar treatment regimes.
Bladder cancer
Bladder cancer is the 4* most common cancer among men (7.7% of all cancers) and the 7* 
most common cancer among women (3.4%) in Scodand. In 1997, a total of 1 208 new 
cases were diagnosed. Incidence has been increasing over time since around 1980 for both 
sexes although this shows signs of reversing in recent data (Figure 7.1). This recent decline 
is thought to be a cohort effect and is occurring across all age groups“ *1209.
Figure 7.1: Cancers of die bladder and kidney in Scodand: trends in incidence (1979-97)
and mortality (1979-99), all ages (European age-standardised rates)
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Incidence o f bladder cancer in Scotland is significantly higher in men than women at all 
ages, and the gap between the sexes increases with age. The risk in men aged over 80 years 
is more than four-fold that in women o f the same age (Figure 7.2). The majority of bladder 
cancers are transitional cell carcinomas, which are known to be associated with cigarette 
smoking and occupational exposure to certain carcinogens20’ , so the difference in incidence 
between the sexes may be due to occupational and lifestyle factors210.
Figure 7.2: .Age-specific incidence o f bladder and kidney cancer in Scotland, patients
diagnosed in 1997, by sex
Age at diagnosis
Incidence of bladder cancer is higher in Scodand than in most other European countries 
(Figure 7.3). However, this may be a reflection of local practices in the registration of 
‘benign’ bladder tumours or ‘papillomas’, since there is no standardisation o f coding of non- 
invasive tumours to take into account recorded level of invasion and grade2" . An increase in 
the registration of small papillomas as malignant may explain the high rates of bladder 
cancer in men in Scotland, particularly in older men, as they will receive investigative 
procedures for urinary symptoms more frequently.
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Over the next decade the incidence of bladder cancer is expected to decline slightly in 
Scodand, although the numbers of cases is predicted to increase due to the ageing 
population, with the gap between males and females widening still further152.
Mortality from bladder cancer has declined slighdy in males over the last 20 years (by around 
1% per year since 1979), and the rates for females have remained stable (Figure 7.1). In 
1999, 449 patients died of bladder cancer in Scodand. Mortality rates and numbers of 
deaths are expected to continue to decline in males, and to begin to decline in females, over 
the next decade152.
Figure 7.3: International comparison o f bladder and kidney cancer incidence, around
1988-92 (world age-standardised rates), both sexes combined
A) Bladder B) Kidney
0  5 10 15 0  5 10 15
Incidence a te  per 100,000 Incidence a te  per 100,000
Source: Cancer Incidence in Five Continents, Vol. VII"
Unusually, survival from bladder cancer is higher for males than females. This may, again, 
be due to an excess of papillomas being diagnosed in males. A study in the USA found that 
females did have a slightly higher proportion of worse stage tumours, but this did not appear 
to completely explain their poorer outcome, because survival was higher for males within 
each stage212.
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In Scotland, survival has improved for patients diagnosed over the last 28 years, with one- 
year survival increasing from 70% to 78% in males, and from 61% to 67% in females. 
Similar improvements are seen at five years after diagnosis from around 55% to 68% in 
males and from 49% to 61% in females (Figure 7.4). Survival is most favourable at younger 
ages, and is higher in males than females at all ages, but particularly in the elderly (ages 75 
and over)1. Survival from bladder cancer in Scodand is similar to the average of that seen in 
Europe although significandy lower than some European countries and the USA (Figure 
7.5). These geographical comparisons, however, are difficult to interpret due to the coding 
problems surrounding invasive bladder cancers.
Kidney cancer
Kidney cancer is the 10* most common cancer among men (2.5% o f all cancers) and the 
15* most common cancer among women (1.7% of all cancers) in Scodand. Incidence has 
been increasing gradually since around 1980 (see Figure 7.1), and in 1997 a total of 486 new 
cases were diagnosed in Scodand. As for bladder cancer, the disease is more common in 
males than females at all ages (see Figure 7.2).
Kidney cancer in adults is rare in Scodand compared to most other European countries or 
the USA, with lower incidence observed only in Asia, England and Wales, and Spain, of the 
countries compared (see Figure 7.3). Tobacco smoking is thought to be one of the major 
causes, especially for renal pelvis tumours, with a moderately increased risk due to obesity 
and a western type diet; however, these factors do not explain the low rates in Scodand. 
The incidence of kidney cancer is predicted to increase by around 50% in the next decade152, 
which will raise the public health importance of these tumours.
Mortality from kidney cancer has increased sligfidy over the last 20 years (see Table 7.1), and 
in 1999 a total of 304 patients died of kidney cancer in Scodand.
Survival from kidney cancer has improved over time, but even now fewer than 40% of 
patients are alive five years after diagnosis. One-year survival has increased from 41% to 
60% and five-year survival has increased from 26% to 39% from 1971-75 to 1991-95 (Figure 
7.4). Survival is similar between the sexes, and decreases with increasing age in both sexes.
F ig ure  7 .4 : Patients diagnosed with bladder and kidney cancer in Scodand during 1971- 
98: trends in relative survival by sex
Survival from kidney cancer is significandy worse in Scodand than in mort other European 
countries and the USA (Figure 7.5).
In this chapter the survival of 1 694 patients diagnosed with bladder or kidney cancer in 
Scodand in 1997 is investigated to identify reasons for differences in survival by deprivation 
category. For definitions of the variables included in the analyses, please refer to Chapter 2.
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Figure 7.5: Bladder and kidney cancer international comparison of five-year relative
survival (with 95% confidence intervals), selected countries, patients 
diagnosed around 1985-89, all ages'
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1 Patients diagnosed 1986-90 aged 15-99 in England and Wales; patients aged 15-99 in Scotland; patients 
diagnosed 1988-92 in USA.
Results and commentary
Incidence of bladder and kidney cancer was broadly similar across deprivation groups for 
Scottish residents in 1997 (Figure 7.6). There was little variation in mortality across the 
deprivation groups for bladder cancer. For kidney cancer, higher mortality was observed for 
affluent compared to deprived patients, but the numbers on which this is based are relatively 
small. Two-year survival was significantly higher in affluent compared to deprived patients 
with bladder cancer (73% compared to 55%) and kidney cancer (66% compared to 43%).
Bladder cancer has previously been reported to be more common in deprived groups of 
patients1’20*. This was not observed for patients diagnosed in Scotland in 1997, but may 
reflect small numbers in analysing data from only one year. Studies looking at incidence and 
deprivation for kidney cancer have not identified a clear relationship1,214. Previous studies of 
socio-economic differences in survival have consistently shown deprived patients with 
bladder cancer and with kidney cancer to have poorer survival than affluent 
patients433,43,2'5 217. However, studies looking at social variations in survival for these cancers 
are sparse.
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Figure 7.6: Patients diagnosed with bladder and kidney cancer in Scotland in 1997:
incidence1 and relative survival2, and mortality1 in 1999, by deprivation 
category
Affluent Carstairs deprivation category Deprived
1 Age-standardised rates per 100,000 person-years at risk (European standard population).
2 Using deprivation-specific life tables; age-standardised to the world standard cancer patient population.
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Bladder and kidney cancers were more common in men, who made up 68°/o of bladder and 
59% of kidney cancer patients in 1997 (Table 7.1). For bladder cancer, the proportion of 
males was similar across the deprivation groups, however, for kidney cancer there were 
significandy fewer males in the deprived group (47% compared to 68% in the affluent 
group). The distribution of age at diagnosis was similar across deprivation groups for 
bladder cancer patients, with a median age of 72 years. The median age at diagnosis for 
kidney cancer patients was 68 years, and patients from deprived areas tended to present at 
an older age than affluent patients (not significant).
Bladder or kidney cancer was the first primary malignancy for 1 535 (91%) o f patients, with 
6 patients having two cancers diagnosed simultaneously, 7 having a previous primary at the 
same site, and 146 having had a previous primary at another site.
Less than half (41%) of patients came from urban areas, and because deprived areas in 
Scotland are largely urban, deprived patients with bladder and kidney cancer were more 
likely to come from urban areas (Table 7.1).
Organisation of services
UK guidelines recommend that patients with suspected urological malignancy be referred to 
cancer centres in large hospitals with the necessary facilities available2". Adequate access to 
radiological and treatment facilities are essential. Multidisciplinary teams are important in 
the management o f bladder and kidney cancer patients, and should comprise urologists with 
oncological expertise and clinical oncologists (for patients with advanced disease). Rapid 
diagnosis in patients with haematuria can be achieved via haematuria clinics with “one-stop” 
visits for cystoscopy and upper urinary tract imaging219. Cystoscopic surveillance is needed 
for patients with superficial disease152.
Of the patients diagnosed in Scotland in 1997, only 46% of bladder and 45% of kidney 
cancer patients attended a regional RT centre at some point during their cancer spell. 
Deprived patients with kidney cancer were significantly less likely to attend a regional RT 
centre than affluent patients (Table 7.2). Despite the recommendations in the guidelines, 
17% of bladder and 23% of kidney cancer patients were only seen in a medium-low or low- 
workload hospital.
203
Table 7 .1 : Patients diagnosed w ith  b ladder and kidney cancer in Scotland  in 1997 : dem ographic data by deprivation  category (num ber and
percentage o f  cases)
Deprivation
category
No. of 
patients
No. of 
fem ales1
M edian age 
(inter-quartile 
range)
Cases for which: No. of urban 
residents2F irn
primary
Simultaneous
primary
Previous 
primary at 
same site
Previous
primary
elsewhere
Bladder
Affluent 255 (21%) 89 (337.) 73 (65-79) 229 (90%) 0 m 2 (17.) 24 (97.) 93 (567.)
2 239 (207.) 65 (277.) 72 (65-79) 214 (907.) 0 m 0 (37.) 25 (107.) 55 (257.)
3 220 (W .) 68 (317.) 73 (65-80) 194 (887.) 0 (37.) 1 (07.) 25 (117.) 59 (277.)
4 248 <21%) 78 (317.) 72 (64-78) 230 (957.) 2 (17.) 1 (37.) 15 (67.) 98 (407.)
Deprived 246 (207,) 88 (367.) 71 (65-78) 224 (917.) 0 (57.) 1 (37.) 21 (97.) 190 (777.)
Total 1,208 (100%) 388 (32%) 72 (65-79) 1091 (90%) 2 (0%) 5 (0%) 110 (9%) 495 (41%)
Kidney
Affluent 81 (177.) 26 (327.) 64 (56-72) 74 (917.) 0 (07.) 0 (37.) 7 (9%) 36 (447.)
2 112 (217.) 44 (397.) 66 (58-74) 99 (887.) 1 (17.) 1 (17.) 11 (107.) 23 (217.)
3 97 <207.) 36 (377.) 69 (61-72) 92 (957.) 0 (07.) 0 (37.) 5 (57.) 27 (28°/.)
4 110 <237.) 47 (437.) 68 (61-76) 98 (897.) 3 (37.) 1 (17.) 8 (37.) 50 (457.)
Deprived 86 (107.) 46 (537.) 69 (61-75) 81 (947.) 0 (07.) 0 (37.) 5 (67.) 71 (857.)
Total 486 (100%) 199 (41%) 68 (59-73) 444 (91%) 4 d% ) 2 (0%) 36 (37.) 207 (43%)
Total 1,694 j a m . 587 J3 *% 1 70 JÉ tU L 1,535 (91%) 6 (°7‘) 7 m . 146 702 (41%)
1 Chi-square test for association between sex and deprivation group for kidney cancer p=0.059
2 Chi-square test for association between urban residence and deprivation group for bladder and kidney cancer p<0.001
Affluent patients were more likely to receive their main treatment (defined as surgery or 
earliest other treatment for non-surgical patients) in a regional RT centre than deprived 
patients with bladder cancer (34% compared to 25%; p=0.03) or kidney cancer (56% 
compared to 29%; p<0.001). Overall, only 27% o f bladder and 38% of kidney cancer 
patients were treated in a regional RT centre. This is in contrast to patients diagnosed in 
East Anglia during 1989-93, where 55% of bladder cancer patients were treated in a regional 
RT centre11. For the Scottish data, the proportion o f  patients (56%) treated in any high- 
workload hospital (regional RT centre or other high-workload hospital) varied significantly 
by deprivation group but with no clear trend. Kidney cancer patients were slightly less 
likely (52%) to be treated in a high-workload hospital than bladder cancer patients, and 
affluent patients were more likely than deprived to be treated in a high-workload hospital 
(not significant).
Overall, 80% of bladder cancer patients attended a specialist department within three 
months of diagnosis, and deprived patients were actually more likely to attend a specialist 
department (p<0.001). For kidney cancer, 63% of patients attended a specialist department, 
and affluent patients were significandy more likely to attend a specialist department (p<0.01) 
compared to the other deprivation groups.
A quarter (24%) of bladder and 11% of kidney cancer patients were seen by a high-workload 
consultant within three months o f diagnosis, and deprived patients were less likely to be 
seen by a high-workload consultant (bladder p=0.047; kidney: p=0.428). O f the 904 
surgically treated bladder cancer patients with consultant details, 61% of affluent compared 
to only 48% of deprived patients were managed at surgery by a medium- or high-workload 
clinician (managing at least 20 bladder cases per year, not significant). For the 227 surgically- 
treated kidney cancer patients with consultant details, 79% of affluent and 67% o f  deprived 
patients were managed by a medium- or high-workload consultant (managing at least 5 
kidney cancer cases per year, not significant).
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Table 7.2 : Patients diagnosed w ith  b ladder and kidney cancer in Scotland  in 1997 : access to  health care by deprivation  category (num ber and
percentage o f  cases)
Deprivation
category
No. of 
patients
Attended a 
regional RT 
centre1
Attended a
specialist
department2
Main treatment 
at a regional RT 
centre3
Treated in a 
high-workload 
hospital4 5*7
Seen by a high- 
workload 
consultant3
Emergency
admission
More than two 
weeks’ delay 
between 
diagnosis and 
treatment*
Widdcf
Affluent 255 121 (*7V.) 192 (757.) 87 (347.) 148 (587.) 65 (257.) 48 (197.) 135 (627.)
2 239 105 (447.) 179 (757.) 61 (267.) 101 (427.) 64 (27%) 49 (217.) 132 (637.)
3 220 105 (487.) 185 (847.) 66 (307.) 139 (637.) 48 (227.) 40 (187.) 120 (627.)
4 248 110 (447.) 202 (817.) 56 (237.) 118 (487.) 69 (287.) 47 (19-/.) 144 (687.)
Deprived 246 115 (477.) 206 (847.) 61 (257.) 165 (677.) 43 (177.) 52 (217.) 128 (657.)
Total 1,208 556 (46%) 964 (90%) 331 (27%) 671 (56%) 289 (24%) 236 (20%) 659 (64%)
Sig& m *' p=0.875 1X0.001 1x0.03 1X0.001 p=0.047 p=0.931 p=0.497
Kdney
Affluent 81 50 (627.) 63 m 45 (567.) 50 (627.) 10 (127.) 32 (W o) 49 (697.)
2 112 54 (487.) 62 (557.) 44 (397.) 53 (477.) 11 (W .) 33 (29-/.) 55 (727.)
3 97 39 (407.) 57 (597.) 33 (347.) 49 (517.) 15 (157.) 35 (367.) 48 (757.)
4 no 47 (417.) 68 (627.) 40 (367.) 60 (557.) 11 (M .) 32 (297.) 58 (787.)
¡Deprived 86 31 (367.) 54 (637.) 25 (297.) 41 (487.) 6 (77.) 32 (377.) 44 (757.)
Total 486 221 (45%) 304 (63%) 187 (39%) 253 (52%) 53 (»% ) 164 (34%) 254 (74%)
__ 1X0.01 1x0.05 1X0.001 1x0280 P-0.428 p=0.477 p-0.148
1 At some point duhng their cancer spell
2 Within 3 months of diagnosis
1 Number of patients whose main treatment was performed at a regional RT centre (surgery, or earliest treatment for non-surgical patients)
* Hospital seeing at least 49 bladder or 18 kidney cancer patients (highest workload quartile; see Chapter 2 for workload bandings)
5 Consultant seeing at least 30 bladder or 10 kidney cancer patients (highest workload quartile); percentage of those with consultant details, seen by consultant within 3 months of 
diagnosis (see Chapter 2 for workload banding?)
* Days between diagnosis and definitive treatment; percentage of those with a definitive treatment date
7 Chi-square test for association
Delay
The most frequent primary symptom for bladder or kidney cancer is macro- or microscopic 
haematuria, and patients with this symptom are generally referred to a urologist. Further 
primary symptoms for kidney cancer are loin pain or a palpable mass. Secondary effects 
include weight loss, fever, back pain, anaemia and general malaise. Only a third of patients 
present with primary symptoms and so there is often a delay in diagnosis, which is reflected 
in the emergency admission rates.
For patients diagnosed in Scodand in 1997, 20% of bladder and 34% of kidney cancer 
patients were admitted as an emergency (Table 7.2). There was no trend in the proportion 
of emergency admissions across the deprivation groups. Older patients were significandy 
more likely to be admitted as an emergency (34% aged 80 and over compared to 21% aged 
under 50). Grade was also an important factor, with 26% of patients with grade 3 tumours 
compared to 14% of patients with grade 1 tumours presenting as an emergency.
For two-thirds of bladder and three-quarters of kidney cancer patients, at least two weeks 
elapsed between diagnosis and definitive treatment. The median wait for treatment was 
higher for kidney cancer patients in the most deprived group (41 days) compared to the 
other deprivation groups (32 days; data not shown). There were no differences between 
deprivation groups in time to surgery for bladder cancer patients.
Mode of presentation
When a patient presents with a suspected bladder cancer they will usually receive an 
endoscopic examination (cystoscopy) and upper urinary tract imaging in the form of 
intravenous urogram or ultrasound. Patients with suspected kidney cancer receive non- 
invasive imaging such as ultrasound, CT scanning or MRI.
Pathological tumour stage and lymph node status are the most important prognostic 
indicators for bladder cancer2“ . Around 70% of bladder tumours are superficial and the rest 
invasive221. For patients diagnosed with invasive bladder cancer in East Anglia during 1989- 
93, 47% were stage 1 tumours, 25% were stage 2, 20% were stage 3, and 9% were stage 4 
tumours. For localised kidney cancers, tumour size is an important prognostic indicator222, 
but kidney cancer is characterised by few early warning signs, so 20-30% of patients present
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with metastases at diagnosis223. Information on stage for bladder and kidney cancers is not 
available on SOCRATES.
Grade and histological type are also important prognostic indicators223-224, in particular grade 
for clear-cell kidney cancer. For patients diagnosed in Scotland in 1997, 19% of bladder and 
67% o f kidney cancer patients had unknown grade. Of patients with known grade, only a 
quarter of bladder and one-tenth of kidney cancer patients presented with well-differentiated 
tumours (Table 7.3). There were differences in grade at presentation across the deprivation 
groups for bladder cancer patients, but the pattern was unclear.
Table 7.3: Patients diagnosed with bladder and kidney cancer in Scotland in 1997: grade
by deprivation category (number and percentage of cases)
Deprivation
category
No. of 
patients
Grade1
1 2 3/4 Unknown
Bladder
Affluent 255 42 (20%) 82 (400/.) 81 (40%) 50 (200/.)
2 239 58 (30%) 48 (23%) 86 (45%) 47 (20%)
3 220 43 (22%) 61 (31%) 91 (470/.) 25 01% )
4 248 46 (23%) 70 (36%) 80 (41%) 52 (21%)
Deprived 246 53 (28%) 62 (33%) 74 (39V.) 57 (23V.)
Total 1,208 242 (25%) 323 (33%) 412 (42% ) 231 (29%)
Significant/ P-=0.090" P-=0.02?
Kidney
Affluent 81 3 02% ) 11 (42°/.) 12 (460/.) 55 (68°/.)
2 112 5 ( tm ) 17 (30V.) 12 (350/0) 78 (70%)
3 97 3 m 13 (39-/.) 17 (52V.) 64 (66%)
4 110 4 (too/.) 24 (37V.) 14 (33V.) 68 (62o/.)
Deprived 86 2 (7%) 14 02%) 11 (41%) 59 (69V.)
TotsU 486 17 (10%) 79 (49%) 66 (41%) 324 (07% )
Significant/ ________ L=0.822" _______ L=0.76?
1 Percentage of patients with a known category, except 'unknown', presented as a percentage of the total
2 Chi-square test for association
1 Significance of association across the deprivation categoties excluding those in the unknown category 
4 Significance of proportion unknown across the deprivation categories
Diagnosis was microscopically verified for most bladder (96%) and kidney (79%) cancer 
patients, and these proportions did not vary significantly across the deprivation groups 
(Table 7.4). Most o f the bladder cancers were transitional cell tumours (93%), and around 
half o f these were papillary. There were no differences in histological type between the 
deprivation groups for bladder cancer patients. Over two-thirds (68%) of the kidney cancer
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patients presented with renal cell carcinomas, 20% with clear cell tumours and 12% with 
other cell types. Deprived patients were less likely to present with clear cell tumour (10% 
compared to 20% overall). A further 5% of bladder and 17% of kidney cancer patients had 
tumours of unspecified histological type.
Figure 7.4: Patients diagnosed with bladder and kidney cancer in Scodand in 1997:
microscopic verification and histological type by deprivation category 
(number and percentage of cases)
Deprivation
category
No. of 
patients
Micro-
scopically
verified
Histological type
Papillary
Transitional
Cell
Other
Transitional
Cell
Other Unspecified
Bladder
Affluent 255 247 (97%) 110 (45%) 119 (49%) 16 (7%) 10 (4%)
2 239 228 (95%) 100 (44%) 107 (47%) 21 (9%) 11 (5%)
3 220 212 (96%) 92 (45%) 110 (52%) 10 (5%) 8 (4%)
4 248 238 (96%) 103 (44%) 119 (50%) 14 (6%) 12 (5%)
Deprived 246 231 (94%) 111 (**%) 101 (44%) 17 (7%) 17 (7%)
Total 1,208 1,156 (96% ) 516 (4S%) 556 (48% ) 78 (7% ) 58 (5% )
__ p=0.542 p —0.610 p -0 2 6 5
Deprivation No. of Micro- Histological type
category patients scopically
verified
Renal cell Clear ceU Other Unspecified
Kidney
Affluent 81 69 (85%) 48 (68%) 12 (17V.) 11 (15V.) 10 (12V.)
2 112 86 (77%) 66 (71%) 19 (20V.) 8 (9V.) 19 (17V.)
3 97 76 (78V.) 51 (60%) 25 (29V.) 9 (11V.) 12 (12V.)
4 110 83 (75%) 53 (62V.) 19 (22V.) 14 (16%) 24 (22V.)
Deprived 86 68 (79%) 55 (80%) 7 (10V.) 7 (10V.) 17 (20V.)
Total 486 382 (79% ) 273 (68% ) 82 (20%) 49 (12%) 82 (17%)
SijpnficancC p-0 .565 p=0.093 p -0 2 7 2
1 Percentage of patients with a known category; except 'unknown', presented as a percentage of the total
2 Chi-square test for association
1 Significance of association between deprivation category and percentage of patients in each category 
excluding those in the unknown category
4 Significance of proportion unknown across the deprivation categories
There was a relationship between grade and histological type for both cancers. For bladder 
cancer, 38% of patients with papillary tumours had well-differentiated tumours compared to 
14% of patients with other transitional cell tumours; 22% of the papillary and 59% of the 
other transitional cell tumours were poorly-differentiated or undifferentiated. For kidney 
cancer, around 50% of patients with renal and clear cell tumours had moderately-
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differentiated tumours; however, patients with clear cell tumours were more likely to have 
well-differentiated tumours (19% compared to 7% of patients with renal cell tumours).
Comorbidity
Overall, 25% o f bladder and 38% of kidney cancer patients had spent more than 10 days in 
hospital in the two years preceding the cancer diagnosis. Comorbidity was lower when 
measured with the disease-based (Scodand or Charlson) indices compared to the bed-days 
index. For bladder cancer, deprived patients had somewhat higher comorbidity than 
affluent patients at the time of diagnosis with all three comorbidity measures, but none was 
significant (Table 7.5). There was no pattern in comorbidity across the deprivation groups 
for kidney cancer patients.
Figure 7.5: Patients diagnosed with bladder and kidney cancer in Scodand in 1997:
comorbidity and post-operative mortality by deprivation category (number 
and percentage of cases)
Deprivation
category
No. of 
patients
Comorbidity 30 day post­
operative 
m ortality4
Bed-days' Scotland2 Chart son3
Bladder
Affluent 255 59 (23%) 41 (16%) 27 (ii% ) 6 (3%)
2 239 56 (23%) 42 (18%) 23 (10V.) 3 (TV.)
3 220 57 (26%) 44 (20%) 26 (12V.) 2 (IV.)
4 248 61 (25%) 52 (21%) 30 (12V.) 2 (1%)
Deprived 246 68 (28*/,) 53 (22%) 35 (14%) 2 (IV.)
Total 1,208 301 (25% ) 232 (19%) 141 (12%) 13 (2% )
Sijpafiimur1 p=0.767 P=0.482 p-0.580 P=0.524
Kidney
Affluent 81 27 (33%) 11 (14%) 8 (10V.) 1 (2V.)
2 112 45 (407V.) 27 (24%) 14 (13%) 1 (IV.)
3 97 42 (43%) 24 (25%) 19 (20V/.) 2 (3%)
4 110 42 (38%) 20 (18V.) 15 (14%) 4 (6%)
Deprived 86 31 (36%) 24 (28V.) 13 (15V.) 3 (6%)
Total 486 187 (38% ) 106 (22%) 69 (14%) 11 (4% )
Sixmficanci p=0.498 p=0.148 ______ L-0.419 p=0.406
1 More than 10 inpatient bed-days in the two yean prior to cancer diagnosis
2 Any one of certain comorbid conditions recorded in the two yean prior to one month after diagnosis (see 
Chapter 1)
3 Any one of certain comorbid conditions recorded in the five yean prior to diagnosis (see Chapter 1)
4 Percentage of patients undergoing surgery (998 bladder cancer patients; 298 kidney cancer patients)
3 Chi-square test for association
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Treatment
Surgical resection is the primary treatment for bladder cancer (a cystectomy) and kidney 
cancer (a nephrectomy) patients with localised disease. For locally advanced kidney cancer 
the surgery can be more complex and is best provided in specialist centres. For bladder 
cancer patients with tumours confined to the bladder wall, cystectomy with extended pelvis 
lymph node dissection has been shown to improve prognosis225. Surgical resection is also 
considered for metastatic tumours especially clear cell kidney tumours.
Patients with localised tumours may receive pre-operative radiotherapy to reduce the tumour 
size. Post-operative radiotherapy or chemotherapy may be given following radical surgery, 
and for bladder cancer, chemotherapy after surgery has been shown to give a better 
prognosis than radiotherapy after surgery. Chemotherapy or radiotherapy may also be given 
as palliation for advanced bladder or kidney disease. Hormone therapy may also be for 
specific rare tumour types.
For patients diagnosed in Scodand in 1997, 82% of bladder and 61% of kidney cancer 
patients received surgery (Table 7.6). A quarter (26%) of bladder cancer patients received 
radiotherapy (21% within 6 months of diagnosis) compared to 14% of kidney cancer 
patients (12% within 6 months). Twelve percent of bladder cancer patients received 
chemotherapy (9% within 6 months) compared to only 4% of kidney cancer patients. Only 
two patients received neo-adjuvant chemotherapy and 10 patients received neo-adjuvant 
radiotherapy.
Deprived patients were significandy less likely to receive surgery alone as treatment for 
bladder cancer (41% compared to 58% of affluent patients; p=0.011) or kidney cancer (49% 
compared to 65%; p=0.039; Table 7.7). Deprived patients were more likely to receive 
radiotherapy alone or, for bladder cancer, radiotherapy in combination with surgery. 
Deprived patients with bladder cancer were also more likely to receive no treatment (15% 
compared to 9% of affluent patients).
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Tabic 7.6: Patients diagnosed w ith  b ladder and kidney cancer in Scotland  in 1997 : treatm ent and tim ings by deprivation  category (num ber and
percentage o f  cases)
Deprivation
category
No. of Suntm Radiotherapy Chemotherapy Hormone therapy
Within 6 Overall Within 6 
months
Overall Within 6 
months
Overall Within 6 
months
Overall
Bladder
Affluent 255 208 m 215 (84%) 48 m 63 (257.) 22 (97.) 26 (W .) 7 (57.) 8 (57.)
2 239 191 ß0%) 198 (957.) 42 (187.) 56 (2)7.) 19 (87.) 28 (127.) 1 (07.) 1 (07.)
3 220 183 p a y .) 188 (95%) 44 (207.) 55 (257.) 20 (97.) 28 (1)7.) 3 (17.) 3 (17.)
4 248 203 <**•) 204 (827.) 52 (217.) 61 (257.) 24 (107.) 36 (157.) 1 (07.) 2 (17.)
Deprived 246 179 (7 * .) 183 (747.) 68 (287.) 81 ())7 .) 20 (87.) 28 (117.) 2 (17.) 2 (17.)
Total 1,206 964 (90%) 988 (82%) 254 (21%) 316 (26%) 105 (9% ) 146 (12%) 14 (1%) 16 ( I * )
Sitm ium a p=0.160 p=0.091 p=0.301 p-0.44) p=0.727 p-0.524 p-0 .31) P-0267
Kidney
Affluent 81 59 Ç 9H 60 (747.) 8 (107.) 12 (157.) 5 (67.) 6 (77.) 2 (27.) 2 (27.)
2 112 68 (61%) 70 (6)7.) 11 (107.) 14 (1)7.) 4 (47.) 4 (47.) 4 (47.) 5 (47.)
3 97 57 m 59 (61%) 12 (127.) 12 (127.) 4 (47.) 5 (57.) 6 (67.) 6 (67.)
4 110 59 (54%) 62 (567.) 13 (127.) 14 (1)7.) 1 (17.) 2 (27.) 6 (57.) 6 (57.)
Depnved 86 44 (51%) 47 (557.) 14 (167.) 16 (197.) 0 (07.) 1 (17.) 3 (37.) 3 (57.)
Total 486 287 (59%) 298 (61%) 58 (12%) 68 (14%) 14 (3% ) 18 (4% ) 21 (4% ) 22 (SX )
Sttm&cma p=0.017 p=0.031 p=0.858 p-0.868 p=0.095 p-0 .15) p-0 .94) p=0.958
1 Chi-square test for association
Overall, a higher proportion of kidney than bladder cancer patients received no treatment 
(27% compared to 11%), and this proportion was similar across the deprivation groups with 
the exception of the most affluent group where only 9% of bladder cancer and 10% of 
kidney cancer patients did not receive any treatment.
Table 7.7: Patients diagnosed with bladder and kidney cancer in Scotland in 1997:
treatment combinations by deprivation category (number and percentage of 
cases)
Treatment com binations Affluent 2 3 4 Deprived
Bladder
Surgery alone 148 (58%) 134 (56%) 118 (54%) 120 (48%) 100 (41%)
Radiotherapy (RT) alone 12 (5%) 13 (5%) 8 (4%) 12 (5%) 22 (9-/.)
Surgery and RT 39 (15%) 36 (15%) 39 (18%) 45 (18-/.) 52 (21%)
Surgery and chemo 15 (6%) 21 (9>/.) 21 (10%) 33 (13%) 23 (9-/.)
Other combination 14 (5%) 8 (3%) 8 (4%) 5 (2-/.) 7 (3%)
Unknown combination 3 (1%) 2 (1%) 4 (2-/.) 6 (2-/.) 5 (2-/.)
No treatment 24 (W .) 25 (10%) 22 (10-/.) 27 (11%) 37 (15%)
Total 255 (100V.) 239 (100%) 220 (100%) 248 (100%) 246 (100%)
Kidney
Surgery alone 53 (65%) 61 (54%) 52 (54%) 56 (51%) 42 (49-/.)
Radiotherapy (RT) alone 5 (6%) 7 (6%) 6 (6%) 10 (9-/-) 10 (12-/.)
Chemotherapy alone 4 (5%) 3 (3%) 3 (3%) 1 (1%) 0 (0-/.)
Surgery and RT 4 (5%) 6 (5%) 5 (5%) 2 (2-/.) 4 (5%)
Other combination 2 < *•) 1 (1%) 2 (2-/.) 2 (2-/-) 4 (1%)
Unknown combination 5 (6%) 2 (2o/.) 1 (1%) 3 (3%) 3 (3%)
No treatment 8 (10°/.) 32 (2W.) 28 (29-/.) 36 (33%) 26 (30-/.)
Total 81 (100%) 112 (100%) 97 (100%) 110 (lOOV.) 86 (lOOV.)
Treatment choices varied by age. For bladder cancer, 77% of patients aged 70 and over 
compared to 88% of younger patients received surgery (p<0.001). Older patients were twice 
as likely as younger patients to receive no treatment (14% compared to 7%) or radiotherapy 
alone (7% compared to 3%). For kidney cancer patients the differences were much larger, 
with 42% of older compared to 16% of younger patients receiving no treatment (p<0.001). 
Treatment choices also varied by age for patients diagnosed with kidney cancer in The 
Netherlands in the 1980s226, with resection rates of 63% in patients aged 70 and over 
compared to 82% in younger patients; the difference was not accounted for by metastatic 
status at presentation.
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Treatment combination was also significantly related to grade at presentation. For bladder 
cancer patients, 76% of patients with well-differentiated, 64% with moderately-differentiated 
and 31% with poorly-differentiated or undifferentiated tumours had surgery alone; 2% with 
well-differentiated, 11% with moderately-differentiated and 37% of patients with poorly- 
differentiated or undifferentiated tumours had surgery with RT. The proportion of bladder 
cancer patients receiving no treatment did not vary according to grade. In contrast, for 
kidney cancer patients with known grade (this only includes 33% of patients), all patients 
with well-differentiated tumours and most (90%) patients with moderately-differentiated 
tumours received surgery alone (4% had no treatment, and 6% other combinations of 
treatment). Kidney cancer patients with poorly-differentiated or undifferentiated tumours 
received more varied treatments, including surgery alone (67%), surgery with RT (11%), RT 
alone (5%), other combinations of treatment (5%) or no treatment (12%).
Radiotherapy after surgery was less likely to be given for papillary than other transitional 
bladder cancers (11% compared to 25%), but these patients were more likely to receive 
chemotherapy instead (13% compared to 7%). Overall, bladder cancer patients with 
papillary tumours were more likely to receive surgery (91% compared to 81% for other 
transitional cell tumours, 77% for other cell types, and 12% for unspecified cell types).
Bladder cancer patients treated in medium-high workload hospitals were more likely to have 
received surgery and chemotherapy than those treated elsewhere. Overall, 80% of patients 
treated in high-workload, 92% in medium-high workload, 86% in medium-low workload, 
and 64% o f patients treated in low-workload hospitals received surgery (p<0.01). The lower 
rate in high-workload hospitals is partly explained by the referral of non-surgical cases to 
these centres for other adjuvant treatments. Chemotherapy was given to around 10% of 
patients in all hospital workload groups, but was more common for patients treated in 
medium-high workload hospitals (19%). For patients who received surgery, around 25% 
went on to have radiotherapy and this did not vary by hospital workload, with the exception 
of those patients treated in small workload hospitals (18% went on to have radiotherapy). 
For patients who did not receive surgery but had radiotherapy (6% of patients), the hospital 
of treatment was by definition the regional RT centre (in the high workload hospital group).
Kidney cancer patients treated in low-workload hospitals were also less likely to receive 
surgery (47% compared to 62% of patients treated in high-workload, 71% in medium-high
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workload and 67% in medium-low workload hospitals). Chemotherapy was rarely given 
outside the regional RT centres.
Treatment intent® (curative or palliative) was less likely to be recorded for affluent patients; 
however, for patients with known treatment intent, affluent patients were more likely to be 
treated with curative intent than deprived patients (68% compared to 60% for bladder 
cancer patients; 57% compared to 45% for kidney cancer patients; not significant). If only 
surgically-treated patients are considered, then the proportion whose intent was curative did 
not vary across the deprivation groups (76% for bladder and 78% for kidney cancer patients, 
overall). This may indicate that deprived patients are presenting with tumours less amenable 
for surgery, or that they have inequitable access to treatment.
Post-operative mortality
The 30-day post-operative mortality rate was 2% for bladder cancer patients and 4% for 
kidney cancer patients. Kidney cancer patients from deprived areas had a higher post­
operative mortality rate than those from affluent areas (6% compared to 2%; not 
significant). Patients whose surgery was managed by a high-worldoad consultant had lower 
post-operative mortality (1%, compared to 2% and 4% for those managed by a medium- 
workload or low-workload consultant, respectively; p=0.081). There was no relationship 
between hospital workload and post-operative mortality rate.
Two-year survival
Univariate analyses
Factors that had an influence on the prognosis of bladder and kidney cancer patients were 
investigated in Cox proportional hazards regression models. In the initial models containing 
deprivation only, the relative risk of death within two years of diagnosis was significantly 
raised for deprived compared to affluent patients with bladder cancer (RR 1.67 (95% Cl 
1.25-2.24)) and kidney cancer (RR 1.87 (95% Cl 1.18-2.96)).
i  Treatment intent it difficult to interpret at it it a very “toft'’ variable; it it not often ttated explicitly in the medical notet 
and the cancer regiatration officer* may uae their own judgement in recording i t
2 1 5
Patient characteristics
Survival was strongly related to age for both bladder and kidney cancers. Two-year survival 
was significantly higher for patients aged under 50 (85%) than patients aged 80 and over 
(40%) with bladder cancer. The corresponding figures for kidney cancer were 72% and 
24%.
Including age in the model significandy improved the model fit, but because there were no 
differences in the age distribution by deprivation group, it did not account for the 
differences in the relative risk o f death between affluent and deprived patients. The model 
containing deprivation and age was used as the null model, and each factor was added and 
then removed from the null model one at a time to test its significance as a prognostic 
factor for bladder and kidney cancer (Table 7.8).
Survival was significantly higher for males than females with bladder cancer, even after 
accounting for age at diagnosis. This appeared to be because females were less likely than 
males to present with papillary tumours, which have better prognosis (data not shown). 
There were no differences in survival by sex for kidney cancer patients. As there were no 
differences in the sex distribution by deprivation group for bladder cancer patients, inclusion 
of sex in the null model did not improve the model fit.
There were no differences in survival by health board of residence, urban or rural residence, 
or whether the patient had a history of cancer, either for bladder o r kidney cancer patients. 
Inclusion of these factors in the null models, therefore, did not improve the model fit.
All three measures of comorbidity were related to survival. Survival for bladder cancer 
patients with a history of at more than 10 days in hospital in the preceding two years was 
37% compared to 74% for patients with 4 or less days spent in hospital. The corresponding 
two-year survival for kidney cancer patients was 42% compared to 60%. Inclusion of 
comorbidity in the null model, therefore, improved die model fit. However, as there were 
no differences in the proportion of patients with comorbidity by deprivation group, 
unsurprisingly, comorbidity did not explain the deprivation-specific differences in the 
relative risk of death.
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Table 7.8: Patients diagnosed with bladder and kidney cancer in Scotland in 1997: univariate influence of individual factors on the relative nsk of
death within two years of diagnosis among deprived compared to affluent patients (Cox proportional hazards regression analysis)
Variable* included in the model1 BLADDER KIDNEY
Relative 95% a P-value3 P -value o f Relative 95% Cl P-value3 P -value o f
risk2 Hiefa a d d ed  term 4 risk2 add ed  t e m f
Initial model: Deprivation category 
Patient characteristics:
1.67 1.25 124 <0.01 • 1.87 1.18 2.96 <0.01 ■
Age (nail model)' 1.91 1.43 157 <0.001 <0.001 1.87 1.17 2.96 <0.01 <0.001’
Sex 1.91 1.42 156 <0.001 0.026 1.96 1.23 3.13 <0.01 0.185
Health board of residence 1.85 1.35 155 <0.001 OHS 105 1.23 3.41 <0.01 0.765
Urban indicator 101 1.48 174 <0.001 0262 1.83 1.14 2.94 0.013 0.711
Previous history of primary cancer 1.91 1.42 156 <0.001 0.460 1.89 1.19 3.01 <0.01 0.426
Bed-days comorbidity index 1.81 1.35 143 <0.001 <0.001 1.81 1.14 2.87 0.012 0.015
Charlson comorbidity index 1.86 1.38 150 <0.001 <0.01 1.75 1.10 2.79 0.019 0.017
Scotland comotbidity index 
Health cate factors:
1.89 1.41 154 <0.001 0.024 1.77 1.11 2.82 0.016 0.021
Attended a high-workload hospital? 1.93 1.43 159 <0.001 <0.001 123 1.39 3.59 <0.01 <0.01
Workload of hospital of main treatment 1.99 1.47 167 <0.001 0.072 119 1.36 3.52 <0.01 0.015
Attended a specialist department? 120 1.63 198 <0.001 <0.001 1.63 1.02 2.60 0.039 <0.001
Emergency admission 1.72 1.28 130 <0.001 <0.001 102 1.27 3.23 <0.01 0.001
Time from diagnosis to treatment 1.84 1.37 147 <0.001 <0.001 1.31 0.82 2.10 0.257 <0.001
Workload of consultant managing treatment 1.81 1.34 143 <0.001 <0.001 1.42 0.89 2.27 0.136 <0.001
Workload of consultant seen within 3 months 
Tumour characteristics:
1.87 1.39 151 <0.001 0.024 1.73 1.09 2.75 0.021 <0.001
Histological verification 1.89 1.41 153 <0.001 <0.001 1.66 1.04 2.64 0.033 <0.001
Grade 1.91 1.42 156 <0.001 <0.001 1.93 1.21 3.07 <0.01 <0.001
Histological type 
Treatment factors:
1.98 1.47 166 <0.001 <0.001 1.55 0.97 2.47 0.065 <0.001
Treatment intent (curative or palliative) 1.77 1.31 138 <0.001 <0.001 1.86 1.16 2.98 0.010 <0.001
Surgery (yes or no) 1.72 1.28 131 <0.001 <0.001 1.23 0.77 1.97 0.395 <0.001
Radiotherapy (yes or no) 1.77 1.32 138 <0.001 <0.001 1.88 1.18 3.00 <0.01 <0.001
Chemotherapy (yes or no) 1.93 1.43 159 <0.001 0.058 1.95 1.22 3.12 <0.01 <0.01
Hormone therapy (yes or no) 1.92 1.43 158 <0.001 0.899 1.79 1.13 2.85 0.014 <0.01
Treatment combination6 1.62 1.21 119 <0.01 <0.001 1.25 0.78 201 0.354 <0.001
1 Each categorical variable is added to the null model containing deprivation category and age 2 Relative risk of death in the deprived compared to affluent group
3 Significance of the difference in the relative risk between affluent and deprived 4 Improvement in model fit when each variable is added to the null model
5 The significance of the age term is tested against the initial model containing only deprivation 6 See Table 7.7 for treatment combinations
Health care factors
Patients who attended a regional RT centre at some point during their cancer spell, or 
whose main treatment was at a regional RT centre, had worse survival than those attending 
or being treated at high-workload or medium-high workload hospitals. However, if only 
surgically treated patients were considered, then those treated in regional RT centres had 
better survival than those treated elsewhere (not significant). Patients treated at low- 
workload hospitals had significantly poorer survival. In a study of patients diagnosed with 
bladder cancer in East Anglia during 1989-93, patients treated at regional RT centres 
compared to other district general hospitals also had a survival advantage but this 
disappeared after adjusting for tumour stage51. Differences in the Scottish data may also, 
therefore, be due to differences in stage at presentation.
For patients diagnosed in Scodand in 1997, those who attended a specialist department had 
significandy better two-year survival than those who did not, both for bladder cancer (66% 
compared to 52%) and especially for kidney cancer padents (61% compared to 26%). 
Deprived padents were significandy less likely to attend a specialist department, and 
inclusion of this factor in the null model appeared to explain a quarter o f the deprivation- 
specific differences in the relative risk o f death for kidney cancer patients (RR reduced from 
1.87 to 1.63).
Patients who were admitted as an emergency had significandy (p<0.001) worse survival than 
patients who were admitted routinely (36% compared to 71% for bladder cancer patients; 
40% compared to 56% for kidney cancer patients). Delay between diagnosis and treatment 
did not influence survival for bladder or kidney cancer patients; however, patients with no 
delay information - because they received no treatment - had significandy poorer survival 
than those for whom information on delay was available.
The workload of the consultant managing the patient at the time of the main treatment was 
related to survival, with higher survival for high-workload consultants. For bladder cancer, 
70% of patients managed by high-workload consultants were alive two years after diagnosis, 
compared to 66% of those managed by medium-high workload, 62% managed by medium- 
low workload, and 57% of patients managed by low-workload consultants (p<0.001). For 
kidney cancer patients, two-year survival was 74% for patients managed by high-workload 
consultants, 64% for medium-workload and 36% for low-workload consultants (p=0.024).
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Information on type of admission, delay and consultant workload all improved the model 
fit. For patients with kidney cancer, delay in diagnosis explained two-thirds of the difference 
in relative risk of death between affluent and deprived (RR reduced from 1.87 to 1.31) and 
rendered the difference non-significant (p=0.257); consultant workload explained a half of 
the difference (RR reduced to 1.42; p=0.136). These two factors were only significant 
prognostic indicators because they had a category “unknown” for patients who did not 
receive any treatment, so the reduction in risk of death between affluent and deprived 
patients is actually explained by the differences in the patients receiving treatment.
Tumour characteristics
Unsurprisingly, patients with microscopically verified tumours had significantly higher 
survival than patients with tumours not microscopically verified. Patients with poorly- 
differentiated or undifferentiated tumours had significandy lower survival than those with 
well-differentiated or moderately-differentiated tumours. For bladder cancer, survival for 
patients w ith grade 3-4 tumours was 46% compared to 75% for patients with grade 2 
tumours and 88% for patients with grade 1 tumours. For kidney cancer patients with 
known grade (33% of patients), two-year survival was 42% for patients with grade 3-4 
tumours, 81% for patients with grade 2 tumours and 100% for patients with grade 1 
tumours. Patients with unknown grade had survival estimates similar to those o f patients 
with grade 3-4 tumours. Inclusion of information on microscopic verification and grade in 
the null model improved the model fit, but did not explain the deprivation-specific 
differences in the relative risk of death two years after diagnosis.
Survival was better for bladder cancer patients with papillary tumours (81% compared to 
55% for other transitional cell tumours, 40% for other cell types, and 33% for unknown cell 
types). Again, inclusion of this factor in the null model improved the model fit but did not 
explain the deprivation-specific differences. In contrast, for kidney cancer patients, 
histological type explained around a third of the difference in the risk of death between 
affluent and deprived patients (RR reduced from 1.87 to 1.55) and the difference was 
rendered marginally non-significant (p=0.065). The effect of this factor on the deprivation- 
specific differences was largely explained by whether the patient received treatment, because 
most (95%) of the unspecified tumours were for patients who did not receive surgery. 
Patients with clear cell tumours had significantly higher survival than patients with renal cell
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tumours (70% compared to 57%), and patients with unknown cell types had significantly 
worse survival (10%; p<0.001).
Treatment factors
Overall, for bladder cancer, survival was highest for patients receiving surgery alone (79%) 
or surgery with chemotherapy (81%), compared to surgery with radiotherapy (46%), 
radiotherapy alone (21%), other treatment combinations (50%) or no treatment (36%). 
Kidney cancer patients treated with surgery alone also had the highest survival (81%), 
compared to 33% for surgery with radiotherapy, 3% for radiotherapy alone, 28% for other 
treatment combinations and 12% for patients who received no treatment. Patients who 
received hormone therapy had worse survival than those who did not receive hormone 
therapy, and these were usually non-surgical patients.
For bladder cancer, treatment intent, surgery, radiotherapy and treatment combination 
improved the model fit when added to the null model, but none of these factors explained 
the deprivation-specific differences in the risk of death when investigated alone. For kidney 
cancer, all o f the treatment factors improved the model fit, and surgery appeared to explain 
around two-thirds of the deprivation-specific differences (RR reduced from 1.87 to 1.23; 
p=0.395). It is probable that deprived patients were presenting with worse prognosis kidney 
cancers not amenable to treatment, because survival was similar across the deprivation 
groups for patients who did not receive surgery. If only patients who received surgery are 
considered, there was still an almost two-fold raised risk of death for deprived compared to 
affluent patients (data not shown).
Multivariate analyses
In the main multivariate analyses, the factors were grouped into patient characteristics, 
tumour characteristics, health care system factors and treatment factors (Table 7.9). Each 
factor was examined allowing for all related factors, and only factors that improved the 
model fit are presented (models 1-4). Deprivation group and age were included in each 
model. The significant factors in each of these group models were then included in the final 
model (Table 7.10; model 5).
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In model 1 the important prognostic indicators for both bladder and kidney cancer patients 
were age and the bed-days comorbidity index. Sex, health board of residence, urban 
indicator, history of cancer, and the Charlson and Scottish comorbidity indices were not 
important prognostic indicators in a model containing age and bed-days score. However, 
the model containing age and bed-days score did not explain the difference in relative risk of 
death between affluent and deprived bladder or kidney cancer patients. For bladder cancer 
patients the relative risk of death for deprived compared to affluent patients increased from 
1.67 to 1.81, and for kidney cancer the risk remained virtually unchanged.
Among the health care factors included in model 2, type of admissions (routine or 
emergency), whether the patient was seen in a specialist department, hospital of treatment, 
and time between diagnosis and treatment were all important explanatory variables. For 
bladder cancer, the relative risk of death in deprived compared to affluent patients increased 
after accounting for these factors (from 1.67 to 2.17). This effect was caused by a very 
strong deprivation-specific gradient in survival among the 244 (20%) of patients who did not 
attend a specialist department. Patients who did not attend a specialist department would be 
expected to be those with very good or very bad prognosis tumours, and in these data 84% 
of the affluent compared to 18% of the deprived patients were treated with curative intent. 
This indicates large differences in tumour stage by deprivation group for this subset of 
patients.
For kidney cancer, the relative risk of death in deprived compared to affluent patients was 
reduced by around 40% (from 1.87 to 1.51; p=0.105) and became non-significant in a model 
containing factors on whether the patient was seen in a specialist department, their hospital 
of treatment workload and time from diagnosis to treatment. This reduction was due to 
inclusion o f time from diagnosis to treatment as a factor in the model; in particular, whether 
or not the patient received any treatment. Patients with more than two weeks wait between 
diagnosis and treatment had better survival than those waiting less than two weeks. This, 
again, is probably a reflection of tumour stage at diagnosis with treatment being performed 
more urgently for the worse prognosis cancers and for patients admitted as an emergency.
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Table 7.9: Patients diagnosed with bladder and kidney cancer in Scotland in 1997:
multivariate influence of groups of factors on the relative risk of death 
among deprived compared to affluent patients (Cox proportional hazards 
regression analysis)
Model
Variables included in the model
BLADDER KIDNEY
Relative
risk
95% Cl 
Low High
P -va lu e Relative
risk
95% C l 
Low High
P -va lu e
Model 0: Null model
Depl: Affluent 1.00 1.00
Dep2 1.15 0.84 1.58 0.369 1.59 1.01 249 0.045
Dep3 1.23 0.89 1.68 0205 1.78 1.13 281 0.013
Dep4 1.27 0.93 1.72 0.128 1.77 1.13 277 0.013
Dep5: Deprived 1.67 1.25 2.24 <0.01 1.87 1.13 296 <0.01
Model 1: Patient characteristics
Depl: Affluent 1.00 1.00
Dep2 1.21 0.88 1.66 0236 1.63 1.04 257 0.034
Dep3 1.17 0.86 1.61 0.319 1.77 1.12 281 0.015
Dep4 1.34 0.98 1.81 0.063 1.72 1.09 270 0.019
Dep5: Deprived 1.81 1.35 243 <0.001 1.81 1.14 287 0.012
B la d d er K id n ey
Ages 30-49 Ages 00-49 1.00 1.00
Ages 50-59 Ages 50-64 0.87 0.35 217 0.768 1.70 0.93 3.09 0.082
Ages 60-69 Ages 65-74 1.76 0.77 4.04 0.179 213 1.19 3.82 0.011
Ages 70-79 Ages 75-79 2.56 1.13 5.80 0.024 267 1.39 5.12 <0.01
Ages 80+ Ages 80+ 4.60 2.03 10.45 <0.001 3.88 2.05 7.37 <0.001
No bed-days 1.00 1.00
1-4 bed-days 0.92 0.69 1.24 0.589 0.85 0.54 1.32 0.460
5-10 bed-days 1.10 0.80 1.51 0.553 1.33 0.88 200 0.179
11+ bed-days 2.48 1.90 3.24 <0.001 1.46 1.02 210 0.037
Model 2: Health care factors1-2
Depl: Affluent 1.00 1.00
Dep2 1.20 0.88 1.65 0.253 1.33 0.83 213 0.234
Dep3 1.32 0.96 1.83 0.091 1.61 1.01 257 0.043
Dep4 1.49 1.09 204 0.012 1.50 0.95 237 0.081
Dep5: Deprived 2.17 1.60 294 <0.001 1.51 0.92 247 0.105
Routine admission 1.00 -
Emergency admission 2.58 2.10 3.17 <0.001 _
Not seen in a specialist department 1.00 1.00
Seen in a specialist department 0.46 0.33 0.62 <0.001 0.53 0.39 0.72 <0.001
Treated at a regional RT centre 1.00 1.00
Treated at a high-workload hospital 0.71 0.55 0.92 <0.01 0.79 0.52 1.21 0.279
Treated at med-high workload hospital 0.71 0.53 0.94 0.016 0.62 0.42 0.92 0.016
Treated at med-low workload hospital 0.66 0.49 0.90 0.010 1.11 0.70 1.76 0.665
Treated at a low-workload hospital 0.78 0.53 1.15 0.204 0.69 0.48 1.00 0.053
Less than two weeks’ wait3 _ 1.00
More than two weeks wait3 _ 0.64 0.44 0.93 0.021
Unknown or no treatment received - 2.68 1.82 3.96 <0.001
1 Age is also included in this model but the results not displayed
2 C on su ltan t w ork load  w as also  sign ifican t bu t is ex c lud ed  because o n ly  those w ith no co n su ltan t  details h ad  
d iffe ren t su rv iva l than th e  rest.
3 T im e b etw een  d iagnosis and  defin itive treatm ent
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Table 7.9 continued.
Model BLADDER KIDNEY
Variables included in the model Relative 95% Cl P -va lu e Relative 95% C l P -va lu e
risk Low High risk Low Hio-h
Model 3: Presentation variables'
Depl: Affluent 1.00 1.00
Dep2 1.13 0.82 1.55 0.448 1.65 1.04 2.60 0.032
Dep3 1.16 0.85 1.60 0.350 1.77 1.11 2.80 0.016
Dep4 1.31 0.97 1.78 0.080 1.74 1.11 2.75 0.016
Dep5: Deprived 1.94 1.45 2.61 <0.001 1.69 1.06 2.70 0.028
B la d d er K id n ey
Transitional cell (TQ Renal cell 1.00 1.00
Papillary TC Gear cell 0.48 0.37 0.61 <0.001 0.75 0.48 1.17 0203
Other specified Other specified 1.57 1.15 2.16 <0.01 1.35 0.85 2.14 0200
Unknown Unknown 1.80 1.22 2.66 <0.01 1.59 1.03 2.46 0.036
B la d d er K id n ey
Grade 1 Grade 1-2 1.00 1.00
Grade 2 1.73 1.13 2.66 0.012 -
Grade 3-4 Grade 3-4 2.39 2.27 5.06 <0.001 4.92 2.69 8.99 <0.001
Unknown Unknown 2.65 1.71 4.11 <0.001 4.03 2.35 6.94 <0.001
Model 4: Treatment variables'
Depl: Affluent 1.00 1.00
Dep2 1.08 0.79 1.48 0.637 1.65 1.03 2.64 0.038
Dep3 1.01 0.74 1.39 0.941 1.65 1.03 2.66 0.038
Dep4 1.15 0.84 1.56 0.389 1.53 0.96 2.44 0.073
Dep5: Deprived 1.61 1.20 2.17 <0.01 1.62 0.99 2.64 0.054
Curative treatment intent 1.00 1.00 1.00
Palliative treatment intent 5.71 4.48 7.29 <0.001 5.39 3.29 8.82 <0.001
Unknown treatment intent 2.43 1.81 3.28 <0.001 4.47 2.60 7.69 <0.001
Surgery alone 1.00 1.00 1.00
Radiotherapy alone 2.38 1.69 3.35 <0.001 5.50 3.32 9.13 <0.001
Surgery and radiotherapy 1.68 1.29 2.18 <0.001 2.18 1.16 4.11 0.016
Surgery and chemotherapy 0.87 0.56 1.38 0.561 2.30 0.31 17.34 0.419
Unknown treatment combination 2.02 1.35 3.03 <0.01 3.44 2.03 5.85 <0.001
No treatment 3.29 2.47 4.38 <0.001 4.06 2.67 6.19 <0.001
1 Age is also included in this model but the results not displayed
In model 3, grade and histological type were both important prognostic indicators for 
bladder cancer, but because there were no differences in the proportion o f patients 
presenting with different grade and histological type of tumour, this did not explain the 
gradient in the deprivation-specific relative risks of death. For kidney cancer, grade and 
histological type were also important prognostic indicators. Deprived patients were more 
likely to present with renal cell tumours which appear to have a worse prognosis than clear 
cell tumours, and to present with tumours of unspecified cell type which had the worst 
prognosis. These differences account for the slight reduction in the relative risk of death 
between affluent and deprived (from 1.87 to 1.69; p=0.028).
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Table 7.10: Patients diagnosed with bladder and kidney cancer in Scodand in 1997:
multivariate influence of all the significant factors on the relative risk of 
death among deprived compared to affluent patients (Cox proportional 
hazards regression analysis)
Model BLADDER KIDNEY
Variables included in the model Relative 95% C l P -va lu e Relative 95% Cl P -va lu e
risk Low High risk Low High
Model 5: Final model
Depl: Affluent 1.00 1.00
Dep2 1.12 0.81 1.55 0.484 1.78 1.10 2.89 0.020
Dep3 1.07 0.77 1.48 0.703 1.58 0.97 2.57 0.066
Dep4 1.27 0.93 1.74 0.140 1.56 0.97 2.50 0.064
Dep5: Deprived 1.82 1.34 2.47 <0.001 1.58 0.95 261 0.078
B la d d er K id n ey
Ages 30-49 Ages 00-49 1.00 1.00
Ages 50-59 Ages 50-64 1.21 0.48 3.06 0.681 1.19 0.64 2.24 0.582
Ages 60-69 Ages 65-74 1.91 0.83 4.41 0.130 1.90 1.01 3.57 0.045
Ages 70-79 Ages 75-79 2.43 1.07 5.56 0.035 1.55 0.77 3.13 0218
Age* 80+ Ages 80+ 3.17 1.38 7.27 <0.01 1.47 0.72 298 0289
No bed-days 1.00 1.00
1-4 bed-days 1.08 0.79 1.46 0.629 0.86 0.55 1.37 0.532
5-10 bed-days 1.12 0.81 1.56 0.490 1.61 1.04 250 0.032
11+ bed-days 1.67 1.25 2.22 <0.001 1.44 0.99 211 0.056
Routine admission 1.00 -
Emergency admission 1.43 1.13 1.82 <0.01 -
Unknown admission type 0.50 0.15 1.67 0263 -
Not seen in a specialist department 1.00 1.00
Seen in a specialist department 0.53 0.39 0.72 <0.001 0.74 0.54 1.02 0.063
Treated in regional RT centre - 1.00
Treated in high-workload hospital - 2.10 1.28 3.43 <0.01
Treated in med-high workload hospital - 1.04 0.66 1.65 0.858
Treated in med-low workload hospital - 2.63 1.57 4.38 <0.001
Treated in low-workload hospital - 1.36 0.89 208 0.158
Not treated in hospital - 2.48 0.55 11.22 0238
B la d d er K id n ey
Transitional cell (TQ Renal cell 1.00 -
Papillary TC Clear cell 0.62 0.48 0.81 <0.001 -
Other specified Other specified 1.34 0.97 1.85 0.073 -
Unknown Unknown 0.89 0.59 1.36 0.600 -
B la d d er K id n ey
Grade 1 Grade 1-2 0.46 0.30 0.71 <0.001 1.00
Grade 2 0.73 0.55 0.97 0.027 .
Grade 3-4 Grade 3-4 1.00 2.04 1.06 3.95 0.034
Unknown Unknown 0.75 0.56 1.00 0.053 0.83 0.45 1.55 0.562
Curative treatment intent 1.00 1.00
Palliative treatment intent 4.64 3.60 5.97 <0.001 5.27 3.17 8.75 <0.001
Unknown treatment intent 2.13 1.57 2.89 <0.001 4.99 2.77 8.98 <0.001
Surgery alone 1.00 1.00
Radiotherapy alone 2.44 1.76 3.40 <0.001 10.41 5.74 18.90 <0.001
Surgery and radiotherapy 1.64 1.15 2.34 <0.01 2.85 1.48 5.48 <0.01
Surgery and chemotherapy 1.27 0.95 1.68 0.102 4.40 0.57 34.16 0.156
Unknown treatment combination 0.97 0.61 1.53 0.892 3.93 2.24 6.89 <0.001
No treatment received 1.42 0.93 2.15 0.102 5.04 3.10 8.20 <0.001
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The treatment-related factors are considered in model 4, and treatment intent (curative or 
palliative) and the specific treatment combination given were both important prognostic 
factors. For bladder cancer, patients receiving surgery alone or in combination with 
chemotherapy had a better prognosis than patients receiving other treatment combinations 
or no treatment. However, information on treatment did not explain the deprivation- 
specific differences in relative risk o f death. For kidney cancer, patients receiving surgery 
alone had the best prognosis, and after accounting for treatment received and the treatment 
intent, around a third of the difference in relative risk of death between affluent and 
deprived patients was explained (RR reduced from 1.87 to 1.62; p=0.054). The treatment 
given probably reflects the stage of the tumour, and so these differences may be a surrogate 
for stage.
Finally, all the significant factors from the grouped models were combined in a multivariate 
model (Table 7.10). After adjusting for all the factors that had a significant influence on 
survival the relative risk of death in deprived compared to affluent patients was increased for 
bladder cancer patients (from 1.67 to 1.82) and reduced by around a third for kidney cancer 
patients (from 1.87 to 1.58; p=0.078). For kidney cancer, the time from diagnosis to 
treatment factor was no longer significant in a model containing details of the specific 
treatment given.
Discussion
Deprived patients with bladder and kidney cancer were less likely than affluent patients to be 
treated in a regional RT centre or other high-workload hospital, despite guidelines 
recommending that all patients be referred to large hospitals with the necessary facilities. 
Patients receiving surgery alone had a better prognosis than those receiving other or 
combination treatments, probably reflecting differences in stage at diagnosis, and deprived 
patients were significantly less likely to receive surgery alone indicating a worse stage at 
diagnosis. They were also less likely to receive any treatment and more likely to receive 
treatment with palliative intent, again pointing to worse prognosis tumours. However, they 
were also less likely to attend a specialist department within three months of diagnosis, 
which may reflect lack of access to multidisciplinary teams to ensure the appropriateness of 
treatment. Deprived patients with bladder cancer were more likely to have comorbidity at 
diagnosis.
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Deprivation-specific differences in outcome for bladder cancer patients do not appear to be 
explained by the factors relating to the patient, tumour, health care system and treatment 
studied in this chapter. It is surprising that of all the factors investigated, of which many 
proved to be of prognostic significance, none explained any of the differences between the 
deprivation groups. Indeed, the relative risk o f death between affluent and deprived patients 
was increased with every single factor investigated with the exception of treatment which 
had virtually no effect on the relative risk (Table 7.8).
A study of bladder cancer patients in South Thames also looked at the relationship between 
hospital, treatment and tumour factors, and survival. They found that case severity was the 
most important influence on survival, and it influenced length of delay before treatment, 
grade and specialty of the surgeon, and main treatment allocation. After adjusting for case 
severity, variations in these processes of care were not strongly associated with variations in 
survival227. The differences in the Scottish data may also be explained by case severity, 
which could not be measured, but none of the factors that could be measured seemed to act 
as a surrogate to stage, in contrast to the South Thames study.
Survival would appear better for affluent than deprived patients if they were more likely to 
have investigations leading to more superficial tumours being recorded as invasive. 
However, it is unlikely that there is a bias in coding of bladder cancer by deprivation group, 
because incidence of bladder cancer is actually higher in the deprived group for patients 
diagnosed in 1997 (Figure 7.6). Deprived patients may be expected to have higher incidence 
of bladder cancer because smoking is a risk factor, so although this recording bias does not 
seem very plausible, it cannot be ruled out.
In contrast to bladder cancer, around 40% of the deprivation-specific gradient for kidney 
cancer patients was explained by differences in treatment. Survival was similar across the 
deprivation groups for patients who received no surgery, which will comprise largely of 
patients with advanced disease. For surgically-treated patients, the proportion treated with 
curative intent was similar across the deprivation groups but survival was lower for deprived 
compared to affluent patients. This could be an indication of worse stage o f  disease at 
presentation, or it could be a real effect. It is most likely a combination of both. Deprived 
patients were less likely to be treated in a high-workload hospital or attend a  specialist
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department, so they may not have been receiving the most effective and timely treatment. 
Without information on stage of disease, these questions cannot be answered.
In conclusion, there are very few studies in the literature looking at deprivation-specific 
differences in survival from bladder and kidney cancer. In this chapter, none of the factors 
investigated explained the differences in survival for bladder cancer. Routine data are clearly 
not sufficient to investigate the differences, and further investigation with data including 
stage is needed. However, it may not be possible to collect stage data of adequate quality 
routinely for bladder cancers22*; a dedicated prospective audit may be necessary.
The kidney cancer analyses were based on a small sample of only 486 patients, so any 
interpretation of the results must be made with caution. Some of the differences between 
affluent and deprived patients were explained by differences in the treatment received. This 
may reflect a worse stage at diagnosis, but the data suggest that some of the differences are 
due to inequity in the access to health care services. It seems clear that if all patients with 
kidney cancer had equal access to multi-disciplinary teams in hospitals with all the necessary 
facilities for optimal treatment, the deprivation-specific gradient in risk of death from kidney 
cancer would be reduced.
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C h a p t e r  8
MELANOMA OF THE SKIN
Background
Melanomas occur at a number of sites, however only cutaneous malignant melanomas of the 
skin (ICD10 code C43) are considered in this chapter and are referred to simply as 
melanoma. Melanoma is the 12* most common cancer among men (1.7% of all cancers) 
and the 10* most common cancer among women (2.7%) in Scodand. A total of 673 new 
cases were diagnosed in 1997. Incidence has doubled over the last 20 years, and is 
continuing to increase rapidly in both sexes (Figure 8.1).
Figure 8.1: Melanoma of the skin in Scodand: trends in incidence (1979-97) and
mortality (1979-99), all ages (European age-standardised rates)
Similar increases in melanoma incidence reported elsewhere are not thought to be due to 
changes in diagnosdc criteria1” , and the Scottish Melanoma Group have stated there has
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been no change in pathological diagnostic criteria in Scotland over the time period1". 
Completeness of ascertainment of cases is verified against a specialist Scottish melanoma 
register which has been running since 1979 so changes in reporting are also an unlikely 
explanation for the increase.
Melanoma is one of the few cancers that are common in both young men and women. 
Incidence is higher in women than men at all ages except the very elderly (aged 80 and over; 
Figure 8.2). Incidence has been increasing in all age groups, and the increase has been 
particularly marked for males aged 80 and over. An overview of trends in incidence, 
mortality and survival in Scodand from 1979-94111 found that incidence of melanoma in 
younger women (aged under 65) had stabilised, but this was not observed in the current data 
for Scodand.
Figure 8.2: Age-specific incidence of melanoma in Scodand during 1997, by sex
Males
Age at diagnosis
Over the last 40 years, the incidence of melanoma has risen steadily worldwide, with the 
highest rates in New Zealand and Australia and the lowest in parts of Asia. Incidence in 
Scodand is relatively low (Figure 8.3), and as two-thirds of all melanomas can be attributed 
to solar radiation2“ , this is probably due to the local climate.
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F ig ure  8 .3 : International comparison of melanoma incidence, around 1988-92 (world 
standardised rates)
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Source: Cancer Incidence in Five Continents, Vol. VII“
Although mortality from melanoma appears relatively unchanged since around 1980 (Figure 
8.1), these age-standardised rates mask an increasing trend in the older age groups. A 
reduction in mortality in younger women has been noted in Europe231, England and Wales232 
and Scodand1", and although a downward trend is not evident from recent Scottish data, 
the mortality rates appear to be fairly constant in the younger women.
Projections of recent trends in incidence and mortality in Scotland132 suggest a further large 
increase in melanoma incidence in the decade up to 2010-14, with up to 75% more cases a 
year expected. Mortality rates are expected to remain unchanged.
For patients diagnosed with melanoma in Scotland in 1971-75, survival at five-years after 
diagnosis was significandy higher in females (67%) than males (49%). Since then survival 
has improved steadily in both sexes and although it is soil higher in females, the gap between 
the sexes has reduced substantially with five-year survival for patients diagnosed in 1991-95 
of 87% for females and 80% for males (Figure 8.4). Similar trends have been observed in 
F.ngland and Wales4. In Scotland the survival rates appear to be levelling off in the most 
recent data of patients diagnosed during 1996-97. The prevailing differences between the
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sexes are probably due to biological behaviour or diagnostic delay231, and stage at 
diagnosis234. In a study by the Scottish Melanoma Group, improvements in survival during 
the mid-1980s were attributed to patients presenting earlier with thinner tumours, but a 
continuing improvement in the late-1980s could not be accounted for by a fall in average 
tumour thickness"1.
Figure 8.4: Patients diagnosed with melanoma in Scotland during 1971-1997: trends in
relative survival by sex
Unlike most cancers, survival from melanoma in Scotland is among the highest when 
compared to other countries in Europe and to the USA (Figure 8.5). Several factors have 
been linked to prognosis of patients with melanoma, the most important being thickness of 
the lesion, number of involved nodes and metastatic status. Site of the lesion on the body, 
sex and age have also been shown to have prognostic value23*. That survival in Scotland 
compares favourably to survival elsewhere may be, in part, due to a successful public 
education campaign in the mid-1980s in Scotland aimed at encouraging earlier diagnosis234. 
As mortality has not declined substantially, an alternative explanation could be lead time or 
length bias237.
231
F ig ure  8 .5 : Melanoma of the skin: international comparison of five-year relative survival 
(with 95% confidence intervals), selected countries, patients diagnosed 
around 1985-89, all ages1
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Relative survival (%)
Sources: Berrino i t  a i6, Gatta it ai.'S9, Coleman it al.'
1 Women diagnosed 1986-90, aged 15-99 in England & Wales; women aged 15-99 in Scotland
In this chapter the survival of 673 patients diagnosed with melanoma in Scodand in 1997 is 
investigated to identify reasons for differences in survival by deprivation category. For 
definitions of the variables included in the analyses, please refer to Chapter 2.
Results and commentary
For patients diagnosed in Scodand in 1997, incidence was twice as high in people from the 
most affluent areas (16.4 per 100 000) as in those from the most deprived areas (7.2). The 
mortality rates (for patients dying in 1999) show very little variation across deprivation 
groups. There was a very large difference in two-year survival ranging from 91% for affluent 
compared to 72% for deprived patients. This translates into an almost three-fold risk of 
death within two years of diagnosis for deprived compared to affluent patients. This large 
survival differential explains why the deprivation-specific trend in incidence is not matched 
by a similar trend in mortality (Figure 8.6).
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Higher incidence and survival for affluent compared to deprived patients has previously 
been shown in a number of studies“54'23®'239. The higher incidence in affluent groups may be 
related to sun exposure on holidays in hot climates240, and if this is the case, the incidence 
differential will be reduced in the future mirroring the increase in economical holidays 
abroad. If incidence in deprived groups does increase in line with affluent groups, the 
difference in survival between affluent and deprived will have even larger public health 
implications. Affluent patients presenting more frequently with thinner lesions may explain 
the higher survival in the affluent group. However, another study by the Scottish Melanoma 
Group found that differences in survival by socio-economic group were not fully accounted 
for by tumour thickness, ulceration, age or body site of tumour244.
Figure 8.8: Patients diagnosed with melanoma in Scotland in 1997: incidence* and two-
year relative survival2, and mortality* in 1999, by deprivation category
>
E
1 Age-standardised rates per 100,000 person-years at risk (Buropean standard population)
2 Using deprivation-specific life tables: adjusted for sex
O f the 673 patients diagnosed in 1997, 183 (27%) were from the affluent group and only 74 
(11%) from the deprived group (Table 8.1). Melanoma was more common in females (60%) 
than males, and the distribution of age o f diagnosis was lower than for most cancers, with a 
median age of 56 years and an inter-quartile range from 41 to 73 years.
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T able 8 .1 : Patients diagnosed w ith  m elanom a in Scotland  during 1997 : dem ographic data by deprivation  category (num ber and percentage o f
caaes)
Deprivation
category
No. or 
patients
No. of 
females
Median age 
(inter-quarule 
range)
Cases for which: No. of urban 
residents'First
primary
Simultaneous
primary
Previous 
primary at 
same site
Previous
primary
elsewhere
Affluent 183 (270.) 109 (600») 54 (42-7)) 177 (970.) i (10.) 0 tw y 5 (30.) 88 (480.)
2 160 (24%) 99 (620.) 54 (41-73) 149 (930.) 0 (00.) 1 (10.) 10 (60.) 44 (280.)
3 119 (ISO.) 73 (610.) 58 (43-71) 102 (86%) 0 m 0 <00.) 17 (140.) 42 (330.)
4 137 (200.) 79 (580.) 56 (36-70) 129 (940.) 1 (10.) 0 (00.) 7 (50.) 66 (480.)
Deprived 74 (11%) 46 (620.) 59 (44-76) 69 (930.) 0 w 0 (00.) 5 (70.) 64 (860.)
Total 673 (100%) 406 (60%) 56 626 _J93%L 2 1 J0 % 1 44 w 304 (* * >
1 Chi-square lest for association: p<0.001
There was no significant difference in sex distribution between the deprivation groups, but 
deprived patients were more likely to be older at presentation (30% aged 75 or over 
compared to 18% of affluent patients). There was no trend in age distribution across the 
deprivation groups (p=0.428).
Melanoma was the first primary malignancy for most patients (93%). The proportion of 
patients with a previous primary varied between the deprivation groups but without a clear 
trend. Deprived areas in Scotland are largely urban; therefore, deprived patients with 
melanoma were more likely to come from urban areas (86% compared to 48% of affluent 
patients).
Organisation of services
There is increasing public awareness of the potential dangers of changes in the size, shape or 
colour of moles on the skin. Information should be available for GPs on sending patients 
with suspected melanoma to rapid referral clinics101. Such clinics aim to see patients within 
two weeks of referral, and should have facilities for immediate biopsy if the likelihood of 
melanoma is considered higji. Prompt pathological confirmation of the diagnosis is needed 
to assess the tumour thickness. Once the diagnosis is confirmed further surgery may be 
required and the patient should have access to this within 2-4 weeks of the first surgical 
episode152.
For patients diagnosed with melanoma in Scotland in 1997, 40% attended a regional RT 
centre at some point during their cancer spell (Table 8.2). Surgery was performed at a high- 
workload hospital (treating at least 20 melanoma patients per year) for 56% patients; 22% 
were treated at a regional RT centre and 34% at other high-workload hospitals. A further 
26% of patients attended only medium-low or low-workload hospitals. The proportion of 
patients treated at a high-workload hospital varied by deprivation group, favouring affluent 
patients (67% affluent compared to 54% deprived; p=0.011).
In Scotland, many melanoma patients are treated as day cases without an inpatient visit, so 
using the hospital discharge information (SMR01) to look at consultant workload and 
specialty of the department of surgery gives a very incomplete picture of care. Overall, 54% 
of patients did not have an SMR01 record at the time of their surgery and most of these 
patients were probably treated as an outpatient.
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Table 8.2 : Patients diagnosed w ith  m elanom a in Scotland  during 1997 : access to  health care by deprivation  category (num ber and percentage o f
cates)
Deprivation
category
No. of Attended a 
regional RT 
centre1
Attended a 
specialist 
department2 *
Main treatment 
at a regional RT 
centre2
Treated in a 
high-workload 
hospital4 567
Seen by a high- 
workload 
consultant2
Emergency
admission
More than two 
weeks’ delay 
between 
diagnosis and 
treatment4
Affluent 183 97 (33%) 136 (74%) 57 (31%) 122 (67V.) 64 (45V.) 8 (4%) 51 (28V.)
2 160 52 (33V.) 121 (76%) 28 (W ,) 85 (53V.) 42 (33V.) 7 (4%) 59 (37V.)
3 119 45 < m 90 (76%) 27 m ) 56 (47V.) 27 (29V.) 4 (TV.) 36 (31V.)
4 137 52 (38V.) 102 (74%) 21 (13V.) 76 (33V.) 44 (40V.) 5 (4%) 45 (33V.)
Deprived 74 25 (34%) 43 15 (20V.) 40 (54V.) 22 (42V.) 11 (15V.) 30 (42%)
Total 673 271 (40%) 492 (73%) 148 (22%) 379 (56%) 199 (38%) 35 (5%) 221 (33%)
f t * — ' fi<0.001 »=0242 K0.01 »=0.011 »=0293 »=0.010 »=0284
1 Within 6 months of diagnosis
2 Within 3 months of diagnosis
J Number of patients whose surgery was performed at a regional centre with RT provision
4 Number of patients whose surgery was performed in a hospital seeing at least 23 melanoma patients per year (highest workload quartile)
5 Consultant seeing at least 20 melanoma patients per year (highest workload quartile); percentage of those with SMR01 consultant details
6 Days between diagnosis and definitive treatment; percentage of those with a definitive treatment date
7 Chi-square test for association
Deprived patients were slightly more likely to be treated as an outpatient (57% compared to 
53% of affluent patients). Overall, o f those treated as an inpatient (46%), 2% were treated in 
a dermatology department, 29% in a plastic surgery department and 15% in general surgery. 
Deprived patients were significantly more likely to be treated in a plastic surgery department 
(75% compared to 65% of affluent patients; p=0.040).
The distribution of affluent and deprived patients varies substantially by health board as do 
the melanoma services available. Differences by deprivation group in the proportion of 
patients treated as an outpatient and the proportion treated in different surgical specialities 
are partly reflected by the services available in different areas. For example, in Lothian, 69% 
o f patients were treated as outpatients compared to 56% of Greater Glasgow patients and 
only 29% of Grampian patients. In Tayside, a high proportion of patients (51%) were 
treated by plastic surgeons compared to 16% of Lothian patients and none of the Highlands 
and Islands patients.
O f patients treated as an inpatient, 38% were managed by a high-workload consultant 
(seeing at least 20 melanoma patients per year), and this did not vary between the 
deprivation groups.
Delay
For a third of patients, at least two weeks elapsed between diagnosis and surgery (Table 8.2), 
and the wait was greater than 1 month for 21% of patients. Deprived patients were more 
likely to have a delay of at least two weeks (42% compared to 28% of affluent patients), 
although again, there was no clear trend across the deprivation groups. Patients with lesions 
on the face, head and neck were most likely to have a delay (43% compared to 33% overall); 
specifically, patients with lentigo maligna tumours had the longest wait (53% waited more 
than two weeks for surgery). Patients with superficial spreading tumours had the shortest 
wait (only 29% waited more than two weeks for surgery).
Kmergency admissions were relatively rare for melanoma (5%; Table 8.2) although still 
higher than might be expected. Deprived patie.its were significantly more likely to present 
as an emergency than patients in the other deprivation groups (15%; p=0.010).
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Mode o f presentation
The signs of early melanoma include change in size, shape or colour of an existing 
melanocytic naevus, or development o f a new brown or black pigmented lesion in an adult. 
In the great majority of cases of suspected melanoma the first appropriate investigation is an 
excision biopsy and histopathological examination to determine the most important features 
of the tumour including tumour thickness, level o f invasion and clearance margins. The 
majority of patients present with early stage melanoma and do not have clinical 
lymphadenopathy or evidence of distant spread. For patients with thin lesions (less than 
1mm thick), no additional investigations are currently considered necessary other than a 
careful examination of the skin for a second primary tumour and for atypical or dysplastic 
naevi. Melanoma patients are generally followed up by hospital specialists at three-monthly 
intervals for a minimum of three years, and five years for patients with thicker tumours241.
Unfortunately, no information on tumour thickness, level of invasion or clearance margins is 
recorded on SOCRATES. The Scottish Melanoma Group collects this information but it 
was not available for the analyses in this chapter. The only factors relating to the tumour 
that can be investigated are the body site and histological type.
Overall, the most common body site for melanoma was the lower limb (Table 8.3); however 
as noted previously239, tumours on the trunk are more common for males. For patients 
diagnosed with melanoma in Scotland in 1997, 33% of the tumours in males were on the 
trunk compared to 14% for females, and 46% of the tumours in females were on the lower 
limb compared to 21% for males. A higher proportion of males than females had tumours 
on the head, neck or face (28% compared to 19%). Tumours on the trunk were less 
common for deprived than affluent patients, and tumours on the lower limb and head, face 
and neck were more common in deprived than affluent patients. In particular, deprived 
women had a higher proportion of head, neck and face tumours than affluent women (20% 
compared to 12%) and a lower proportion of lesions on the upper limb (13% compared to 
22%); deprived men had a lower proportion o f trunk lesions than affluent men (21% 
compared to 34%). Site of lesion on the body was also related to age, with lesions on the 
head, neck and face more common in elderly patients (56% of patients aged 80 and over 
compared to 12% of patients aged under 50).
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Table 8.3: Patients diagnosed w ith  m elanom a in Scotland  during 1997 : body site and histological type by deprivation  category (num ber and
percentage o f  cases)
Deprivation No. of Site1 Type1
category patien ts Head, face 
and neck
Trunk Lower limb Upper limb Unknown Superficial
spreading
Lentigo
maligna
Nodular Acral Other and 
unspecified
Affluent 183 36 (* »•) 43 (24%) 67 (37V.) 34 (W .) 3 (2%) 97 (73%) 13 00%) 13 (10»/.) 9 (7»/.) 51 (28»/.)
2 160 31 37 (23%) 57 (Ì6%) 33 (21%) 2 (1%) 90 (82"/») 12 (11%) 4 (4%) 4 0%) 50 (31%)
3 119 32 (2V.) 27 (24%) 37 02%) 18 (16%) 5 (4%) 53 (77"/») 5 0*7») 9 (13%) 2 (3%) 50 (42%)
4 137 33 (2 * .) 27 ÇKT/.) 51 <39%) 21 (16%) 5 (4%) 67 (73%) 8 (9»/.) 11 (12»/.) 6 (7»/.) 45 (33%)
Deprived 74 18 <26%) 12 07%) 29 (42»/») 10 (14%) 5 (7%) 38 (81%) 2 (4%) 5 (11%) 2 (4%) 27 (36»/»)
Total 673 150 am 146 m 241 07%) 116 (18%) 20 (3%) 345 m 40 (9%) 42 (9%f 23 (5%) 223 (33%)
p-0.80? p-0.121’ -0.3481 p-0.127‘
1 Percentage of patients with a known category; except 'unknown', presented as a percentage of the total
; Significance of association between deprivation category and percentage of patients in each category excluding those in the unknown category 
} Significance of proportion unknown across the deprivation categories
Diagnosis was microscopically verified for all patients. However, the histological type of the 
tumour was unspecified for 33% of patients (Table 8.3). For patients with known 
histological type, 77% were superficial spreading tumours, 9% lentigo maligna, 9% nodular 
and 5% acral. Women were significantly more likely to have superficial spreading tumours 
(82% compared to 68% of males) and less likely to have nodular tumours (6% compared to 
15%). The same pattern was seen for young and old patients. There were no differences in 
histological type between the deprivation groups.
Body site and histological type are related. Acral tumours occur on the soles and palms, and 
were therefore contained within the upper and lower limb sites (100%). These are tumours 
with a high risk of recurrence. Lentigo maligna tumours occurred predominantly on the 
face (88%).
Patients with lesions on the head, face or neck were the most likely to attend the plastic 
surgery department, and to be treated as an inpatient (Table 8.4). Over half of patients with 
lentigo maligna or acral tumours were referred to the plastic surgery unit. Patients with 
superficial tumours were more likely to be treated as outpatients, although this varied 
substantially by health board of residence.
Table 8.4: Patients diagnosed with melanoma in Scotland during 1997: body site and
histological type by surgical department (number and percentage o f cases)
1 Chi-square test for association: p<0.001 
1 Chi-square test for association: p<0.001
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Acral tumours, which are difficult to excise completely, were largely (82%) treated in the 
regional RT centres and other high-workload hospitals (Table 8.5). Tumours on the head, 
face and neck were also more often treated in regional RT centres or other high-workload 
hospitals than tumours on other sites of the body.
Table 8.5: Patients diagnosed with melanoma in Scodand during 1997: body site and
histological type by hospital workload (number and percentage of cases)
Site and type Hospital of surgery
Regional 
RT centre
High-
workload
hospital
Medium-
high
workload
hospital
Medium-low
workload
hospital
Low-
workload
hospital
No
hospital
details
Site1
Head/face/neck 27 (18%) 72 (48%) 12 (S'/.) 10 (**) 24 (16%) 5 (3%)
Trunk 30 (21%) 42 (29V.) 27 (18V.) 16 (11%) 20 (14%) 11 (8V.)
Lower limb 25 (22>/.) 34 (29%) 17 (15V.) 12 (10%) 20 (17V.) 8 (TV.)
Upper limb 59 (24%) 81 (34V.) 17 (7"/.) 34 (14%) 31 (13V.) 19 (8%)
Unknown 7 (35%) 2 (10V.) 1 (5V.) 5 (25V.) 4 (20V.) 1 (5%)
Type2
Superficial 61 (18%) 122 (35V.) 48 (14V.) 46 (13%) 43 (12V.) 25 (7-/.)
Lentigo maligna 5 (1)% ) 21 (53%) 4 (10V.) 3 (8V.) 7 (18V.) 0 (0V.)
Nodular 7 (17V.) 10 (24%) 5 (12V.) 8 (19V.) 9 (21%) 3 (7V.)
Acral 9 (39V.) 10 (43%) 0 <w.) 1 (4%) 1 (4%) 2 (9V.)
Other and unknown 66 (30V.) 68 (30V.) 17 <?/.) 19 (9V.) 39 (17V.) 14 (6%)
Total 148 (22% ) 231 (34%) 74 77 0 ’ * ) 99 <**>. 44 j m .
1 Chi-square test for association: p<0.01
2 Chi-square test for association: p<0.001
Comorbidity
Overall, 17% o f patients had spent more than 10 days in hospital during the two years prior 
to diagnosis. Comorbidity was lower when measured by the disease-based measures 
(Charlson or Scottish indices). For all three comorbidity measures, deprived patients had 
much higher comorbidity at the time of cancer diagnosis. With the bed-days score, 
comorbidity in deprived patients was double that in affluent patients (27% compared to 
14%; Table 8.6). Comorbidity was also strongly related to age, for example, 17% of patients 
aged 80 and over had comorbidity as measured by the Charlson score, compared to none 
aged less than 50 years (data not shown).
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T a b le  8 .6 : P a tie n ts  d ia g n o s e d  w ith  m e la n o m a  sk in  c a n c e r  in  S c o d a n d  d u r in g  1 9 9 7 :
c o m o rb id ity  b y  d e p r iv a t io n  c a te g o ry  (n u m b e r  a n d  p e rc e n ta g e  o f  ca ses)
Deprivation
category
No. of 
patients
Comorbidity
Bed-days' Scotland2 Chari son3
Affluent 183 26 (14%) 9 (5%) 2 (1%)
2 160 19 (12%) 11 (7%) 6 (4%)
3 119 24 (20%) 7 (6%) 11 (9%)
4 137 25 (18%) 11 (8%) 6 (4%)
Deprived 74 20 (27%) 10 (14%) 8 (11%)
Total 673 114 (17%) 48 (7%) 33 (3%)
SiinificM ct p<0.01 p=0.173 p<0.01
1 More than 10 inpatient bed-days in the two years prior to cancer diagnosis
2 Any one of certain comorbid conditions recorded in the two years prior to one month after diagnosis (see 
Chapter 1)
3 Any one of certain comorbid conditions recorded in the 6ve years prior to diagnosis (see Chapter 1)
4 Chi-square test for association
Treatment
Surgical excision of thin primary melanomas is currendy the only curative therapy for 
melanoma. The exact margin of excision of normal skin around the tumour varies with 
tumour thickness, and the maximum margin currendy considered necessary even for thick 
melanomas is 3cm of normal skin. The great majority of patients with early stage melanoma 
can be treated with local anaesthesia, but a small proportion require skin grafting which may 
involve an inpatient stay and general anaesthesia. Patients with stage 3 disease, where 
melanoma has spread to the local draining lymph nodes, require full surgical lymph node 
dissection, and patients with advanced disease may obtain palliative benefit from surgical 
debulking and reduction of the tumour load. Adjuvant radiotherapy and chemotherapy are 
not considered for early stage tumours. Patients with local-regional recurrence may be put 
forward for systemic adjuvant clinical trials, and some patients with metastatic tumour may 
also receive chemotherapy. No clinical trials have confirmed significant survival benefits 
from adjuvant chemotherapy. Radiotherapy may be offered to patients with advanced 
disease to relieve pain from bone metastases.
For patients diagnosed with melanoma in Scotland in 1997, 97% had their tumour excised 
surgically, and the surgical intent was recorded as curative for 92% of patients. Three 
percent received palliative radiotherapy and 1% chemotherapy. These proportions did not 
vary by deprivation group (Table 8.7).
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T a b le  8 .7 : P a tien ts d ia g n o sed  w ith  m e la n o m a  skin c a n c e r  in  S c o d a n d  d u rin g  1 9 9 7 :
tre a tm e n t re c e iv e d  b y  d e p riv a tio n  c a te g o ry  ( n u m b e r  and  p e rc e n ta g e  o f  cases)
Deprivation
category
No. of 
patients
Surgery Radiotherapy Chemotherapy
Affluent 183 180 (98%) 5 (3%) 6 (3%)
2 160 159 (99%) 2 (1%) 2 (1%)
3 119 114 (96%) 5 (4%) 1 (1%)
4 137 133 (97%) 5 (4%) 1 (1%)
Deprived 74 72 (97%) 2 (3%) 0 (0%)
Total 673 658 (98%) 19 (3%) 10 (1%)
Sijpiificjfict' t>=0.424 p=0.642 p=0.197
Chi-square test for association
Two-year survival
Univariate analyses
Factors that had an influence on the differences in two-year survival between deprivation 
groups were investigated in Cox proportional hazards regression models. In the initial 
model containing deprivation only, the relative risk of death within two years of diagnosis 
was substantially raised for deprived compared to affluent patients with melanoma (RR=2.89 
(95% Cl: 1.36-6.15); p<0.01). This is a much larger excess risk than seen for the other 
cancers studied in this thesis, but based on a smaller sample o f patients.
Patient characteristics
Survival was strongly related to age, with two-year survival decreasing with increasing age 
(97% for patients aged under 50, 91% for ages 50-69, 82% for ages 70-79, and 61% for 
those aged 80 or over). The Scottish Melanoma Group study of patients diagnosed during 
1979-94 found that younger patients had thinner tumours but this only partly explained their 
better survival1" . For patients diagnosed in 1997, including age in the model significantly 
(p<0.001) improved the model fit. Age differences did not explain the deprivation-specific 
differences in survival: the relative risk of death in deprived compared to affluent patients 
was reduced from 2.89 to 2.54. The model containing deprivation and age was used as the 
null model, and each factor was added and then removed from the null model one at a time 
to test its significance as a prognostic factor for melanoma (Table 8.8).
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Table 8.8: Patients diagnosed with melanoma in Scotland during 1997: univariate
influence of individual factors on the relative risk of death within two years 
of diagnosis among deprived compared to affluent patients (Cox 
proportional hazards regression analysis)
Variables included in the model1 Relative 95% C l P-value* P -va lu e o f
risk2 Low High a d d edterm 4
Initial model: Deprivation category 
Patient characteristics:
2.89 1.36 6.15 <0.01
Age (null model? 2.54 1.18 5.43 0.017 <0.001
Sex 2.64 1.23 5.65 0.012 <0.001
Health board of residence 2.06 0.89 4.77 0.09 0.63
Urban indicator 2.40 1.10 5.24 0.028 0.54
Previous history of primary cancer 2.45 1.14 5.27 0.021 0 J7
Bed-days comorbidity index 1.87 0.86 4.06 0.114 <0.001
Charison comorbidity index Z22 1.03 4.79 0.042 <0.01
Scottish comorbidity index 2.40 1.12 5.17 0.025 0.14
Health care factors:
Attended a high-workload hospital? 2.93 1.36 6.31 <0.01 0.06
Workload of hospital of surgery 2.62 1.21 5.68 0.015 0.48
Specialty of department of surgery4 2.61 1.21 5.62 0.014 0.68
Emergency admission7 2.26 1.05 4.87 0.037 0.07
Time from diagnosis to surgery Z59 1.20 5.57 0.015 <0.001
Consultant workload6 Z78 1.28 6.01 0.010 0.012
Tumour characteristics':
Histological type Z64 1.23 5.67 0.013 0.025
Site of lesion on the body Z10 0.96 4.57 0.061 <0.001
Treatment factors:
Treatment intent (curative or palliative) Z85 1.32 6.15 <0.01 <0.001
Surgery (yes or no) Z65 1.23 5.71 0.013 <0.001
Radiotherapy (yes or no) Z43 1.13 5.24 0.023 <0.001
Chemotherapy (yes or no) 3.33 1.52 7.32 <0.01 <0.001
1 Each categorical variable is added individually to the null model containing deprivation category and age
2 Relative risk of death in the deprived compared to affluent group
5 Significance of the difference in the relative risk between affluent and deprived
* Improvement in model fit when each categorical variable is added to the null model
’ The significance of the age term is tested against the initial model containing only deprivation category
6 Includes category "Unknown’  for all patients not treated in the inpatient setting
7 Outpatients were all assumed to be routinely admitted
* See Table 8.3 for histological type and body site groupings
In agreement with studies in the literature, survival was significantly higher for females than 
males (92% compared to 83%). This difference remained after adjusting for variations in 
age and site of lesion on the body, and may be accounted for by tumour stage242, although 
this was not found to be the case in an audit of Yorkshire patients229. Adding sex to the null 
model improved the model fit but did not explain the differences in survival between the 
deprivation groups (RR reduced from 2.89 to 2.64). Survival did not vary significantly by
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health board, and survival was similar for urban and rural residents. Adding these residential 
factors to the null model did not, therefore, improve the model fit. Survival was 
significantly lower for patients who had a previous primary cancer at any site (76% 
compared to 89%; p<0.01), but this difference was accounted for by the older age of 
patients with a previous primary. Adding cancer history to the null model including 
deprivation and age, therefore, did not improve the model fit.
.All three measures of comorbidity were independently and very strongly related to survival. 
Patients who had spent more than 10 days in hospital in the two years prior to the 
melanoma diagnosis had significandy poorer two-year survival than those with fewer or no 
days spent in hospital (54%, compared to 78% for 5-10 days and 93% for <5 days; 
p<0.001). Any comorbidity compared to no comorbidity was associated with reduced 
survival when measured with both the Charlson index (55% at two-years compared to 90%; 
p<0.001) and the Scottish index (69% at two-years compared to 90%; p<0.001). The bed- 
days and Charlson indices both improved the fit o f  the model compared to the null model; 
however, the Scottish index was no longer a significant factor after adjusting for age (Table 
8.8). Differences in comorbidity measured by the bed-days index accounted for half the 
difference in risk of death between affluent and deprived patients reducing the relative risk 
from 2.89 to 1.87 and rendering the difference non-significant.
Health care factors
Patients attending a regional RT centre at some point during their cancer spell had 
significandy worse survival than patients attending other high-workload hospitals. This was 
because patients with worse prognosis were being referred to the regional RT centres for 
radiotherapy. If patients receiving radiotherapy are excluded from the analyses then there 
were no differences in survival by hospital group (data not shown). Patients who had their 
surgery completely outside the hospital setting had the highest survival (93%), presumably 
because these were patients with very small lesions excised by their GP. Patients who 
received their surgery at a regional RT centre had the lowest survival (84%); these 
differences in survival were not significant. There were no differences in survival by surgical 
department (dermatology, general medicine or plastic surgery), and those treated as 
inpatients had similar survival to those treated as outpatients. Adding workload of the 
hospital of surgery or specialty of the department of surgery to the null model did not 
improve the model fit (Table 8.8).
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Patients who presented as an emergency admission had poorer survival (71%) than those 
admitted routinely (88%) or with treated as outpatients (89%; p<0.001); however, inclusion 
of this factor in the null model did not improve the model fit. Survival was not influenced 
by length of time between diagnosis and surgery (less than or greater than two weeks). 
However, patients not assigned to a waiting time (i.e. those who had no surgery) had 
significantly poorer survival (p<0.001). Inclusion of time from diagnosis to surgery in the 
null model improved the model fit but only as an indication of whether or not the patient 
received any surgery. Of patients treated as inpatients, those who were managed by a high- 
workload consultant (>25 cases per year) at surgery had the highest survival (90%) but there 
was no trend across the other consultant workload groups. After adjusting for age, patients 
who were managed by a high-workload clinician had a relative risk of death of 0.38 
compared to those managed by a low-workload clinician (p=0.076). Inclusion o f clinician 
workload in the null model improved the model fit but did not explain the deprivation- 
specific differences in survival (Table 8.8).
Tumour characteristics
Survival varied by histological type; with significantly lower two-year survival for patients 
with nodular tumours than other types (69% compared to 94% for superficial spreading, 
90% for lentigo maligna, 83% for acral and 84% for other and unknown tumour types). 
Previous research had suggested that acral melanomas had the worst prognosis245,244 but 
evidence is conflicting245 and this is not supported by the analyses presented here. Site of 
the lesion on the body was also significantly related to survival, with poorer survival for 
patients with head, neck and face lesions compared to other locations (79% compared to 
95% for upper limb, 92% for trunk and 91% for lower limb; p<0.001). The twenty patients 
with lesions at other and unknown locations had significantly poorer survival (60%). The 
Scottish Melanoma Group study of patients diagnosed during 1979-94 found no difference 
in survival by body site or histological type once tumour thickness was controlled for"1. In 
the Yorkshire audit259 survival also varied significantly by body site, but again this difference 
disappeared when case-mix factors including tumour thickness were adjusted for in their 
model. For patients diagnosed in Scotland in 1997, body site explained around a quarter of 
the differences in risk of death between affluent and deprived patients, reducing it from 2.89 
to 2.10 and rendering it marginally non-significant (p=0.06). This may actually be an
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underlying measure of tumour thickness. Histological type also improved the model fit, but 
only explained a small proportion of the deprivation-specific differences.
Treatment factors
Unsurprisingly, patients who were treated with curative intent had significantly higher two- 
year survival than those treated with palliative intent (93% compared to 39%). Survival was 
77% for the small group (6%) of patients whose treatment intent was unknown. Most 
patients (87%) were treated with curative intent; 6% were treated with palliative intent. The 
small number o f patients who did not receive surgery had significantly poorer survival than 
those who did receive surgery (36% compared to 90%). Patients who received 
chemotherapy or radiotherapy had a significantly lower survival than those who did not. Of 
those patients treated with palliative intent, a third received radiotherapy. Inclusion of 
treatment information improved the model fit but did not explain the deprivation-specific 
differences in survival (Table 8.8), as the relative risk of death for deprived compared to 
affluent patients was virtually unchanged from the null model.
M ultivariate analyses
In the main multivariate analyses, the factors were grouped into patient characteristics, 
tumour characteristics, health care system factors and treatment factors (Table 8.9). Each 
factor was examined allowing for all related factors, and only factors that improved the 
model fit are presented (models 1-4). Deprivation group and age were included in each 
model. The significant factors in each of these group models were then included in the final 
model (Table 8.10; model 5).
In model 1, age, sex and the bed-days comorbidity score were important patient-related 
factors improving the model fit. Health board of residence, urban indicator, previous 
cancer history, and the Charlson and Scottish comorbidity indices did not improve the 
model fit once age, sex and bed-days had been included. Differences in age, sex and 
comorbidity only explained around a quarter o f  the deprivation-specific differences (RR 
reduced from 2.89 to 2.23).
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Table 8.9: Patients diagnosed with melanoma in Scotland during 1997: multivariate
influence of the factors grouped on the relative risk of death within two 
years of diagnosis among deprived compared to affluent patients (Cox 
proportional hazards regression analyses) 12
1 The wail variable was also significant but is excluded because only those not assigned a wait (i.e. the non- 
surgical patients) had different survival than the rest
2 Age is also included in this model but the tesults not displayed
5 These patients have no hospital inpatient record at the time of surgery so were probably treated as 
outpatients
Table 8.9 continued.
Model Relative 95% Cl P -va lu e
Variables included in  the model r isk Low Hiah
Model 3: Presentation variables2
Depl: Affluent 1.00
Dep2 1.27 0.59 2.74 0.544
Dep3 1.90 0.92 3.95 0.084
Dep4 1.73 0.84 3.54 0.136
Dep5: Deprived 2.12 0.97 4.64 0.059
Superficial 1.00
Lentigo maligna 0.61 0.19 1.93 0.398
Nodular 2.82 1.33 5.99 <0.01
Acral 2.30 0.75 7.06 0.147
Other and unknown 1.37 0.76 246 0290
Head, face and neck 1.00
Trunk 0.72 0.35 1.48 0.369
Upper limb 0.50 0.19 1.28 0.147
Lower limb 0.68 0.36 1.28 0.234
Other and unknown 5.57 231 13.41 <0.001
Model 4: Treatment variables2
Depl: Affluent 1.00
Dep2 1.05 0.48 233 0.902
Dep3 1.97 0.94 4.10 0.072
Dep4 1.95 0.94 4.07 0.075
Dep5: Deprived 269 1.24 5.85 0.012
Curative treatment intent 1.00
Palliative treatment intent 7.22 3.65 14.28 <0.001
Unknown treatment intent 3.33 1.45 7.67 <0.01
No surgery 1.00
Surgery 0.35 0.15 0.82 0.015
No radiotherapy 1.00
Radiotherapy 4.10 1.79 9.41 <0.01
1 The wait variable was also significant but is excluded because only those not assigned a wait (i.e. the non- 
surgical patients) had different survival than the rest
2 Age is also included in this model but the results not displayed
3 These patients have no hospital inpatient record at the time of surgery so were probably treated as 
outpatients
Model 2 included the health care system factors, and consultant and hospital workload were 
important explanatory variables improving the model fit. Time from diagnosis to treatment 
also significantly predicted survival but was excluded from the model, because the difference 
was only between those with a waiting time (i.e. received surgery) and those without (i.e. no 
surgery), in other words measuring the fact o f  surgery, not time to surgery. After 
accounting for consultant and hospital workload, information on the specialty o f the 
department of surgery and type of admission (routine or emergency) did not improve the 
model fit. After adjusting for consultant and hospital workload the gradient in relative risk 
of death across the deprivation groups was actually more pronounced (RR increased from 
2.89 to 3.25; Table 8.9). The reason for this is no t clear.
2 4 9
In model 3, histological type and body site were both important explanatory variables. 
Patients with unknown site (n=20) had a significandy higher relative risk o f death than those 
with known site; if only patients with known site were considered then the risk of death 
between affluent and deprived patients was reduced to 1.8 (p=0.162; data not shown). 
Overall, inclusion of body site and histological type in the model reduced the relative risk of 
death for deprived compared to affluent patients from 2.89 to 2.12 and rendered the 
difference marginally non-significant (p=0.059).
In model 4, treatment intent (curative or palliative) was an important predictor o f survival 
along with surgery and radiotherapy (although only 19 patients received radiotherapy). 
Whether the patient received chemotherapy did not influence survival after adjusting for 
treatment intent, surgery and radiotherapy. After adjusting fo r these treatment factors, the 
deprivation-specific difference in relative risk of death only reduced slightly from 2.89 to 
2.69.
Finally, all the significant factors from the grouped models w ere combined in a multivariate 
model. After adjusting for all the factors that had a significant influence on survival from 
melanoma, including age, sex, bed-days comorbidity score, site of the lesion on the body, 
treatment intent (curative or palliative), surgery and radiotherapy, the relative risk of death in 
deprived compared to affluent patients was reduced by around a half from 2.89 to 1.92 
(Table 8.10). The risk of death within two years of diagnosis for deprived patients was still 
double that of affluent patients, however the confidence interval, which contains unity, is 
very wide reflecting the small number of cases (N=673) on which the analysis was based.
In this final model, the relative risk of death decreased with increasing age, was significantly 
higher for women compared to men, and was decreased w ith  increasing comorbidity as 
measured by the number of days spent in hospital in the preceding two years. Patients with 
tumours on the head, face and neck had the worst prognosis o f  patients with known body 
site. The Yorkshire audit“ * found the same, and it was accounted for by tumour thickness. 
Patients treated with palliative or unknown treatment intent had, unsurprisingly, significantly 
poorer survival than those treated curatively. Patients receiving radiotherapy also had poor 
survival.
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Table 8.10: Patients diagnosed with melanoma in Scotland during 1997: multivariate
influence of all the significant variables on the relative risk of death at two 
years after diagnosis among deprived compared to affluent patients (Cox 
proportional hazards regression analysis)
Model Relative 95% Cl P -va lu e
Variables included in che model risk Low Hiarh
Model 5: Final model
Depl: Affluent 1.00
Dep2 1.06 0.47 2.39 0.885
Dep3 1.88 0.88 4.05 0.105
Dep4 1.85 0.87 3.94 0.113
Dep5: Deprived 1.92 0.86 4.31 0.112
Ages 15-49 1.00
Ages 50-59 1.91 0.68 5.34 0219
Ages 60-64 1.76 0.59 5.21 0.309
Ages 65-69 1.76 0.50 6.18 0.380
Ages 70-74 2.62 0.92 7.49 0.072
Ages 75-79 3.94 1.51 10.28 <0.01
Ages 80+ 7.77 3.06 19.73 <0.001
Males 1.00
Females 0.47 0.27 0.81 <0.01
No bed-days comorbidity 1.00
1-4 bed-days comorbidity 0.75 0.35 1.57 0.440
5-10 bed-days comocbidity 2.08 0.94 4.64 0.072
11+ bed-days comorbidity 5.31 2.77 10.18 <0.001
Head, face and neck 1.00
Trunk 0.69 0.33 1.45 0.330
Upper limb 0.40 0.15 1.04 0.059
Lower limb 0.88 0.46 1.68 0.703
Other and unknown 1.49 0.61 3.67 0.382
Curative treatment intent 1.00
Palliative treatment intent 10.00 5.18 19.28 <0.001
Unknown treatment intent 5.08 2.25 11.50 <0.001
No radiotherapy 1.00
Radiotherapy 3.35 1.34 8.37 0.010
Discussion
Of the cancers investigated in depth in this thesis, melanoma proved the most difficult to 
analyse using routine data sources. The main setback was that tumour thickness was not 
recorded on SOCRATES. A more minor problem was that many melanoma patients were 
treated as outpatients, and so for these patients there is no information about the surgical 
department they attended or the consultants they were seen by.
lésion thickness is thought to be the most important factor in the prognosis of 
melanoma1 age, sex, level of invasion and body site are also important. MacKie et
a l1*  found that deprived patients were more likely to present with thicker tumours in a
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study of patients diagnosed in Scotland during 1979-93. They showed an increase in the 
proportion of thin tumours over time in all deprivation groups (affluent, intermediate and 
deprived), which was significant in intermediate and deprived women and affluent and 
intermediate men. Over 50% of all tumours were less than 1.5 mm thick, but this varied by 
sex and deprivation group, with only 39% of deprived men having thin tumours. The 
difference in tumour thickness between the deprivation groups was no longer evident in the 
most recent period they studied (1991-93) for females, and they speculate that a common 
factor, such as poor nutrition leading to low levels of antioxidants, or immunological defects, 
could instead be responsible for the difference in survival between deprivation groups.
In a study of patients diagnosed in Yorkshire during 1992-94, deprived patients were only 
slightly more likely than affluent patients to present with thicker or metastatic lesions. 
When lesion thickness was included in their survival model adjusting for all case mix factors 
(age, sex, lesion site and lesion thickness), the differences in the relative risk of death 
between high and low socio-economic groups they had previously identified was essentially 
unchanged (RR reduced from 1.25 to 1.22)“ 9. They suggest that this was because there was 
no great difference in lesion thickness by socio-economic group and hypothesise that this is 
due to public awareness leading to early recognition and presentation across the socio­
economic groups.
Public education campaigns in the mid-1980s in Scotland may have led to earlier self-referral 
across the deprivation groups. A questionnaire to patients presenting with melanoma in 
Edinburgh during the public health campaign indicated that younger patients were the most 
likely to have been influenced, and this age group had a higher proportion of thin 
tumours“4.
For patients diagnosed with melanoma in Scotland in 1997, the deprived were older, were 
more likely to be treated as an outpatient, and to have a longer wait from diagnosis to 
surgery. They were also more likely to present as an emergency and to have comorbidity at 
diagnosis. The most affluent patients were more likely to be treated in a regional RT centre 
or other high-workload hospital than patients in the other deprivation groups were.
To be treated as an outpatient implies thin tumours of good prognosis, capable of being 
dealt with in dermatology clinics; inpatients being those in need of reconstructive surgery or
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nodal dissection. However, the specialty o f the department of surgery and whether the 
patient was seen as an inpatient or outpatient seems to be more determined by the local 
services available than factors relating directly to the tumour. This was also found in the 
Yorkshire audit. Despite the differences in melanoma services across Scodand, patients 
treated as outpatients did have higher survival than those treated as inpatients, implying a 
higher proportion of inpatients have tumours of worse prognosis, as would be expected.
There is no effective adjuvant treatment for melanoma, prompt surgery to remove the 
primary lesion being the only proven cure at the present time. The steeply rising incidence 
of melanoma, along with the much more slowly rising mortality suggests that surgical 
approaches to managing melanoma have improved over the past 30 years, or that melanoma 
is being treated earlier at a time when it is more amenable to surgical cure than was 
previously the case247’24*. If the higher survival in affluent patients is because they are 
presenting with thinner tumours, then the issue of lead-time bias should be considered244. 
These patients may be living longer with the disease, but their actual time of death may not 
have changed. However, as improvements in survival over time in Scodand are sustained at 
even 10 years after diagnosis1 when the effects of this bias would be expected to be gready 
reduced, the improvements in survival over time, and the gradient in survival between 
deprivation groups, are both likely to be real.
Another potential problem to be considered is whether the cancer registry is ascertaining all 
melanoma cases, particularly because some patients are not treated within the hospital 
setting. This problem has been identified for cancer registries in England and Wales249 for 
patients treated in the outpatient and GP setting. This means that patients with better 
prognosis are most likely to be missed by the registry, making survival look worse than it 
actually is. Due to differences in local services, this could present bias in deprivation-specific 
analyses. Ascertainment problems should be minimised in Scodand, however, because the 
registry database is frequendy compared to databases independently collected by the Scottish 
Melanoma Group, and any missed cases are investigated.
It is interesting that consultant workload was an important determinant of survival in the 
multivariate model of factors relating to hospital services (Model 2; Table 8.9). The 
numbers o f  cases available for analysis, particularly for consultant workload, which could 
only be measured for inpatients, prevented a further breakdown of workload by specialty. It
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would be interesting to look at the influence of workload within dermatology, general 
surgery and plastic surgery with a larger set of patients.
In conclusion, when the factors are investigated individually, differences in the relative risk 
of death between affluent and deprived patients appeared to be largely accounted for by 
comorbidity and site of the lesion on the body. When all the important factors were 
considered together the independent indicators of prognosis for patients with melanoma 
were age, sex, bed-days comorbidity score, site o f the lesion on the body, treatment intent 
(curative or palliative) and radiotherapy. These factors explained half of the observed 
differences in the risk of death between affluent and deprived patients. For melanoma, only 
patients with late stage disease would receive treatment with palliative intent, including 
radiotherapy. The inclusion of these factors in the final model is, therefore, an indicator of 
stage of the disease. It was postulated earlier that site of the lesion on the body may also be 
a marker of differences in tumour thickness. Continued campaigns to promote awareness 
and early diagnosis should, therefore, continue and be targeted at deprived groups and 
particularly men.
The importance of comorbidity in the prognosis for patients with melanoma, independently 
of age, is also of public health significance and should be investigated further with a  larger 
set o f patients.
As well as the probable impact of tumour thickness on the factors in the final model, the 
remaining differences in relative risk o f death between affluent and deprived patients may be 
accounted for by tumour thickness, although recent data from the Scottish Melanoma 
Group and the audit of Yorkshire patients have not identified any major differences in the 
distribution of tumour thickness by deprivation group. These analyses were greatly 
hampered because no information on tumour thickness was available.
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GENERAL DISCUSSION
The main a im  of this thesis was to identify the most important determinants of social 
variation in cancer survival in Scotland. Six cancers were identified as having significant 
differences in survival between deprivation groups, on the basis of the number of avoidable 
deaths within five years of diagnosis. The influence on the survival gradient of four types of 
explanatory variables: those relating to the patient, the tumour, health care system and 
treatment w ere studied. The cancers included were breast, colon, rectal, bladder and kidney 
cancers, and melanoma of the skin. The underlying purpose of this thesis was to investigate 
the use of routine data sources to look at prognosis and patterns of cancer care. The 
Scottish linked database of cancer registry data, hospital discharge records and deaths was 
utilised.
Limitations o f  the materials and methods that could affect interpretation o f the results will 
be discussed first, followed by a discussion of the importance of the different explanatory 
variables. T he potential impact o f reducing avoidable deprivation-specific differences in 
survival is also discussed as part of the overall conclusion.
Limitations of the methods and material
Survival analyse«
Cause-specific survival was not used in the analyses because of uncertainty in the accuracy of 
death certification and the subjectivity of the definition of “cause-specific” (see Chapter 1). 
In Chapter 3 , the very large differences in survival estimates when using relative compared 
to cause-specific survival methodology were illustrated (see Table 3.7). The cause-specific 
estimates w ere generally higher than the relative survival estimates, suggesting that the 
differences m ay be due to inaccurate recording of cancer on death certificates. An 
alternative explanation could be an inappropriate choice of life table for the relative survival 
analysis. This is less plausible than inaccurate death certification because the gradients in 
survival across deprivation groups were similar both for the cause-specific and the relative 
survival analyses, whereas inappropriate life tables would be expected to have changed the 
deprivation gradient.
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Even if cause-specific survival were accurate, competing causes o f death become more 
important as time passes, so overall survival within two years of diagnosis should not be 
heavily influenced by death from competing causes. Melanoma has been used to explore 
the effect of adjusting for cause of death. If the analyses in chapter 8 were re-run using 
cause-specific deaths (and censoring non-cancer deaths) instead of all deaths, the relative risk 
of death for deprived compared to affluent melanoma patients would have been reduced 
slightly (from 2.89 to 2.27; data not shown) but it was still statistically significant.
Of the 78 patients dying within two years o f diagnosis, 57 (73%) had melanoma or another 
related condition (see Appendix 1.1) mentioned on the death certificate and so w ere 
counted as cause-specific deaths. For 8 (13%) patients, another cancer was mentioned on  
the death certificate, and for five of these melanoma was the first or only registered 
malignancy, so arguably they, and probably all of these 8 deaths, should have been included 
as cause-specific deaths. The remaining 13 (17%) patients had no mention of cancer on  
their death certificate and this proportion varied by deprivation group. These patients w ere 
all elderly (aged 75 or older) and two-thirds had comorbidity measured by the bed-days 
index. Therefore, counting only the specific causes o f death would probably underestimate 
the “true” difference in survival between affluent and deprived patients. Differences in  
underlying mortality between deprivation groups could probably be better adjusted for w ith 
age and comorbidity instead.
Relative survival was not a practical option for the in-depth analyses, as current multivariate 
relative survival methods involve generalised linear modelling where aggregated data instead 
of individual-level data are analysed (see Chapter 1). Because this method is based on  
aggregated data it is not as powerful as Cox proportional hazards regression modelling. A  
STATA algorithm to perform multivariate relative survival at an individual level is currently 
being developed (Mr A. Sloggett, personal communication).
Model checking and validation
The validity of the final Cox proportional hazards models was not discussed in the individual 
chapters. Initially, the survival curves for each factor and each cancer were examined to  
check that they did not cross or diverge considerably. In the few circumstances where the 
curves did cross, an attempt was made to group levels o f the factor in a meaningful way.
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For each cancer, the factors in the final model were assessed for proportionality using time- 
dependent modelling (see Chapter 1). On the whole, the factors were proportional or could 
be grouped to  satisfy the proportionality assumption (for example, other surgery and 
unspecified surgery were grouped for breast cancer). However, sometimes it was not 
possible to perform any grouping (for example, for some factors the “unknown” group had 
a non-proportional hazard). In the final models, non-proportionality could not be resolved 
for treatment objective (breast, melanoma, bladder, kidney and colon), treatment (breast, 
melanoma, bladder and colon) and specialist department (kidney). There is, therefore, a 
small possibility o f bias in the final results because of this non-proportionality. However, 
where factors could be grouped, the final deprivation-specific estimates were not 
significantly influenced by the grouping. Interaction terms were not considered, due to the 
added complexity of the models what would arise.
Timeliness o f follow-up
In the analyses presented in Chapters 3 and 4, patients diagnosed in the most recent time 
period (1991-95) were only followed up until the end of 1998. This means that the five-year 
survival estimates were based on the three-year survival estimate for patients diagnosed 
1991-95, the conditional fourth-year survival estimate for patients diagnosed 1991-94, and 
the conditional fifth-year survival estimate for patients diagnosed 1991-93. The overall five- 
year estimate m ay be somewhat biased, therefore, if the shape of the survival curves for 
patients who have already survived three or four years after diagnosis is changing 
significantly over time. Assuming that no such bias exists means that more timely survival 
estimates can be presented. Changes affecting survival in the first year after diagnosis 
(treatment-related, for example) are likely to be much larger than those affecting survival in 
years 4 and 5, conditional on already having survived 3 years, which is reasonable 
justification, I believe, for the approach taken.
An alternative approach which aims at even more timely detection of changes in survival is 
called “period monitoring”2“ . It uses more up-to-date information: for example, the one- 
year survival estimates for patients diagnosed during 1991-95 and followed up until 1998 
would be based o n  patients diagnosed during 1993-98 rather than those diagnosed 1991-95, 
the two-year survival estimates would be based on those diagnosed 1992-97, etc. The results 
would then be presented as one-, three-, and five-year survival estimates for follow-up 
period 1998 rather than diagnosis period 1991-95. This approach was not considered in
Chapters 3 and 4 of this thesis because of the difficulties in interpreting trends in data that 
contain changing cohorts of patients. The timeliest data available was used for the in-depth 
analyses in Chapters 5-8.
The deprivation measurement
Area-based measures o f  deprivation applied to individuals will always result in some degree 
o f mis-classification. From the analyses performed in Chapter 1 (see Table 1.2) w e might 
expect at least 5% of the patients in the in-depth analyses to have been mis-classified. This 
means that the most deprived group will include some patients who are not so deprived and 
the most affluent group will include some patients who are not so affluent. This type o f bias 
will lead to an under-estimate of the magnitude o f differences in survival between the 
deprivation groups, and so should not affect the interpretation of the results presented in 
this thesis.
Quality of the inpatient discharge data
In this thesis the inpatient discharge database was utilised for information on previous 
diagnoses (for the Charlson and Scottish comorbidity score), time previously spent as an 
inpatient (bed-days comorbidity score), breast cancer operation codes, department 
specialties, consultant codes, and types of admission (emergency or routine).
Record linkage using probability matching, as was used to link the hospital inpatient 
discharge data to the cancer registry database, may produce around 4% false positive 
matches (wrong link) and 2% false negative matches (missed link) (see Chapter 1). For the 
patients analysed in this thesis, 6% of cancer patients with an hospital inpatient history did 
not have cancer mentioned on any of their inpatient discharge records (see Table 2.8). This 
means, for example, that up to 6% of patients would in fact have had comorbidity but be 
recorded as having no comorbidity, leading to the magnitude of real differences in survival 
by comorbidity group being reduced. For breast cancer operations, department specialty, 
consultant information and type of admission, this misdassification could lead to biased 
results if the probability of a mis-match varied between the deprivation groups. However, 
there were no differences in the proportion of patients with an inpatient history containing 
no mention of cancer across the deprivation groups.
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For a further 5°/o of patients, the specific cancer recorded by the cancer registry was not 
mentioned on any of the inpatient records, although another or unspecific cancer code was 
recorded (see Table 2.8). As the cancer registry diagnosis code was used in this thesis, this 
will not have affected the analyses. Quality assurance o f a sample of the 1996/97 inpatient 
discharge data found the diagnosis codes to be only 89% accurate in general (see Table 2.5), 
however, from the data presented in this thesis, it appears that recording of cancer 
diagnoses is more accurate (95%). This is useful to know for further studies which may rely 
on the inpatient diagnoses codes. The diagnostic and probability matching errors combined 
(11%) give some indication of the expected accuracy and completeness of cancer registries 
that register solely from electronic sources (although the availability of pathology laboratory 
data should reduce the diagnostic errors).
In most hospitals in Scotland, inpatient data are entered onto a patient information system. 
Staff record admissions, transfers and discharges with timescales as near to real-time as 
possible. This is sometimes achieved by ward staff having access to the systems in wards, 
and by departments other than medical records also having access. In other hospitals there 
are communication mechanisms so that all changes are notified to staff responsible for data 
input (usually medical records staff). Most hospitals use a combination of sources of 
information — admission systems, bed state reports, ward clerks, bed bureau and secretaries, 
and the information is collected by medical records staff, admissions clerks, ward clerks, 
nursing and A&E clerical staff. In addition to the staff mentioned above, clinical coding 
supervisors and managers hold responsibility for the completion o f hospital inpatient 
discharge data.
Given the number of sources and people entering the data, it is not surprising that the 
quality has been found to be quite low for some data fields when an exercise was undertaken 
to re-abstract information for a 1% sample of records (see Table 2.5). However, most of 
the data fields used for this thesis were recorded to a very high accuracy: the date of 
admission and date of discharge were 99% accurate, so there should be no bias in bed-days 
comorbidity scores reported across the deprivation groups. Similarly, recording o f specialty 
(100%) and type o f  admission (98%) were also accurate. The accuracy o f the breast cancer 
operation codes w as discussed previously and no problems were identified (see Chapter 5 
discussion). The factors that could be affected by the quality of the inpatient data are the 
Charlson and Scottish comorbidify scores, due to the low accuracy of the diagnostic codes
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(89%) and a large variability in accuracy between hospitals. These indices were only 
significant in the final colon cancer model, but they do show a trend of increasing relative 
risk of death with increasing comorbidity, as would be expected.
In summary, therefore, variations in the quality of the hospital inpatient data is very unlikely 
to have an important influence on the analyses presented.
Quality o f the cancer registry data
In the analyses performed for this thesis, the quality o f the cancer registry (SOCRATES) 
data is a much bigger issue. Many of the factors used in the analyses in Chapters 5-8 were 
collected for the first time for patients diagnosed in 1997 (see Chapter 1).
The results of reviewing re-abstracted data for a random sample of records for patients 
diagnosed in 1997 are shown in Table 2.4. Date of diagnosis is recorded by the cancer 
registration officers (CROs) and can be subjective (see Chapter 1 for definition). In the re­
abstraction exercise this date varied for 25% of patients (by more than 6 weeks for 5% of 
patients), and may have led to bias in the “Time from diagnosis to surgery” factor, especially 
as the date of surgery also varied for 17% o f patients receiving surgery. This factor was 
important for the colon and rectal cancer analyses, and results should thus be interpreted 
with caution.
There was a  good level o f agreement in the recording o f tumour site (97%) and whether the 
tumour was histologically verified (98%). Whether or not the patient received surgery, 
radiotherapy, chemotherapy and hormone therapy was also accurately recorded (96-98%). 
Half of the discrepancies (9%) in the morphology code were in the recoding from one non­
specific code to another, and most of the remaining discrepancies were in the coding of a 
more specific code within a general code. These differences would not have influenced the 
broad bandings of histological type used in this thesis.
Major discrepancies were found in the recording of clinical and pathological breast staging 
factors and colorectal tumour stage. These differences were mainly due to the recording 
versus non-recording o f an informative value for the factor rather than a difference in an 
actual recorded informative value. The re-abstraction exercise demonstrated that the CROs 
had some problems in extracting this new information from the medical notes. Whether
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the number of discrepancies varied significantly by hospital could not be investigated 
because of the largc number o f  hospitals and relatively small sample size (461 breast records 
and 457 colorectal records).
If there was no bias in the distribution of unstaged cancers (i.e. all stages of cancer were 
equally likely to be unrecorded) then the relative risk of death for the unstaged cancers 
should be similar to the average risk of death for all staged cancers combined. This appears 
to occur for metastatic status for breast cancer, and so missing metastatic status should not 
bias the deprivation-specific analyses. This is further supported by the fact that imputation 
of metastatic status does not influence the final results.
For breast cancer, patients with no information on pathological and clinical tumour size or 
nodal status appeared to have a worse prognosis than the average prognosis of patients who 
had this information recorded. This suggests that the cancers in the unstaged group were 
actually more advanced. Deprived patients were more likely to have missing information. 
For patients with known pathological details, however, deprived patients were more likely to 
present with a worse distribution anyway, which may explain the worse survival in the 
unstaged patients. There were no differences in the distribution of the known clinical 
factors by deprivation group. That both clinical and pathological information were 
independently predictive o f outcome in the final breast cancer model may be because 
information was not always missing for the same patients (i.e. a patient may have missing 
pathological size but clinical size recorded), as well as the within stage variability reported in 
the breast cancer chapter.
For colon and rectal cancers, patients with no information on Dukes’ stage also appeared to 
have a worse prognosis than the average prognosis of patients who had this information 
recorded. Conversely, however, affluent patients were more likely to have this information 
missing. The *mpllcat1ons o f this were discussed in detail in Chapter 6.
Systematic variation
Bearing in mind these potential data problems, attention will now be turned to the results.
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Age
Ageism is a term of the moment, and there is evidence that it existed for access and 
treatment among patients diagnosed in Scotland in 1997. Elderly patients were less likely 
than younger patients to attend a regional RT centre, and less likely to receive surgery, 
chemotherapy or radiotherapy for all of the cancers investigated. This was true for patients 
presenting with both early stage and late stage tumours, and those with no comorbidity 
according to the bed-days index. O f course, very elderly patients will be less suitable for 
treatment because of frailty and other conditions that it is not possible to measure with 
routine data.
Although age was an important prognostic factor for all the cancers investigated, there were 
no differences in the age distribution of patients across the deprivation groups, and 
therefore, age did not explain the differences in survival between the deprivation groups.
Sex
Females with melanoma have previously been shown to have a better prognosis than males, 
and this was also observed with these data: the risk o f death within two-years of diagnosis 
was double in males than females, even after accounting for differences in the important 
factors including site o f  the lesion on the body. As there were no differences in the 
proportion of female patients across the deprivation groups, this factor did not explain any 
of the survival differences between affluent and deprived patients.
There were no differences in the proportion of males and females across the deprivation 
groups for the other cancers investigated with the exception of kidney cancer, and there 
were no differences in survival between the sexes for kidney or the other sites. Sex is 
therefore not an important factor in explaining the deprivation-specific differences in 
survival.
Place o f residence
After accounting for deprivation, survival did not vary by health board of residence and 
urban or rural residence for any o f the cancers investigated. This highlights the importance 
of adjusting for deprivation when looking at residential factors.
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Multiple primary tumours
There were no differences between the deprivation groups in the proportion of patients 
who had a previous primary cancer for any of the cancers investigated. Many survival 
analysis studies would exclude patients who had a previous primary cancer from the 
analyses, however, in this study it was important to include these patients to see whether 
observed differences in survival were partly accounted for by a history of cancer. That this 
factor was not a strong predictor of outcome is encouraging for studies where different 
populations are compared and multiple tumours cannot be excluded (e.g. for a registry 
which has only been running for a short time).
Comorbidity
Improved general health status may explain some of the improvements in survival that have 
been observed for most cancers over time in Scodand, as the all-cause mortality rate for 
Scodand fell by approximately 22%, from 11.4 to 8.9 per 1 000, over the period 1971 to 
1995. This reduction implies a decreasing prevalence o f co-existing chronic disease in cancer 
patients, leading to a greater proportion of patients for whom intensive (and potentially 
more effective) treatment can be considered appropriate, and perhaps also to a greater 
resilience of patients to the side-effects of treatment.
For all the cancers investigated in this thesis, comorbidity was an important prognostic 
factor in the final model. This highlights the importance of comorbidity in cancer patient 
survival. If it had been possible to perform multivariate analysis using relative survival or 
reliable cause-specific death information, however, the importance of comorbidity as an 
independent prognostic indicator might have been reduced.
It is not possible to measure comorbidity using routine cancer registry data. For this thesis, 
comorbidity was measured using the hospital inpatient data, and this will tend to 
underestimate comorbidity both because of missed links, as discussed earlier, and because 
only specific illnesses of sufficient severity to result in an inpatient stay will be recorded. 
Comorbidity is complex and notoriously difficult to explain with a single measure, and this is 
highlighted in these analyses. For colon cancer patients, the two disease-based measures 
(Charlson and Scottish indexes) were independently predictive of survival, and the 
cumulative illness measure (bed-days score) did not explain extra survival variations in a 
model containing the two disease-based measures. For breast, rectal, bladder, kidney and
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melanoma cancer patients, however, the bed-days score was a strong predictor of survival 
and the two disease-based measures did not explain any extra variation in the data. Clearly, 
any comprehensive comorbidity index will have to take into account both the impact of 
specific diseases and the accumulated effects of ill health.
Deprived patients had higher comorbidity than affluent patients for all the cancer 
investigated, with the exception o f kidney cancer. As well as its impact as an independent 
factor in the models, insofar as measures reflect clinical comorbidity, it is likely to have 
influenced clinical judgement in treatment choices and referral. Factors leading to
comorbidity are embedded in everyday life and are difficult but not impossible to change.
Tumour biology
Differences in the histological types of tumours between the deprivation groups were 
observed for breast cancer (lobular tumours were less common in deprived patients than 
affluent patients), and kidney cancer (clear cell tumours were less common in deprived 
patients). These were both histological types with a better prognosis than the other 
histological types, but these factors were not strong enough prognostic indicators to feature 
in the final multivariate models. Differences in survival between the deprivation groups 
were therefore not accounted for by differences in histological type.
Deprived patients with breast cancer were more likely to have tumours with negative 
oestrogen receptor (ER) status than affluent patients, and ER status was an important 
prognostic indicator in the final breast cancer model, because prognosis is worse for women 
with ER-negative tumours. In a basic model containing deprivation, age and ER status, 
around a quarter of the differences in survival between affluent and deprived patients 
appeared to be accounted for by ER status (see Table 5.8). So, ER status is clearly 
important in explaining part of the deprivation-specific differences in breast cancer survival, 
but it is not something that can be altered. This is unavoidable.
Tumour grade was an important prognostic indicator for patients with breast, colon, kidney 
and bladder cancers. Grade was not well recorded, but deprived patients with breast cancer 
appeared slightly more likely to present with poorly-differentiated or undifferentiated 
tumours. For patients with colon, rectum, bladder or kidney cancer, there were no
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differences in the distribution of grade at diagnosis. Overall, grade was not an important 
factor in explaining the socio-economic differences in survival for the cancers studied here.
Delay in diagnosis and tumour stage
For many forms of cancer there is a clear association between extent o f  disease at diagnosis 
and survival. Public health campaigns and public involvement in screening programmes 
have led to a better understanding of cancer risk and symptoms, and the potential value of 
early diagnosis, so trends in increasing public awareness of cancer may well have led to 
earlier diagnosis, independendy o f improvements in diagnostic techniques and screening. 
This could lead to an increase in deprivation-specific survival gradients if deprived patients 
are less likely to attend screening or to be influenced by public awareness campaigns.
Information on the extent of disease (stage) was available for breast, colon and rectal 
cancers, although the completeness of this information was quite low and it varied between 
the deprivation groups, hindering interpretation. Information on tumour thickness is not 
available for melanoma of the skin, and this made final interpretation o f the melanoma data 
difficult: the factors identified as responsible for differences in survival between the 
deprivation groups may be independent prognostic indicators or may simply be acting as a 
surrogate for tumour thickness. Information on stage was not available for bladder and 
kidney cancer, and this again hindered interpretation of the data, because factors could not 
be attributed as important without the caveat that they be acting as a surrogate to stage. 
The difficulty in collecting stage routinely for urological cancers has been pointed out 
previously (see Chapter 7) and it may be necessary to gather data prospectively (on a 
population basis) for future studies of urological cancers.
Lack of stage information, or complete stage information, was a major drawback in the use 
of routine data for these analyses. Despite the problem of missing data, it was still clear that 
deprived patients with breast and rectal cancers were more likely to present with metastatic 
tumours than affluent patients, and this could account for around half the deprivation- 
specific differences in survival for breast cancer.
For rectal cancer patients, a combination of factors, including stage, explained almost half 
the deprivation-specific differences in survival in the final model. A number of these 
important factors would be expected to be related to stage, including type of admission.
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time from diagnosis to treatment and treatment intent, and they may have been significant 
contributors in the final model because they, in fact, explained survival variations for 
patients with unknown stage. When only these factors were included in the model, along 
with deprivation and age, the relative risk of death was increased slightly compared to the 
final rectal model in Chapter 5 (from 1.41 to 1.47; data not shown), so factors relating to 
tumour stage seem to account for nearly half the differences in survival between deprivation 
groups for rectal cancer. In a data set with more complete stage information, we might 
speculate that about half the deprivation-specific differences for rectal cancer patients would 
therefore be accounted for by stage.
Health care system factors
Hospital o f  treatment
Notwithstanding general improvements in diagnosis and treatment over time, the 
organisation of cancer care is important in ensuring patients are referred to centres at which 
the best available cancer services can be delivered (Calman-Hine process101). There are five 
regional RT centres in Scotland, and for the patients considered in this thesis, 74% of breast, 
40% of colon, 51% of rectal, 46% of bladder, 45% of kidney and 40% of melanoma patients 
attended one of these centres within three months of their cancer diagnosis. There is some 
evidence that an early effect of the breast screening programme in Scotland was to 
accelerate for breast cancer patients the tendency towards managed care and specialist 
referral which is permeating cancer services in Scotland251. The data presented here would 
certainly support that, with large differences in the proportion o f patients attending these 
RT centres by cancer and the highest proportion for breast cancer patients.
The hospital of treatment was categorised by the workload o f the hospital, based on the 
number of patients treated with the cancer of interest over the three-year period 1996-98. 
The regional RT centres were included as a separate category. In the final models, the 
hospital of treatment was only an important prognostic factor for breast and kidney cancer 
patients. Breast cancer patients treated at the regional RT centres or other high-workload 
hospitals had a better prognosis than those treated at lower-workload hospitals even after 
adjusting for stage. Deprived patients with breast cancer were significantly less likely than 
affluent patients to be treated at a regional RT centre, and this influenced the treatments 
they received. Hospital of treatment was clearly an important factor in explaining the
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deprivation-specific differences in breast cancer survival, whether because of treatment 
options available or an effect of multidisciplinary care. There was no clear trend in 
prognosis across the levels of hospital workload for kidney cancer, probably because of the 
small numbers o f cases in the analysis, so no conclusions can be drawn on the importance 
of hospital workload for kidney cancer patients with the current data.
Specialist department
Similar proportions of patients with breast, colon, rectal and bladder cancer attended a 
specialist department within three months of diagnosis (80%-88%), but this proportion was 
lower for melanoma of the skin (73%) and kidney cancer (63%) patients. Patients with 
cancer of the rectum, bladder and kidney had a better prognosis if they attended a specialist 
department within three months of diagnosis. This will partly be explained by patients 
deemed fit for adjuvant radiotherapy or chemotherapy attending a specialist department, by 
definition. However, this factor was still significant in the models after taking account of 
these treatment factors. The real implication underlying the impact o f  attending a specialist 
department may be related to expertise o f consultants and/or access to multidisciplinary 
teams.
Rectal cancer patients from all deprivation groups were equally likely to attend a specialist 
department, so unsurprisingly, this factor did not explain deprivation-specific differences in 
survival. Deprived bladder cancer patients were actually more likely to attend a specialist 
department, possibly reflecting their higher rates of palliative radiotherapy. Differences in 
survival between the deprivation groups for bladder cancer patients were increased after 
accounting for whether or not patients attended a specialist department due to differences 
for those who did not attend a specialist department. Affluent patients who did not attend a 
specialist department appeared to have very good prognosis tumours and deprived patients 
who did not attend a specialist department appeared to have a very poor prognosis.
For kidney cancer, deprived patients were less likely to attend a specialist department even 
though they were more likely to receive radiotherapy than affluent patients. The fact that 
deprived patients were less likely to attend a specialist department, either reflecting lack of 
access to these services or more advanced tumours, appeared to explain some of the 
differences in survival between affluent and deprived patients. These are factors that are to 
a certain extent remediable.
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Managing consultant
With the routine data available, w e could identify the medical code of the consultant 
managing the patient at time of surgery but not whether the operation was actually 
performed by that consultant; the consultant may not even have been present at the 
operation. For this reason, consultant workload may not be expected to have a strong 
influence on outcome. Given problems with the consultant information, no attempt was 
made to look at consultant expertise. The presence of a multidisciplinary team, which may 
actually be more important than specialism or workload, could not be measured with the 
data. Attendance at a specialist department was the closest surrogate available for 
measuring the presence of a multi-disciplinary team and specialised consultants. We might 
expect, therefore, for the specialist department to be a stronger factor in the models than 
consultant workload.
Deprived patients with breast, rectal, bladder and kidney cancer were less likely than affluent 
patients to be seen by a high-workload consultant. For breast cancer, increasing workload 
appeared to be related to better outcome initially (see Table 5.8), but after taking account o f 
tumour characteristics this difference disappeared. For colon and rectal cancer patients, 
increasing consultant workload was also related to better outcome and it remained 
significant for colon cancer patients after adjusting for all other factors (see Table 6.9). It 
was surprising that it was not important for rectal cancer, where surgery is more 
complicated, however, specialist department was an important factor in this model. 
Consultant workload could not easily be measured for melanoma because so many patients 
were treated as outpatients.
Emergency admission does not imply that the patient had emergency surgery, just that their 
admission to hospital with suspected cancer was not through a routine appointment. 
Emergency admissions are likely to reflect worse tumour stage at presentation. For colon, 
rectal and bladder cancer patients, patients with an emergency admission had a poorer 
prognosis after adjusting for the other important prognostic factors. However, there were 
no differences across the deprivation groups in the proportion of patients presenting as an 
emergency with rectal or bladder cancer. Deprived patients with colon cancer were more 
likely to present as an emergency but this did not appear to impact on the deprivation- 
specific differences in survival.
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Treatment
Treatment intent was an important prognostic factor for all the cancers investigated. It is a 
difficult factor to interpret because it is not often stated explicitly in the medical notes and 
the CROs may have to use their own judgement in recording it. One might expect it to be a 
surrogate of tumour stage, but for those cancers with stage information, it explained extra 
variability in the data on top of stage. For cancers with no stage information, it did not 
explain the deprivation-specific differences in survival. Although a “soft” variable, it 
successfully and consistendy differentiated between good and poor prognosis: within a given 
stage, patients recorded as being treated with palliative intent always had much poorer 
survival than those recorded as being treated with curative intent.
Only broad categories of type of treatment were available to test the hypothesis that patients 
from different deprivation groups were treated unequally. However, clear differences 
emerged, and more detailed treatment information might have yielded even clearer results 
on the association between treatment and deprivation. For breast cancer, it was possible to 
group the types o f surgical intervention into mastectomy versus breast conserving surgery, 
and there were large differences between deprivation groups in the proportion of women 
receiving each type of surgery.
Treatment is related to clinical judgement, which is related to stage at diagnosis, host factors 
and the setting in which you are seen. Some of the differences in treatment observed may 
be just, but deprived patients were consistently less likely to receive any treatment, and if 
they did receive treatment there were differences in the treatment combinations they 
received. The recorded type of treatment and the specific combination of treatment were 
important prognostic factors for breast, colon, kidney and bladder cancer patients, even 
after adjusting for the other important prognostic factors. These differences in treatment 
would appear not to be justified by the available data on extent of disease, and the survival 
differences between deprivation groups must therefore be to some extent avoidable with 
more equitable access to treatment.
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C onclusions
Differences between deprivation groups in tumour biology, tumour stage, comorbidity, 
hospital and consultant, and treatments were identified for the cancers investigated. The 
most important determinants of the deprivation-specific differences in cancer survival for 
patients diagnosed in Scodand in 1997 appeared to be comorbidity, extent of disease at 
diagnosis, and access to and implementation of optimal treatment. As determinants of the 
deprivation-specific gradient in survival, the differences in tumour stage could be seen as 
unacceptable, differences in treatment as unjust and differences in comorbidity as 
unavoidable.
The routine data available provided a wealth of information and a powerful tool for 
identifying avoidable causes of inequalities in cancer survival in Scodand between 
deprivation groups. They also caused some interpretative difficulty, particularly on disease 
stage. This information was collected from the medical notes, so even a prospective audit 
study would have had similar problems unless clinicians can be encouraged to take better 
care at recording stage information. It is clear that reliable stage information is needed for 
analyses such as those undertaken in this thesis, although problems in collecting this type of 
information must be acknowledged.
Not all of the variation in survival between deprivation groups could be explained using the 
information routinely available. There may be other factors that have not been accounted 
for, and the lack of information on stage for bladder, kidney and melanoma patients falls 
into this category. The specialty o f  consultants performing operations, the effect of 
multidisciplinary teams and more detailed information on treatment regimes could also be 
important. Alternatively, the remaining differences that are not accounted for may be due 
to the crudeness of the factors used and the missing data.
Overall, the deprivation-specific differences in survival for these six cancers are most 
unlikely to be explained by the various limitations in the material available or the methods of 
analysis, with the possible exception of colon cancer, where bias from missing stage 
information may have hindered interpretation. Differences in underlying mortality were 
adjusted for using comorbidity indices. Any bias in the use of the ecological Carstairs 
deprivation measure will have diluted the effects o f deprivation rather than enhanced them. 
Data quality was generally good, with the exception of stage for breast and colorectal cancer.
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The overall findings for each cancer are now briefly summarised, and an estimate is given of 
the number of deaths that could be avoided within five years o f  diagnosis. These are 
derived from the impact (% reduction) of the adjusted risk estimates for patients diagnosed 
in 1997, applied to the number of avoidable deaths estimated for patients diagnosed in 1991- 
95 (see Chapter 4).
Between half and two-thirds o f the deprivation-specific survival differences observed 
between affluent and deprived women with breast cancer diagnosed in 1997 can be 
attnbuted to differences in stage at diagnosis, ER status and access to optimal treatment. 
These differences in survival should therefore be largely avoidable by carefully targeted 
awareness campaigns aimed at earlier diagnosis of deprived women and more rigorous 
adherence by oncologists to consensus guidelines on how to treat cancer patients. If 
implementing such policies could realistically reduce inequalities in survival in breast cancer 
survival between deprivation groups by one half, some 60 breast cancer deaths within five 
years of diagnosis might be avoided each year in Scotland.
Around half o f the difference in survival for rectal cancer patients was explained by deprived 
patients having worse comorbidity and stage at diagnosis, on their being more likely to 
present as an emergency and be treated with palliative intent (probably as a result of later 
stage and poor host response), and being less likely to be treated in a regional RT centre or 
other high-workload hospital. These differences in survival should again be largely avoidable 
by carefully targeted awareness campaigns aimed at deprived patients and by ensuring that 
rectal cancer patients attend appropriate hospitals to ensure optimal treatment. If 
implementing such policies could reduce inequalities in rectal cancer survival between 
deprivation groups by around one half, around 20 rectal cancer deaths within five years of 
diagnosis might be avoided each year.
For kidney cancer patients, around a third of the deprivation-specific differences were 
explained by differences in the treatment received. This may reflect a worse stage at 
diagnosis influencing the clinician judgement, but the data suggest that some of the 
differences are due to inequity in access to health care services. If all kidney cancer patients 
had equal access to multi-disciplinary teams in hospitals with the necessary facilities for 
optimal treatment, it seems reasonable to suggest that around one fifth of the differences in
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survival should be avoidable. If this were achieved then 6 kidney cancer deaths within five 
years of diagnosis might be avoided each year.
Finally, deprivation-specific differences in survival for melanoma patients were explained by 
largely unavoidable factors including age, sex, comorbidity and site of the lesion on the 
body, and factors directly relating to thick tumours including palliative treatment intent and 
the provision of radiotherapy. Sex and site of lesion on the body may also be indirect 
markers of tumour thickness. The melanoma analyses were greatly hampered because no 
information on tumour thickness was available. If the important prognostic factors 
identified are truly measures of tumour thickness, then continued campaigns to promote 
awareness and early diagnosis, particularly in deprived men, could reduce the deprivation- 
specific differences in melanoma survival by one half, and some 9 melanoma deaths within 
five years of diagnosis might be avoided each year.
Deprivation-specific differences in colon cancer survival were increased, not reduced, by the 
factors investigated, after adjusting for differences in survival for patients with unstaged 
tumours. It is not possible to discern if this is real or a data quality artefact. For bladder 
cancer, none of the factors investigated explained the differences in survival, illustrating that 
the routine data were not sufficient. Further investigation is required, particularly with data 
on stage of disease.
Although this thesis has not successfully identified all the reasons for inequalities in cancer 
survival between deprivation groups in Scotland for the six cancers studied, it has 
highlighted specific areas where changes in policy would go a long way to reducing the 
inequalities, most importantly by enabling earlier diagnosis and ensuring that all patients have 
access to optimal treatment. Given the crudeness of the measures and the incompleteness 
o f information with these routine data, it is likely that the factors identified as important 
actually explain more of the observed differences in survival between the deprivation groups 
than we have been able to illustrate.
In addressing the underlying aim o f this thesis, we can conclude that it is indeed possible 
and useful to analyse routine data to provide meaningful and timely insights into differences 
in survival between deprivation groups in Scotland. Overall, to the extent that each o f the
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survival analyses and policy implications discussed here are plausible, then it may be 
suggested that almost 100 deaths from the six cancers considered here might be avoided 
within 5 years of diagnosis every year in Scodand. The total avoidable mortality for these 
cancers, if all deprivation groups had the same survival as the most affluent group, is 
estimated to be around 10%, and could be reduced to around 6% by reducing inequalities in 
stage at diagnosis and access to optimal treatment. Because of the limitations discussed 
relating to the available data, it is likely that removing these inequalities would actually reduce 
the avoidable mortality even further.
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PUBLICATIONS
A number of publications have been, or are in the process of being, written as a result of the 
work in this thesis:
1. The analyses in Chapter 4 were also done on English data, and published in: 
“Richards MA, Stockton D, Babb P, Coleman MP (2000). How m any deaths 
have been avoided through improvements in cancer survival? BMJ; 320:895-8.”
2. Chapter 3 was used as the basis of the summary chapter in: “Scottish Cancer 
Intelligence Unit (2000). Trends in Cancer Survival in Scotland 1971-1995. 
Edinburgh: Information and Statistics Division.”
3. The following articles are in draft form and should all be submitted for 
publication within the next six months:
a. A paper describing the STATA algorithm strel2, which includes the analyses 
on the sensitivity of the algorithm and comparisons of the estimates with 
those provided by the surv3 package.
b. A paper on the European avoidable deaths analysis: “Avoidable deaths: what 
if cancer survival in Great Britain was the same as in Europe?”
c. A paper comparing the two methods of estimating the number o f  avoidable 
deaths.
d. A comparison of the various comorbidity measures as prognostic indicators 
for cancer
4. I also intend to write papers based on the main results of Chapters 5-8.
